WO2011061214A1 - Novel heterocyclic acrylamides and their use as pharmaceuticals - Google Patents

Novel heterocyclic acrylamides and their use as pharmaceuticals Download PDF

Info

Publication number
WO2011061214A1
WO2011061214A1 PCT/EP2010/067647 EP2010067647W WO2011061214A1 WO 2011061214 A1 WO2011061214 A1 WO 2011061214A1 EP 2010067647 W EP2010067647 W EP 2010067647W WO 2011061214 A1 WO2011061214 A1 WO 2011061214A1
Authority
WO
WIPO (PCT)
Prior art keywords
naphthyridin
dihydro
mmol
azetidin
oxo
Prior art date
Application number
PCT/EP2010/067647
Other languages
French (fr)
Inventor
Vincent Gerusz
Sonia Escaich
Mayalen Oxoby
Alexis Denis
Original Assignee
Fab Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2012539312A priority Critical patent/JP5816629B2/en
Priority to DK10776385.6T priority patent/DK2501693T3/en
Priority to AU2010320963A priority patent/AU2010320963B2/en
Priority to PL10776385T priority patent/PL2501693T3/en
Priority to CA2776849A priority patent/CA2776849A1/en
Priority to US13/510,564 priority patent/US8846711B2/en
Priority to KR1020127011047A priority patent/KR20130010456A/en
Application filed by Fab Pharma Sas filed Critical Fab Pharma Sas
Priority to ES10776385.6T priority patent/ES2526567T3/en
Priority to CN201080051981.2A priority patent/CN102656158B/en
Priority to MX2012005759A priority patent/MX2012005759A/en
Priority to NZ599444A priority patent/NZ599444A/en
Priority to EP10776385.6A priority patent/EP2501693B1/en
Priority to BR112012011793A priority patent/BR112012011793A2/en
Publication of WO2011061214A1 publication Critical patent/WO2011061214A1/en
Priority to IL218934A priority patent/IL218934A0/en
Priority to ZA2012/02489A priority patent/ZA201202489B/en
Priority to HK13103790.1A priority patent/HK1176358A1/en
Priority to US14/463,994 priority patent/US9051321B2/en
Priority to US14/703,004 priority patent/US9321769B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/12—Radicals substituted by halogen atoms or nitro or nitroso radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Definitions

  • the invention relates to novel heterocyclic acrylamide compounds, to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.
  • the invention particularly relates to new compounds capable of inhibiting bacterial and/or parasite fatty acid biosynthesis and their use as antibacterial and/or antiparasitic agents.
  • antibiotic-resistant pathogens has become a serious worldwide healthcare problem. Indeed, some infections are now caused by multi-drug resistant organisms that are no longer responsive to currently available treatments. There is therefore an immediate need for new antibacterial / antiparasitic agents with a novel mode of action.
  • the bacterial fatty acid biosynthesis (FASII system) has recently generated a lot of interest for the development of novel antibacterial / antiparasitic agents (Rock et al. J. Biol. Chem. 2006, 281 , 17541; Wright and Reynolds Curr. Opin. Microbiol. 2007, 10, 447).
  • the organization of components in the bacterial fatty acid biosynthesis pathway based on discrete enzymes is fundamentally different from the multifunctional FASI system found in mammals, therefore allowing good prospects of selective inhibition.
  • the overall high degree of conservation in many enzymes of the bacterial FASII system should also allow the development of broader-spectrum antibacterial / antiparasitic agents.
  • Fabl represents the enoyl-ACP reductase responsible for the last step of the fatty acid biosynthetic elongation cycle.
  • Fabl reduces the double bond in the fra/7s-2-enoyl-ACP intermediate to the corresponding acyl-ACP product.
  • This enzyme has been shown to constitute an essential target in major pathogens such as E. coli (Heath et al. J. Biol. Chem. 1995, 270, 26538; Bergler et al. Eur. J. Biochem. 1996, 242, 689) and S.
  • isoniazid is a prodrug restricted to the treatment of susceptible tuberculosis.
  • the fact that isoniazid requires activation by hydrogen-peroxyde inducible enzymes enhances the possibilities of resistance by lack of activation or increased detoxification (Rosner et al. Antimicrob. Agents Chemother. 1993, 37, 2251 and ibid 1994, 38, 1829).
  • Triclosan a widely used consumer goods preservative with broad spectrum antimicrobial activity, has been found to be a reversible, tight-binding inhibitor of E. coli Fabl (Ward et al. Biochemistry 1999, 38, 12514). Intravenous toxicology studies on this compound indicated a LD 50 on rats of 29 mg/kg clearly ruling out intravenous injection (Lyman et al. Ind. Med. Surg. 1969, 38, 42). Derivatives based on the 2-hydroxydiphenyl ether core of Triclosan have been reported (Tonge et al. J. Med. Chem.
  • WO 2007/135562 (Mutabilis SA) describes a series of hydroxyphenyl derivatives that display a selective spectrum of activity on species containing FabI and related targets, in contrast to Triclosan.
  • WO 2008/098374, WO 2008/009122, WO 2007/067416, WO 2007/053131, WO 03/088897 and WO 01/27103 all describe a series of acrylamide derivatives which are claimed to be FabI inhibitors.
  • One of the purposes of the invention is to provide novel compounds active on FabI and related targets with improved pharmacological and/or physico-chemical properties over existing compounds.
  • - W and X independently represent a bond or a -(CH 2 )i-4 group, such that W and X together contain 1-5 carbon atoms;
  • R2 represents an H, F, CN, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl,
  • R a , Rb and R c independently represent H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 - C 6 ) alkynyl, or an NR a Rb group may optionally form a 3- to 7-membered nitrogen containing saturated heterocycie optionally containing 1 to 3 additional heteroatoms selected from N, O or S wherein said heterocycie may be optionally substituted by one or more (Ci-C 6 ) alkyl groups;
  • R d and R e independently represent H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, halo(d-C 6 ) alkyl, halo(d-C 6 ) alkyl-0-(d-C 6 ) alkyl- or (Ci-C 6 ) alkyl-0-(Ci- C 6 ) alkyl-;
  • R f represents (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, halo(d-C 6 ) alkyl or -(Ci-Ce) alkyl-Ar, wherein Ar represents phenyl or naphthyl;
  • - n represents an integer selected from 0 to 2;
  • - R3 is a pyridyl ring optionally fused to a 5, 6 or 7 membered aromatic, partially aromatic or saturated heterocycle containing 1-3 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups;
  • R5 is selected from the group consisting of F, C0 2 Rd, COR d , CONR a R b , OR d ,
  • Figure 1 relates to the in vivo antibacterial activity of Example 12 at 100 mg/kg.
  • Figure 2 relates to the in vivo antibacterial activity of Example 15 at 50 mg/kg.
  • - W and X independently represent a bond or a -(CH 2 )i -4 group, such that W and X together contain 1-5 carbon atoms;
  • Rl represents an H, F, CN, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl,
  • R2 represents an H, F, CN, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl,
  • R a , Rb and R c independently represent H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 - C 6 ) alkynyl, or an NR a Rb group may optionally form a 3- to 7-membered nitrogen containing saturated heterocycle optionally containing 1 to 3 additional heteroatoms selected from N, O or S wherein said heterocycle may be optionally substituted by one or more (Ci-C 6 ) alkyl groups;
  • R d and R e independently represent H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, halo(d-C 6 ) alkyl, halo(d-C 6 ) alkyl-0-(d-C 6 ) alkyl- or (Ci-C 6 ) alkyl-0-(Ci- C 6 ) alkyl-;
  • - n represents an integer selected from 0 to 2;
  • R3 is a pyridyl ring optionally fused to a 5, 6 or 7 membered aromatic, partially aromatic or saturated heterocycle containing 1-3 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups;
  • the compounds of the invention may have good in vitro and/or in vivo activity and display surprisingly improved pharmacological, physical and/or chemical properties over previously described Fabl inhibitors as confirmed by data presented herein.
  • compounds of the invention which have been tested display surprisingly less serum binding than previously described acrylamide derivatives.
  • compounds of the invention which have been tested appear to demonstrate parenteral (such as subcutaneous) and oral bioavailability.
  • Certain compounds of the invention also appear to reduce the apparition of resistance mechanisms by being selective of FabI and related targets while avoiding hitting structurally unrelated targets such as FabK.
  • compounds of the invention which have been tested appear to demonstrate greater solubility than previously described FabI inhibitors.
  • salts which are not harmful to the patient.
  • Such salts include
  • Acid addition salts include salts of inorganic acids as well as organic acids.
  • Suitable inorganic acids include hydrochloric,
  • hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
  • Suitable organic acids include formic, acetic,
  • compositions include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference.
  • metal salts include lithium, sodium, potassium, magnesium salts and the like.
  • ammonium and alkylated ammonium salts include ammonium, methylammonium,
  • alkaline salts include, for example, sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, ethylamine, propylamine, trimethylamine, diethylamine, triethylamine, ⁇ , ⁇ -dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, piperidine, piperazine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine, N-methylglucamine.
  • bases such as, for example, methylamine, ethylamine, propylamine, trimethylamine, diethylamine, triethylamine, ⁇ , ⁇ -dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, piperidine, piperazine, picoline, dicyclohexylamine, morpholine, benz
  • the compounds of formula (I) can be in racemic forms, as well as in the form of pure enantiomers or non racemic (scalemic) mixture of enantiomers, including when the compounds of formula (I) have more than one stereogenic centre.
  • the compounds of formula (I) have unsaturated carbon carbon double bonds, both the cis (Z) and trans (E) isomers and their mixtures belong to the invention.
  • halogen means a fluorine, chlorine, bromine or iodine atom.
  • references herein to "(Ci-Ce) alkyl” means any linear, branched hydrocarbon groups having 1 to 6 carbon atoms, or cyclic hydrocarbon groups having 3 to 6 carbon atoms.
  • Representative examples of such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl, n-pentyl, isopentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • references herein to "(C 2 -C 6 ) alkenyl” means any linear, branched hydrocarbon groups of 2 to 6 carbon atoms, or cyclic hydrocarbon group having 3 to 6 carbon atoms having at least one double bond. Representative examples of such alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. References to "halo(C 2 - C 6 ) alkenyl” mean a (C 2 -C 6 ) alkenyl group substituted by one or more halogen atoms as herein defined.
  • references herein to "(C 2 -C 6 ) alkynyl” means any linear, or branched hydrocarbon groups of 2 to 6 carbon atoms, having at least one triple bond .
  • Representative examples of such alkynyl groups include ethynyl, propargyl and butynyl .
  • References to "halo(C 2 -C 6 ) alkynyl” mean a (C 2 -C 6 ) alkynyl group substituted by one or more halogen atoms as herein defined.
  • Het within the definition of Rl and R5 include those selected from the group comprising furyl, tetrahydrofuryl, benzofuryl, tetrahydrobenzofuryl, thienyl, tetrahydrothienyl, benzothienyl, tetrahydrobenzo- thienyl, pyrrolyl, pyrrolidinyl, indolyl, indolinyl, tetrahydroindolyl, oxazolyl, oxazolinyl, oxazolidinyl, benzoxazolyl, tetrahydrobenzoxazolyl, oxazolopyridinyl, tetrahydrooxazolopyridinyl, oxazolopyrimidinyl, tetrahydrooxazolopyrimidinyl, oxazolopyrazinyl, oxazolopyridazinyl,
  • N R a Rb saturated nitrogen containing heterocycles within the definition of N R a Rb include those selected from the g roup comprising, pyrrolidinyl, oxazol id inyl, thiazolid inyl , piperidinyl, piperazinyl and morphol inyl .
  • W and X both represent CH 2 , thus forming an azetid inyl ring which is substituted at the 3 position by Rl and R2.
  • one of W and X represents CH 2 and the other represents CH 2 CH 2 , thus forming a pyrrolidinyl ring which is substituted at the 3 position by Rl and R2.
  • one of W and X represents a bond and the other represents CH 2 CH 2 CH 2 , th us forming a pyrrolid inyl ring wh ich is substituted at the 2 position by Rl and R2.
  • W and X both represent CH 2 CH 2 , th us forming a piperidinyl ring which is substituted at the 4 position by Rl and R2.
  • one of W and X represents CH 2 and the other represents CH 2 CH 2 , thus forming a piperidinyl ring which is substituted at the 3 position by Rl and R2.
  • one of W and X represents a bond and the other represents CH 2 CH 2 CH 2 CH 2 , thus forming a piperidinyl ring which is substituted at the 2 position by Rl and R2.
  • W and X both represent CH 2 , thus forming an azetidinyl ring which is substituted at the 3 position by Rl and R2.
  • Rl represents an H, F, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, OR d , S(0) n R a , Y-Ar or Z-Het group each of which may be optionally substituted by one or more R4 groups.
  • Rl represents an H, (Ci-C 6 ) alkyl, OR d , S(0) n R a , Y-Ar or Z-Het group each of which may be optionally substituted by one or more R4 groups.
  • Rl represents H
  • Rl represents (Ci-C 6 ) alkyl optionally substituted by one or more R4 groups
  • Rl represents ethyl or propyl optionally substituted by one or more OR d groups (such as -OH).
  • Rl represents propyl or ethyl substituted by an OH group.
  • Rl represents propyl or (CH 2 ) 2 OH .
  • R d represents (Ci-C 6 ) alkyl (e.g. butyl, pentyl or -(CH 2 ) 2 -CH(Me)), halo(d-C 6 ) alkyl (e.g . -CH 2 -CF 3 or -CH3-CF3), -(Ci-C 6 ) alkyl-0-(Ci-C 6 ) alkyl (e.g . -(CH 2 ) 2 -OMe or -(CH 2 ) 3 -OMe) or (C 2 -C 6 ) alkenyl (e.g .
  • R d represents (Ci-C 6 ) alkyl, such as butyl .
  • Rl represents S(0) n R a
  • n 2 and R a represents (Ci-C 6 ) alkyl, such as pentyl .
  • Rl represents Y-Ar
  • Rl represents phenyl, -O-phenyl, - 0-CH 2 -phenyl or -CH 2 -0-phenyl each of which may be optionally substituted by one or more R4 groups (such as -CH 2 -0-fluorophenyl).
  • Ar represents phenyl .
  • Y represents a bond or a linker selected from O or -0-(d-C 6 ) alkylene (such as -0-CH 2 - or -CH 2 -0-).
  • Rl represents Z-Het
  • Rl represents -0-CH 2 - thienyl, -0-(CH 2 ) 2 -thienyl or -benzofuranyl optionally substituted by an R4 group (such as methyl) .
  • Rl represents - benzofuranyl optionally substituted by an R4 group (such as methyl).
  • R a represents (Ci-C 6 ) alkyl (e.g . methyl)
  • R f represents (Ci-C 6 ) alkyl (e.g .
  • halo(d-C 6 ) alkyl e.g . -CH2-CF3 or -(Ci-Ce) alkyl-Ar (e.g. -CH 2 -phenyl).
  • R a represents (Ci-C 6 ) alkyl (e.g. methyl)
  • R f represents (Ci-C 6 ) alkyl (e.g . propyl).
  • Het represents benzothiophenyl, benzofuranyl, benzoxazolyl, oxadiazolyl, pyridyl, pyrazolyl, thienyl, thiazolyl, furanyl or pyrimidinyl each of which may be optionally substituted by one or more R4 groups.
  • Het represents benzoxazolyl, oxadiazolyl, pyridyl, thienyl, thiazolyl or pyrimidinyl each of which may be optionally substituted by one or more R4 groups.
  • Z represents a bond or a linker selected from O, S or -0-(Ci- C 6 ) alkylene (such as -0-CH 2 -, -0-(CH 2 ) 2 - or -0-(CH 2 ) 3 -) or
  • Rl represents OR d (such as -O-pentyl) or Z-Het (such as -O- CH 2 -thienyl).
  • Rl represents Z-Het, such as -0-CH 2 - thienyl.
  • R2 represents an H or OR d group. In a further embodiment, R2 represents an H or OH group. In a yet further embodiment, R2 represents H .
  • R4 represents halogen (such as bromine, chlorine or fluorine), (Ci-Ce) alkyl (such as methyl), (C 2 -C 6 ) alkenyl or (C 2 -C 6 ) alkynyl. In a further embodiment, R4 represents halogen (such as fluorine) or (Ci-C 6 ) alkyl (such as methyl). In a yet further embodiment, R4 represents fluorine or methyl. In a further embodiment, R4 represents halogen (such as fluorine), (Ci-Ce) alkyl (such as methyl), (C 2 -C 6 ) alkenyl or (C 2 -C 6 ) alkynyl. In a further embodiment, R4 represents halogen (such as fluorine) or (Ci-C 6 ) alkyl (such as methyl). In a yet further embodiment, R4 represents fluorine or methyl .
  • ring systems within the definition of R3 include heterocycles of formula (a)-(i) :
  • An example of a compound of formula (I) wherein two R5 groups together with the atom to which they are attached together form a Het group optionally substituted by one or more (Ci-C 6 ) alkyl groups include a spiro ring system of formula (j) :
  • a further examples of a ring system within the definition of R3 includes the heterocycle of formula (k) :
  • R3 is a pyridyl ring or a pyridyl ring fused to a 5, 6 or 7 membered aromatic, partially aromatic or saturated heterocycle containing 1-5 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups.
  • R3 is a pyridyl ring or a pyridyl ring fused to a 5 or 6 membered aromatic, partially aromatic or saturated heterocycle containing 1-5 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups.
  • R3 is a pyridyl ring or a pyridyl ring fused to a 6 membered aromatic, partially aromatic or saturated heterocycle containing 1-5 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups.
  • R3 is a pyridyl ring fused to a 6 membered aromatic, partially aromatic or saturated heterocycle containing 1-5 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups.
  • R3 represents a heterocycle of formula (k) :
  • R5 groups such as (Ci-C 6 ) alkyl optionally substituted by C0 2 Rd (e.g . - CH 2 -C0 2 H), NR a Rb (e.g . -CH 2 -N(Me) 2 ) or Het optionally substituted by one or more (Ci-C 6 ) alkyl groups (e.g. -(CH 2 ) 2 -piperazinyl-Me).
  • C0 2 Rd e.g . - CH 2 -C0 2 H
  • NR a Rb e.g . -CH 2 -N(Me) 2
  • Het optionally substituted by one or more (Ci-C 6 ) alkyl groups (e.g. -(CH 2 ) 2 -piperazinyl-Me).
  • R3 represents a heterocycle of formula (a), (b), (c), (d), (f), (i), (j) or (k) :
  • R5 groups such as C0 2 R d (e.g. C0 2 Me), NR a R b (e.g . NH 2 ), CONR a R b (e.g . CONH 2 ), NR c COR d (e.g . NHCOMe) or (Ci-C 6 ) alkyl optionally substituted by F, C0 2 R d (e.g . -CH 2 -C0 2 H), CONR a R b , OR d (e.g . CH 2 OH), NR a R b (e.g .
  • NR a CORd or Het optionally substituted by one or more (Ci-C 6 ) alkyl groups (e.g . - (CH 2 ) 2 -piperazinyl-Me).
  • R3 represents a heterocycle of formula (a) or (j) :
  • R5 groups such as C0 2 R d (e.g. C0 2 Me), NR a R (e.g . NH 2 ), CONR a R (e.g . CONH 2 ), NR c COR d (e.g . NHCOMe) or (Ci-C 6 ) alkyl optionally substituted by F, C0 2 R d (e.g . -CH 2 -C0 2 H), CONR a R b , OR d (e.g . CH 2 OH), NR a R b (e.g .
  • R3 represents a heterocycle of formula (a), (b) or (c) :
  • R5 groups such as C0 2 R d (e.g. C0 2 Me), NR a R (e.g . NH 2 ), CONR a R (e.g . CONH 2 ), NR c COR d (e.g . NHCOMe) or (Ci-C 6 ) alkyl optionally substituted by F, C0 2 R d ,CONR a R b , ORd (e.g . CH 2 OH), NR a R b or NR a COR d .
  • C0 2 R d e.g. C0 2 Me
  • NR a R e.g . NH 2
  • CONR a R e.g . CONH 2
  • NR c COR d e.g NHCOMe
  • Ci-C 6 alkyl optionally substituted by F, C0 2 R d ,CONR a R b , ORd (e.g . CH 2 OH),
  • R3 represents a heterocycle of formula (c) :
  • R5 groups such as NR a Rb (e.g. 2-NH 2 ) or NRcCORd (e.g . 2-NHCOMe).
  • R3 represents a heterocycle of formula (a) or (b) :
  • R5 groups such as C0 2 R d (e.g . 3- C0 2 Me), CONRaRb (e.g . 3-CONH 2 ) or (Ci-C 6 ) alkyl optionally substituted by OR d (e.g. 3-CH 2 OH).
  • R3 represents a heterocycle of formula (a) :
  • R5 groups such as C0 2 R d (e.g . 3- C0 2 Me), CONRaRb (e.g . 3-CONH 2 ) or (Ci-C 6 ) alkyl optionally substituted by OR d (e.g 3-CH 2 OH).
  • R3 represents a heterocycle of formula (a) :
  • n 1 or 2. In a further embodiment, n represents 2.
  • R a , Rb and R c independently represent H, (Ci-C 6 ) alkyl, or an NR a Rb group may optionally form a 3- to 7-membered nitrogen containing saturated heterocycle optionally containing 1 to 3 additional heteroatoms selected from N, O or S wherein said heterocycle may be optionally substituted by one or more (Ci-C 6 ) alkyl groups.
  • R d and R e independently represent H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, halo(d-C 6 ) alkyl, halo(d-C 6 ) alkyl-0-(d-C 6 ) alkyl- or (d-C 6 ) alkyl-0-(d- C 6 ) alkyl-.
  • R d and R e independently represent H, (Ci-C 6 ) alkyl, halo(Ci-Ce) alkyl-0-(Ci-C 6 ) alkyl- or (d-C 6 ) alkyl-0-(Ci-C 6 ) alkyl-.
  • R f represents (Ci-C 6 ) alkyl (e.g . ethyl or propyl), halo(d-C 6 ) alkyl (e.g. -CH 2 -CF 3 ) or -(d-C 6 ) alkyl-Ar (e.g. -CH 2 -phenyl).
  • the compound of formula (I) is selected from :
  • the compound of formula (I) is selected from:
  • the compound of formula (I) is selected from
  • the compound of formula (I) is selected from
  • the compound of formula (I) is selected from
  • the compound of formula (I) is selected from
  • the compounds of formula (I) and their salts may be prepared by processes known to the skilled chemist to be applicable for preparing chemically related compounds. Such processes use known starting materials or intermediates which may be obtained by standard procedures of organic chemistry. The following processes provide a variety of non-limiting routes for the production of the compounds of formula (I) and their intermediates used therein. These processes constitute further aspects of the invention. According to a further aspect of the invention, there is provided a process for preparing a compound of formula (I) as defined above which comprises: reacting a compound of formula (II)
  • R3 is as defined above for compounds of formula (I), with a compound of formula (III) :
  • R3 is as defined above for compounds of formula (I) and L 1 represents a suitable leaving group, such as a halogen atom, e.g. fluorine, chlorine, bromine or an alkoxy group, with a compound of formula (III) :
  • W, X, Rl and R2 are as defined above for compounds of formula (I), with a compound of formula L 2 -R3, wherein L 2 represents a suitable leaving group, such as a halogen atom, e.g. fluorine, chlorine, bromine or an alkoxy group; optionally thereafter followed by:
  • L 2 represents a suitable leaving group, such as a halogen atom, e.g. fluorine, chlorine, bromine or an alkoxy group
  • Process (a) typically comprises the use of EDC, a base such as TEA or DIPEA or DMAP, the optional use of HOBT, and a solvent such as DMF.
  • Process (b) typically comprises the use of a base such as TEA or DIPEA or DMAP, and a solvent such as DCM, THF, ACN or DMF.
  • a base such as TEA or DIPEA or DMAP
  • a solvent such as DCM, THF, ACN or DMF.
  • Process (c) typically comprises the use of suitable coupling conditions known to the one skilled in the art such as the Heck coupling (Chem. Rev. 2000, 100, 3009), a non-limiting example comprises the use of a palladium catalyst, a phosphine ligand, a suitable base and solvent.
  • suitable coupling conditions known to the one skilled in the art such as the Heck coupling (Chem. Rev. 2000, 100, 3009)
  • a non-limiting example comprises the use of a palladium catalyst, a phosphine ligand, a suitable base and solvent.
  • Process (d) typically comprises any suitable deprotection reaction, the conditions of which will depend upon the nature of the protecting group. In most instances such a deprotection reaction will typically comprise the use of a suitable acid.
  • Process (e) typical ly comprises interconversion proceed ures known by one skil led in the art.
  • compounds of formula (I) in which Rl or R2 represents hyd rogen may be converted by methods known by one skilled in the art into compounds of formula (I) in which Rl or R2 represents C0 2 R a , COR a , CON R a Rb, CH 2 OR c , CH 2 N R a R b , S0 2 N R a R b , wherein R a , R b and R c are as defined above for compounds of formula (I) .
  • the compounds of formula (II), (III), (IV), (V) and L 2 -R3 are either known or may be prepared in accordance with known procedures such as those described herein. As illustrated by the examples given below, the hereinbefore disclosed compounds of formula (I) have valuable biological properties. They are particularly useful as antibacterial agents having a selective spectrum of activity in vitro and in vivo against bacterial strains relying on Fabl and related targets.
  • Such strains encompass Staphylococcus aureus including multiresistant strains (such as methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) strains), Acinetobacter baumannii, Bacillus anthracis, Chlamydophila pneumoniae, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Neisseria meningitidis and also bacteria such as Mycobacterium tuberculosis carrying homologous Fabl enzymes such as InhA or other organisms such as Plasmodium falciparum.
  • MSSA methicillin-susceptible Staphylococcus aureus
  • MRSA methicillin-resistant Staphylococcus aureus
  • the compound of the invention is used in the treatment of Staphylococcus aureus microbial infections including multiresistant strains such as methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin- intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) strains.
  • MSSA methicillin-susceptible Staphylococcus aureus
  • MRSA methicillin-resistant Staphylococcus aureus
  • VRSA vancomycin- intermediate Staphylococcus aureus
  • the compounds of formula (I) are therefore particularly suitable as active principles of a medicament.
  • a compound of formula (I) as hereinbefore defined for use in therapy.
  • a pharmaceutical composition comprising a compound of formula (I) as hereinbefore defined, in association with a pharmaceutically acceptable excipient or carrier.
  • Said pharmaceutical compositions are advantageously formulated to be administered under oral, topical, parental including injectable routes, such as intravenous administration, with individual doses appropriate for the patient to be treated.
  • compositions according to the invention can be solid, liquid or in the form of a gel/cream and be present in the pharmaceutical forms commonly used in human medicine, such as for example, plain or sugar-coated tablets, gelatin capsules, granules, suppositories, injectable preparations, ointments, creams, gels; they are prepared according to the customary methods.
  • the active ingredient/s can be incorporated using excipients which are customarily used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting agents, dispersants or emulsifiers, preservatives.
  • excipients which are customarily used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting agents, dispersants or emulsifiers, preservatives.
  • excipients which are customarily used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, aqueous or non-aqueous vehicles, fatty substances of animal or
  • the dose administered varies according to the condition treated, the patient in question, the administration route and the product envisaged. It can, for example, be comprised between 0.01 g and 10 g per day, by oral route or by intramuscular or intravenous route in humans.
  • compositions are particularly useful to treat human or animal infections by microbial pathogens such as Staphylococcus aureus including multiresistant strains, Acinetobacter baumannii, Bacillus anthracis, Chlamydophila pneumoniae, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Neisseria meningitidis, S. intermedius, P. multocida, B. bronchiseptica, M. haemolytica and A. pleuropneumoniae. and also bacteria such as Mycobacterium tuberculosis or other organisms such as Plasmodium falciparum.
  • microbial pathogens such as Staphylococcus aureus including multiresistant strains, Acinetobacter baumannii, Bacillus anthracis, Chlamydophila pneumoniae, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Kleb
  • compositions can also be useful in multitherapy, in combination with other medicaments, for example with antibiotics.
  • multitherapy may typically comprise either a composition comprising the compound of formula (I) additionally comprising one or more other medicaments, such as antibiotics or co-administration (i.e. sequential or simultaneous administration).
  • the invention therefore also relates to a method of treatment of microbial infections which comprises administering to a patient in need thereof an efficient amount of a compound of formula (I) as hereinbefore defined.
  • the invention also relates to a compound of formula (I) as hereinbefore defined for use in the treatment of microbial infections.
  • the invention also relates to the use of a compound of formula (I) as hereinbefore defined in the manufacture of a medicament for the treatment of microbial infections.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) as hereinbefore defined for use in the treatment of microbial infections.
  • H NMR proton nuclear magnetic resonance
  • d doublet
  • t triplet
  • q quadruplet
  • m multiplet
  • dd doublet of doublets
  • dt doublet of triplets
  • br broad .
  • J indicates the NMR coupling constant measured in Hertz.
  • CDCI 3 is deuteriochloroform
  • DMSO-d 6 is hexadeuteriodimethylsulfoxide
  • CD 3 OD is tetradeuteriomethanol .
  • Mass spectra were obtained using electrospray ionization (ESI) techniques on an Agilent 1100 Series LCMS.
  • Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography. Flash chromatography was carried out on Flashsmart Pack cartridge irregular silica 40-60pm or spherical silica 20- 40pm. Preparative thin layer chromatography was carried out on Analtech Silica Gel GF 1000 ⁇ 20x20 cm.
  • ESI electrospray ionization
  • HPLC high pressure liquid chromatography
  • LCMS liquid chromatography coupled with a mass spectrometer
  • M in the context of mass spectrometry refers to the molecular peak
  • MS mass spectrometer
  • NMR nuclear magnetic resonance
  • pH refers to potential of hydrogen
  • TEA triethylamine
  • DIPEA /V,/V-diisopropylethylamine
  • HOBt 1- hydroxybenzotriazole
  • DCM dichloromethane
  • EtOAc refers to ethyl acetate
  • DMF refers to ⁇ /,/V-dimethylformamide
  • ED AC refers A/-(3- dimethylaminopropyl)-/V'-ethylcarbodiimide hydrochloride
  • DMAP or 4-DMAP refers to 4-(di)
  • Lithium aluminum hydride (12.4 g, 326.7 mmol) was portionwisely added to a suspension of 2-amino-3-carboxypyridine (30.0 g, 217.2 mmol) in THF (350 mL) at 0°C. Once the addition was completed, the reaction mixture was stirred at room temperature for 15 minutes and then at reflux overnight. The mixture was then cooled to 0°C and hydrolyzed by the successive addition of water (18 mL), a solution of sodium hydroxyde (18 mL) and water (30 mL) again. The resulting white suspension was filtered on Clarcel ® and the cake was washed with THF (200 mL) and a mixture of CHCI 3 /MeOH (250 mL, 9 : 1). After concentration to dryness of the filtrate, the title product was obtained as a yellow solid (24.2 g, 90%).
  • Step 6 tert-Butyl (E)-3-(7-Oxo-5,6,7,8-tetrahydro-l,8-naphthyridin-3-yl)- acrylate
  • tert-Butyl acrylate (31.2 ml_, 210 mmol), diisopropylethylamine (19.4 ml_, 110 mmol) and P(o-tolyl) 3 (3.2 g, 10.5 mmol) were successively added to a suspension of 6-bromo-3,4-dihydro-lH-l,8-naphthyridin-2-one (11.9 g, 52.5 mmol; which may be prepared as described in Dl, Step 5) in propionitrile (83 ml_) and dimethylformamide (46 ml_).
  • the resulting mixture was then purged with argon prior to the addition of palladium acetate (1.2 g, 5.2 mmol).
  • Trifluoroacetic acid (31 mL) was added to a suspension of tart-butyl (E)-3-(7-Oxo- 5,6,7,8-tetrahydro-l,8-naphthyridin-3-yl)-acrylate (1.1 g, 3.76 mmol; which may be prepared as described in Dl, Step 6) in dichloromethane (31 mL).
  • the reaction mixture was stirred at room temperature for 1 hour and concentrated to dryness.
  • the resulting residue was solubilized in a solution of hydrochloric acid in dioxane (4N, 60 mL). After 10 minutes stirring at room temperature, the precipitate was filtered and washed with diethyl ether to afford the title product as a pale yellow solid (4.5 g, quantitative).
  • Step 2 2-Amino-5-bromo-3-(hydroxymethyl)pyridine Bromine (10.4 mL, 202 mmol) was added dropwise over 1 hour to a solution of 2- amino-3-(hydroxymethyl)pyridine (25.1 g, 202 mmol) in acetic acid (500 mL) at room temperature. After complete addition the reaction mixture was stirred for an extra hour. After concentration to dryness, the residue was partitioned between 1M Na2C03 (750mL) and ethyl acetate (500 mL). The aqueous layer was separated and extracted one more time with ethyl acetate (500 mL).
  • Boc 2 0 (15.58 g, 71.4 mmol) and triethylamine (10.85 mL, 78 mmol) were successively added to a solution of ethyl isonipecotate (10.2 g, 64.9 mmol) in dichloromethane (50 mL) at room temperature. The reaction mixture was stirred overnight. The reaction mixture was diluted by addition of a saturated solution of ammonium chloride (50 mL) . The aqueous layer was separated and extracted with dichloromethane (2 x 50 mL) . The combined organic phases were dried over sodium sulphate, filtered and concentrated to dryness. The title product was obtained as a colorless oil ( 16.1 g, 96%, py >95%) .
  • Step 8 (E)-3-(l'-Methyl-2-oxo-2,4-dihydro-lH- spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylic acid Sodium triacetoxyborohydride (671 mg, 3.17 mmol) and paraformaldehyde (95 mg, 3.17 mmol) were successively added to a suspension of (E)-3-(2-oxo-2,4- dihydro-lH-spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylic acid (455 mg, 1.58 mmol) in 1,2-dichloroethane (40 ml_) at room temperature.
  • the reaction mixture was then heated to 70°C and stirred for 2 hours.
  • the reaction mixture was cooled to room temperature, the precipitated product filtered and washed with H 2 0 (50 ml_) and MeOH (3 x 50 ml_) and dried .
  • the title product was obtained as a white solid (319 mg, 66%, py 74.1%).
  • Step 1 tert- Butyl 4-[(4-fluorophenoxy)methyl]piperidine-l-carboxylate
  • Step 3 6-[(lE)-3- ⁇ [4-(4-Fluorophenoxy)methyl]piperidin-l-yl ⁇ -3- oxoprop-l-en-l-yl]-3 4-dihydro-l 8-naphthyridin-2(lH)-one
  • Step 1 l-(Diphenylmethyl)azetidin-3-yl methanesulfonate
  • Step 2 l-(Diphenylmethyl)-3-phenox azetidine
  • Step 4 6-[(lE)-3-Oxo-3-(3-phenoxyazetidin-l-yl)prop-l-en-l-yl]-3,4- dih dro-l,8-naphthyridin-2(lH)-one
  • Step 3 6-[(lE)-3- ⁇ [3-(4-Fluorophenoxy)methyl]piperidin-l-yl ⁇ -3- oxo rop-l-en-l-yl]-3 4-dihydro-l 8-naphthyridin-2(lH)-one
  • Step 4 6-[(lE)-3-Oxo-3-(3-phenoxypyrrolidin-l-yl)prop-l-en-l-yl]-3,4- dihydro-l,8-naphthyridin-2(lH)-one
  • Step 2 tert- Butyl 3-cyanoazetidine-l-carboxylate
  • Step 3 tert-Butyl 3-[(Z)-amino(hydroxyimino)methyl]azetidine-l- carboxylate
  • terf-butyl 3-cyanoazetidine-l-carboxylate (190 mg, 1.04 mmol; which may be prepared as described in Step 2) was dissolved in ethanol (2.9 mL), then hydroxylamine hydrochloride (101 mg, 1.46 mmol) and triethylamine (247 pL,
  • Step 4 tert-Butyl 3-(5-methyl-l,2,4-oxadiazol-3-yl)azetidine-l- carboxylate
  • terf-butyl 3-[(Z)-amino(hydroxyimino)methyl]azetidine-l- carboxylate (170 mg, 0.74 mmol; which may be prepared as described in Step 3) was dissolved in acetonitrile (7.4 mL) and cooled to 0 °C under nitrogen.
  • DIPEA 387 pL, 2.22 mmol
  • acetyl chloride 105 pL, 1.48 mmol
  • Step 6 6- ⁇ (lE)-3-[3-(5-Methyl-l 2 4-oxadiazol-3-yl)azetidin-l-yl]-3- oxoprop-l-en-l-yl ⁇ -3 4-dihydro-l 8-naphthyridin-2(lH)-one
  • thiophene-2-methanol (332 ⁇ _, 3.50 mmol) was dissolved in tetrahydrofuran (2 ml_) and cooled at 0 °C under nitrogen .
  • Thionyl chloride (305 ⁇ _, 4.20 mmol) was added dropwise and the reaction mixture was allowed to warm to room temperature and heated at 50 °C for 2 h.
  • the crude mixture was concentrated under reduced pressure to give a dark oil (480 mg, quantitative). The product was used in the next step without further purification.
  • Step 2 l-(Diphenylmethyl)-3-(2-thienylmethoxy)azetidine
  • Step 4 6- ⁇ (lE)-3-Oxo-3-[3-(2-thienylmethoxy)azetidin-l-yl]prop-l-en-l- l ⁇ -3,4-dihydro-l,8-naphthyridin-2(lH)-one
  • terf-butyl 2-[(Z)-amino(hydroxyimino)methyl]piperidine-l- carboxylate 150 mg, 0.62 mmol; which may be prepared as described in Step 1) was dissolved in acetonitrile (6.2 mL) and cooled at 0 °C under nitrogen. DIPEA (324 pL, 1.86 mmol) and acetyl chloride (88 pL, 1.24 mmol) were added dropwise and the reaction mixture was allowed to warm to room temperature then heated to 100 °C for 4 h, cooled and concentrated . The residue was taken up in EtOAc and water. The two layers were separated and the aqueous phase extracted with EtOAc.
  • Step 4 6- ⁇ (lE)-3-[2-(5-Methyl-l 2 4-oxadiazol-3-yl)piperidin-l-yl]-3- oxo rop-l-en-l-yl ⁇ -3 4-dihydro-l 8-naphthyridin-2(lH)-one
  • Step 1 l-(Diphenylmethyl)-3-(pentyloxy)azetidine
  • Step 3 6- ⁇ (lE)-3-Oxo-3-[3-(pentyloxy)azetidin-l-yl]prop-l-en-l-yl ⁇ -3,4- dih dro-l,8-naphthyridin-2(lH)-one
  • Step 1 tert- Butyl 3-(pyridin-3-yloxy)pyrrolidine-l-carboxylate
  • Step 3 6- ⁇ (lE)-3-Oxo-3-[3-(pyridin-3-yloxy)pyrrolidin-l-yl]prop-l-en-l- yl ⁇ -3,4-dihydro-l,8-naphthyridin-2(lH)-one
  • Step 1 tert-Butyl (2R)-2- ⁇ [(2-bromophenyl)amino]carbonyl ⁇ pyrrolidine- 1-carbox late
  • terf-butyl (2R)-2- ⁇ [(2-bromophenyl)amino]carbonyl ⁇ pyrrolidine- 1-carboxylate (194 mg, 0.53 mmol; which may be prepared as described in Step 1) was dissolved in DME (4 mL) under nitrogen at room temperature. Cul (6 mg, 0.03 mmol), Cs 2 C0 3 (261 mg, 0.80 mmol) and 1,10-phenanthroline (26 mg, 0.14 mmol) were added then the reaction mixture was heated at 85 °C for 24 h. The mixture was cooled to room temperature and concentrated to dryness. The residue was dissolved in dichloromethane and filtered on Celite to eliminate the cupper residue. The filtrate was concentrated and the residue purified on preparative TLC (Pentane/EtOAc, 85/15 to 50/50) to give the title compound (88 mg, 58%) as a solid .
  • Step 4 6- ⁇ (lE)-3-[2-(l,3-Benzoxazol-2-yl)piperidin-l-yl]-3-oxoprop-l-en- l- l ⁇ -3,4-dihydro-l,8-naphthyridin-2(lH)-one
  • Step 3 6-[(lE)-3- ⁇ 3-[(2-Methylprop-2-en-l-yl)oxy]azetidin-l-yl ⁇ -3- oxo rop-l-en-l-yl]-3 4-dihydro-l 8-naphth ridin-2( lH)-one
  • thiazole-2-methanol 500 mg, 4.3 mmol was dissolved in THF (2.6 mL) and cooled to 0 °C under nitrogen.
  • Thionyl chloride (377 pL, 5.2 mmol) was added dropwise and the reaction mixture was allowed to warm to room temperature then heated at 50 °C for 2 h.
  • the crude mixture was concentrated under reduced pressure to give an orange solid (684 mg, 94%).
  • Step 2 tert- Butyl 3-(l,3-thiazol-2-ylmethoxy)azetidine-l-carboxylate
  • Step 4 6- ⁇ (lE)-3-Oxo-3-[3-(l,3-thiazol-2-ylmethoxy)azetidin-l-yl]prop- l-en-l-yl ⁇ -3,4-dihydro-l,8-naphthyridin-2(lH)-one
  • Step 2 2- ⁇ [l-(Diphenylmethyl)azetidin-3-yl]oxy ⁇ -lH-isoindole-l,3(2H)- dione
  • Step 4 (2E)-l-Pyrimidin-2-ylacetone 0-(l-diphenylmethylazetidin-3- l)oxime
  • Step 6 6- ⁇ (lE)-3-[3-( ⁇ [(l)-l-Methyl-2-pyrimidin-2- ylethylidene]amino ⁇ oxy)azetidin-l-yl]-3-oxoprop-l-en-l-yl ⁇ -3 4-dihydro- -naphthyridin-2(lH)-one
  • Step 5 6- ⁇ (lE)-3-[3-(Pentylsulfonyl)azetidin-l-yl]-3-oxoprop-l-en-l-yl ⁇ - -dihydro-l,8-naphthyridin-2(lH)-one
  • Step 3 tert- Butyl 3-(pyridin-4-ylmethoxy)azetidine-l-carboxylate
  • Step 5 5- ⁇ (lE)-3-Oxo-3-[3-(pyridin-4-ylmethoxy)azetidin-l-yl]prop-l-en- l-yl ⁇ pyridin-2-amine
  • Step 3 Methyl 6-[(lE)-3-tert-butoxy-3-oxoprop-l-en-l-yl]-2-oxo-l, 2,3,4- tetrahydro-l,8-naphthyridine-3-carboxylate
  • Step 4 (2E)-3-[6-(Methoxycarbonyl)-7-oxo-5,6,7,8-tetrahydro-l,8- na hthyridin-3-yl]acrylic acid
  • Step 5 Methyl 6-[(lE)-3- ⁇ 4-[(4-fluorophenoxy)methyl]piperidin-l-yl ⁇ -3- oxoprop-l-en-l-yl]-2-oxo-l 2 3 4-tetrahydro-l 8-naphthyridine-3- carboxylate
  • the second isolated fraction gave the oxidized derivative (6-[(lE)-3- ⁇ 4-[(4- fluorophenoxy)methyl]piperidin-l-yl ⁇ -3-oxoprop-l-en-l-yl]-2-oxo-l,2-dihydro-l,8- naphthyridine-3-carboxamide) as a white solid (2.3 mg, 18%).
  • Step 3 3-(Hydroxymethyl)-6-[(lE)-3- ⁇ 4-[(4- fluorophenoxy)methyl]piperidin-l-yl ⁇ -3-oxoprop-l-en-l-yl]-3 4-dihydro- l,8-naphthyridin-2(lH)-one
  • Triethylamine (870 ml, 62.67 mmol) and mesyl chloride (390 ⁇ _, 50.13 mmol) were successively added to a solution of l-benzhydrylazetan-3-ol (1.0 g, 41.78 mmol) in dichloromethane (10 mL) at room temperature.
  • the reaction mixture was stirred for 1 hour and then diluted by addition of water (20 mL).
  • the aqueous phase was separated and extracted with dichloromethane (2 x 40 mL).
  • the combined organic phases were washed with a saturated solution of sodium chloride (40 mL), dried over sodium sulfate, filtered and concentrated to dryness.
  • the title compound was obtained as a yellow solid (1.5 g, 100%).
  • Step 4 (E)-6-(3-Oxo-3-(3-(2-(thiophen-2-yl)ethoxy)azetidin-l-yl)prop-l- enyl)-3 -dihydro-l 8-naphthyridin-2(l )-one
  • the reaction mixture was stirred overnight and then partitioned between ethyl acetate (40 mL) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (99 : 1 to 95 : 5) as eluent. The residue was triturated with acetone to give a white solid (40 mg, 27%).
  • Step 5 (E)-6-(3-Oxo-3-(3-(3-(thiophen-2-yl)propoxy)azetidin-l-yl)prop- l-enyl)-3,4-dihydro-l,8-naphthyridin-2(l/ )-one
  • the reaction mixture was stirred overnight and then partitioned between ethyl acetate (30 mL) and water (30 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (99 : 1 to 95 : 5) as eluent. The residue was triturated in acetone to give the title compound as a white solid (40.0 mg, 27%).
  • the aqueous layer was separated and extracted with ethyl acetate (3 x 20 mL).
  • the combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness.
  • the residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (95 : 5 to 9 : 1) as eluent.
  • the title product was obtained as a yellow oil (267 mg, 36%).
  • Step 5 (E)-6-(3-(3-((3-Methylthiophen-2-yl)methoxy)azetidin-l-yl)-3- oxoprop- -enyl)-3,4-dihydro-l,8-naphthyridin-2(lW)-one
  • the reaction mixture was stirred overnight and then partitioned between ethyl acetate (30 mL) and water (30 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (100 : 0 to 95 : 5) as eluent. The residue was triturated in acetone to give a white solid (66.0 mg, 44%).
  • Step 5 6-[3-(3-(4-Methyl-thiophen-2ylmethoxy)-azetidin-l-yl)-3-oxo- propenyl]-3,4-dihydro-lW-[l,8]naphthyridin-2-one
  • the reaction mixture was stirred at room temperature overnight and then partitioned between ethyl acetate (20 mL) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 ml). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 20 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (99 : 1 to 95 : 5) as eluent. The residue was triturated with acetone to give a white solid (40 mg, 27%).
  • Triethylamine (2.2 mL, 16.0 mmol) and a solution of thionyl chloride (1.3 mL, 17.7 mmol) in dichloromethane (20 mL) were successively added to a solution of (5- methyl-thiophen-2-yl)-methanol (1.9 g, 14.6 mmol) in dichloromethane (20 mL) at 0°C.
  • the reaction mixture was stirred 2 hours at reflux then cooled to room temperature.
  • the mixture was then partitioned between water (15 mL) and ethyl acetate (20 mL). The organic phase was separated, dried over sodium sulfate, filtered and concentrated to dryness.
  • Step 3 l-Benzhydryl-((5-methylthiophen-2-yl)methoxy)-azetidine
  • the aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL).
  • the combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL).
  • the organic phase was dried over sodium sulfate, filtered and concentrated to dryness.
  • the residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (90 : 10) as eluent.
  • the title product was obtained as a yellow solid (580.0 mg, 49%).
  • Step 5 (E)-6-(3-(3-((5-Methylthiophen-2-yl)methoxy)azetidin-l-yl)-3- oxoprop- -enyl)-3,4-dihydro-l,8-naphthyridin-2(lW)-one
  • Step 3 (E 6-[3-(2-Methoxyethoxy)azetidin-l-yl)-3-oxoprop-l-enyl]-3,4- dihydro-l,8-naphthyridin-2( lH)-one
  • the aqueous layer was separated and successively extracted with ethyl acetate (2 x 30 mL) and dichloromethane (2 x 20 mL).
  • the combined organic phases were washed with a saturated solution of sodium chloride (3 x 20 mL), dried over sodium sulfate, filtered and concentrated to dryness.
  • the residue was purified by chromatography on silica gel, using dichloromethane/methanol (98: 2 to 95 : 5) as eluent. After precipitation in a mixture of dichloromethane and diethyl ether, the title product was obtained as a yellow solid (70 mg, 54%).
  • Step 1 l-Benzh dryl-3-(3-methoxypropoxy -azetidine
  • Step 3 (E 6-[3-(3-methoxypropoxy)azetidin-l-yl)-3-oxoprop-l-enyl]- 3,4-dihydro-l,8-naphthyridin-2(l/ )-one
  • the aqueous layer was separated and extracted successively with ethyl acetate (2 x 20 ml_) and dichloromethane (2 x 20 ml_).
  • the combined organic phases were washed with a saturated solution of sodium chloride (3 x 20 ml_), dried over sodium sulfate, filtered and concentrated to dryness.
  • the residue was purified by chromatography on silica gel, using dichloromethane/methanol (99 : 1 to 97 : 3) as eluent.
  • the title product was obtained as a grey solid (30 mg, 23%).
  • Step 2 3-Isobutoxyazetidine h drochloride 1-Chloroethyl chloroform ate (83 ⁇ _, 0.77 mmol) was added to a solution of 1- benzhydryl-3-isobutoxyazetidine (175 mg, 0.60 mmol) in 1,2-dichloroethane (3 mL) at room temperature. The reaction mixture was then heated up to 70°C and stirred for 1.5 hours. After cooling down to room temperature, methanol (3 mL) was added and the reaction mixture was heated again to 70°C and stirred for an additional 1.5 hours. After concentration to dryness, the crude mixture was triturated in pentane (2 x 5 mL) to give a yellow oil (98 mg, quantitative) which was used in the next step without further purification .
  • Step 3 (E 6-[3-(3-Isobutoxyazetidin-l-yl)-3-oxoprop-l-enyl]-3,4- dihydro- -naphthyridin-2( lH)-one
  • 3-Isobutoxyazetidine hydrochloride (98 mg, 0.6 mmol), EDCI (113 mg, 0.6 mmol), HOBt (80 mg, 0.6 mmol) and diisopropylethylamine (170 pL, 1.0 mmol) were successively added to a solution of 3-(chloromethyl)-l-methyl-lH-pyrazole (100 mg, 0.4 mmol) in dimethylormamide (10 mL) at room temperature.
  • the reaction mixture was stirred over a week-end and then diluted by addition ethyl acetate (20 mL) and water (2 x 20 mL).
  • Step 1 3-(Chloromethy -l-methyl-lH-pyrazole
  • Step 2 3-(( l-Benzhydrylazetidin-3-yloxy)methyl-lH-pyrazole
  • reaction mixture was partioned between ethyl acetate (30 mL) and water (30 mL).
  • the aqueous phase was separated and extracted with ethyl acetate (2 x 20 mL).
  • the combined organic phases were washed with brine (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness.
  • the residue was purified by chromatography on silica gel, using petroleum ether/dichloromethane/ethyl acetate (5 : 0 : 5 to 0 : 5 : 5) as eluent.
  • the title product was obtained as a yellow oil (301 mg, 67%).
  • Step 4 (E)-6-(3-(3-((l-Methyl-lH-pyrazol-3-yl)methoxy)azetidin-l-yl)-3- oxoprop- -enyl)-3,4-dihydro- -naphthyridin-2(l/ )-one
  • the reaction mixture was stirred overnight and then diluted by addition of ethyl acetate (30 mL) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with a saturated solution of sodium chloride (4 x 100 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (98: 2 to 95 : 5) as eluent. The trituration of the residue in methanol allowed the isolation of the title product as a white solid (39 mg, 27%).
  • Step 2 tert- Buty - thiazol-5- lmethox -azetidine-l-carboxylate
  • Triethylamine (10.3 mL, 74 mmol) and a solution of thionyl chloride (2.9 mL, 40.7 mmol) in chloroforme (19 mL) were successively added to a solution of furfuryl alcohol (3.7 g, 37 mmol) in chloroforme (38 mL) at 0°C.
  • the reaction mixture was then allowed to reach room temperature and stirred for 2 hours.
  • Water (50 mL) was then added and the organic phase was separated and washed with water (2 x 50 mL), dried over sodium sulphate, filtered and concentrated to dryness.
  • Step 3 3-(Furan- -ylmethoxy)-azetidine hydrochlo
  • Step 4 (E)-6-(3-(3-(Furan-2-ylmethoxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3 4-dihydro-l 8-naphthyridin-2(l )-one
  • the reaction mixture was stirred for 2 days and then diluted by addition of ethyl acetate (50 mL) and water (50 mL).
  • the aqueous layer was separated and successively extracted with ethyl acetate (2 x 50 mL) and dichloromethane (2 x 50 mL).
  • the combined organic phases were washed with a saturated solution of sodium chloride (3 x 60 mL), dried over sodium sulfate, filtered and concentrated to dryness.
  • the residue was purified by chromatography on silica gel, using dichloromethane/methanol (10 :0 to 95 : 5) as eluent. After trituration of the isolated solid in diethylether, the title product was obtained as a white solid (236 mg, 34%).
  • Step 1 JV-Boc ethylisopinecotate
  • Boc 2 0 (15.8 g, 71.4 mmol) and triethylamine (10 mL, 77.8 mmol) were successively added to a solution of ethylisopinecotate (10.2 g, 64.9 mmol) in dichloromethane (50 mL) at room temperature. The reaction mixture was stirred overnight. The reaction mixture was diluted by addition of a saturated solution of ammonium chloride (50 ml_). The aqueous layer was separated and extracted with dichloromethane (2 x 50 ml_). The combined organic phases were dried over sodium sulphate, filtered and concentrated to dryness. The title product was obtained as a yellow oil (16.7 g, 100%).
  • Step 2 1-tert-Butyl 4-ethyl 4-((2-amino-5-bromopyridin-3- yl)methyl)piperidi -l,4-dicarboxylate
  • the lithium salt of /V-Boc ethylisopinecotate was then canulated dropwise over 30 minutes to the lithium salt of 5-bromo-3-(bromomethyl)pyridine-2-amine.
  • the mixture was stirred at -78°C for 2 hours and allowed to warm to room temperature.
  • the reaction mixture was quenched with a saturated solution of ammonium chloride (150 mL) and ethyl acetate (150 mL) was added.
  • the organic phase was washed with water (2 x 50 mL) and brine (100 mL), dried over sodium sulphate, filtered and concentrated to dryness.
  • the residue was purified by chromatography on silica gel, using dichloromethane/AcOEt (95 : 5 to 9 : 1) as eluent.
  • the title product was obtained as a yellow oil (1.25 g, 20%).
  • Step 4 (E)-tert-Butyl 6-(3-ethoxy-3-oxoprop-l-enyl)-2-oxo-2 4-dihydro- lH-spiro[[l,8]naphthyridine-3,4'-piperidine]-l'-carboxylate
  • Ethyl acrylate (2.3 ml_, 21.2 mmol), diisopropylethylamine (3.7 ml_, 21.2 mmol) and P(o-tolyl) 3 (323 mg, 1.06 mmol) were successively added to a suspension of tert-butyl 6-bromo-2-oxo-2,4-dihydro-lH-spiro[[l,8]naphthyridine-3,4'-piperidine]- l'-carboxylate (2.10 g, 5.3 mmol) in propionitrile (20 ml_) and dimethylformamide (5 ml_) in a sealed tube.
  • Trifluoroacetic acid (5 mL) was added to a suspension of (E)-tert- butyl 6-(3-ethoxy- 3-oxoprop-l-enyl)-2-oxo-2,4-dihydro-lH-spiro[[l,8]naphthyridine-3,4'-piperidine]- l'-carboxylate (1.52 g, 3.66 mmol) in dichloromethane (20 mL). The reaction mixture was stirred at room temperature for 1 hour and concentrated to dryness. The resulting residue was partitioned between an aqueous solution of sodium hydroxide (IN, 60 mL) and dichloromethane (40 mL).
  • Step 6 (E)-Ethyl 3-(l'-methyl-2-oxo-2,4-dihydro-lH- spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylate
  • Step 7 (E)-3-(7-Oxo-5,6,7,8-tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride
  • Step 8 (E)-l'-Methyl-6-(3-oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l- yl)prop-l-enyl)-l -spiro[[l 8]naphthyridine-3 4'-piperidin]-2(4H)-one
  • Triethylamine (4.6 mL, 33 mmol) and glycine methyl ester hydrochloride (3.8 g, 30.26 mmol) were successively added to a solution of p-anisaldehyde (2.0 g, 14.7 mmol) in dichloromethane (150 mL) at 0°C.
  • Sodium sulfate (10 g) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was then filtered and concentrated to dryness. The resulting residue was portioned in ethyl acetate and filtered in order to remove the triethylamine salts.
  • the title compound was obtained as a pale yellow solid (4.43 g, 100%).
  • Step 3 Methyl 2-(((2-amino-5-bromopyridin-3-yl)methyl)(4- methoxybenzyl)amino)acetate
  • Step 4 7-Bromo-4-(4-methoxybenzyl)-4,5-dihydro-lH-pyrido[2,3- e] [l,4]diazepin-2(3tt)-one
  • Step 5 (E)-tert-Butyl 3-(4(4-methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro- lH-pyrido[2,3-e] [l,4]diazepin-7-yl)acrylate
  • terf-Butyl acrylate (972 ⁇ _, 6.64 mmol), diisopropylethylamine (612 ⁇ _, 3.47 mmol) and P(o-tolyl) 3 (100 mg, 0.33 mmol) were successively added to a suspension of 7-bromo-4-(4-methoxybenzyl)-4,5-dihydro-lH-pyrido[2,3- e][l,4]diazepin-2(3H)-one (600 mg, 1.66 mmol) in propionitrile (10 mL) and dimethylformamide (2 mL).
  • the resulting mixture was then purged with argon prior to the addition of palladium acetate (40 mg, 0.16 mmol).
  • the mixture was purged with argon a second time and refluxed overnight.
  • the reaction mixture was then filtered on Celite ® .
  • the filtrate was concentrated to dryness and the residue was solubilized in ethyl acetate (30 mL).
  • the aqueous phase was separated and extracted with ethyl acetate (2 x40 mL).
  • the combined organic phases were washed with a saturated solution of sodium chloride (2x 20 mL), dried over sodium sulfate, filtered and concentrated to dryness.
  • the residue was purified by chromatography on silica gel, using dichloromethane/ethyl actetate (7 : 3) as eluent.
  • the title product was obtained as a yellow solid (112 mg, 16%).
  • Step 6 (E)-3-(4-(4-Methoxybenzyl)-2-oxo-2,3,4,5-tetrahyd pyrido[2,3-e] [l,4]diazepin-7-yl)acrylic acid hydrochloride
  • Trifluoroacetic acid (1 mL) was added to a suspension of (E)-tert- butyl 3-(4(4- methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-lH-pyrido[2,3-e][l,4]diazepin-7- yl)acrylate (112 mg, 0.27 mmol) in dichloromethane (1 mL) at room temperature. The reaction mixture was then stirred for 1 hour and concentrated to dryness. The resulting residue was suspended in a solution of hydrochloric acid in dioxane 4N (2 mL). After 10 minutes stirring at room temperature, the precipitate was filtered and washed with diethyl ether to afford the title product as a pale yellow solid (110 mg, quantitative).
  • Step 7 (E)-4-(4-Methoxybenzyl)-7-(3-oxo-3-(3-(thiophen-2- ylmethoxy)azetidin-l-yl)prop-l-enyl)-4,5-dihydro-lH-pyrido[2,3- e] [l,4]diazepin-2(3H)-one

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to novel heterocyclic acrylamide compounds (I), to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.

Description

NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS
PHARMACEUTICALS
FIELD OF THE INVENTION
The invention relates to novel heterocyclic acrylamide compounds, to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds. BACKGROUND OF THE INVENTION
The invention particularly relates to new compounds capable of inhibiting bacterial and/or parasite fatty acid biosynthesis and their use as antibacterial and/or antiparasitic agents. The emergence of antibiotic-resistant pathogens has become a serious worldwide healthcare problem. Indeed, some infections are now caused by multi-drug resistant organisms that are no longer responsive to currently available treatments. There is therefore an immediate need for new antibacterial / antiparasitic agents with a novel mode of action.
The bacterial fatty acid biosynthesis (FASII system) has recently generated a lot of interest for the development of novel antibacterial / antiparasitic agents (Rock et al. J. Biol. Chem. 2006, 281 , 17541; Wright and Reynolds Curr. Opin. Microbiol. 2007, 10, 447). The organization of components in the bacterial fatty acid biosynthesis pathway based on discrete enzymes is fundamentally different from the multifunctional FASI system found in mammals, therefore allowing good prospects of selective inhibition. The overall high degree of conservation in many enzymes of the bacterial FASII system should also allow the development of broader-spectrum antibacterial / antiparasitic agents.
Among all the monofunctional enzymes of the bacterial FASII system, Fabl represents the enoyl-ACP reductase responsible for the last step of the fatty acid biosynthetic elongation cycle. Using the cofactor NAD(P)H as a hydride source, Fabl reduces the double bond in the fra/7s-2-enoyl-ACP intermediate to the corresponding acyl-ACP product. This enzyme has been shown to constitute an essential target in major pathogens such as E. coli (Heath et al. J. Biol. Chem. 1995, 270, 26538; Bergler et al. Eur. J. Biochem. 1996, 242, 689) and S. aureus (Heath et al. J. Biol. Chem. 2000, 275, 4654). However, other isoforms have been isolated such as FabK from S. pneumoniae (Heath et al. Nature 2000, 406, 145) and FabL from B. subtilis (Heath et al. J. Biol. Chem. 2000, 275, 40128). Although FabK is structurally and mechanistically unrelated to Fabl (Marrakchi et a/. Biochem J. 2003, 370, 1055), the similarity of Fabl with FabL (β. subtilis), InhA ( . tuberculosis) and PfENR (P. falciparum) still offers opportunities of interesting activity spectra (Heath et a/. Prog. Lipid Res. 2001, 40, 467).
Several Fabl inhibitors have already been reported in the literature (Tonge et al. Acc. Chem. Res. 2008, 41 , 11). Some of them such as diazaborines (Baldock et a/. Science 1996, 274, 2107) and isoniazid in its activated form (Tonge et al. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13881) act by covalently modifying the cofactor NAD+. However some drawbacks are associated with these products. Diazaborines are only used experimentally because of their inherent toxicity (Baldock et al. Biochem. Pharmacol. 1998, 55, 1541) while isoniazid is a prodrug restricted to the treatment of susceptible tuberculosis. The fact that isoniazid requires activation by hydrogen-peroxyde inducible enzymes (Schultz et al. J. Am. Chem. Soc. 1995, 117, 5009) enhances the possibilities of resistance by lack of activation or increased detoxification (Rosner et al. Antimicrob. Agents Chemother. 1993, 37, 2251 and ibid 1994, 38, 1829).
Other inhibitors act by interacting noncovalently with the enzyme-cofactor complex. For instance Triclosan, a widely used consumer goods preservative with broad spectrum antimicrobial activity, has been found to be a reversible, tight-binding inhibitor of E. coli Fabl (Ward et al. Biochemistry 1999, 38, 12514). Intravenous toxicology studies on this compound indicated a LD50 on rats of 29 mg/kg clearly ruling out intravenous injection (Lyman et al. Ind. Med. Surg. 1969, 38, 42). Derivatives based on the 2-hydroxydiphenyl ether core of Triclosan have been reported (Tonge et al. J. Med. Chem. 2004, 47, 509, ACS Chem Biol. 2006, 1 , 43 and Bioorg. Med. Chem. Lett. 2008, 18, 3029; Surolia et al. Bioorg. Med. Chem. 2006, 14, 8086 and ibid 2008, 16, 5536; Freundlich et al. J. Biol. Chem. 2007, 282, 25436) as well as other inhibitors based on various classes of high throughput screening derived templates (Seefeld et al. Bioorg. Med. Chem. Lett. 2001, 11 , 2241 and J. Med. Chem. 2003, 46, 1627; Heerding et a/. Bioorg. Med. Chem. Lett. 2001, 11 , 2061; Miller et al. J. Med. Chem. 2002, 45, 3246; Payne et al. Antimicrob. Agents Chemother. 2002, 46, 3118; Sacchettini et al. J. Biol. Chem. 2003, 278, 20851 ; Moir et al. Antimicrob. Agents Chemother. 2004, 48, 1541; Montellano et al. J. Med. Chem. 2006, 49, 6308; Kwak et al. Int. J. Antimicro. Ag. 2007, 30, 446; Lee et al. Antimicrob. Agents Chemother. 2007, 51 , 2591; Kitagawa et al. J. Med. Chem. 2007, 50, 4710, Bioorg. Med. Chem. 2007, _?5, 1106 and Bioorg. Med. Chem. Lett. 2007, _? 7, 4982; Takahata et a/. J. Antibiot. 2007, 60, 123; Kozikowski et a/, β/'oorg. etf. Cftem. Lett. 2008, 3565), nevertheless none of these inhibitors have succeeded yet as a drug. Interestingly, some classes of these inhibitors display activity on both FabI and FabK: predominantly FabK for the dual compounds based on phenylimidazole derivatives of 4-pyridones (Kitagawa et al. J. Med. Chem. 2007, 50, 4710), predominantly FabI for the indole derivatives (Payne et al. Antimicrob. Agents Chemother. 2002, 46, 3118; Seefeld et a/. J. Med. Chem. 2003, 46, 1627). However, the moderate activity on the second enzyme might prove to be a drawback for such compounds as it may lead to an increase of resistance mechanisms due to the added selection pressure (Tonge et a/. Acc. Chem. Res. 2008, 41 , 11).
Despite the attractiveness of FabI as an antibacterial / antiparasitic target, it is still largely unexploited at this time since there are no drugs on the market or within advanced clinical phases.
WO 2007/135562 (Mutabilis SA) describes a series of hydroxyphenyl derivatives that display a selective spectrum of activity on species containing FabI and related targets, in contrast to Triclosan. WO 2008/098374, WO 2008/009122, WO 2007/067416, WO 2007/053131, WO 03/088897 and WO 01/27103 (Affinium Pharmaceuticals Inc) all describe a series of acrylamide derivatives which are claimed to be FabI inhibitors.
One of the purposes of the invention is to provide novel compounds active on FabI and related targets with improved pharmacological and/or physico-chemical properties over existing compounds.
SUMMARY OF THE INVENTION
According to a first aspect of the invention, there is provided a compound of formula (I) :
Figure imgf000005_0001
R1
(I)
wherein :
- W and X independently represent a bond or a -(CH2)i-4 group, such that W and X together contain 1-5 carbon atoms;
- Rl represents an H, F, CN, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, C02Rd, CORd, CONRaRb, OCORd, ORd, NRaRb, ON = CRdRe, NRcCORd, NRcCOORd, OCONRaRb, NRcCONRaRb, NRcS02Ra, S(0)nRa, S02NRaRb, -C(Ra) = N-0-Rf, Y-Ar or a Z- Het group, wherein Ar represents phenyl or naphthyl, Het represents a 4-10 membered monocyclic or bicyclic saturated or unsaturated heterocycie containing 1-5 heteroatoms selected from N, O and S and Y and Z independently represent a bond or a linker selected from O, S, CO, (Ci-C6) alkylene, -0-(d-C6) alkylene, -CO- (Ci-C6) alkylene or -ON=CRd-(Ci-C6) alkylene, wherein said Rl group may be optionally substituted by one or more R4 groups;
- R2 represents an H, F, CN, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl,
C02Rd, CORd, CONRaR , OCORd, ORd, NRaRb, ON = CRdRe, NRcCORd, NRcCOORd, OCONRaRb, NRcCONRaRb, NRcS02Ra, S(0)nRa or S02NRaRb group;
- Ra, Rb and Rc independently represent H, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2- C6) alkynyl, or an NRaRb group may optionally form a 3- to 7-membered nitrogen containing saturated heterocycie optionally containing 1 to 3 additional heteroatoms selected from N, O or S wherein said heterocycie may be optionally substituted by one or more (Ci-C6) alkyl groups;
- Rd and Re independently represent H, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, halo(d-C6) alkyl, halo(d-C6) alkyl-0-(d-C6) alkyl- or (Ci-C6) alkyl-0-(Ci- C6) alkyl-;
- Rf represents (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, halo(d-C6) alkyl or -(Ci-Ce) alkyl-Ar, wherein Ar represents phenyl or naphthyl;
- R4 represents halogen, CN, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, C02Rd, CORd, CONRaRb, OCORd, ORd, NRaRb, ON = CRdRe, NRcCORd, NRcCOORd, OCONRaRb, NRcCONRaRb, NRcS02Ra, S(0)nRa, or S02NRaRb;
- n represents an integer selected from 0 to 2; - R3 is a pyridyl ring optionally fused to a 5, 6 or 7 membered aromatic, partially aromatic or saturated heterocycle containing 1-3 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups;
- R5 is selected from the group consisting of F, C02Rd, CORd, CONRaRb, ORd,
=0, NRaRb, NRcCORd or (Ci-C6) alkyl optionally substituted by F, C02Rd,CONRaRb, ORd, NRaRb, NRaCORd or Het optionally substituted by one or more (Ci-Ce) alkyl groups, or two R5 groups together with the atom to which they are attached may together form a Het group optionally substituted by one or more (Ci-C6) alkyl groups;
or a pharmaceutically acceptable salt or solvate thereof.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 relates to the in vivo antibacterial activity of Example 12 at 100 mg/kg; and
Figure 2 relates to the in vivo antibacterial activity of Example 15 at 50 mg/kg.
DETAILED DESCRIPTION OF THE INVENTION
According to one particular aspect of the invention which may be mentioned, there is provided a compound of formula (I) :
Figure imgf000006_0001
R1
(I)
wherein :
- W and X independently represent a bond or a -(CH2)i-4 group, such that W and X together contain 1-5 carbon atoms;
- Rl represents an H, F, CN, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl,
C02Rd, CORd, CONRaRb, OCORd, ORd, NRaRb, ON = CRdRe, NRcCORd, NRcCOORd,
OCONRaRb, NRcCONRaRb, NRcS02Ra, S(0)nRa, S02NRaRb, Y-Ar or a Z-Het group, wherein Ar represents phenyl or naphthyl, Het represents a 4-10 membered monocyclic or bicyclic saturated or unsaturated heterocycle containing 1-5 heteroatoms selected from N, O and S and Y and Z independently represent a bond or a linker selected from O, CO, (Ci-C6) alkylene, -0-(d-C6) alkylene, -CO-(d-C6) alkylene or
Figure imgf000007_0001
alkylene, wherein said Rl group may be optionally substituted by one or more R4 groups;
- R2 represents an H, F, CN, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl,
C02Rd, CORd, CONRaRb, OCORd, ORd, NRaRb, ON=CRdRe, NRcCORd, NRcCOORd, OCONRaRb, NRcCONRaRb, NRcS02Ra, S(0)nRa or S02NRaRb group;
- Ra, Rb and Rc independently represent H, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2- C6) alkynyl, or an NRaRb group may optionally form a 3- to 7-membered nitrogen containing saturated heterocycle optionally containing 1 to 3 additional heteroatoms selected from N, O or S wherein said heterocycle may be optionally substituted by one or more (Ci-C6) alkyl groups;
- Rd and Re independently represent H, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, halo(d-C6) alkyl, halo(d-C6) alkyl-0-(d-C6) alkyl- or (Ci-C6) alkyl-0-(Ci- C6) alkyl-;
- R4 represents halogen, CN, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, C02Rd, CORd, CONRaRb, OCORd, ORd, NRaRb, ON = CRdRe, NRcCORd, NRcCOORd, OCONRaRb, NRcCONRaRb, NRcS02Ra, S(0)nRa, or S02NRaRb;
- n represents an integer selected from 0 to 2;
- R3 is a pyridyl ring optionally fused to a 5, 6 or 7 membered aromatic, partially aromatic or saturated heterocycle containing 1-3 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups;
- R5 is selected from the group consisting of F, C02Rd, CORd, CONRaRb, ORd, =0, NRaRb, NRcCORd or (Ci-C6) alkyl optionally substituted by F, C02Rd,CONRaRb,
ORd, NRaRb, NRaCORd, or two R5 groups together with the atom to which they are attached may together form a Het group optionally substituted by one or more (Ci- C6) alkyl groups;
or a pharmaceutically acceptable salt or solvate thereof.
The compounds of the invention may have good in vitro and/or in vivo activity and display surprisingly improved pharmacological, physical and/or chemical properties over previously described Fabl inhibitors as confirmed by data presented herein. For example, compounds of the invention which have been tested display surprisingly less serum binding than previously described acrylamide derivatives. Furthermore, compounds of the invention which have been tested appear to demonstrate parenteral (such as subcutaneous) and oral bioavailability. Certain compounds of the invention also appear to reduce the apparition of resistance mechanisms by being selective of FabI and related targets while avoiding hitting structurally unrelated targets such as FabK. In addition, compounds of the invention which have been tested appear to demonstrate greater solubility than previously described FabI inhibitors.
In the present context, the term "pharmaceutically acceptable salt" is intended to indicate salts which are not harmful to the patient. Such salts include
pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts and pharmaceutically acceptable akaline addition salts. Acid addition salts include salts of inorganic acids as well as organic acids.
Representative examples of suitable inorganic acids include hydrochloric,
hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
Representative examples of suitable organic acids include formic, acetic,
trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p- aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like.
Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium,
dimethylammonium, trimethylammonium, ethylammonium,
hydroxyethylammonium, diethylammonium, butylammonium,
tetramethylammonium salts and the like.
Representative examples of alkaline salts include, for example, sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, ethylamine, propylamine, trimethylamine, diethylamine, triethylamine, Ν,Ν-dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, piperidine, piperazine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine, N-methylglucamine. According to the invention, the compounds of formula (I) can be in racemic forms, as well as in the form of pure enantiomers or non racemic (scalemic) mixture of enantiomers, including when the compounds of formula (I) have more than one stereogenic centre. In case the compounds of formula (I) have unsaturated carbon carbon double bonds, both the cis (Z) and trans (E) isomers and their mixtures belong to the invention.
References herein to "halogen" means a fluorine, chlorine, bromine or iodine atom.
References herein to "(Ci-Ce) alkyl" means any linear, branched hydrocarbon groups having 1 to 6 carbon atoms, or cyclic hydrocarbon groups having 3 to 6 carbon atoms. Representative examples of such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl, n-pentyl, isopentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
References herein to "(C2-C6) alkenyl" means any linear, branched hydrocarbon groups of 2 to 6 carbon atoms, or cyclic hydrocarbon group having 3 to 6 carbon atoms having at least one double bond. Representative examples of such alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. References to "halo(C2- C6) alkenyl" mean a (C2-C6) alkenyl group substituted by one or more halogen atoms as herein defined.
References herein to "(C2-C6) alkynyl" means any linear, or branched hydrocarbon groups of 2 to 6 carbon atoms, having at least one triple bond . Representative examples of such alkynyl groups include ethynyl, propargyl and butynyl . References to "halo(C2-C6) alkynyl" mean a (C2-C6) alkynyl group substituted by one or more halogen atoms as herein defined. Illustrative examples of Het within the definition of Rl and R5 include those selected from the group comprising furyl, tetrahydrofuryl, benzofuryl, tetrahydrobenzofuryl, thienyl, tetrahydrothienyl, benzothienyl, tetrahydrobenzo- thienyl, pyrrolyl, pyrrolidinyl, indolyl, indolinyl, tetrahydroindolyl, oxazolyl, oxazolinyl, oxazolidinyl, benzoxazolyl, tetrahydrobenzoxazolyl, oxazolopyridinyl, tetrahydrooxazolopyridinyl, oxazolopyrimidinyl, tetrahydrooxazolopyrimidinyl, oxazolopyrazinyl, oxazolopyridazinyl, oxazolotriazinyl, isoxazolyl, benzoisoxazolyl, tetrahydrobenzoisoxazolyl, thiazolyl, thiazolinyl, thiazol id inyl, benzothiazolyl, tetra- hyd robenzothiazolyl, thiazolopyridinyl, tetrahydrothiazolopyrid inyl, thiazolopyri- mid inyl, tetrahydrothiazolopyrimid inyl, thiazolopyrazinyl, thiazolopyridazinyl, thia- zolotriazinyl, isothiazolyl, benzoisothiazolyl, tetrahydrobenzoisothiazolyl , imidazolyl , benzimidazolyl, tetrahyd robenzimidazolyl, pyrazolyl, indazolyl, tetrahyd roindazolyl, triazolyl, oxadiazolyl, thiad iazolyl, tetrazolyl, pyranyl, d ihydropyranyl, tetrahydropyranyl, benzopyranyl, dioxanyl, benzodioxanyl, d ioxolanyl, benzodioxolanyl, pyridinyl, pyridonyl, piperid inyl, tetrahyd ropyrid inyl, quinol inyl , isoq uinolinyl, tetra- and perhydro-quinolinyl and isoq uinolinyl, pyrimid inyl, quinazol inyl, pyrazinyl, pyrazid inyl, piperazinyl, q uinoxal inyl, piridazinyl, cinnol inyl, phtalazinyl, triazinyl, purinyl, pyrazolopyrid inyl, tetrahydropyrazolopyrid nyl, pyrazolopyrimid inyl, pyrazolopyrazinyl, pyrazolotriazinyl, triazolopyridinyl, tetra- hyd rotriazolopyridinyl, triazolopyrimid inyl, triazolopyrazinyl, triazolotriazinyl, oxetanyl, azetid inyl and morpholinyl .
Il lustrative examples of saturated nitrogen containing heterocycles within the definition of N RaRb include those selected from the g roup comprising, pyrrolidinyl, oxazol id inyl, thiazolid inyl , piperidinyl, piperazinyl and morphol inyl . In one embodiment, W and X both represent CH2, thus forming an azetid inyl ring which is substituted at the 3 position by Rl and R2.
In an alternative embodiment, one of W and X represents CH2 and the other represents CH2CH2, thus forming a pyrrolidinyl ring which is substituted at the 3 position by Rl and R2.
In an alternative embodiment, one of W and X represents a bond and the other represents CH2CH2CH2, th us forming a pyrrolid inyl ring wh ich is substituted at the 2 position by Rl and R2.
In a further alternative embod iment, W and X both represent CH2CH2, th us forming a piperidinyl ring which is substituted at the 4 position by Rl and R2.
In a further alternative embodiment, one of W and X represents CH2 and the other represents CH2CH2, thus forming a piperidinyl ring which is substituted at the 3 position by Rl and R2. In a yet further alternative embodiment, one of W and X represents a bond and the other represents CH2CH2CH2CH2, thus forming a piperidinyl ring which is substituted at the 2 position by Rl and R2.
In a most particular embodiment, W and X both represent CH2, thus forming an azetidinyl ring which is substituted at the 3 position by Rl and R2.
In one embodiment, Rl represents an H, F, (Ci-C6) alkyl, (C2-C6) alkenyl, ORd, S(0)nRa, -C(Ra) = N-0-Rf, Y-Ar or Z-Het group each of which may be optionally substituted by one or more R4 groups.
In a further embodiment, Rl represents an H, F, (Ci-C6) alkyl, (C2-C6) alkenyl, ORd, S(0)nRa, Y-Ar or Z-Het group each of which may be optionally substituted by one or more R4 groups.
In a yet further embodiment, Rl represents an H, (Ci-C6) alkyl, ORd, S(0)nRa, Y-Ar or Z-Het group each of which may be optionally substituted by one or more R4 groups.
In a still yet further embodiment, Rl represents ORd, Z-Het or -C(Ra) = N-0-Rf, such as a Z-Het group (i.e. benzofuranyl optionally substituted by a methyl group).
In one embodiment, Rl represents H.
When Rl represents (Ci-C6) alkyl optionally substituted by one or more R4 groups, in one embodiment Rl represents ethyl or propyl optionally substituted by one or more ORd groups (such as -OH). In a further embodiment, Rl represents propyl or ethyl substituted by an OH group. In a yet further embodiment, Rl represents propyl or (CH2)2OH .
When Rl represents ORd, in one embodiment Rd represents (Ci-C6) alkyl (e.g. butyl, pentyl or -(CH2)2-CH(Me)), halo(d-C6) alkyl (e.g . -CH2-CF3 or -CH3-CF3), -(Ci-C6) alkyl-0-(Ci-C6) alkyl (e.g . -(CH2)2-OMe or -(CH2)3-OMe) or (C2-C6) alkenyl (e.g . - CH2-CH=CH-Me or -CH2-C(Me)=CH-Me). When Rl represents ORd, in a further embodiment Rd represents (Ci-C6) alkyl, such as pentyl or (C2-C6) alkenyl such as -CH2-CH =CH-Me.
When Rl represents ORd, in a yet further embodiment Rd represents (Ci-C6) alkyl, such as butyl .
When Rl represents S(0)nRa, in one embodiment n represents 2 and Ra represents (Ci-C6) alkyl, such as pentyl . When Rl represents Y-Ar, in one embodiment, Rl represents phenyl, -O-phenyl, - 0-CH2-phenyl or -CH2-0-phenyl each of which may be optionally substituted by one or more R4 groups (such as -CH2-0-fluorophenyl).
In one embodiment, Ar represents phenyl .
In one embodiment, Y represents a bond or a linker selected from O or -0-(d-C6) alkylene (such as -0-CH2- or -CH2-0-).
When Rl represents Z-Het, in one embodiment, Rl represents benzoxazolyl, oxadiazolyl, benzofuranyl, -S-thienyl, -O-benzothiophenyl, -O-benzofuranyl, -O- pyridyl, -0-CH2-pyridyl, -0-CH2-thienyl, -0-(CH2)2-thienyl, -0-(CH2)3-thienyl, -O- CH2-thiazolyl, -0-CH2-pyrazolyl, -0-CH2-furanyl, -0-CH2-benzothiophenyl, or - ON =C(Me)-CH2-pyrimidinyl each of which may be optionally substituted by one or more R4 groups.
When Rl represents Z-Het, in a further embodiment, Rl represents benzoxazolyl, oxadiazolyl, -O-pyridyl, -0-CH2-pyridyl, -0-CH2-thienyl, -0-CH2-thiazolyl or - ON =C(Me)-CH2-pyrimidinyl each of which may be optionally substituted by one or more R4 groups (such as methyloxadiazolyl) .
When Rl represents Z-Het, in a yet further embodiment, Rl represents -0-CH2- thienyl, -0-(CH2)2-thienyl or -benzofuranyl optionally substituted by an R4 group (such as methyl) . When Rl represents Z-Het, in a still yet further embodiment, Rl represents - benzofuranyl optionally substituted by an R4 group (such as methyl). When Rl represents -C(Ra) = N-0-Rf, in one embodiment, Ra represents (Ci-C6) alkyl (e.g . methyl) and Rf represents (Ci-C6) alkyl (e.g . ethyl or propyl), halo(d-C6) alkyl (e.g . -CH2-CF3) or -(Ci-Ce) alkyl-Ar (e.g. -CH2-phenyl).
When Rl represents -C(Ra) = N-0-Rf, in a further embodiment, Ra represents (Ci-C6) alkyl (e.g. methyl) and Rf represents (Ci-C6) alkyl (e.g . propyl).
In one embodiment, Het represents benzothiophenyl, benzofuranyl, benzoxazolyl, oxadiazolyl, pyridyl, pyrazolyl, thienyl, thiazolyl, furanyl or pyrimidinyl each of which may be optionally substituted by one or more R4 groups.
In a further embodiment, Het represents benzoxazolyl, oxadiazolyl, pyridyl, thienyl, thiazolyl or pyrimidinyl each of which may be optionally substituted by one or more R4 groups.
In one embodiment, Z represents a bond or a linker selected from O, S or -0-(Ci- C6) alkylene (such as -0-CH2-, -0-(CH2)2- or -0-(CH2)3-) or
Figure imgf000013_0001
alkylene (such as -ON=C(Me)-CH2-).
In a further embodiment, Z represents a bond or a linker selected from O or -O- (Ci-C6) alkylene (such as -0-CH2-) or
Figure imgf000013_0002
alkylene (such as - ON=C(Me)-CH2-). In one embodiment, Rl represents ORd (such as -O-pentyl) or Z-Het (such as -O- CH2-thienyl). In a further embodiment, Rl represents Z-Het, such as -0-CH2- thienyl.
In one embodiment, R2 represents an H or ORd group. In a further embodiment, R2 represents an H or OH group. In a yet further embodiment, R2 represents H .
In one embodiment, R4 represents halogen (such as bromine, chlorine or fluorine), (Ci-Ce) alkyl (such as methyl), (C2-C6) alkenyl or (C2-C6) alkynyl. In a further embodiment, R4 represents halogen (such as fluorine) or (Ci-C6) alkyl (such as methyl). In a yet further embodiment, R4 represents fluorine or methyl. In a further embodiment, R4 represents halogen (such as fluorine), (Ci-Ce) alkyl (such as methyl), (C2-C6) alkenyl or (C2-C6) alkynyl. In a further embodiment, R4 represents halogen (such as fluorine) or (Ci-C6) alkyl (such as methyl). In a yet further embodiment, R4 represents fluorine or methyl .
Examples of ring systems within the definition of R3 include heterocycles of formula (a)-(i) :
Figure imgf000014_0001
Figure imgf000014_0002
(9) ( ) (i)
each of which may be optionally substituted, or further substituted as appropriate, by one or more R5 groups.
An example of a compound of formula (I) wherein two R5 groups together with the atom to which they are attached together form a Het group optionally substituted by one or more (Ci-C6) alkyl groups include a spiro ring system of formula (j) :
Figure imgf000015_0001
(j)-
A further examples of a ring system within the definition of R3 includes the heterocycle of formula (k) :
Figure imgf000015_0002
(k)
which may be optionally substituted, or further substituted as appropriate, by one or more R5 groups.
In one embodiment, R3 is a pyridyl ring or a pyridyl ring fused to a 5, 6 or 7 membered aromatic, partially aromatic or saturated heterocycle containing 1-5 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups.
In a further embodiment, R3 is a pyridyl ring or a pyridyl ring fused to a 5 or 6 membered aromatic, partially aromatic or saturated heterocycle containing 1-5 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups.
In a yet further embodiment, R3 is a pyridyl ring or a pyridyl ring fused to a 6 membered aromatic, partially aromatic or saturated heterocycle containing 1-5 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups.
In a still yet further embodiment, R3 is a pyridyl ring fused to a 6 membered aromatic, partially aromatic or saturated heterocycle containing 1-5 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups.
In one embodiment, R3 represents a heterocycle of formula (k) :
Figure imgf000016_0001
which may be optionally substituted, or further substituted as appropriate, by one or more R5 groups, such as (Ci-C6) alkyl optionally substituted by C02Rd (e.g . - CH2-C02H), NRaRb (e.g . -CH2-N(Me)2) or Het optionally substituted by one or more (Ci-C6) alkyl groups (e.g. -(CH2)2-piperazinyl-Me).
In one embodiment, R3 represents a heterocycle of formula (a), (b), (c), (d), (f), (i), (j) or (k) :
Figure imgf000016_0002
(d) (0 (i)
Figure imgf000016_0003
each of which may be optionally substituted, or further substituted as appropriate, by one or more R5 groups, such as C02Rd (e.g. C02Me), NRaRb (e.g . NH2), CONRaRb (e.g . CONH2), NRcCORd (e.g . NHCOMe) or (Ci-C6) alkyl optionally substituted by F, C02Rd (e.g . -CH2-C02H), CONRaRb, ORd (e.g . CH2OH), NRaRb (e.g . -CH2-N(Me)2), NRaCORd or Het optionally substituted by one or more (Ci-C6) alkyl groups (e.g . - (CH2)2-piperazinyl-Me).
In a further embodiment, R3 represents a heterocycle of formula (a) or (j) :
Figure imgf000017_0001
(a) (j)
each of which may be optionally substituted, or further substituted as appropriate, by one or more R5 groups, such as C02Rd (e.g. C02Me), NRaR (e.g . NH2), CONRaR (e.g . CONH2), NRcCORd (e.g . NHCOMe) or (Ci-C6) alkyl optionally substituted by F, C02Rd (e.g . -CH2-C02H), CONRaRb, ORd (e.g . CH2OH), NRaRb (e.g . -CH2-N(Me)2), NRaCORd or Het optionally substituted by one or more (Ci-C6) alkyl groups (e.g . - (CH2)2-piperazinyl-Me).
In a further embodiment, R3 represents a heterocycle of formula (a), (b) or (c) :
Figure imgf000017_0002
(a) (b) (c)
each of which may be optionally substituted, or further substituted as appropriate, by one or more R5 groups, such as C02Rd (e.g. C02Me), NRaR (e.g . NH2), CONRaR (e.g . CONH2), NRcCORd (e.g . NHCOMe) or (Ci-C6) alkyl optionally substituted by F, C02Rd,CONRaRb, ORd (e.g . CH2OH), NRaRb or NRaCORd.
In a further embodiment, R3 represents a heterocycle of formula (c) :
Figure imgf000018_0001
(C)
optionally substituted by one or more R5 groups, such as NRaRb (e.g. 2-NH2) or NRcCORd (e.g . 2-NHCOMe).
In a yet further embodiment, R3 represents a heterocycle of formula (a) or (b) :
Figure imgf000018_0002
(a) (b)
optionally further substituted by one or more R5 groups, such as C02Rd (e.g . 3- C02Me), CONRaRb (e.g . 3-CONH2) or (Ci-C6) alkyl optionally substituted by ORd (e.g. 3-CH2OH).
In a yet further embodiment, R3 represents a heterocycle of formula (a) :
Figure imgf000018_0003
(a)
optionally further substituted by one or more R5 groups, such as C02Rd (e.g . 3- C02Me), CONRaRb (e.g . 3-CONH2) or (Ci-C6) alkyl optionally substituted by ORd (e.g 3-CH2OH).
In a still yet further embodiment, R3 represents a heterocycle of formula (a) :
Figure imgf000018_0004
(a)
which has no further R5 substituents. In one embodiment, n represents 1 or 2. In a further embodiment, n represents 2.
In one embodiment, Ra, Rb and Rc independently represent H, (Ci-C6) alkyl, or an NRaRb group may optionally form a 3- to 7-membered nitrogen containing saturated heterocycle optionally containing 1 to 3 additional heteroatoms selected from N, O or S wherein said heterocycle may be optionally substituted by one or more (Ci-C6) alkyl groups.
In one embodiment, Rd and Re independently represent H, (Ci-C6) alkyl, (C2-C6) alkenyl, halo(d-C6) alkyl, halo(d-C6) alkyl-0-(d-C6) alkyl- or (d-C6) alkyl-0-(d- C6) alkyl-.
In a further embodiment, Rd and Re independently represent H, (Ci-C6) alkyl, halo(Ci-Ce) alkyl-0-(Ci-C6) alkyl- or (d-C6) alkyl-0-(Ci-C6) alkyl-.
In one embodiment, Rf represents (Ci-C6) alkyl (e.g . ethyl or propyl), halo(d-C6) alkyl (e.g. -CH2-CF3) or -(d-C6) alkyl-Ar (e.g. -CH2-phenyl).
In one embodiment, the compound of formula (I) is selected from :
6-[(lE)-3-Azetidin-l-yl-3-oxoprop-l-en-l-yl]-3,4-dihydro-l,8-naphthyridin-2(lH)- one (El);
6-[(lE)-3-Oxo-3-pyrrolidin-l-ylprop-l-en-l-yl]-3,4-dihydro-l,8-naphthyridin- 2(lH)-one (E2);
6-[(lE)-3-Oxo-3-piperidin-l-ylprop-l-en-l-yl]-3,4-dihydro-l,8-naphthyridin-2(lH)- one (E3);
6-{(lE)-3-[4-(2-Hydroxyethyl)piperidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E4);
6-[(lE)-3-{[4-(4-Fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l-yl]-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E5);
6-[(lE)-3-Oxo-3-(3-phenoxyazetidin-l-yl)prop-l-en-l-yl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E6);
6-[(lE)-3-Oxo-3-(2-phenylpyrrolidin-l-yl)prop-l-en-l-yl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E7);
6-[(lE)-3-Oxo-3-(4-propylpiperidin-l-yl)prop-l-en-l-yl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E8); 6-[(lE)-3-{[3-(4-Fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l-yl]-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E9);
6-[(lE)-3-Oxo-3-(3-phenoxypyrrolidin-l-yl)prop-l-en-l-yl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E10);
6-{(lE)-3-[3-(5-Methyl-l,2,4-oxadiazol-3-yl)azetidin-l-yl]-3-oxoprop-l-en-l-yl}- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (El l);
6-{(lE)-3-Oxo-3-[3-(2-thienylmethoxy)azetidin-l-yl]prop-l-en-l-yl}-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E12);
6-{(lE)-3-[2-(5- Methyl- 1,2, 4-oxadiazol-3-yl)piperid in- l-yl]-3-oxoprop-l-en-l-yl}- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E13);
6-{(lE)-3-[4-Hydroxy-4-phenylpiperidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E14);
6-{(lE)-3-Oxo-3-[3-(pentyloxy)azetidin-l-yl]prop-l-en-l-yl}-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E15);
6-{(lE)-3-Oxo-3-[3-(pyridin-3-yloxy)pyrrolidin-l-yl]prop-l-en-l-yl}-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E16);
6-{(lE)-3-[3-(Benzyloxy)azetidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E17);
6-{(lE)-3-[2-(l,3-Benzoxazol-2-yl)piperidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E18);
6-[(lE)-3-{3-[(2-Methylprop-2-en-l-yl)oxy]azetidin-l-yl}-3-oxoprop-l-en-l-yl]- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E19);
6-{(lE)-3-Oxo-3-[3-(l,3-thiazol-2-ylmethoxy)azetidin-l-yl]prop-l-en-l-yl}-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E20);
6-{(lE)-3-[3-({[(lE)-l-Methyl-2-pyrimidin-2-ylethylidene]amino}oxy)azetidin-l- yl]-3-oxoprop-l-en-l-yl}-3,4-dihydro-l,8-naphthyridin-2(lH)-one (E21);
6-{(lE)-3-[3-(Pentylsulfonyl)azetidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E22);
5-{(lE)-3-Oxo-3-[3-(pyridin-4-ylmethoxy)azetidin-l-yl]prop-l-en-l-yl}pyridin-2- amine (E23);
N-(5-{(lE)-3-Oxo-3-[3-(pyridin-4-ylmethoxy)azetidin-l-yl]prop-l-en-l-yl}pyridin- 2-yl)acetamide (E24);
Methyl 6-[(lE)-3-{4-[(4-fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l- yl]-2-oxo-l,2,3,4-tetrahydro-l,8-naphthyridine-3-carboxylate (E25);
6-[(lE)-3-{4-[(4-Fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l-yl]-2- oxo-l,2,3,4-tetrahydro-l,8-naphthyridine-3-carboxamide (E26); 6-[(lE)-3-{4-[(4-Fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l-yl]-2- oxo-1, 2-dihydro-l,8-naphthyridine-3-carboxamide (E27); and
3-(Hydroxymethyl)-6-[(lE)-3-{4-[(4-fluorophenoxy)methyl]piperidin-l-yl}-3- oxoprop-l-en-l-yl]-3,4-dihydro-l,8-naphthyridin-2(lH)-one (E28);
or a pharmaceutically acceptable salt or solvate thereof.
In an alternative embodiment, the compound of formula (I) is selected from:
(E)-6-(3-Oxo-3-(3-(2-(thiophen-2-yl)ethoxy)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E29);
(E)-6-(3-Oxo-3-(3-(3-(thiophen-2-yl)propoxy)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E30);
(E)-6-(3-(3-((3-Methylthiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E31);
6-[3-(3-(4-Methyl-thiophen-2ylmethoxy)-azetidin-l-yl)-3-oxo-propenyl]-3,4- dihydro-lH-[l,8]naphthyridin-2-one (E32);
(E)-6-(3-(3-((5-Methylthiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E33);
E 6-[3-(2-Methoxyethoxy)azetidin-l-yl)-3-oxoprop-l-enyl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E34);
E 6-[3-(3-Methoxypropoxy)azetidin-l-yl)-3-oxoprop-l-enyl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E35);
E 6-[3-(3-Butoxyazetidin-l-yl)-3-oxoprop-l-enyl]-3,4-dihydro-l,8-naphthyridin- 2(lH)-one (E36);
E 6-[3-(3-Isobutoxyazetidin-l-yl)-3-oxoprop-l-enyl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E37);
(E)-6-(3-(3-((l- Methyl- lH-pyrazol-3-yl)methoxy)azetid in- l-yl)-3-oxoprop- 1-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E38);
(E)-6-(3-Oxo-3-(3-(thiazol-5-ylmethoxy)azetidin-l-yl)prop-l-enyl)-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E39);
(E)-6-(3-(3-(Furan-2-ylmethoxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E40);
(E)-l'-Methyl-6-(3-oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l-enyl)-lH- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E41);
(E)-7-(3-Oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l-enyl)-4,5-dihydro- lH-pyrido[2,3-e][l,4]diazepin-2(3H)-one (E42); (E)- Ethyl 2-(2-oxo-6-(3-oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l- enyl)-l,2-dihydropyrido[2,3-c/]pyrimidin-3(4H)-yl)acetate (E43);
(E)-3-(2-(4-Methylpiperazin-l-yl)ethyl)-6-(3-oxo-3-(3-(thiophen-2- ylmethoxy)azetidin-l-yl)prop-l-enyl)-3,4-dihydropyrido[2,3-c/]pyrirnidin-2(lH)-one (E44);
(E)-3-(3-((Dimethylamino)methyl)-lH-pyrrolo[2,3-/3]pyridin-5-yl)-l-(3-(thiophen- 2-ylmethoxy)azetidin-l-yl)prop-2-en-l-one (E45);
(E)-6-(3-Oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l-enyl)-lH- imidazo[4,5-b]pyridin-2(3H)-one (E46);
(E)-6-(3-Oxo-3-(3-(3,3,3-trifluoropropoxy)azetidin-l-yl)prop-l-enyl)-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E47);
(E)-6-(3-Oxo-3-(3-(4,4,4-trifluorobutoxy)azetidin-l-yl)prop-l-enyl)-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E48);
6-((E)-3-(3-((E)-But-2-enyloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E49);
6-((E)-3-(3-((Z)-But-2-enyloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E50);
6-((E)-3-(3-((E)-2-Methylbut-2-enyloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E51);
(E)-6-(3-(3-(Benzo[/3]thiophen-2-ylmethoxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E52);
(E)-6-(3-(3-((4-Bromothiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E53);
(E)-6-(3-(3-((4-Chlorothiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E54);
6-((E)-3-Oxo-3-(3-((Z)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E55);
6-((E)-3-Oxo-3-(3-((Z)-l-(2,2,2-trifluoroethoxyimino)
ethyl )azetid in- l-yl)prop-l-enyl)-3,4-dihydro-l,8-naphthyridin-2(lH)-one (E56); 6-((E)-3-(3-((Z)-l-(Ethoxyimino)ethyl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E57);
(E)-6-(3-(3-(Benzofuran-3-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E58);
(E)-6-(3-(3-(Benzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E59); (E)-6-(3-(3-(Benzofuran-7-yloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E60);
(E)-6-(3-(3-(Benzo[/3]thiophen-3-yloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E61);
(E)-6-(3-Oxo-3-(3-(thiophen-2-ylthio)azetidin-l-yl)prop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E62);
(E)-6-(3-(3-Butoxyazetid in- l-yl)-3-oxoprop-l-enyl)-l '-methyl- 1H- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E63);
l'-Methyl-6-((E)-3-oxo-3-(3-((E)-l-(benzyloxyimino)ethyl)azetidin-l-yl)prop-l- enyl)-lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E64);
l'-Methyl-6-((E)-3-oxo-3-(3-((E)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)- lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E65);
(E)-l'-Methyl-6-(3-oxo-3-(3-(2-(thiophen-2-yl)ethoxy)azetidin-l-yl)prop-l-en-l- yl)-lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E66);
(E)-6-(3-(3-(3-Methylbenzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E67);
(E)-l'-Methyl-6-(3-(3-(3-methylbenzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)- lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E68);
(E)-6-(3-(3-(Benzofuran-2-yl)azetid in- l-yl)-3-oxoprop-l-en-l-yl)-l '-methyl- 1H- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E69);
6-((E)-3-Oxo-3-(3-((E)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E70); and
6-((E)-3-Oxo-3-(3-((Z)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E71);
or a pharmaceutically acceptable salt or solvate thereof.
In a further embodiment, the compound of formula (I) is selected from
6-{(lE)-3-Oxo-3-[3-(2-thienylmethoxy)azetidin-l-yl]prop-l-en-l-yl}-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E12) or 6-{(lE)-3-Oxo-3-[3-(pentyloxy)azetidin-l- yl]prop-l-en-l-yl}-3,4-dihydro-l,8-naphthyridin-2(lH)-one (E15) or a
pharmaceutically acceptable salt or solvate thereof.
In a further embodiment, the compound of formula (I) is selected from
6-{(lE)-3-Oxo-3-[3-(2-thienylmethoxy)azetidin-l-yl]prop-l-en-l-yl}-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E12); (E)-6-(3-Oxo-3-(3-(2-(thiophen-2-yl)ethoxy)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E29);
(E)-6-(3-(3-(Benzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E59);
(E)-6-(3-(3-Butoxyazetid in- l-yl)-3-oxoprop-l-enyl)-l '-methyl- 1H- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E63);
(E)-l'-Methyl-6-(3-oxo-3-(3-(2-(thiophen-2-yl)ethoxy)azetidin-l-yl)prop-l-en-l- yl)-lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E66);
(E)-6-(3-(3-(3-Methylbenzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E67);
(E)-l'-Methyl-6-(3-(3-(3-methylbenzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)- lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E68);
(E)-6-(3-(3-(Benzofuran-2-yl)azetid in- l-yl)-3-oxoprop-l-en-l-yl)-l '-methyl- 1 H- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E69);
6-((E)-3-Oxo-3-(3-((E)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E70); and
6-((E)-3-Oxo-3-(3-((Z)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E71);
or a pharmaceutically acceptable salt or solvate thereof.
In a further embodiment, the compound of formula (I) is selected from
6-{(lE)-3-Oxo-3-[3-(2-thienylmethoxy)azetidin-l-yl]prop-l-en-l-yl}-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E12) or a pharmaceutically acceptable salt or solvate thereof.
In a yet further embodiment, the compound of formula (I) is selected from
(E)-6-(3-(3-(Benzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E59); and
(E)-6-(3-(3-(3-Methylbenzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E67);
or a pharmaceutically acceptable salt or solvate thereof.
The compounds of formula (I) and their salts may be prepared by processes known to the skilled chemist to be applicable for preparing chemically related compounds. Such processes use known starting materials or intermediates which may be obtained by standard procedures of organic chemistry. The following processes provide a variety of non-limiting routes for the production of the compounds of formula (I) and their intermediates used therein. These processes constitute further aspects of the invention. According to a further aspect of the invention, there is provided a process for preparing a compound of formula (I) as defined above which comprises: reacting a compound of formula (II)
Figure imgf000025_0001
(Π)
wherein R3 is as defined above for compounds of formula (I), with a compound of formula (III) :
H
Figure imgf000025_0002
R1
(HI)
wherein W, X, Rl and R2 are as defined above for compounds of formula (I); or
(b) reacting a compound of formula (IV) :
Figure imgf000025_0003
(IV)
wherein R3 is as defined above for compounds of formula (I) and L1 represents a suitable leaving group, such as a halogen atom, e.g. fluorine, chlorine, bromine or an alkoxy group, with a compound of formula (III) :
H
— N
Figure imgf000025_0004
(III)
wherein W, X, Rl and R2 are as defined above for compounds of formula (I); or
(c) reacting a compound of formula (V) :
Figure imgf000026_0001
R1
(V)
wherein W, X, Rl and R2 are as defined above for compounds of formula (I), with a compound of formula L2-R3, wherein L2 represents a suitable leaving group, such as a halogen atom, e.g. fluorine, chlorine, bromine or an alkoxy group; optionally thereafter followed by:
(d) deprotecting a protected derivative of compound (I); and optionally thereafter followed by: (e) interconversion of a compound of formula (I) to a further compound of formula (I).
Process (a) typically comprises the use of EDC, a base such as TEA or DIPEA or DMAP, the optional use of HOBT, and a solvent such as DMF.
Process (b) typically comprises the use of a base such as TEA or DIPEA or DMAP, and a solvent such as DCM, THF, ACN or DMF.
Process (c) typically comprises the use of suitable coupling conditions known to the one skilled in the art such as the Heck coupling (Chem. Rev. 2000, 100, 3009), a non-limiting example comprises the use of a palladium catalyst, a phosphine ligand, a suitable base and solvent.
Process (d) typically comprises any suitable deprotection reaction, the conditions of which will depend upon the nature of the protecting group. In most instances such a deprotection reaction will typically comprise the use of a suitable acid. Process (e) typical ly comprises interconversion proced ures known by one skil led in the art. For example, compounds of formula (I) in which Rl or R2 represents hyd rogen may be converted by methods known by one skilled in the art into compounds of formula (I) in which Rl or R2 represents C02Ra, CORa, CON RaRb, CH2ORc, CH2N RaRb, S02N RaRb, wherein Ra, Rb and Rc are as defined above for compounds of formula (I) .
If appropriate, the reactions previously described in processes (a), (b), (c), (d ) or (e) are followed or preceded by one or more reactions known to the skilled of the art and are performed in an appropriate order to achieve the requ isite su bstitutions on W, X, Rl , R2 and R3 defined above to afford other compounds of formula (I) . Non-limiting examples of such reactions whose conditions can be found in the literature include :
protection of reactive functions,
deprotection of reactive functions,
halogenation,
dehalogenation,
deal kylation,
alkylation of amine, aniline, alcohol and phenol,
M itsunobu reaction on hyd roxyl groups,
cycloadd ition reactions on appropriate groups,
red uction of nitro, esters, cyano, aldehydes,
transition metal-catalyzed coupling reactions,
acylation,
sulfonylation/introduction of sulfonyl groups,
saponification/hyd rolysis of esters g roups,
amidification or transesterification of ester groups,
esterification or amidification of carboxylic groups,
halogen exchange,
nucleophilic substitution with amine, thiol or alcohol,
reductive amination,
oxime formation on carbonyl and hyd roxylamine g roups,
S-oxidation,
N-oxidation,
sal ification . The compounds of formula (II), (III), (IV), (V) and L2-R3 are either known or may be prepared in accordance with known procedures such as those described herein. As illustrated by the examples given below, the hereinbefore disclosed compounds of formula (I) have valuable biological properties. They are particularly useful as antibacterial agents having a selective spectrum of activity in vitro and in vivo against bacterial strains relying on Fabl and related targets. Such strains encompass Staphylococcus aureus including multiresistant strains (such as methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) strains), Acinetobacter baumannii, Bacillus anthracis, Chlamydophila pneumoniae, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Neisseria meningitidis and also bacteria such as Mycobacterium tuberculosis carrying homologous Fabl enzymes such as InhA or other organisms such as Plasmodium falciparum. In one embodiment, the compound of the invention is used in the treatment of Staphylococcus aureus microbial infections including multiresistant strains such as methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin- intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) strains.
The compounds of formula (I) are therefore particularly suitable as active principles of a medicament.
According to a further aspect of the invention, there is provided a compound of formula (I) as hereinbefore defined for use in therapy. According to a further aspect of the invention, there is provided a pharmaceutical composition comprising a compound of formula (I) as hereinbefore defined, in association with a pharmaceutically acceptable excipient or carrier.
Said pharmaceutical compositions are advantageously formulated to be administered under oral, topical, parental including injectable routes, such as intravenous administration, with individual doses appropriate for the patient to be treated.
The compositions according to the invention can be solid, liquid or in the form of a gel/cream and be present in the pharmaceutical forms commonly used in human medicine, such as for example, plain or sugar-coated tablets, gelatin capsules, granules, suppositories, injectable preparations, ointments, creams, gels; they are prepared according to the customary methods. The active ingredient/s can be incorporated using excipients which are customarily used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting agents, dispersants or emulsifiers, preservatives. These compositions can also be present in the form of a powder intended to be dissolved extemporaneously in an appropriate vehicle, for example, non-pyrogenic sterile water.
The dose administered varies according to the condition treated, the patient in question, the administration route and the product envisaged. It can, for example, be comprised between 0.01 g and 10 g per day, by oral route or by intramuscular or intravenous route in humans.
Said compositions are particularly useful to treat human or animal infections by microbial pathogens such as Staphylococcus aureus including multiresistant strains, Acinetobacter baumannii, Bacillus anthracis, Chlamydophila pneumoniae, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Neisseria meningitidis, S. intermedius, P. multocida, B. bronchiseptica, M. haemolytica and A. pleuropneumoniae. and also bacteria such as Mycobacterium tuberculosis or other organisms such as Plasmodium falciparum. Said compositions can also be useful in multitherapy, in combination with other medicaments, for example with antibiotics. It will be appreciated that such multitherapy may typically comprise either a composition comprising the compound of formula (I) additionally comprising one or more other medicaments, such as antibiotics or co-administration (i.e. sequential or simultaneous administration). The invention therefore also relates to a method of treatment of microbial infections which comprises administering to a patient in need thereof an efficient amount of a compound of formula (I) as hereinbefore defined. The invention also relates to a compound of formula (I) as hereinbefore defined for use in the treatment of microbial infections.
The invention also relates to the use of a compound of formula (I) as hereinbefore defined in the manufacture of a medicament for the treatment of microbial infections.
The invention also relates to a pharmaceutical composition comprising a compound of formula (I) as hereinbefore defined for use in the treatment of microbial infections.
Examples
Proton nuclear magnetic resonance ( H NMR) spectra were recorded on a 400 MHz Brijker instrument, and chemical shifts are reported in parts per million downfield from the internal standard tetramethylsilane (TMS). Abbreviations for NMR data are as follows: s=singlet, d = doublet, t=triplet, q = quadruplet, m = multiplet, dd =doublet of doublets, dt=doublet of triplets, br=broad . J indicates the NMR coupling constant measured in Hertz. CDCI3 is deuteriochloroform, DMSO-d6 is hexadeuteriodimethylsulfoxide, and CD3OD is tetradeuteriomethanol . Mass spectra were obtained using electrospray ionization (ESI) techniques on an Agilent 1100 Series LCMS. Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography. Flash chromatography was carried out on Flashsmart Pack cartridge irregular silica 40-60pm or spherical silica 20- 40pm. Preparative thin layer chromatography was carried out on Analtech Silica Gel GF 1000 μηι 20x20 cm.
The meaning of certain abbreviations is given herein. ESI refers to electrospray ionization, HPLC refers to high pressure liquid chromatography, LCMS refers to liquid chromatography coupled with a mass spectrometer, M in the context of mass spectrometry refers to the molecular peak, MS refers to mass spectrometer, NMR refers to nuclear magnetic resonance, pH refers to potential of hydrogen, TEA refers to triethylamine, DIPEA refers to /V,/V-diisopropylethylamine, HOBt refers to 1- hydroxybenzotriazole, DCM refers to dichloromethane, EtOAc refers to ethyl acetate, DMF refers to Λ/,/V-dimethylformamide, ED AC refers A/-(3- dimethylaminopropyl)-/V'-ethylcarbodiimide hydrochloride, DMAP or 4-DMAP refers to 4-(dimethylamino)pyridine, TLC refers to thin layer chromatography.
The starting materials are commercially available unless indicated otherwise.
Intermediate 1
(E)-3-(7-Oxo-5,6,7,8-tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (Dl)
Step 1: 2-Amino-3-(hydroxymethyl)pyridine
Figure imgf000031_0001
Lithium aluminum hydride (12.4 g, 326.7 mmol) was portionwisely added to a suspension of 2-amino-3-carboxypyridine (30.0 g, 217.2 mmol) in THF (350 mL) at 0°C. Once the addition was completed, the reaction mixture was stirred at room temperature for 15 minutes and then at reflux overnight. The mixture was then cooled to 0°C and hydrolyzed by the successive addition of water (18 mL), a solution of sodium hydroxyde (18 mL) and water (30 mL) again. The resulting white suspension was filtered on Clarcel® and the cake was washed with THF (200 mL) and a mixture of CHCI3/MeOH (250 mL, 9 : 1). After concentration to dryness of the filtrate, the title product was obtained as a yellow solid (24.2 g, 90%).
*H NMR (DMSO-c/6, 400 MHz) : δ (ppm) : 7.84 (d, J = 4Hz, 1H), 7.37 (d, J = 7.2 Hz, 1H), 6.55-6.52 (m, 1H), 5.64 (br s, NH2), 4.34 (s, 2H).
Step 2: 2-Amino-5-bromo-3-(hydroxymethyl)pyridine
Figure imgf000031_0002
Bromine (8.4 mL, 189.4 mmol) was added dropwise over 1 hour to a solution of 2- amino-3-(hydroxymethyl)pyridine (19.6 g, 157.8 mmol; which may be prepared as described in Dl, Step 1) in acetic acid (350 mL) at room temperature. The reaction mixture was then stirred overnight. After concentration to dryness, the residue was partitioned between a saturated solution of potassium carbonate (300 mL) and ethyl acetate (200 ml_). The aqueous layer was separated and extracted with ethyl acetate (2 x 200 ml_). The combined organic phases were washed with a saturated solution of sodium chloride (200 ml_), dried over sodium sulfate, filtered and concentrated to dryness. After trituration of the residue in pentane, the title product was obtained as a yellow solid (27.0 g, 84%).
*H NMR (DMSO-c/6, 400 MHz) : δ (ppm) : 7.90 (d, J = 2.8 Hz, 1H), 7.53 (d, J = 2 Hz, 1H), 5.93 (br s, NH2), 5.29 (br s, OH), 4.31 (s, 2H).
Step 3: 2-Amino-5-bromo-3-(bromomethyl)pyridine hydrobromide
Figure imgf000032_0001
A solution of 2-amino-5-bromo-3-(hydroxymethyl)pyridine (27.0 g, 133.0 mmol; which may be prepared as described in Dl, Step 2) in hydrobromic acid (48% in H20, 72 ml_) was stirred at reflux overnight. The reaction mixture was then concentrated to dryness (toluene was used to azeotrope the residual H20). The title product was obtained as pale brown solid (47.0 g, 100%) which was used in the next step without further purification.
*H NMR (DMSO-c/6, 400 MHz) : δ (ppm) :8.1 (d, J = 2 Hz, 1H), 7.97 (d, J = 2Hz, 1H), 4.41 (s, 2H). Step 4: 6-Bromo-2-oxo-l,2,3,4-tetrahydro-lW-l,8-naphthyridine-3- methy lea r boxy late
Figure imgf000032_0002
Dimethylmalonate (32 ml_, 276.7 mmol) was added to a solution of sodium methoxide (25% in methanol, 63 ml_, 76.1 mmol) in methanol (150 ml_) at room temperature. After 45 minutes stirring, 2-amino-5-bromo-3-(bromomethyl)pyridine hydrobromide (24 g, 69.2 mmol; which may be prepared as described in Dl, Step 3) was added to the mixture which was stirred at room temperature overnight. A large quantity of water was finally added to the mixture. The formed precipitate was filtered, washed with petroleum ether and dried under high vacuum to afford the title product as a brown solid (16.6 g, 84%).
LCMS (ESI-APCI) m/z 285.0-287.0 (M + H)+ Step 5: 6-Bromo-3,4-dihydro-lW-l,8-naphthyridin-2-one
Figure imgf000033_0001
A solution of sodium hydroxide (IN, 248 ml_) was added to a suspension of 6- bromo-2-oxo-l,2,3,4-tetrahydro-lH-l,8-naphthyridine-3-methylcarboxylate (16.6 g, 58.24 mmol; which may be prepared as described in Dl, Step 4) in methanol (620 ml_) at room temperature. The reaction mixture was then refluxed for 4 hours and cooled down to room temperature. A solution of hydrochloric acid (IN, 248 ml_) was then added and the mixture was refluxed overnight. The methanol was removed and the residue filtered. The resulting precipitate was washed with water and dried under high vacuum to afford the title product as a white solid (7.7 g, 58%).
LCMS (ESI-APCI) m/z 227.0-229.0 (M + H)+
Step 6: tert-Butyl (E)-3-(7-Oxo-5,6,7,8-tetrahydro-l,8-naphthyridin-3-yl)- acrylate
i-butyl acrylate,
Figure imgf000033_0002
tert-Butyl acrylate (31.2 ml_, 210 mmol), diisopropylethylamine (19.4 ml_, 110 mmol) and P(o-tolyl)3 (3.2 g, 10.5 mmol) were successively added to a suspension of 6-bromo-3,4-dihydro-lH-l,8-naphthyridin-2-one (11.9 g, 52.5 mmol; which may be prepared as described in Dl, Step 5) in propionitrile (83 ml_) and dimethylformamide (46 ml_). The resulting mixture was then purged with argon prior to the addition of palladium acetate (1.2 g, 5.2 mmol). The mixture was purged with argon again and refluxed overnight. The reaction mixture was then filtered on Celite®. The filtrate was concentrated to dryness and the residue was solubilized in ethyl acetate (200 ml_). The resulting solution was washed with a saturated solution of sodium chloride (3 x 100 ml_), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (98: 2) as eluent. After trituration with Et20/petroleum ether (1/1), the title product was obtained as a yellow solid (4.35 g, 40%).
LCMS (ESI-APCI) m/z 275.0 (M + H)+ Step 7: (E)-3-(7-Oxo-5,6,7,8-tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride
Figure imgf000034_0001
Trifluoroacetic acid (31 mL) was added to a suspension of tart-butyl (E)-3-(7-Oxo- 5,6,7,8-tetrahydro-l,8-naphthyridin-3-yl)-acrylate (1.1 g, 3.76 mmol; which may be prepared as described in Dl, Step 6) in dichloromethane (31 mL). The reaction mixture was stirred at room temperature for 1 hour and concentrated to dryness. The resulting residue was solubilized in a solution of hydrochloric acid in dioxane (4N, 60 mL). After 10 minutes stirring at room temperature, the precipitate was filtered and washed with diethyl ether to afford the title product as a pale yellow solid (4.5 g, quantitative).
LCMS (ESI-APCI) m/z 219 (M + H)+
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.68 (br s, OH), 8.35 (s, 1H), 8.02 (s, 1H), 7.54 (d, J = 16.0 Hz, 1 H), 6.50 (d, J = 16.0 Hz, 1H), 2.90 (t, J = 7.6 Hz, 2H), 2.50 (t, J = 7.6 Hz, 2H). The triplet CH2 at 2.5 ppm is hidden by DMSO.
Intermediate 2
(E)-Ethyl 3-(l'-methyl-2-oxo-2 4-dihydro-lH-spiro[[l 8]naphthyridine- 3,4'-piperidine]-6-yl)acrylate (D2)
Step 1: 2-Amino-3-(hydroxymethyl)pyridine
Figure imgf000034_0002
A solution of 2.4M lithium aluminum hydride in THF (181 mL g, 434 mmol) was added portionwise to a suspension of 2-amino-3-carboxypyridine (30.0 g, 217 mmol) in THF (350 mL) at 0°C. Once the addition was completed, the reaction mixture was stirred at room temperature for 15 minutes and then at reflux overnight. The mixture was then cooled to 0°C and hydrolyzed by the successive addition of water (18 mL), a IM solution of sodium hydroxide (18 mL) and water (50 mL). The resulting white suspension was stirred for one hour, filtered over Celite® and the cake was washed with THF (400 mL). After concentration to dryness of the filtrate, the title product was obtained as a light brown oil (25.1 g, 87%, py 93.1%). LCMS m/z 125.0 (M + H)+
Step 2: 2-Amino-5-bromo-3-(hydroxymethyl)pyridine Bromine (10.4 mL, 202 mmol) was added dropwise over 1 hour to a solution of 2- amino-3-(hydroxymethyl)pyridine (25.1 g, 202 mmol) in acetic acid (500 mL) at room temperature. After complete addition the reaction mixture was stirred for an extra hour. After concentration to dryness, the residue was partitioned between 1M Na2C03 (750mL) and ethyl acetate (500 mL). The aqueous layer was separated and extracted one more time with ethyl acetate (500 mL). The combined organic phases were washed with a saturated solution of sodium chloride (500 mL), dried over sodium sulfate, filtered and concentrated to dryness. After trituration of the residue in DCM / heptane and extra washing with DCM the title product was obtained as a light yellow solid (30.0 g, 70%, py 97.3%).
LCMS m/z 203.0 (M + H)+ -Amino-5-bromo-3-(bromomethyl)pyridine hydrobromide
Figure imgf000035_0002
A solution of 2-amino-5-bromo-3-(hydroxymethyl)pyridine (34.6 g, 170.0 mmol) in hydrobromic acid (48% in H20, 93 mL) was stirred at reflux overnight. The reaction mixture was cooled to room temperature, the precipitated product filtered and washed with H20 (100 mL) and dried . The title product was obtained as a light yellow solid (36.1 g, 56%, py 96.5%).
*H NMR (DMSO-c/6, 400 M Hz) : δ (ppm) : 8.27 (dd, J = 2 Hz and 6 Hz, 2H), 4.75 (s, 2H). -Boc ethylisonipecotate
Figure imgf000035_0003
Boc20 (15.58 g, 71.4 mmol) and triethylamine (10.85 mL, 78 mmol) were successively added to a solution of ethyl isonipecotate (10.2 g, 64.9 mmol) in dichloromethane (50 mL) at room temperature. The reaction mixture was stirred overnight. The reaction mixture was diluted by addition of a saturated solution of ammonium chloride (50 mL) . The aqueous layer was separated and extracted with dichloromethane (2 x 50 mL) . The combined organic phases were dried over sodium sulphate, filtered and concentrated to dryness. The title product was obtained as a colorless oil ( 16.1 g, 96%, py >95%) .
*H NM R (CDCI3, 400 M Hz) : δ (ppm) : 4.14 (q, J = 7 Hz, 2H), 4.02 (br, 2H), 2.83 (m, 2H), 2.44 (m, 1 H), 1.87 (m, 2H), 1.62 (m, 2H), 1.45 (s, 9H), 1.25 (t, J = 7 Hz, 3H) . Step 5: tert-Butyl 6-bromo-2-oxo-2,4-dihydro-lH- spiro[ [ l,8] naphthyridine-3,4'-piperidine]-l'-carboxylate
Figure imgf000036_0001
A solution of 1.8 M LDA in TH F ( 1.6 mL, 2.88 mmol) was added dropwise over 15 minutes to a cold (-78°C) solution of 5-bromo-3-(bromomethyl)pyridine-2-amine hydrobromide ( 1.0 g, 2.88 mmol) in dry TH F ( 10 mL) under argon . The reaction mixture was stirred for an additional 15 minutes. In a separate flask, a solution of 1.8 M LDA in TH F (4.81 mL, 8.65 mmol) was added dropwise over 30 minutes to a cold solution of /V-Boc ethylisonipecotate (2.23 g, 8.65 mmol) in dry THF (20 ml) . The reaction mixture was stirred for an additional 30 minutes. The lithium salt of N- Boc ethylisonipecotate was then added via cannula dropwise over 30 minutes to the lithium salt of 5-bromo-3-(bromomethyl)pyridine-2-amine. The mixture was stirred at -78°C for 2 hours and allowed to warm to room temperature. The reaction mixture was quenched with a saturated solution of ammonium chloride (30 mL) and ethyl acetate (30 mL) was added . The layers were separated and the organic phase was washed with water (2 x 30 mL) and brine (50 mL), dried over sodium sulphate, filtered and concentrated to dryness. The residue was triturated with EtOAc. The title product was obtained as a white solid (257 mg, 19%, py 85.7%) .
LCMS m/z 394 (M-H)~ Step 6: (E)-tert-Butyl 6-(3-tert-butoxy-3-oxoprop-l-enyl)-2-oxo-2 4- dihydro-lH-spiro[ [ l,8] naphthyridine-3,4'-piperidine]-l'-carboxylate
Figure imgf000037_0001
Tert-Butyl acrylate (3.9 mL, 26.8 mmol), diisopropylethylamine (2.46 mL, 14.1 mmol) and P(o-tolyl)3 (409 mg, 1.34 mmol) were successively added to a suspension of terf-butyl 6-bromo-2-oxo-2,4-dihydro-lH-spiro[[l,8]naphthyridine- 3,4'-piperidine]-l'-carboxylate (2.66 g, 6.7 mmol) in propionitrile (107 mL) and dimethylformamide (40 mL) in a sealed tube. The resulting mixture was then purged with argon prior to the addition of palladium acetate (151 mg, 0.673 mmol). The mixture was purged with argon again and refluxed overnight. The reaction mixture was then filtered on Celite® and the cake was washed with DCM (50mL). The filtrate was concentrated to dryness and the residue was triturated with dichloromethane. The title product was obtained as a light grey solid (1.83 g, 61%, py 79.9%).
LCMS m/z 442 (M-H)~ Step 7: (E)-3-(2-Oxo-2,4-dihydro-lH-spiro[[l,8]naphthyridine-3,4'- piperidine]-6-yl)acrylic acid hydrochloride
Figure imgf000037_0002
Trifluoroacetic acid (5.5 mL) was added to a suspension of (E)-3-(2-oxo-2,4- dihydro-lH-spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylic acid hydrochloride (540 mg, 1.21 mmol) in dichloromethane (5.5 mL). The reaction mixture was stirred at room temperature for 1 hour and concentrated to dryness. The resulting residue was suspended in a solution of hydrochloric acid, 4N in dioxane (11 ml) . After 10 minutes stirring at room temperature, the precipitate was filtered and triturated with diethyl ether. The title product was obtained as a white solid (455 mg, 109%, py 98.9%).
LCMS m/z 288 (M + H -HCI)+
Step 8: (E)-3-(l'-Methyl-2-oxo-2,4-dihydro-lH- spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylic acid
Figure imgf000037_0003
Sodium triacetoxyborohydride (671 mg, 3.17 mmol) and paraformaldehyde (95 mg, 3.17 mmol) were successively added to a suspension of (E)-3-(2-oxo-2,4- dihydro-lH-spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylic acid (455 mg, 1.58 mmol) in 1,2-dichloroethane (40 ml_) at room temperature. The reaction mixture was then heated to 70°C and stirred for 2 hours. The reaction mixture was cooled to room temperature, the precipitated product filtered and washed with H20 (50 ml_) and MeOH (3 x 50 ml_) and dried . The title product was obtained as a white solid (319 mg, 66%, py 74.1%).
LCMS m/z 302 (M + H)+
Example 1
6-[(lE)-3-Azetidin-l-yl-3-oxoprop-l-en-l-yl]-3 4-dihydro-l 8- naphthyridin-2( lH)-one (El)
Figure imgf000038_0001
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (50 mg, 0.20 mmol), prepared (as in J. Med. Chem. 2003, 46, 9, 1627- 1635) from 6-bromo-3,4-dihydro-l,8- naphthyridin-2(lH)-one described in US 4,866,074 (Rorer Pharmaceutical Corp.), DMF (4.8 mL), HOBt (32 mg, 0.23 mmol), DIPEA (78 μΙ_, 0.47 mmol), azetidine (16 μΙ_, 0.23 mmol) and EDAC (45 mg, 0.23 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified twice on preparative TLC (eluent: dichloromethane/MeOH, 95/5) to give the title compound (31 mg, 62%) as a white solid.
LCMS (ESI+) m/z 258 (M + H)+: 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.65 (br s, 1H), 8.40-8.31 (m, 1H), 8.06- 7.98 (m, 1H), 7.37 (d, J = 15.9 Hz, 1 H), 6.68 (d, J = 15.9 Hz, 1H), 4.27 (t, J = 7.5 Hz, 2H), 3.93 (t, J = 7.5 Hz, 2H), 2.90 (t, J = 7.2 Hz, 2H), 2.23 (qt, J = 7.5 Hz, 2H). The other CH2 of the naphthyridinone moiety is hidden by DMSO signal. Example 2
6-[(lE)-3-Oxo-3-pyrrolidin-l-ylprop-l-en-l-yl]-3 4-dihydro-l 8- naphthyridin-2( lH)-one (E2)
Figure imgf000039_0001
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (50 mg, 0.20 mmol), DMF (4.8 ml_), HOBt (32 mg, 0.23 mmol), DIPEA (78 μΙ_, 0.47 mmol), pyrrolidine (20 μΙ_, 0.23 mmol) and EDAC (45 mg, 0.23 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was diluted in dichloromethane and washed with water. The organic layer was concentrated to dryness and the residue was purified on preparative TLC (eluent: dichloromethane/MeOH, 95/5) to give the title compound (33 mg, 62%) as a white solid .
LCMS (ESI+) m/z 272 (M + H)+: 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.64 (br s, 1H), 8.38-8.31 (m, 1H), 8.07- 8.01 (m, 1H), 7.42 (d, J = 15.3 Hz, 1H), 6.96 (d, J = 15.3 Hz, 1 H), 3.63 (t, J = 6.8 Hz, 2H), 3.39 (t, J = 6.8 Hz, 2H), 2.91 (t, J = 7.2 Hz, 2H), 1.91 (qt, J = 6.8 Hz, 2H), 1.81 (qt, J = 6.8 Hz, 2H). The other CH2 of the naphthyridinone moiety is hidden by DMSO signal.
Example 3
6-[(lE)-3-Oxo-3-piperidin-l-ylprop-l-en-l-yl]-3 4-dihydro-l 8- naphthyridin-2(lH)-one (E3)
Figure imgf000039_0002
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (50 mg, 0.20 mmol), DMF (4.8 ml_), HOBt (32 mg, 0.23 mmol), DIPEA (78 μΙ_, 0.47 mmol), piperidine (23 μΙ_, 0.23 mmol) and EDAC (45 mg, 0.23 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was diluted in dichloromethane and washed with water. The organic layer was concentrated to dryness and the residue was purified on preparative TLC (eluent: dichloromethane/MeOH, 95/5) to give the title compound (39 mg, 69%) as a white solid .
LCMS (ESI+) m/z 286 (M + H)+: 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.64 (br s, 1H), 8.39-8.31 (m, 1H), 8.12- 8.07 (m, 1H), 7.42 (d, J = 15.3 Hz, 1H), 7.24 (d, J = 15.3 Hz, 1H), 3.72-3.58 (m, 2H), 3.58-3.46 (m, 2H), 2.91 (t, J = 6.9 Hz, 2H), 1.70-1.57 (m, 2H), 1.57-1.42 (m, 4H). The other CH2 of the naphthyridinone moiety is hidden by DMSO signal.
Example 4
6-{(lE)-3-[4-(2-Hydroxyethyl)piperidin-l-yl]-3-oxoprop-l-en-l-yl}-3 4- dihydro-l,8-naphthyridin-2(lH)-one (E4)
Figure imgf000040_0001
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (50 mg, 0.20 mmol), DMF (4.8 ml_), HOBt (32 mg, 0.23 mmol), DIPEA (78 μΙ_, 0.47 mmol), 4-piperidineethanol (30 mg, 0.23 mmol) and EDAC (45 mg, 0.23 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on column chromatography (eluent: dichloromethane/MeOH, 95/5) to give a white solid. This solid was triturated in MeOH, filtered, washed with MeOH and diethyl ether and dried to give the title compound (35 mg, 55%) as a white solid .
LCMS (ESI+) m/z 330 (M + H)+: 100%. Two peaks due to its protonation during the analysis.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.64 (br s, 1H), 8.35-8.32 (m, 1H), 8.11- 8.07 (m, 1H), 7.42 (d, J = 15.3 Hz, 1H), 7.24 (d, J = 15.3 Hz, 1H), 4.52-4.42 (m, 1H), 4.38 (t, J = 5.1 Hz, 1H), 4.32-4.22 (m, 1H), 3.52-3.42 (m, 2H), 3.11-2.96 (m, 1H), 2.91 (t, J = 7.5 Hz, 2H), 2.69-2.57 (m, 1H), 1.81-1.57 (m, 3H), 1.37 (q, J = 6.6 Hz, 2H), 1.12-0.93 (m, 2H). The other CH2 is hidden by DMSO signal. Example 5
6-[(lE)-3-{ [4-(4-Fluorophenoxy) methyl] piperidin-l-yl}-3-oxoprop-l-en- l-yl]-3,4-dihydro-l,8-naphthyridin-2( lH)-one (E5)
Step 1: tert- Butyl 4-[(4-fluorophenoxy)methyl]piperidine-l-carboxylate
Figure imgf000041_0001
4-Fluorophenol (0.52 g, 4.64 mmol) and triphenylphosphine (1.22 g, 4.64 mmol) were added to a solution of N-boc-piperidine-4-methanol (500 mg, 2.32 mmol) in anhydrous THF (12 mL) under nitrogen. The reaction mixture was cooled to 0 °C and DEAD (670 μΙ_, 3.69 mmol) was added dropwise. The solution was allowed to warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure then diluted with dichloromethane and filtered. The filtrate was washed three times with NaOH 0.2N, dried over Na2S04 and concentrated. The residue was purified on column chromatography (eluent: pentane / EtOAc 95/5) to give the title compound (538 mg, 75%) as a yellow oil. *H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 7.17-7.02 (m, 2H), 6.98-6.88 (m, 2H), 4.02-3.88 (m, 2H), 3.79 (d, J = 6.3 Hz, 2H), 2.83-2.60 (m, 2H), 1.96-1.79 (m, 1H), 1.79-1.64 (m, 2H), 1.39 (s, 9H), 1.23-1.04 (m, 2H). -[(4-Fluorophenoxy)methyl]piperidine hydrochloride
Figure imgf000041_0002
To a cooled solution of tert-butyl 4-[(4-fluorophenoxy)methyl]piperidine-l- carboxylate (538 mg, 1.74 mmol; which may be prepared as described in Step 1) in dichloromethane (11.5 mL) was added dropwise HCI 4N in dioxane (8.5 mL). The solution was warmed to room temperature and stirred for 1 h. The solvent was evaporated under reduced pressure to give the title compound (416 mg, 97%) as a white solid.
*H NMR (DMSO-c/e, 300 MHz) : 5(ppm) : 9.12-8.88 (m, 1H), 8.80-8.56 (m, 1H), 7.17-7.02 (m, 2H), 7.01-6.86 (m, 2H), 3.82 (d, J = 6.6 Hz, 2H), 3.32-3.21 (m, 2H), 2.97-2.78 (m, 2H), 2.10-1.95 (m, 1H), 1.94-1.81 (m, 2H), 1.58-1.37 (m, 2H).
Step 3: 6-[(lE)-3-{ [4-(4-Fluorophenoxy)methyl]piperidin-l-yl}-3- oxoprop-l-en-l-yl]-3 4-dihydro-l 8-naphthyridin-2(lH)-one
Figure imgf000042_0001
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (30 mg, 0.12 mmol), DMF (3 ml_), 4-[(4-fluorophenoxy)methyl]piperidine hydrochloride (34 mg, 0.14 mmol; which may be prepared as described in Step 2), DIPEA (48 μΙ_, 0.28 mmol) and ED AC (27 mg, 0.14 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on preparative TLC (eluent: dichloromethane/NH3 7N in MeOH, 2.5%) to give a pale yellow solid . This solid was triturated in acetone, filtered, washed with acetone and diethyl ether then dried to give the title compound (22 mg, 45%) as a white solid.
LCMS (ESI+) m/z 410 (M + H)+: 100%.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 10.64 (br s, 1H), 8.40-8.25 (m, 1H), 8.16- 8.04 (m, 1H), 7.44 (d, J = 15.3 Hz, 1H), 7.26 (d, J = 15.3 Hz, 1H), 7.18-7.05 (m, 2H), 7.02-6.85 (m, 2H), 4.60-4.25 (m, 2H), 3.90-3.73 (m, 2H), 3.16-3.01 (m, 1H), 2.98-2.80 (m, 2H), 2.77-2.60 (m, 1H), 2.13-1.93 (m, 1H), 1.91-1.70 (m, 2H), 1.34-1.05 (m, 2H). The CH2 missing is hidden by DMSO signal.
Example 6
6-[(lE)-3-Oxo-3-(3-phenoxyazetidin-l-yl)prop-l-en-l-yl]-3 4-dihydro- l,8-naphthyridin-2(lH)-one (E6)
Step 1: l-(Diphenylmethyl)azetidin-3-yl methanesulfonate
Figure imgf000043_0001
A 100 mL flask was charged with l-diphenylmethylazetidin-3-ol (1.5 g, 6.27 mmol) and pyridine (15 mL). The solution was cooled to -20°C and methane sulfonyl chloride (0.73 mL, 9.4 mmol) was added dropwise. The reaction mixture was stirred at -20°C for lh and then left 3 days at 4°C. The solution was poured on ice and the resulting precipitate was filtered, washed 3 times with H20 and 3 times with pentane. The solid was dried under reduced pressure to give the title compound (1.92 g, 96%) as a white solid.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 7.44-7.03 (m, 10H), 5.16-4.96 (m, 1H), 4.59-4.42 (m, 1H), 3.61-3.21 (m, 4H), 3.18 (s, 3H).
Step 2: l-(Diphenylmethyl)-3-phenox azetidine
Figure imgf000043_0002
To a cooled solution of phenol (149 mg, 1.58 mmol) in DMF (3.9 mL), NaH (60% in oil, 95 mg, 2.37 mmol) was added portionwise and the suspension was stirred at 0 °C for 15 min. l-(Diphenylmethyl)azetidin-3-yl methanesulfonate (500 mg, 1.58 mmol; which may be prepared as described in Step 1) was then added and the reaction mixture stirred at 80 °C overnight and concentrated under reduced pressure. The residue was purified on column chromatography (eluent: pentane/EtOAc 98/2 to 95/5) to give the title compound (332 mg, 67%) as a light yellow solid .
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 7.49-7.34 (m, 3H), 7.32-7.07 (m, 9H), 6.96-6.87 (m, 1H), 6.85-6.72 (m, 2H), 4.88-4.75 (m, 1H), 4.51 (br s, 1H), 3.66- 3.58 (m, 2H), 3.00-2.92 (m, 2H).
Step 3: 3-Phenoxyazetidine hydrochloride
Figure imgf000044_0001
A 50 ml_ flask was charged with l-(diphenylmethyl)-3-phenoxyazetidine (328 mg, 1.04 mmol; which may be prepared as described in Step 2) and 1,2-dichloroethane (4.6 ml_). 1-Chloroethyl chloroformate (164 μΙ_, 1.35 mmol) was added and the reaction mixture was stirred at 70 °C for 1.5 h . After cooling to room temperature, MeOH (4.6 ml_) was added and the reaction mixture was stirred at 70 °C for 1.5 h. The reaction mixture was concentrated to dryness. The crude product was triturated in pentane to give the title compound (204 mg, quantitative) as pale yellow crystals. This product was used in the next step without further purification. *H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 9.70-9.38 (m, 2H), 7.29-7.18 (m, 2H), 7.08-6.93 (m, 1H), 6.90-6.78 (m, 2H), 5.13-4.98 (m, 1H), 4.51-4.29 (m, 2H), 4.04-3.80 (m, 2H).
Step 4: 6-[(lE)-3-Oxo-3-(3-phenoxyazetidin-l-yl)prop-l-en-l-yl]-3,4- dih dro-l,8-naphthyridin-2(lH)-one
Figure imgf000044_0002
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (30 mg, 0.12 mmol), DMF (3 ml_), 3-phenoxyazetidine hydrochloride (26 mg, 0.14 mmol; which may be prepared as described in Step 3), DIPEA (48 μΙ_, 0.28 mmol) and ED AC (27 mg, 0.14 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on preparative TLC (eluent: dichloromethane/NH3 7N in MeOH, 2.5%) to give a pale yellow solid . This solid was triturated in acetone, filtered, washed with acetone and diethyl ether then dried to give the title compound (15 mg, 36%) as a white solid.
LCMS (ESI+) m/z 350 (M + H)+: 100%. *H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.66 (br s, 1H), 8.37-8.29 (m, 1H), 8.05- 7.98 (m, 1H), 7.42 (d, J = 15.8 Hz, 1H), 7.37-7.25 (m, 2H), 7.04-6.94 (m, 1H), 6.91-6.82 (m, 2H), 6.76 (d, J = 15.8 Hz, 1H), 5.14-5.03 (m, 1H), 4.79-4.67 (m, 1H), 4.47-4.37 (m, 1 H), 4.26-4.15 (m, 1 H), 3.95-3.84 (m, 1 H), 2.95-2.80 (m, 2H). The CH2 missing is hidden by the DMSO signal.
Example 7
6-[(lE)-3-Oxo-3-(2-phenylpyrrolidin-l-yl)prop-l-en-l-yl]-3 4-dihydro- l,8-naphthyridin-2( lH)-one (E7)
Figure imgf000045_0001
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (30 mg, 0.12 mmol), DMF (3 ml_), 2-phenylpyrrolidine (21 mg, 0.14 mmol), DIPEA (48 μΙ_, 0.28 mmol) and EDAC (27 mg, 0.14 mmol). The reaction mixture was stirred at room temperature and concentrated to dryness. LC/MS showed the presence of the target compound and no starting material after 24 h. The residue was purified on preparative TLC (eluent: dichloromethane/NH3 7N in MeOH, 2.5%) to give a pale yellow solid . This solid as triturated in acetone, filtered, washed with acetone and dried to give the title compound (7 mg, 17%) as a white solid.
LCMS (ESI+) m/z 348 (M + H)+: 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.73-10.49 (m, 1H), 8.41-8.35 (m, 0.5H), 8.19-8.05 (m, 1H), 7.66-7.56 (m, 0.5H), 7.48-7.00 (m, 6.5H), 6.58 (d, J = 15.3 Hz, 0.5H), 5.46-5.09 (m, 1H), 4.05-3.55 (m, 2H), 2.99-2.77 (m, 2H), 2.01-1.61 (m, 4H). The other CH2 is hidden by DMSO signal.
Example 8
6-[(lE)-3-Oxo-3-(4-propylpiperidin-l-yl)prop-l-en-l-yl]-3 4-dihydro-l 8- naphthyridin-2( lH)-one (E8)
Figure imgf000046_0001
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (30 mg, 0.12 mmol), DMF (3 ml_), 4-/V-propylpiperidine (18 mg, 0.14 mmol), DIPEA (48 μΙ_, 0.28 mmol) and EDAC (27 mg, 0.14 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. LC/MS showed the presence of the target compound and no starting material after 24 h. The residue was purified on preparative TLC (eluent: dichloromethane/NH3 7N in MeOH, 2.5%) to give a white solid. This solid was triturated in acetone, filtered, washed with acetone and diethyl ether to give the title compound (15 mg, 38%) as a white solid.
LCMS (ESI+) m/z 328 (M + H)+: 100%.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 10.64 (br s, 1H), 8.40-8.27 (m, 1H), 8.14- 8.02 (m, 1H), 7.42 (d, J = 15.3 Hz, 1H), 7.23 (d, J = 15.3 Hz, 1H), 4.55-4.15 (m, 2H), 3.10-2.97 (m, 1 H), 2.96-2.81 (m, 2H), 1.80-1.62 (m, 2H), 1.60-1.40 (m, 1H), 1.39-1.11 (m, 4H), 1.07-0.91 (m, 1 H), 0.87 (t, J = 7.2 Hz, 3H). The 2 CH2 missing are hidden by the DMSO signal.
Example 9
6-[(lE)-3-{ [3-(4-Fluorophenoxy) methyl] piperidin-l-yl}-3-oxoprop-l-en- l-yl]-3,4-dihydro-l,8-naphthyridin-2(lH)-one (E9)
Ste 1: tert- Butyl 3-[(4-fluorophenoxy)methyl]piperidine-l-carboxylate
Figure imgf000046_0002
4-Fluorophenol (520 mg, 4.64 mmol) and triphenylphosphine (1.22 g, 4.64 mmol) were added to a solution of N-boc-piperidine-3-methanol (500 mg, 2.32 mmol) in anhydrous THF (12 ml_) under nitrogen. The reaction mixture was cooled to 0 °C and DEAD (673 μΙ_, 3.71 mmol) was added dropwise. The solution was allowed to warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure then diluted with dichloromethane and filtered. The filtrate was washed three times with NaOH 0.2N, dried over Na2S04 and concentrated. The residue was purified on column chromatography (eluent: pentane / EtOAc 95/5) to give the title compound (300 mg, 42%) as a yellow oil . *H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 7.18-7.03 (m, 2H), 7.01-6.87 (m, 2H), 4.09-3.55 (m, 4H), 3.02-2.76 (m, 1H), 1.95-1.52 (m, 3H), 1.49-1.19 (m, 12H). Ste 2: 3-[(4-Fluorophenoxy)methyl]piperidine hydrochloride
Figure imgf000047_0001
To a cooled solution of tert- butyl 3-[(4-fluorophenoxy)methyl]piperidine-l- carboxylate (300 mg, 1.03 mmol; which may be prepared as described in Step 1) in dichloromethane (6.8 ml_) was added dropwise HCI 4N in dioxane (5.0 ml_). The solution was warmed to room temperature and stirred for 1 h. The solvent was evaporated under reduced pressure to give the title compound (267 mg, quantitative) as a white solid.
The product was used in the next step without further analysis. Step 3: 6-[(lE)-3-{ [3-(4-Fluorophenoxy)methyl]piperidin-l-yl}-3- oxo rop-l-en-l-yl]-3 4-dihydro-l 8-naphthyridin-2(lH)-one
Figure imgf000047_0002
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (30 mg, 0.12 mmol), DMF (3 ml_), 3-[(4-fluorophenoxy)methyl]piperidine hydrochloride (35 mg, 0.14 mmol; which may be prepared as described in Step 2), DIPEA (48 μΙ_, 0.28 mmol) and EDAC (27 mg, 0.14 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on preparative TLC (eluent: dichloromethane/NH3 7N in MeOH, 2.5%) to give a pale yellow solid . This solid was triturated in methanol, filtered, washed with methanol and diethyl ether then dried to give the title compound (23 mg, 47%) as a white solid .
LCMS (ESI+) m/z 410 (M + H)+: 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.64 (br s, 1H), 8.38-8.22 (m, 1H), 8.15- 7.87 (m, 1 H), 7.53-6.84 (m, 6H), 4.60-3.95 (m, 2H), 3.95-3.73 (m, 2H), 3.20-2.98 (m, 1H), 2.98-2.78 (m, 2H), 2.77-2.58 (m, 1H), 2.00-1.58 (m, 3H), 1.56-1.26 (m, 2H). The CH2 missing is hidden by the DMSO signal.
Example 10
6-[(lE)-3-Oxo-3-(3-phenoxypyrrolidin-l-yl)prop-l-en-l-yl]-3 4-dihydro- l,8-naphthyridin-2(lH)-one (E10)
Ste 1: tert- Butyl 3-hydroxypyrrolidine-l-carboxylate
Figure imgf000048_0001
To a solution of 3-pyrrolidinol (1.82 g, 20.87 mmol) and triethylamine (6.4 mL, 45.92 mmol) in dichloromethane (104 mL) was added di-tert-butyldicarbonate (5.01 g, 22.96 mmol) in portions at 5 °C. After stirring at room temperature for 16 h the reaction mixture was washed with HCI 0.1N, saturated NaHC03 solution and brine then dried over Na2S04. The combined organic layers were concentrated under reduced pressure to give the title compound (3.78 g, 97%) as a dark orange oil.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 4.95-4.84 (m, 1H), 4.30-4.13 (m, 1H), 3.35-3.01 (m, 4H), 1.92-1.64 (m, 2H), 1.39 (s, 9H).
Step 2: tert- Butyl 3-phenoxypyrrolidine-l-carboxylate
Figure imgf000049_0001
Phenol (503 mg, 5.34 mmol) and triphenylphosphine (1.40 g, 5.34 mmol) were added to a solution of tert-butyl 3-hydroxypyrrolidine-l-carboxylate (500 mg, 2.67 mmol; which may be prepared as described in Step 1) in anhydrous THF (13 ml_) under nitrogen. The reaction mixture was cooled to 0 °C and DEAD (775 μΙ_, 4.27 mmol) was added dropwise. The solution was allowed to warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure then diluted with dichloromethane and filtered. The filtrate was washed three times with NaOH 0.2N and brine, dried over Na2S04 then concentrated. The residue was purified on column chromatography (eluent: pentane EtOAc 9/1) to give the title compound (175 mg, 25%) as a yellow oil .
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 7.37-7.21 (m, 2H), 7.03-6.85 (m, 3H), 5.08-4.92 (m, 1H), 3.60-3.32 (m, 4H), 2.19-1.93 (m, 2H), 1.47-1.27 (m, 9H). Step 3: 3-Phenoxypyrrolidine hydrochloride
Figure imgf000049_0002
To a cooled solution of tart-butyl 3-phenoxypyrrolidine-l-carboxylate (172 mg, 0.65 mmol; which may be prepared as described in Step 2) in dichloromethane (4.3 ml_) was added dropwise HCI 4N in dioxane (3.2 ml_). The solution was warmed to room temperature and stirred for 1 h. The solvent was evaporated under reduced pressure to give the title compound (135 mg, quantitative) as an orange oil .
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 9.77-9.58 (m, 1H), 9.57-9.38 (m, 1H), 7.37-7.26 (m, 2H), 7.03-6.90 (m, 3H), 5.18-5.09 (m, 1H), 3.59-3.07 (m, 4H), 2.27-2.03 (m, 2H).
Step 4: 6-[(lE)-3-Oxo-3-(3-phenoxypyrrolidin-l-yl)prop-l-en-l-yl]-3,4- dihydro-l,8-naphthyridin-2(lH)-one
Figure imgf000050_0001
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (30 mg, 0.12 mmol), DMF (3 ml_), 3-phenoxypyrrolidine hydrochloride (28 mg, 0.14 mmol; which may be prepared as described in Step 3), DIPEA (48 μΙ_, 0.28 mmol) and ED AC (27 mg, 0.14 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on preparative TLC (eluent: dichloromethane/NH3 7N in MeOH, 2.5%) to give a pale yellow solid . This solid was triturated in methanol, filtered, washed with methanol, acetone and diethyl ether then dried to give the title compound (30 mg, 68%) as a white solid .
LCMS (ESI+) m/z 364 (M + H)+: 100%.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 10.74-10.61 (m, 1H), 8.42-8.29 (m, 1H), 8.14-8.00 (m, 1H), 7.46 (d, J = 15.6 Hz, 1H), 7.37-7.21 (m, 2H), 7.11-6.81 (m, 4H), 5.22-5.02 (m, 1 H), 4.03-3.47 (m, 4H), 3.00-2.78 (m, 2H), 2.37-1.99 (m, 2H). The CH2 missing is hidden by the DMSO signal.
Example 11
6-{(lE)-3-[3-(5-Methyl-l 2 4-oxadiazol-3-yl)azetidin-l-yl]-3-oxoprop-l- en-l-yl}-3,4-dihydro-l,8-naphthyridin-2(lH)-one (El l)
Step 1: Azetidine-3-carbonitrile hydrochloride
Figure imgf000050_0002
A 50 ml_ flask was charged with l-benzhydrylazetane-3-carbonitrile (500 mg, 2.01 mmol) and 1,2-dichloroethane (8.9 ml_). 1-chloroethyl chloroformate (285 μΙ_, 2.61 mmol) was added and the reaction mixture was stirred at 70 °C for 1.5 h. After cooling to room temperature, methanol (8.9 ml_) was added and the reaction mixture was stirred at 70 °C for 1.5h. The reaction mixture was concentrated to dryness. The crude mixture was triturated in pentane to give a dark solid (250 mg, quantitative) which was used without further purification.
Step 2: tert- Butyl 3-cyanoazetidine-l-carboxylate
Figure imgf000051_0001
To a solution of azetidine-3-carbonitrile hydrochloride (250 mg, 2.01 mmol theoretical; which may be prepared as described in Step 1) and triethylamine (1.12 ml_, 8.04 mmol) in dichloromethane (10.2 mL) was added di-tert-butyldicarbonate (482 mg, 2.21 mmol) portionwise at 5 °C. After stirring at room temperature for 16 h, the reaction mixture was washed with HCI 0.5N and brine then dried over Na2S04. The solvent was removed under reduced pressure and the crude mixture purified on column chromatography (eluent: Pentane/EtOAc 95/5 to 4/1) to give the compound (190 mg, 52%) as a clear oil.
*H NMR (CDCIs, 300 MHz) : δ (ppm) : 4.29-4.05 (m, 4H), 3.48-3.29 (m, 1H), 1.44 (s, 9H).
Step 3: tert-Butyl 3-[(Z)-amino(hydroxyimino)methyl]azetidine-l- carboxylate
Figure imgf000051_0002
In a 16 mL vial, terf-butyl 3-cyanoazetidine-l-carboxylate (190 mg, 1.04 mmol; which may be prepared as described in Step 2) was dissolved in ethanol (2.9 mL), then hydroxylamine hydrochloride (101 mg, 1.46 mmol) and triethylamine (247 pL,
1.77 mmol) were added. The reaction mixture was stirred at reflux for 3 h, cooled and concentrated. The residue was taken up in EtOAc and water, the aqueous layer extracted with EtOAc, dried over Na2S04 and concentrated to give the product as a white solid (170 mg, 76%).
*H NMR (DMSO-c/e, 300 MHz) δ (ppm) : 9.10 (s, 1H), 5.54-5.43 (br s, 2H), 4.00-
3.78 (m, 4H), 3.23-3.08 (m, 1H), 1.37 (s, 9H).
Step 4: tert-Butyl 3-(5-methyl-l,2,4-oxadiazol-3-yl)azetidine-l- carboxylate
Figure imgf000052_0001
In a 16 mL vial, terf-butyl 3-[(Z)-amino(hydroxyimino)methyl]azetidine-l- carboxylate (170 mg, 0.74 mmol; which may be prepared as described in Step 3) was dissolved in acetonitrile (7.4 mL) and cooled to 0 °C under nitrogen. DIPEA (387 pL, 2.22 mmol) and acetyl chloride (105 pL, 1.48 mmol) were added dropwise and the reaction mixture was allowed to warm to room temperature then heated to 80 °C overnight, cooled and concentrated. The residue was taken up in EtOAc and water, the aqueous layer extracted with EtOAc, dried over Na2S04 and concentrated . The residue was taken up in o-xylene (8.4 mL) and heated to 150 °C for 2 h and concentrated. The crude mixture was purified on column chromatography (eluent: Pentane/EtOAc 7/3) to give the title compound (97 mg, 55%) as an oil.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 4.30-4.13 (m, 2H), 4.03-3.84 (m, 3H), 2.59 (s, 3H), 1.39 (s, 9H). -Azetidin-3-yl-5-methyl-l,2,4-oxadiazole hydrochloride
Figure imgf000052_0002
To a cooled solution of tert- butyl 3-(5-methyl-l,2,4-oxadiazol-3-yl)azetidine-l- carboxylate (97 mg, 0.41 mmol; which may be prepared as described in Step 4) in dichloromethane was added dropwise HCI 4N in dioxane (2.0 mL). The solution was warmed to room temperature and stirred for 1 h. The solvent was evaporated under reduced pressure to give the title compound (101 mg, quantitative) as a white solid . The product was used in the next step without further analysis.
Step 6: 6-{(lE)-3-[3-(5-Methyl-l 2 4-oxadiazol-3-yl)azetidin-l-yl]-3- oxoprop-l-en-l-yl}-3 4-dihydro-l 8-naphthyridin-2(lH)-one
Figure imgf000053_0001
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (30 mg, 0.12 mmol), DMF (3 ml_), 3-azetidin-3-yl-5-methyl-l,2,4-oxadiazole hydrochloride (25 mg, 0.14 mmol; which may be prepared as described in Step 5), DIPEA (48 μΙ_, 0.28 mmol) and ED AC (27 mg, 0.14 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on preparative TLC (eluent: dichloromethane/NH3 7N in MeOH, 2.5%) to give a white solid . This solid was triturated in acetone and diethyl ether, filtered, washed with acetone and diethyl ether then dried to give the title compound (23 mg, 56%) as a white solid.
LCMS (ESI+) m/z 340 (M + H)+: 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.67 (br s, 1H), 8.41-8.30 (m, 1H), 8.07- 7.98 (m, 1H), 7.43 (d, J = 15.8 Hz, 1H), 6.75 (d, J = 15.8 Hz, 1H), 4.75-4.62 (m, 1H), 4.48-4.25 (m, 2H), 4.16-3.95 (m, 2H), 2.96-2.81 (m, 2H), 2.60 (s, 3H). The CH2 missing is hidden by the DMSO signal .
Example 12
6-{(lE)-3-Oxo-3-[3-(2-thienylmethoxy)azetidin-l-yl]prop-l-en-l-yl}-3 4- dihydro-l,8-naphthyridin-2(lH)-one (E12)
Step 1: 2-(Chloromethyl)thiophene
Figure imgf000053_0002
In a 15 ml_ flask, thiophene-2-methanol (332 μΙ_, 3.50 mmol) was dissolved in tetrahydrofuran (2 ml_) and cooled at 0 °C under nitrogen . Thionyl chloride (305 μΙ_, 4.20 mmol) was added dropwise and the reaction mixture was allowed to warm to room temperature and heated at 50 °C for 2 h. The crude mixture was concentrated under reduced pressure to give a dark oil (480 mg, quantitative). The product was used in the next step without further purification. *H NMR (CDCI3, 300 MHz) : δ (ppm) : 7.36-7.30 (m, 1H), 7.11-7.04 (m, 1H), 6.99- 6.93 (m, 1H), 4.82 (s, 2H).
Step 2: l-(Diphenylmethyl)-3-(2-thienylmethoxy)azetidine
Figure imgf000054_0001
To a solution of l-diphenylmethylazetidin-3-ol (359 mg, 1.5 mmol) in DMF (1 mL) at 0 °C under nitrogen was added NaH (60% in oil, 66 mg, 1.65 mmol). The suspension was stirred for 0.5 h at 0 °C then treated with 2- (chloromethyl)thiophene (464 mg, 3.5 mmol; which may be prepared as described in Step 1) dissolved in DMF (2 mL).
The mixture was allowed to warm to room temperature then heated at 80 °C overnight. The reaction mixture was cooled, acetic acid (2 drops) was added and the mixture concentrated under reduced pressure. The crude material was purified on column chromatography (eluent: Pentane/EtOAc, 9/1 to 7/3) to give the product (204 mg, 41%) as an orange oil.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 7.50-7.46 (m, 1H), 7.43-7.36 (m, 4H), 7.29-7.21 (m, 4H), 7.20-7.12 (m, 2H), 7.06-7.02 (m, 1H), 6.99-6.94 (m, 1H), 4.62-4.48 (m, 2H), 4.39 (br s, 1H), 4.23-4.12 (m, 1H), 3.36-3.27 (m, 2H), 2.80- 2.70 (m, 2H).
Step 3: 3-(2-Thienylmethoxy)azetidine hydrochloride
Figure imgf000054_0002
A 50 mL flask was charged with l-(diphenylmethyl)-3-(2-thienylmethoxy)azetidine (204 mg, 0.61 mmol; which may be prepared as described in Step 2) and 1,2- dichloroethane (2.7 mL). 1-Chloroethyl chloroformate (86 pL, 0.79 mmol) was added and the reaction mixture was stirred at 70 °C for 1.5 h. After cooling to room temperature, methanol (2.7 mL) was added and the reaction mixture was stirred at 70 °C for 1.5 h. The reaction mixture was concentrated to dryness. The crude mixture was triturated in pentane to give a dark wax (140 mg, quantitative) which was used without further purification.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 9.21-8.85 (m, 2H), 7.62-7.52 (m, IH), 7.16-7.08 (m, IH), 7.04-6.97 (m, I H), 4.67 (s, 2H), 4.51-4.39 (m, IH), 4.13-3.96 (m, 2H), 3.84-3.68 (m, 2H).
Step 4: 6-{(lE)-3-Oxo-3-[3-(2-thienylmethoxy)azetidin-l-yl]prop-l-en-l- l}-3,4-dihydro-l,8-naphthyridin-2(lH)-one
Figure imgf000055_0001
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (30 mg, 0.12 mmol), DMF (3 ml_), 3-(2-thienylmethoxy)azetidine hydrochloride (29 mg, 0.14 mmol; which may be prepared as described in Step 3), DIPEA (48 μΙ_, 0.28 mmol) and EDAC (27 mg, 0.14 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on preparative TLC (eluent: dichloromethane/NH3 7N in MeOH, 2.5%) to give a brown solid. This solid was triturated in acetone and diethyl ether, filtered, washed with diethyl ether then dried to give the title compound (8 mg, 18%) as a pale brown solid.
LCMS (ESI+) m/z 370 (M + H)+: 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.66 (br s, IH), 8.39-8.30 (m, IH), 8.04- 7.98 (m, IH), 7.58-7.51 (m, IH), 7.39 (d, J = 15.6 Hz, IH), 7.15-7.07 (m, IH), 7.04-6.98 (m, IH), 6.70 (d, J = 15.6 Hz, IH), 4.67 (s, 2H), 4.51-4.39 (m, 2H), 4.18-4.05 (m, 2H), 3.77-3.68 (m, IH), 2.95-2.85 (m, 2H). The CH2 missing is hidden by the DMSO signal.
Example 13
6-{(lE)-3-[2-(5-Methyl-l 2 4-oxadiazol-3-yl)piperidin-l-yl]-3-oxoprop-l- en-l-yl}-3,4-dihydro-l,8-naphthyridin-2(lH)-one (E13) Step 1: tert-Butyl 2-[(Z)-amino(hydroxyimino)methyl]piperidine-l- carboxylate
Figure imgf000056_0001
In a 16 mL vial, A/-boc-2-cyanopiperidine (500 mg, 2.38 mmol) was dissolved in ethanol (6.7 mL), then hydroxylamine hydrochloride (231 mg, 3.33 mmol) and triethylamine (0.56 mL, 4.05 mmol) were added. The reaction mixture was stirred at reflux for 5 h, cooled and concentrated . The residue was taken up in EtOAc and water. The two layers were separated and the aqueous phase extracted with EtOAc. The combined organics were dried on Na2S04 and concentrated to give the product as a white solid (550 mg, 95%).
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 9.16 (s, 1H), 5.19 (br s, 2H), 4.71-4.57 (m, 1H), 3.87-3.70 (m, 1H), 3.07-2.89 (m, 1H), 2.11-1.89 (m, 1H), 1.62-1.36 (m, 5H), 1.38 (s, 9H). Step 2: tert-Butyl 2-(5-methyl-l,2,4-oxadiazol-3-yl)piperidine-l- carboxylate
Figure imgf000056_0002
In a 16 mL vial, terf-butyl 2-[(Z)-amino(hydroxyimino)methyl]piperidine-l- carboxylate (150 mg, 0.62 mmol; which may be prepared as described in Step 1) was dissolved in acetonitrile (6.2 mL) and cooled at 0 °C under nitrogen. DIPEA (324 pL, 1.86 mmol) and acetyl chloride (88 pL, 1.24 mmol) were added dropwise and the reaction mixture was allowed to warm to room temperature then heated to 100 °C for 4 h, cooled and concentrated . The residue was taken up in EtOAc and water. The two layers were separated and the aqueous phase extracted with EtOAc. The combined organics were dried on Na2S04 and concentrated. The residue was taken up in o-xylene (7 mL) and heated to 150 °C for 3 h then concentrated. The crude mixture was purified on column chromatography (eluent: Pentane/EtOAc 7/3) to give the product (55 mg, 33%) as a yellow oil. *H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 5.38-5.26 (m, IH), 3.95-3.81 (m, IH), 2.99-2.76 (m, I H), 2.57 (s, 3H), 2.17-2.05 (m, IH), 1.87-1.68 (m, IH), 1.66-1.52 (m, 2H), 1.45-1.20 (m, 11H). Step 3: 2-(5-Methyl-l,2,4-oxadiazol-3-yl)piperidine hydrochloride
Figure imgf000057_0001
To a cooled solution of terf-butyl 2-(5-methyl-l,2,4-oxadiazol-3-yl)piperidine-l- carboxylate (55 mg, 0.21 mmol; which may be prepared as described in Step 2) in dichloromethane (1.7 ml_) was added dropwise HCI 4N in dioxane (1.3 ml_). The solution was warmed to room temperature and stirred for 2 h. The solvent was evaporated under reduced pressure to give the title compound (47 mg, quantitative) as a white powder.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 9.58-9.09 (m, 2H), 4.73-4.52 (m, IH), 3.17-2.94 (m, 2H), 2.68 (s, 3H), 2.20-2.04 (m, IH), 1.88-1.51 (m, 5H).
Step 4: 6-{(lE)-3-[2-(5-Methyl-l 2 4-oxadiazol-3-yl)piperidin-l-yl]-3- oxo rop-l-en-l-yl}-3 4-dihydro-l 8-naphthyridin-2(lH)-one
Figure imgf000057_0002
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (30 mg, 0.12 mmol), DMF (3 ml_), 2-(5-methyl-l,2,4-oxadiazol-3-yl)piperidine hydrochloride (29 mg, 0.14 mmol; which may be prepared as described in Step 3), DIPEA (48 μΙ_, 0.28 mmol) and EDAC (27 mg, 0.14 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on preparative TLC (eluent: dichloromethane/NH3 7N in MeOH, 2.5%) to give an oil . This oil was taken up in acetone, diethyl ether and concentrated . The resulting wax was finally dissolved in dichloromethane, concentrated and dried to give the title compound (15 mg, 34%) as a yellow solid. LCMS (ESI+) m/z 368 (M + H)+: 100%.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 10.65 (br s, 1H), 8.44-8.29 (m, 1H), 8.17- 8.02 (m, 1H), 7.49 (d, J = 15.3 Hz, 1H), 7.31 (d, J = 15.3 Hz, 1H), 5.97-5.77 (m, 1H), 4.57-4.23 (m, 1H), 3.26-3.04 (m, 1 H), 2.98-2.78 (m, 2H), 2.58 (s, 3H), 2.37- 2.12 (m, 1H), 1.97-1.09 (m, 5H). The CH2 missing is hidden by the DMSO signal.
Example 14
6-{(lE)-3-[4-Hydroxy-4-phenylpiperidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4- dih dro-l,8-naphthyridin-2(lH)-one (E14)
Figure imgf000058_0001
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (30 mg, 0.12 mmol), DMF (3 ml_), 4-hydroxy-4-phenylpiperidine (25 mg, 0.14 mmol), DIPEA (48 pl_, 0.28 mmol) and EDAC (27 mg, 0.14 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on preparative TLC (eluent: dichloromethane/MeOH, 95/5) to give a white solid . This solid was triturated in acetone and diethyl ether, filtered, washed with diethyl ether and then dried to give the title compound (18.5 mg, 41%) as a white solid.
LCMS (ESI+) m/z 378 (M + H)+: 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.64 (br s, 1H), 8.39-8.30 (m, 1H), 8.14- 8.06 (m, 1H), 7.57-7.45 (m, 3H), 7.40-7.16 (m, 4H), 5.17 (s, 1H), 4.52-4.11 (m, 2H), 3.57-3.39 (m, 1 H), 3.16-2.99 (m, 1 H), 2.97-2.82 (m, 2H), 1.98-1.56 (m, 4H). The CH2 missing is hidden by the DMSO signal. Example 15
6-{(lE)-3-Oxo-3-[3-(pentyloxy)azetidin-l-yl]prop-l-en-l-yl}-3 4-dihydro- l,8-naphthyridin-2( lH)-one (E15)
Step 1: l-(Diphenylmethyl)-3-(pentyloxy)azetidine
Figure imgf000059_0001
A solution of l-diphenylmethylazetidin-3-ol (300 mg, 1.25 mmol) in THF (4.5 mL) was cooled to 0 °C. t-BuOK (1M in THF, 3.75 mL) was added dropwise and the reaction mixture was stirred at room temperature for 1 h then cooled to 0°C. 1- Iodopentane (816 pL, 6.25 mmol) was added and the solution was stirred at room temperature for 18 h. The reaction mixture was diluted with H20 and extracted twice with EtOAc. The organic layers were combined, dried over Na2S04 and concentrated to dryness. The residue was purified on column chromatography (eluent: pentane/EtOAc, 95/5) to give the title compound (267 mg, 69%) as a clear oil.
LCMS (ESI+) m/z 310 (M + H)+: 100%.
Ste 2: l-(Diphenylmethyl)-3-(pentyloxy)azetidine
Figure imgf000059_0002
A 25 mL flask was charged with l-(diphenylmethyl)-3-(pentyloxy)azetidine (267 mg, 0.86 mmol; which may be prepared as described in Step 1) and 1,2- dichloroethane (3.8 mL). 1-Chloroethyl chloroformate (123 pL, 1.13 mmol) was added and the reaction mixture was stirred at 70 °C for 1.5 h. After cooling to room temperature, methanol (3.8 mL) was added and the reaction mixture was stirred at 70 °C for 1.5 h. The reaction mixture was concentrated to dryness. The crude mixture was triturated in pentane to give a clear oil (145 mg, 94%) which was used without further purification.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 9.29-8.80 (m, 2H), 4.38-4.24 (m, 1H), 4.19-4.01 (m, 2H), 3.84-3.68 (m, 2H), 3.40-3.27 (m, 2H), 1.57-1.39 (m, 2H), 1.37-1.18 (m, 4H), 0.87 (t, J = 6.8 Hz, 3H). Step 3: 6-{(lE)-3-Oxo-3-[3-(pentyloxy)azetidin-l-yl]prop-l-en-l-yl}-3,4- dih dro-l,8-naphthyridin-2(lH)-one
Figure imgf000060_0001
A 16 mL vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (40 mg, 0.16 mmol), DMF (3.8 mL), l-(diphenylmethyl)-3-(pentyloxy)azetidine (34 mg, 0.19 mmol; which may be prepared as described in Step 2), DIPEA (63 pL, 0.38 mmol) and EDAC (36 mg, 0.19 mmol). The reaction mixture was stirred at room temperature for 48 h and concentrated to dryness. The residue was purified on preparative TLC (eluent: dichloromethane/ MeOH, 9/1) to give a beige solid . This solid was triturated in acetone to give the title compound (5 mg, 9%) as a white solid.
LCMS (ESI+) m/z 344 (M + H)+: 85%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.67 (br s, 1H), 8.37-8.28 (m, 1 H), 8.03- 7.93 (m, 1H), 7.40 (d, J = 15.6 Hz, 1H), 6.70 (d, J = 15.6 Hz, 1H), 4.52-4.39 (m, 1H), 4.36-4.25 (m, 1 H), 4.18-3.98 (m, 2H), 3.76-3.62 (m, 1 H), 2.96-2.82 (m, 2H), 1.58-1.44 (m, 2H), 1.36-1.18 (m, 4H), 0.92-0.77 (m, 3H). The two CH2 missing are hidden by the DMSO signal and the water peak.
Example 16
6-{(lE)-3-Oxo-3-[3-(pyridin-3-yloxy)pyrrolidin-l-yl]prop-l-en-l-yl}-3 4- dihydro-l,8-naphthyridin-2(lH)-one (E16)
Step 1: tert- Butyl 3-(pyridin-3-yloxy)pyrrolidine-l-carboxylate
Figure imgf000060_0002
To a solution of tert- butyl 3-hydroxypyrrolidine-l-carboxylate (500 mg, 2.67 mmol) in anhydrous THF (13 ml_) under nitrogen were added 3-hydroxypyridine (508 mg, 5.34 mmol) and triphenylphosphine (1.40 g, 5.34 mmol). The reaction mixture was cooled to 0 °C and DEAD (775 μΙ_, 4.27 mmol) was added dropwise. The solution was allowed to warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure then diluted with dichloromethane and filtered . The filtrate was washed three times with NaOH 0.2N, dried over Na2S04 then concentrated. The residue was purified on column chromatography (eluent: pentane/acetone 9/1 to 7/3) to give the title compound (606 mg, 86%) as a wax.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 8.35-8.23 (m, 1H), 8.22-8.12 (m, 1H),
7.48- 7.25 (m, 2H), 5.16-4.99 (m, 1H), 3.64-3.31 (m, 4H), 2.27-1.95 (m, 2H),
1.49- 1.28 (m, 9H). The desired product is contaminated with some hydrogenated DEAD residue.
Ste 2: 3-(Pyrrolidin-3-yloxy)pyridine hydrochloride
Figure imgf000061_0001
To a cooled solution of tart-butyl 3-(pyridin-3-yloxy)pyrrolidine-l-carboxylate (600 mg, 2.27 mmol; which may be prepared as described in Step 1) in dichloromethane (15 ml_) was added dropwise HCI 4N in dioxane (11.1 ml_). The solution was warmed to room temperature and stirred for 1 h. The solvent was evaporated under reduced pressure to give the title compound (263 mg, 58%) as a yellow wax. LCMS (ESI+) m/z 165 (M + H (-HCI))+ : 100%. Step 3: 6-{(lE)-3-Oxo-3-[3-(pyridin-3-yloxy)pyrrolidin-l-yl]prop-l-en-l- yl}-3,4-dihydro-l,8-naphthyridin-2(lH)-one
Figure imgf000061_0002
A 16 mL vial was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro-l,8- naphthyridin-3-yl)acrylic acid hydrochloride (40 mg, 0.16 mmol), DMF (3.8 mL), 3- (pyrrolidin-3-yloxy)pyridine hydrochloride (64 mg, 0.32 mmol; which may be prepared as described in Step 2), DIPEA (63 pL, 0.38 mmol) and HATU (72 mg, 0.19 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on chromatography column (eluent: dichloromethane/ MeOH, 95/5) to give a beige solid. This solid was triturated in acetone and diethyl ether, filtered, washed with acetone and diethyl ether then dried to give the title compound (7.3 mg, 13%) as a beige solid.
LCMS (ESI+) m/z 365 (M + H)+: 100%.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 10.71-10.62 (m, IH), 8.40-8.28 (m, 2H), 8.24-8.17 (m, I H), 8.02 (s, IH), 7.51-7.41 (m, 2H), 7.40-7.32 (m, IH), 7.08-6.91 (m, I H), 5.29-5.11 (m, I H), 4.03-3.61 (m, 3.5 H), 3.55-3.41 (m, 0.5H), 2.98-2.84 (m, 2H), 2.33-2.03 (m, 2H). The CH2 missing is hidden by the DMSO signal.
Example 17
6-{(lE)-3-[3-(Benzyloxy)azetidin-l-yl]-3-oxoprop-l-en-l-yl}-3 4-dihydro- l,8-naphthyridin-2(lH)-one (E17) Ste 1: 3-(Benzyloxy)-l-(diphenylmethyl)azetidine
Figure imgf000062_0001
To a solution of l-diphenylmethylazetidin-3-ol (300 mg, 1.3 mmol) in DMF (2.6 mL) at 0 °C under nitrogen was added NaH (60% in oil, 56 mg, 1.4 mmol). The suspension was stirred for 0.5 h at 0 °C then treated with benzyl bromide (236 pL, 2.0 mmol). The mixture was allowed to warm to room temperature then heated to 80 °C overnight. The reaction mixture was cooled, acetic acid (20 drops) was added and the mixture concentrated under reduced pressure. The crude material was purified on column chromatography (eluent: Pentane/EtOAc, 95/5 to 70/30) to give the product (104 mg, 24%) as an orange oil.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 7.47-7.12 (m, 15H), 4.40 (s, I H), 4.37 (s, 2H), 4.22-4.11 (m, IH), 3.38-3.28 (m, 2H), 2.82-2.74 (m, 2H). Ste 2: 3-(Benzyloxy)azetidine hydrochloride
Figure imgf000063_0001
A 16 mL vial was charged with 3-(benzyloxy)-l-(diphenylmethyl)azetidine (103 mg, 0.31 mmol; which may be prepared as described in Step 1) and 1,2-dichloroethane (1.4 mL). 1-Chloroethyl chloroformate (45 pL, 0.41 mmol) was added and the reaction mixture was stirred at 70 °C for 1.5 h . After cooling to room temperature, methanol (1.4 mL) was added and the reaction mixture was stirred at 70 °C for 1.5 h. The reaction mixture was cooled and concentrated to dryness. The residue was purified on column chromatography (eluent: Pentane/NH3 7N in MeOH, 98/2) to give the title compound (57 mg, 92%).
LCMS (ESI+) m/z 164 (M + H+ (-HQ)) : 100%.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 7.40-7.23 (m, 5H), 4.36 (s, 2H), 4.34-4.21 (m, 1 H), 3.57-3.24 (m, 4H). Step 3: 6-{(lE)-3-[3-(Benzyloxy)azetidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4- dih dro-l,8-naphthyridin-2(lH)-one
Figure imgf000063_0002
A 16 mL vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (60 mg, 0.24 mmol), DMF (5.8 mL), 3-(benzyloxy)azetidine hydrochloride (58 mg, 0.29 mmol; which may be prepared as described in Step 2), DIPEA (96 pL, 0.58 mmol), DMAP (2.4 mg, 0.02 mmol) and EDAC (56 mg, 0.29 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified by precipitation in MeOH/H20 and then triturated in acetone/diethyl ether to give the title compound as a beige solid (33 mg, 38%). LC-MS (ESI+) m/z 364 (M + H)+ : 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.66 (br s, 1H), 8.40-8.30 (m, 1H), 8.06- 7.97 (m, 1H), 7.46-7.26 (m, 6H), 6.71 (d, J = 15.6 Hz, 1H), 4.53-4.35 (m, 4H), 4.19-4.04 (m, 2H), 3.82-3.70 (m, 1H), 2.98-2.84 (m, 2H). The CH2 missing is hidden by the DMSO signal.
Example 18
6-{(lE)-3-[2-(l 3-Benzoxazol-2-yl)piperidin-l-yl]-3-oxoprop-l-en-l-yl}- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E18)
Step 1: tert-Butyl (2R)-2-{[(2-bromophenyl)amino]carbonyl} pyrrolidine- 1-carbox late
Figure imgf000064_0001
In a 500 mL flask, /V-Boc-D-Proline (300 mg, 1.39 mmol) was dissolved in dichioromethane (35 mL) and cooled to 0 °C under nitrogen. /V-Methylmorpholine (153 pL, 1.39 mmol) was added followed by dropwise addition of /so-butyl chloroformate (180 pL, 1.39 mmol) and the reaction mixture stirred at 0 °C for 1 h . 2-Bromoaniline (1.31 mL, 1.39 mmol) was dissolved in dichioromethane (5 mL) then added quickly to the activated acid at 0 °C. The mixture was stirred overnight from 0 °C to room temperature. The reaction mixture was diluted with dichioromethane, washed with water, dried over Na2S04 and concentrated under reduced pressure. The crude mixture was purified on column chromatography (eluent: Pentane/EtOAc, 50/50 to 0/100 then EtOAc/MeOH 80/20) to give the product (394 mg, 77%) as a yellow oil. This product was used in the next step without further purification.
LCMS (ESI+) m/z 369 (M + )+ : 7%.
Step 2: tert-Butyl (2R)-2-(l,3-benzoxazol-2-yl)pyrrolidine-l-carboxylate
Figure imgf000065_0001
In a 25 mL flask, terf-butyl (2R)-2-{[(2-bromophenyl)amino]carbonyl}pyrrolidine- 1-carboxylate (194 mg, 0.53 mmol; which may be prepared as described in Step 1) was dissolved in DME (4 mL) under nitrogen at room temperature. Cul (6 mg, 0.03 mmol), Cs2C03 (261 mg, 0.80 mmol) and 1,10-phenanthroline (26 mg, 0.14 mmol) were added then the reaction mixture was heated at 85 °C for 24 h. The mixture was cooled to room temperature and concentrated to dryness. The residue was dissolved in dichloromethane and filtered on Celite to eliminate the cupper residue. The filtrate was concentrated and the residue purified on preparative TLC (Pentane/EtOAc, 85/15 to 50/50) to give the title compound (88 mg, 58%) as a solid .
LCMS (ESI+) m/z 289 (M + H)+: 9%.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 7.78-7.62 (m, 2H), 7.43-7.31 (m, 2H), 5.08-4.94 (m, 1H), 4.60-4.34 (m, 2H), 2.42-1.80 (m, 4H), 1.37 (s, 3H), 1.06 (s, 6H).
Ste 3: 2-[(2R)-Pyrrolidin-2-yl]-l,3-benzoxazole trifluoroacetate
Figure imgf000065_0002
In a 16 mL flask, trifluoroacetic acid (4 mL) was added to a mixture of terf-butyl (2R)-2-(l,3-benzoxazol-2-yl)pyrrolidine-l-carboxylate (88 mg, 0.31 mmol; which may be prepared as described in Step 2) dissolved in dichloromethane (4 mL) at 0 °C under nitrogen. The reaction was allowed to warm to room temperature and stirred for 3 h. The reaction mixture was concentrated to dryness and the residue used in the next step without further purification.
LCMS (ESI+) m/z 189 (M + H)+: 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.20-9.80 (m, 1H), 9.70-9.30 (m, 1H), 7.88-7.77 (m, 2H), 7.54-7.41 (m, 2H), 5.17-5.05 (m, 1H), 3.45-3.33 (m, 2H), 2.43-2.24 (m, 2H), 2.16-2.02 (m, 2H). Step 4: 6-{(lE)-3-[2-(l,3-Benzoxazol-2-yl)piperidin-l-yl]-3-oxoprop-l-en- l- l}-3,4-dihydro-l,8-naphthyridin-2(lH)-one
Figure imgf000066_0001
A 16 mL vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (60 mg, 0.24 mmol), DMF (5.8 mL), 2-[(2R)-pyrrolidin-2-yl]-l,3-benzoxazole trifluoroacetate (0.31 mmol theory; which may be prepared as described in Step 3), DIPEA (96 pL, 0.58 mmol), DMAP (2.4 mg, 0.02 mmol) and EDAC (56 mg, 0.29 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on preparative TLC (eluent: dichloromethane/ MeOH, 95/5) and column chromatography (eluent: dichloromethane/ MeOH, 98/2) to give the title compound (12 mg, 13%) as a white solid.
LC-MS (ESI+) m/z 389 (M + H)+ : 100%.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 10.71-10.51 (m, 1H), 8.45-8.18 (m, 1H), 8.12-7.78 (m, 1H), 7.75-7.54 (m, 2H), 7.47-7.26 (m, 3H), 7.12-6.92 (m, 1H), 5.83-5.71 (m, 0.2H), 5.31-5.16 (m, 0.8H), 4.04-3.56 (m, 2H), 3.04-2.74 (m, 4H), 2.16-1.94 (m, 2H). The CH2 missing is hidden by the DMSO signal. Example 19
6-[(lE)-3-{3-[(2-Methylprop-2-en-l-yl)oxy]azetidin-l-yl}-3-oxoprop-l- en-l-yl]-3,4-dihydro-l,8-naphthyridin-2(lH)-one (E19)
Ste 1: l-(Diphenylmethyl)-3-[(2-meth lprop-2-en-l-yl)oxy]azetidine
Figure imgf000066_0002
A solution of l-diphenylmethylazetidin-3-ol (239 mg, 1.0 mmol) in THF (3.6 was cooled to 0 °C. t-BuOK (1M in THF, 3.6 mL) was added dropwise and reaction mixture was stirred at room temperature for 1 h then cooled to 0 °C Bromo-2-methyl-l-propene (504 μΙ_, 5.0 mmol) was added and the solution was stirred from 0 °C to room temperature overnight. The reaction mixture was diluted with H20 and extracted twice with EtOAc. The organic layers were combined, dried over Na2S04 and concentrated to dryness to give the title compound (276 mg, 94%) as a yellow oil.
*H NMR (CDCI3, 300 MHz) : δ (ppm) : 7.50-7.07 (m, 10H), 4.89 (d, J = 17.4 Hz, 2H), 4.36 (br s, 1 H), 4.21-4.10 (m, 1 H), 3.77 (br s, 2H), 3.55-3.46 (m, 2H), 2.95- 2.85 (m, 2H), 1.72 (s, 3H). Ste 2: 3-[(2-Methylprop-2-en-l-yl)oxy]azetidine hydrochloride
Figure imgf000067_0001
A 16 ml_ flask was charged with l-(diphenylmethyl)-3-[(2-methylprop-2-en-l- yl)oxy]azetidine (276 mg, 0.94 mmol; which may be prepared as described in Step 1) and 1,2-dichloroethane (4.1 ml_). 1-Chloroethyl chloroformate (135 μΙ_, 1.24 mmol) was added and the reaction mixture was stirred at 70 °C for 1.5 h. After cooling to room temperature, methanol (4.1 ml_) was added and the reaction mixture was stirred at 70 °C for 1.5 h. The reaction mixture was concentrated to dryness and the residue was triturated in pentane to give the final product (192 mg, quantitative) as a brown oil.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 9.37-8.88 (m, 2H), 4.92 (d, J = 20.2 Hz, 2H), 4.40-4.28 (m, 1H), 4.15-4.03 (m, 2H), 3.88-3.72 (m, 4H), 1.67 (s, 3H).
Step 3: 6-[(lE)-3-{3-[(2-Methylprop-2-en-l-yl)oxy]azetidin-l-yl}-3- oxo rop-l-en-l-yl]-3 4-dihydro-l 8-naphth ridin-2( lH)-one
Figure imgf000067_0002
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (60 mg, 0.24 mmol), DMF (5.8 mL), 3-[(2-methylprop-2-en-l-yl)oxy]azetidine hydrochloride (78 mg, 0.48 mmol; which may be prepared as described in Step 2), DIPEA ( 119 μΙ_, 0.72 mmol), DMAP (2.4 mg, 0.02 mmol) and EDAC (56 mg, 0.29 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was precipitated in methanol/water and then filtered. The resulting solid was dissolved in chloroform and washed with water to give a beige solid. This solid was triturated in diethyl ether to give the title compound (13 mg, 16%) as a white solid. LCMS (ESI+) m/z 328 (M + H)+: 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.67 (br s, 1H), 8.41-8.29 (m, 1H), 8.06- 7.96 (m, 1H), 7.39 (d, J = 15.9 Hz, 1H), 6.71 (d, J = 15.9 Hz, 1H), 5.03-4.94 (m, 1H), 4.92-4.82 (m, 1 H), 4.53-4.42 (m, 1 H), 4.41-4.27 (m, 1 H), 4.21-4.03 (m, 2H), 3.88-3.69 (m, 3H), 2.95-2.84 (m, 2H), 1.69 (m, 3H). The CH2 missing is hidden by the DMSO signal. Example 20
6-{(lE)-3-Oxo-3-[3-(l 3-thiazol-2-ylmethoxy)azetidin-l-yl]prop-l-en-l- yl}-3,4-dihydro-l,8-naphthyridin-2( lH)-one (E20) -(Chloromethyl)-l,3-thiazol-3-ium chloride
Figure imgf000068_0001
In a 50 mL flask, thiazole-2-methanol (500 mg, 4.3 mmol) was dissolved in THF (2.6 mL) and cooled to 0 °C under nitrogen. Thionyl chloride (377 pL, 5.2 mmol) was added dropwise and the reaction mixture was allowed to warm to room temperature then heated at 50 °C for 2 h. The crude mixture was concentrated under reduced pressure to give an orange solid (684 mg, 94%).
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 7.88-7.76 (m, 2H), 5.16-5.01 (m, 2H).
Step 2: tert- Butyl 3-(l,3-thiazol-2-ylmethoxy)azetidine-l-carboxylate
Figure imgf000068_0002
To a solution of A/-Boc-azetidin-3-ol (260 mg, 1.5 mmol) in DMF (3.5 mL) at 0 °C under nitrogen was added NaH (60% in oil, 126 mg, 3.15 mmol). The suspension was stirred for 0.5 h at 0 °C then treated with 2-(chloromethyl)-l,3-thiazol-3-ium chloride (510 mg, 3.0 mmol; which may be prepared as described in Step 1) dissolved in DMF (1 mL) and DIPEA (1.05 mL). The mixture was allowed to warm to room temperature then heated to 80 °C overnight. The reaction mixture was cooled, water (20 drops) was added and the mixture concentrated under reduced pressure. The crude material was purified on column chromatography (eluent: Pentane/EtOAc, 90/10 to 50/50) to give the product (193 mg, 48%) as a brown oil. LCMS (ESI+) m/z 271 (M + H)+: 100%.
Ste 3: 2-[(Azetidin-3-yloxy)methyl]-l,3-thiazole hydrochloride
Figure imgf000069_0001
To a solution of tart-butyl 3-(l,3-thiazol-2-ylmethoxy)azetidine-l-carboxylate (193 mg, 0.71 mmol; which may be prepared as described in Step 2) dissolved in diethyl ether (2.6 mL) at room temperature was added HCI 2N in diethyl ether (7.1 mL).
The reaction mixture was stirred for 1.5 h then concentrated to dryness. The resulting solid was triturated with diethyl ether, collected and dried to give the title compound (138 mg, quantitative) as a brown oil.
*H NMR (CDCI3, 300 MHz) : δ (ppm) : 9.40-8.90 (m, 2H), 7.89-7.71 (m, 2H), 4.83
(s, 2H), 4.64-4.59 (m, 1H), 4.18-4.03 (m, 2H), 3.91-3.79 (m, 2H).
Step 4: 6-{(lE)-3-Oxo-3-[3-(l,3-thiazol-2-ylmethoxy)azetidin-l-yl]prop- l-en-l-yl}-3,4-dihydro-l,8-naphthyridin-2(lH)-one
Figure imgf000069_0002
A 16 ml_ vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (60 mg, 0.24 mmol), DMF (5.8 ml_), 2-[(azetidin-3-yloxy)methyl]-l,3-thiazole hydrochloride (99 mg, 0.48 mmol; which may be prepared as described in Step 3), DIPEA ( 119 μΙ_, 0.72 mmol), DMAP (2.4 mg, 0.02 mmol) and EDAC (56 mg, 0.29 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was precipitated in methanol/water and then filtered. The resulting solid was purified on column chromatography (eluent: 96/4 dichloromethane/MeOH) then triturated in pentane and MeOH to give the title compound (21 mg, 24%) as a white solid.
LCMS (ESI+) m/z 371 (M + H)+: 100%.
*H NM R (DMSO-c/e, 300 MHz) : δ (ppm) : 10.66 (br s, 1H), 8.40-8.29 (m, 1H), 8.03- 7.99 (m, 1H), 7.84-7.74 (m, 2H), 7.40 (d, J = 15.6 Hz, 1H), 6.72 (d, J = 15.5 Hz, 0.9H), 6.48 (d, J = 16.0 Hz, 0.1H), 4.82 (s, 2H), 4.61-4.45 (m, 2H), 4.20-4.11 (m, 2H), 3.85-3.74 (m, 1H), 2.95-2.84 (m, 2H). The CH2 missing is hidden by the DMSO signal.
Example 21
6-{(lE)-3-[3-({[(lE)-l-Methyl-2-pyrimidin-2- ylethylidene]amino}oxy)azetidin-l-yl]-3-oxoprop-l-en-l-yl}-3 4-dihydro- l,8-naphthyridin-2(lH)-one (E21)
Ste 1: l-Pyrimidin-2-ylacetone
Figure imgf000070_0001
In a 100 ml_ flask, acetone (1.44 ml_, 19.6 mmol) was added to KH (30% in oil, 2.89 g, 21.6 mmol) in THF (15 ml_) at 0 °C under nitrogen. The reaction mixture was stirred for 0.25 h then additional THF (15 ml_) was added. AIBN (74 mg, 0.45 mmol) followed by 2-chloropyrimidine (500 mg, 4.36 mmol) were added cautiously and the reaction mixture kept at 0 °C for 1 h. HCI 3N was added until the pH = 6. The two layers were separated and the aqueous phase extracted with dichloromethane. The combined extracts were dried over Na2S04 then concentrated. The residue was purified on column chromatography (eluent: EtOAc/ pentane 20/80 to 80/20) to give the title compound (247 mg, 42%) as a yellow oil (keto/enol form 2 : 1). LCMS (ESI+) m/z 137 (M + H)+: 100%.
*H NMR (CDCI3, 300 MHz) : δ (ppm) : 13.71-13.67 (m, 0.3H), 8.71 (d, J = 5.0 Hz, 2H), 8.60-8.48 (m, 0.8H), 7.21 (t, J = 5.0 Hz, 1H), 6.97-6.87 (m, 0.4H), 5.57 (br s, 0.4H), 4.13 (s, 2H), 2.29 (s, 3H), 2.09 (s, 1.2H).
Step 2: 2-{[l-(Diphenylmethyl)azetidin-3-yl]oxy}-lH-isoindole-l,3(2H)- dione
Figure imgf000071_0001
To a solution of A/-benzhydrylazetidin-3-ol (1.0 g, 4.18 mmol) in anhydrous THF (66 mL) under nitrogen were added /V-hydroxyphthalimide (750 mg, 4.60 mmol) and triphenylphosphine (2.19 g, 8.36 mmol). The reaction mixture was cooled to 0 °C and DEAD (1.52 mL, 8.36 mmol) was added dropwise. The solution was allowed to warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced. The residue was purified on column chromatography (eluent: pentane/EtOAc 7/3 to 4/6) to give the title compound (600 mg, 37%) as a wax.
LCMS (ESI+) m/z 385 (M + H)+: 100%.
*H NMR (CDCIs, 300 MHz) : δ (ppm) : 7.88-7.79 (m, 2H), 7.78-7.68 (m, 2H), 7.50- 7.35 (m, 4H), 7.30-7.25 (m, 4H), 7.20-7.00 (m, 2H), 4.97-4.86 (m, 1H), 4.49 (s, 1H), 3.62-3.50 (m, 2H), 3.40-3.26 (m, 2H).
Step 3: 3-(Aminooxy)-l-(diphenylmethyl)azetidine
Figure imgf000071_0002
To a solution of 2-{[l-(diphenylmethyl)azetidin-3-yl]oxy}-lH-isoindole-l,3(2H)- dione (600 mg, 1.56 mmol; which may be prepared as described in Step 2) in ethanol (13.3 mL) was added hydrazine hydrate (100 pL, 2.06 mmol). The resulting mixture was heated to reflux for 2 h then concentrated under reduced pressure. The residue was taken up in dichloromethane/methanol mixture then filtered . The filtrate was concentrated and the residue purified on column chromatography (eluent: Dichloromethane/ NH3 7N in MeOH, 2% to 5%) to give the title compound (307 mg, 77%) as a clear oil.
LCMS (ESI+) m/z 255 (M + H)+: 100%.
Step 4: (2E)-l-Pyrimidin-2-ylacetone 0-(l-diphenylmethylazetidin-3- l)oxime
Figure imgf000072_0001
A solution of l-pyrimidin-2-ylacetone (27 mg, 0.2 mmol; which may be prepared as described in Step 1) and 3-(aminooxy)-l-(diphenylmethyl)azetidine (51 mg, 0.2 mmol; which may be prepared as described in Step 3) in ethanol (2 ml_) under nitrogen was stirred at 80 °C overnight. The crude mixture was concentrated to dryness to give the title compound (75 mg, quantitative) as a brown oil.
LC-MS (ESI+) m/z 373 (M + H)+ : 100%.
*H NMR (CDCI3, 300 MHz) : δ (ppm) : 8.69 (dd, J = 5.1, 1.5 Hz, 2H), 7.51-7.31 (m, 6H), 7.26-7.11 (m, 5H), 4.98-4.73 (m, 1H), 4.54-4.30 (m, 1H), 4.07 (s, 1H), 3.84 (s, 1H), 3.67-3.40 (m, 2H), 3.18-2.91 (m, 2H), 1.91 (s, 3H).
Ste 5: (2E)-l-Pyrimidin-2-ylacetone O-azetidin-3-yloxime hydrochloride
Figure imgf000072_0002
A 25 ml_ flask was charged with (2E)-l-pyrimidin-2-ylacetone 0-(l- diphenylmethylazetidin-3-yl)oxime (372 mg, 1.0 mmol; which may be prepared as described in Step 4) and 1,2-dichloroethane (8.8 ml_). 1-Chloroethylchloroformate (576 μΙ_, 5.28 mmol) was added and the reaction mixture was heated to 70 °C for 3 h. After cooling to room temperature, methanol (8.8 mL) was added and the reaction mixture was heated to 70 °C for 3 h. The reaction mixture was concentrated to dryness and the crude mixture triturated in pentane and diethyl ether to give the title compound (240 mg, 99%) as a dark solid .
LCMS (ESI+) m/z 207 (M + H (-HCI))+ : 17%.
Step 6: 6-{(lE)-3-[3-({ [(l)-l-Methyl-2-pyrimidin-2- ylethylidene]amino}oxy)azetidin-l-yl]-3-oxoprop-l-en-l-yl}-3 4-dihydro- -naphthyridin-2(lH)-one
Figure imgf000073_0001
A 16 mL vial was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro-l,8- naphthyridin-3-yl)acrylic acid hydrochloride (60 mg, 0.24 mmol), DMF (6 mL), (2E)-l-pyrimidin-2-ylacetone O-azetidin-3-yloxime hydrochloride (117 mg, 0.48 mmol; which may be prepared as described in Step 5), DIPEA (160 pL, 0.96 mmol) and DMAP (3 mg, 0.024 mmol). The reaction mixture was cooled to 0 °C and EDAC (56 mg, 0.29 mmol) was added . The reaction mixture was allowed to warm to room temperature, stirred overnight then concentrated to dryness. The crude mixture was purified on column chromatography (eluent: dichloromethane/ MeOH, 2% to 6%) then triturated in diethyl ether and dichloromethane to give the product (8 mg, 8%) and as a beige solid.
LCMS (ESI+) m/z 407 (M + H)+: 100%.
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 10.66 (br s, 1H), 8.82-8.71 (2xd, J = 4.8 Hz, 1H), 8.40-8.31 (m, 1H), 8.08-7.98 (m, 1H), 7.52-7.17 (m, 3H), 6.81-6.65 (2xd, J = 15.9 Hz, 1 H), 5.18-4.99 (m, 1H), 4.60-4.40 (m, 1H), 4.32-4.13 (m, 2H), 4.12-4.06 (m, 1H), 4.04-3.77 (m, 2H), 2.98-2.86 (m, 2H), 1.90-1.85 (2xs, 3H). The CH2 missing is hidden by the DMSO signal.
Example 22
6-{(lE)-3-[3-(Pentylsulfonyl)azetidin-l-yl]-3-oxoprop-l-en-l-yl}-3 4- dihydro-l,8-naphthyridin-2(lH)-one (E22) Step 1: l-(Diphenylmethyl)azetidin-3-yl methanesulfonate
Figure imgf000074_0001
To a solution of dibenzylazetidin-3-ol (500 mg, 2.09 mmol) in TH F (21 ml_) at 0 °C under nitrogen was added methanesulfonyl chloride ( 194 μ Ι_, 2.51 mmol) and triethylamine (612 μ Ι_, 4.39 mmol). The reaction mixture was stirred for 1 h then concentrated to dryness. The residue was dissolved in dichloromethane, washed with water and brine. The organic layer was dried over Na2S04, filtered and concentrated to dryness to give the title product (0.61 g, 92%) as a yellow oil .
LCMS (ESI+) m/z 318 (M + H)+ : 20%.
NM R (DMSO-c/6, 300 M Hz) : δ (ppm) : 7.45-7.14 (m, 10H), 5.16-5.05 (m, 1 H), 4.40 (s, 1 H), 3.67-3.58 (m, 2H), 3.25-3.14 (m, 2H), 2.99 (s, 3H).
Ste 2: l-(Diphenylmethyl)-3-(pentylthio)azetidine
Figure imgf000074_0002
To a solution of pentanethiol (248 μ Ι_, 2.0 mmol) in DMSO (2.5 ml_) at 0 °C under nitrogen was added NaH (60% in oil, 80 mg, 2.0 mmol). The suspension was stirred for 0.5 h at 0 °C then treated with l-(diphenylmethyl)azetidin-3-yl methanesulfonate (317 mg, 1.0 mmol; which may be prepared as described in Step 1) and the mixture allowed to warm to room temperature overnight. Saturated NaHC03 (5 ml_) was added and the mixture was extracted with diethyl ether. The organic layer was separated from the aqueous and the organic washed with brine, dried over Na2S04 and concentrated to give the product (312 mg, 96%) as a yellow oil . *H NMR (CDCI3, 300 MHz) : δ (ppm) : 7.83-7.69 (m, 10H), 4.39 (br s, 1H), 3.63- 3.49 (m, 3H), 3.01-2.90 (m, 2H), 2.61 (br s, 2H), 2.53-2.43 (m, 2H), 1.56-1.45 (m, 2H), 1.35-1.27 (m, 4H), 0.93-0.82 (m, 3H). Ste 3: l-(Diphenylmethyl)-3-(pentylsulfonyl)azetidine
Figure imgf000075_0001
To a solution of l-(diphenylmethyl)-3-(pentylthio)azetidine (228 mg, 0.70 mmol; which may be prepared as described in Step 2) in methanol (6.3 mL) and water (6.3 mL) was added H2S04 IN (0.7 mL). The reaction mixture was stirred for 10 minutes, then oxone (1.08 g, 1.75 mmol) was added and the mixture stirred at room temperature for 12 h. A solution of saturated NaHC03 (5 mL) was added and the mixture extracted with ethyl acetate. The two layers were separated and the organic washed with brine, dried over Na2S04, filtered and concentrated . The crude was then purified on column chromatography (pentane/EtOAc, 100/0 then 90/10) to give the title product (75 mg, 30%) as a pale yellow oil. The less pure fraction (/V-oxide) can be recycled in hydrogenolysis conditions.
LC-MS (ESI+) m/z 358 (M + H)+ : 100%.
*H NMR (CDCI3, 300 MHz) : δ (ppm) : 7.45-7.15 (m, 10H), 4.51 (s, 1H), 3.97-3.84 (m, 1H), 3.58-3.42 (m, 4H), 2.92-2.83 (m, 2H), 1.84-1.70 (m, 2H), 1.43-1.27 (m, 4H), 0.93-0.85 (m, 3H).
Step 4: 3-(Pentylsulfonyl)azetidine hydrochloride
Figure imgf000076_0001
A 16 mL flask was charged with l-(diphenylmethyl)-3-(pentylsulfonyl)azetidine (136 mg, 0.38 mmol; which may be prepared as described in Step 3) and 1,2- dichloroethane (1.7 mL). 1-Chloroethyl chloroformate (53 pL, 0.49 mmol) was added and the reaction mixture was stirred at 70 °C for 1.5 h . After cooling to room temperature, methanol (1.7 mL) was added and the reaction mixture stirred at 70 °C for 1.5 h. The reaction mixture was concentrated dryness. LCMS analysis showed a mixture of the final product and the starting material. The residue was dissolved again in 1,2-dichloroethane and 1-chloroethyl chloroformate (4 eq ., 164 pL) was added. The reaction mixture was stirred at 70 °C for 5 h and overnight after addition of methanol . No starting material was detected by TLC monitoring, so the reaction mixture was concentrated to dryness and the resulting solid triturated in pentane to give the title product (39 mg, 45%) as a dark orange oil .
LCMS (ESI+) m/z 192 (M + H(-HCI))+ : 100%.
Step 5: 6-{(lE)-3-[3-(Pentylsulfonyl)azetidin-l-yl]-3-oxoprop-l-en-l-yl}- -dihydro-l,8-naphthyridin-2(lH)-one
A 16 mL vial flask was successively charged with (2E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (40 mg, 0.16 mmol), DMF (3.9 mL), 3-(pentylsulfonyl)azetidine hydrochloride (39 mg, 0.17 mmol; which may be prepared as described in Step 4), DIPEA (106 pL, 0.64 mmol), DMAP (2 mg, 0.02 mmol) and EDAC (36 mg, 0.19 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified on preparative TLC (eluent: 90/10 DCM/MeOH) then triturated in pentane with a drop of acetone to give the title compound (12 mg, 19%) as a white solid .
LCMS (ESI+) m/z 392 (M + H)+: 100%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 10.68 (br s, 1 H), 8.41-8.25 (m, 1H), 8.06- 7.76 (m, 1 H), 7.50-7.36 (m, 1H), 6.84-5.94 (m, 1 H), 4.63-4.03 (m, 4H), 3.23-3.11 (m, 2H), 2.97-2.85 (m, 2H), 1.72-1.45 (m, 2H), 1.43-1.22 (m, 4H), 0.92-0.80 (m, 3H). The CH2 missing is hidden by the DMSO signal.
Example 23
5-{(lE)-3-Oxo-3-[3-(pyridin-4-ylmethoxy)azetidin-l-yl]prop-l-en-l- yl}pyridin-2-amine (E23)
Step 1: tert- Butyl (2E)-3-(6-aminopyridin-3-yl)acrylate
Figure imgf000077_0001
To a solution of 2-amino-5-bromopyridine (300 mg, 1.73 mmol) in DMF (1.5 mL) and proprionitrile (3.5 mL) under Argon were added DIPEA (613 pL, 3.71 mmol), tert-butyl acrylate (1.02 mL, 7.06 mmol), tri(o-tolyl)phosphine (106 mg, 0.35 mmol) and palladium acetate (39 mg, 0.17 mmol). The mixture was stirred at 100 °C for 20h, then allowed to come back to room temperature, filtered through Celite pad and rinsed with EtOAc. The residue obtained after concentration was purified by flash chromatography (eluent: 95/5 DCM/MeOH) to give the title compound as an orange solid (380 mg, quantitative).
LCMS (ESI+) m/z 221 (M + H)+: 100%. Step 2: (2E)-3-(6-Aminopyridin-3-yl)acrylic acid hydrochloride
Figure imgf000077_0002
CIH
To a solution of tart-butyl (2E)-3-(6-aminopyridin-3-yl)acrylate (380 mg, 1.73 mmol; which may be prepared as described in Step 1) in DCM (3.45 mL) under Argon was added trifluoroacetic acid (3.45 mL). The mixture was stirred at room temperature for lh, then HCI 4N in dioxane (6.9 mL) was added. A beige solid started precipitating at the half of the addition. After concentration, the solid was triturated in Et20, filtered, rinsed with Et20 and dried under vaccum to give the title compound as a beige solid (265 mg, 76%).
LCMS (ESI+) m/z 165 (M - (HCI) + H)+ : 100%.
Step 3: tert- Butyl 3-(pyridin-4-ylmethoxy)azetidine-l-carboxylate
Figure imgf000078_0001
A solution of A/-Boc-azetidin-3-ol (500 mg, 2.89 mmol) in THF (10 ml_) was cooled to 0 °C. t-BuOK (1M in THF, 11.6 ml_) was added dropwise and the reaction mixture was stirred at room temperature for 0.25 h then cooled to 0 °C. A solution of 4- bromomethylpyridine hydrobromide (2.19 g, 8.67 mmol) in dichloromethane (5 ml_) stirred with DIPEA (4 ml_, 24 mmol) for 0.5h was then added. The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with H20 and extracted twice with EtOAc. The organics were separated from the aqueous layer and combined, dried over Na2S04 and concentrated to dryness. The crude mixture was purified by column chromatography (eluent: Pentane/EtOAc, 1/1 to 7/3) to give the title product (313 mg, 41%) as a yellow oil.
LCMS (ESI+) m/z 265 (M)+ : 28%.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 8.54 (d, J = 5.9 Hz, 2H), 7.34 (d, J = 5.9 Hz, 2H), 4.49 (s, 2H), 4.39-4.25 (m, 1H), 4.06-3.90 (m, 2H), 3.80-3.65 (m, 2H), 1.37 (s, 9H). -[(Azetidin-3-yloxy)methyl]pyridine dihydrochloride
Figure imgf000078_0002
To a solution of tert- butyl 3-(pyridin-4-ylmethoxy)azetidine-l-carboxylate (313 mg, 1.18 mmol; which may be prepared as described in Step 3) in diethyl ether (4 ml_) at 0 °C was added HCI 2N in diethyl ether (12 ml_). The reaction mixture was stirred for 1 h then mixture was filtered . The resulting solid was rinsed with diethyl ether and collected to give the title compound as a white solid (155 mg, 65%).
*H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 9.76-9.17 (m, 2H), 8.92-8.84 (m, 2H), 8.01-7.88 (m, 2H), 4.81 (s, 2H), 4.60-4.46 (m, 1H), 4.23-4.09 (m, 2H), 3.98-3.84 (m, 2H).
Step 5: 5-{(lE)-3-Oxo-3-[3-(pyridin-4-ylmethoxy)azetidin-l-yl]prop-l-en- l-yl}pyridin-2-amine
Figure imgf000079_0001
To a solution of (2E)-3-(6-aminopyridin-3-yl)acrylic acid hydrochloride (42 mg, 0.21 mmol; which may be prepared as described in Step 2) in DMF (5 ml_) were added 4-[(azetidin-3-yloxy)methyl]pyridine dihydrochloride (50 mg, 0.25 mmol; which may be prepared as described in Step 4), DIPEA (171 μΙ_, 1.04 mmol), DMAP (2.5 mg, 0.02 mmol) and EDAC (48 mg, 0.25 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was partitioned between a NaHC03 5% solution and DCM . The aqueous phase was extracted twice with DCM, dried over sodium sulfate, filtered and concentrated under vacuum to give an orange solid. The crude was purified on preparative TLC (eluent: 90/10 DCM/MeOH + 1% NH4OH) to give the title compound (21 mg, 33%) as a pale yellow solid.
LCMS (ESI+) m/z 156 (M/2+H)2+ : 100%; m/z 311 (M + H)+ : 25%.
*H NMR (DMSO-c/6, 400 MHz) : δ (ppm) : 8.55 (dd, J = 1.5, 4.4 Hz, 2H), 8.12 (d, J = 2.2 Hz, 1H), 7.75 (dd, J = 2.4, 8.8 Hz, 1H), 7.36 (dd, J = 1.5, 4.4 Hz, 2H), 7.29 (d, J = 15.7 Hz, 1H), 6.47-6.41 (m, 4H), 4.54 (s, 2H), 4.48-4.43 (m, 2H), 4.16-4.09 (m, 2H), 3.83-3.76 (m, 1 H)
Example 24
N-(5-{(lE)-3-Oxo-3-[3-(pyridin-4-ylmethoxy)azetidin-l-yl]prop-l-en-l- yl}pyridin-2-yl)acetamide (E24)
Figure imgf000080_0001
To a solution of 5-{(lE)-3-oxo-3-[3-(pyridin-4-ylmethoxy)azetidin-l-yl]prop-l-en- l-yl}pyridin-2-amine (16 mg, 0.05 mmol) and acetic anhydride (6 μΙ_, 0.06 mmol) in THF (2.4 ml_) was added NaHC03 (5.5 mg, 0.065 mmol). The reaction mixture was warmed at 60 °C and stirred for 40h. LCMS showed that some starting material was remaining. Another portion of acetic anhydride (6 μΙ_) and NaHC03 (5.5 mg) were added and the mixture was stirred at 60 °C for 24h. These additions were repeated twice over 48h. The mixture was then concentrated, partitioned between water and ethyl acetate. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed wih brine, dried over sodium sulfate, filtered and concentrated under vacuum to give an oil. The crude was purified on preparative TLC (eluent: 90/10 DCM/MeOH) to give the title compound (2.3 mg, 12%) as a pale yellow solid .
LCMS (ESI+) m/z 177 (M/2+H)2+ : 100%; m/z 353 (M + H)+ : 22%.
*H NMR (DMSO-c/e, 400 MHz) : δ (ppm) : 10.66 (s, 1H), 8.58-8.54 (m, 3H), 8.14- 8.07 (m, 2H), 7.42 (d, J = 15.7 Hz, 1H), 7.37 (d, J = 5.9 Hz, 2H), 6.76 (d, J = 15.7 Hz, 1H), 4.54 (s, 2H), 4.53-4.45 (m, 2H), 4.21-4.13 (m, 2H), 3.86-3.80 (m, 1H), 2.10 (s, 3H) Example 25
Methyl 6-[(lE)-3-{4-[(4-fluorophenoxy) methyl] piperidin-l-yl}-3-oxoprop- l-en-l-yl]-2-oxo-l 2 3 4-tetrahydro-l 8-naphthyridine-3-carboxylate
(E25) Ste 1: tert- Butyl 4-[(4-fluorophenoxy)methyl]piperidine-l-carboxylate
Figure imgf000080_0002
4-Fluorophenol (520 mg, 4.64 mmol) and triphenylphosphine (1.22 g, 4.64 mmol) were added to a solution of N-boc-piperidine-4-methanol (500 mg, 2.32 mmol) in anhydrous THF (12 mL) under nitrogen. The reaction mixture was cooled to 0 °C and DEAD (670 μΙ_, 3.69 mmol) was added dropwise. The solution was allowed to warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure then diluted with dichloromethane and filtered. The filtrate was washed three times with NaOH 0.2N, dried over Na2S04 and concentrated. The residue was purified on column chromatography (eluent: pentane / EtOAc 95/5) to give the title compound (538 mg, 75%) as a yellow oil . *H NMR (DMSO-c/6, 300 MHz) : δ (ppm) : 7.17-7.02 (m, 2H), 6.98-6.88 (m, 2H), 4.02-3.88 (m, 2H), 3.79 (d, J = 6.3 Hz, 2H), 2.83-2.60 (m, 2H), 1.96-1.79 (m, 1H), 1.79-1.64 (m, 2H), 1.39 (s, 9H), 1.23-1.04 (m, 2H).
Ste 2: 4-[(4-Fluorophenoxy)methyl]piperidine hydrochloride
Figure imgf000081_0001
To a cooled solution of tart-butyl 4-[(4-fluorophenoxy)methyl]piperidine-l- carboxylate (538 mg, 1.74 mmol; which may be prepared as described in Step 1) in dichloromethane (11.5 mL) was added dropwise HCI 4N in dioxane (8.5 mL). The solution was warmed to room temperature and stirred for 1 h. The solvent was evaporated under reduced pressure to give the title compound (416 mg, 97%) as a white solid.
*H NMR (DMSO-c/e, 300 MHz) : δ (ppm) : 9.12-8.88 (m, 1H), 8.80-8.56 (m, 1H), 7.17-7.02 (m, 2H), 7.01-6.86 (m, 2H), 3.82 (d, J = 6.6 Hz, 2H), 3.32-3.21 (m, 2H), 2.97-2.78 (m, 2H), 2.10-1.95 (m, 1H), 1.94-1.81 (m, 2H), 1.58-1.37 (m, 2H).
Step 3: Methyl 6-[(lE)-3-tert-butoxy-3-oxoprop-l-en-l-yl]-2-oxo-l, 2,3,4- tetrahydro-l,8-naphthyridine-3-carboxylate
Figure imgf000081_0002
To a suspension of methyl 6-bromo-2-oxo-l,2,3,4-tetrahydro-l,8-naphthyridine-3- carboxylate (300 mg, 1.06 mmol), prepared as in J. Med. Chem. 2003, 46, 9, 1627-1635, in DMF (1 ml_) and proprionitrile (3.5 ml_) under Argon were added DIPEA (175 μΙ_, 2.271 mmol), tert- butyl acrylate (615 ml_, 4.24 mmol), tri(o- tolyl)phosphine (64 mg, 0.21 mmol) and palladium acetate (48 mg, 0.21 mmol). The mixture was stirred at 100 °C overnight. LCMS analysis showed that some unreacted starting material was remaining, so 24 mg of palladium acetate and 64 mg of tri(o-tolyl)phosphine were added. After 5h at 100 °C, the reaction was allowed to come back to room temperature, filtered through Celite pad and rinsed with methanol. The residue obtained after concentration was purified by flash chromatography (eluent: gradient DCM/EtOAc) to give the title compound as an orange solid (115 mg, 32%) contaminated with traces of tri(o-tolyl)phosphine oxide.
LCMS (ESI+) m/z 333 (M + H)+: 100%.
Step 4: (2E)-3-[6-(Methoxycarbonyl)-7-oxo-5,6,7,8-tetrahydro-l,8- na hthyridin-3-yl]acrylic acid
Figure imgf000082_0001
To a solution of methyl 6-[(lE)-3-tert-butoxy-3-oxoprop-l-en-l-yl]-2-oxo-l, 2,3,4- tetrahydro-l,8-naphthyridine-3-carboxylate (115 mg, 0.346 mmol; which may be prepared as described in Step 3) in DCM (693 μΙ_) at 0 °C under Argon was added TFA (693 μΙ_). The reaction was allowed to come back to room temperature under strirring for 2h and then concentrated under vacuo to give the title compound (103 mg, quantitative) as a brown solid. The product was used without further purification.
LCMS (ESI+) m/z 277 (M + H)+: 100%.
Step 5: Methyl 6-[(lE)-3-{4-[(4-fluorophenoxy)methyl]piperidin-l-yl}-3- oxoprop-l-en-l-yl]-2-oxo-l 2 3 4-tetrahydro-l 8-naphthyridine-3- carboxylate
Figure imgf000083_0001
To a solution of (2E)-3-[6-(methoxycarbonyl)-7-oxo-5,6,7,8-tetrahydro-l,8- naphthyridin-3-yl]acrylic acid (96 mg, 0.35 mmol; which may be prepared as described in Step 4) in DMF (8 ml_) were added 4-[(4- fluorophenoxy)methyl]piperidine hydrochloride (102 mg, 0.42 mmol; which may be prepared as described in Step 2), DIPEA (144 μΙ_, 0.83 mmol), 4-DMAP (17 mg, 0.14 mmol) and EDAC (80 mg, 0.42 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to dryness. The residue was purified by flash chromatography on silica gel (eluent: dichloromethane/MeOH from 100/0 to 80/20) to give a first solid which is purified again on preparative TLC (eluent: dichloromethane/MeOH 95/5) to give the title compound (15 mg, 8%) as a white solid .
LCMS (ESI+) m/z 468 (M + H)+: 100%.
*H NMR (CDCIs, 400 MHz) : δ (ppm) : 10.23 (s, 1 H), 8.44 (s, 1H), 7.69 (s, 1H), 7.60 (d, J = 16.0 Hz, 1H), 6.99-6.89 (m, 3H), 6.83-6.80 (m, 2H), 4.85-4.71 (m, 1H), 4.21-4.10 (m, 1 H), 3.84-3.74 (m, 5H), 3.71 (t, J = 6.9 Hz, 1H), 3.45-3.38 (m, 1H), 3.20-3.14 (m, 2H), 2.80-2.68 (m, 1H), 2.15-2.03 (m, 1H), 2.03-1.88 (m, 2H), 1.40-1.34 (m, 2H). Examples 26 and 27
6-[(lE)-3-{4-[(4-Fluorophenoxy) methyl] piperidin-l-yl}-3-oxoprop-l-en- l-yl]-2-oxo-l 2 3 4-tetrahydro-l 8-naphthyridine-3-carboxamide (E26); and
6-[(lE)-3-{4-[(4-Fluorophenoxy) methyl] piperidin-l-yl}-3-oxoprop-l-en- l-yl]-2-oxo-l,2-dihydro-l,8-naphthyridine-3-carboxamide (E27)
Figure imgf000084_0001
Example 26 Example 27
A solution of methyl 6-[(lE)-3-{4-[(4-fluorophenoxy)methyl]piperidin-l-yl}-3- oxoprop-l-en-l-yl]-2-oxo-l,2,3,4-tetrahydro-l,8-naphthyridine-3-carboxylate (13 mg, 0.028 mmol) in ammonium hydroxide (33% in water, 0.5 mL) and in ammonia (2M in ethanol, 0.5 mL) was stirred at 90 °C for lh30. The mixture was concentrated to dryness and the residue was purified on preparative TLC (eluent: dichloromethane/MeOH 90/10) to give 6-[(lE)-3-{4-[(4- fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l-yl]-2-oxo-l,2,3,4- tetrahydro-l,8-naphthyridine-3-carboxamide (1.6 mg, 12%) as a white solid .
LCMS (ESI+) m/z 453 (M + H)+: 100%.
*H NMR (CDCIs, 400 MHz) : δ (ppm) : 8.52 (s, 1H), 8.29 (s, 1H), 7.77 (s, 1H), 7.60 (d, J = 16.0 Hz, 1 H), 7.17 (br s, 1H), 7.02-6.94 (m, 2H), 6.90 (d, J = 15.0 Hz, 1H), 6.85-6.80 (m, 2H), 5.50 (br s, 1H), 4.84-4.72 (m, 1H), 4.22-4.12 (m, 1H), 3.84- 3.74 (m, 2H), 3.56 (t, J = 7.4 Hz, 1H), 3.50-3.38 (m, 1H), 3.31-3.14 (m, 2H), 2.80-2.70 (m, 1H), 2.16-1.88 (m, 3H), 1.44-1.32 (m, 2H).
The second isolated fraction gave the oxidized derivative (6-[(lE)-3-{4-[(4- fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l-yl]-2-oxo-l,2-dihydro-l,8- naphthyridine-3-carboxamide) as a white solid (2.3 mg, 18%).
LCMS (ESI+) m/z 451 (M + H)+: 100%.
*H NMR (DMSO-c/6, 400 MHz) : δ (ppm) : 12.92 (s, 1H), 9.00 (d, J = 2.0 Hz, 1H), 8.90 (d, J = 3.9 Hz, 1 H), 8.79-8.77 (m, 2H), 7.84 (d, J = 4.3 Hz, 1 H), 7.55 (d, J = 15.0 Hz, 1H), 7.44 (d, J = 15.0 Hz, 1H), 7.13-7.08 (m, 2H), 6.97-6.93 (m, 2H), 4.58-4.50 (m, 1H), 4.40-4.32 (m, 1H), 3.84 (d, J = 6.4 Hz, 2H), 3.22-3.12 (m, 1H), 2.77-2.68 (m, 1H), 2.12-1.96 (m, 1H), 1.92-1.80 (m, 2H), 1.30-1.12 (m, 2H).
Example 28
3-(Hydroxymethyl)-6-[ (lE)-3-{4-[(4-f luorophenoxy) methyl] piperidin-1- yl}-3-oxoprop-l-en-l-yl]-3 4-dihydro-l 8-naphthyridin-2(lH)-one (E28)
Step 1: l-Acryloyl-4-[(4-fluorophenoxy)methyl]piperidine
Figure imgf000085_0001
To a solution of acrylic acid (34 μΙ_, 0.49 mmol) in dichloromethane (2.4 ml_) cooled at 0 °C was added 4-methylmorpholine (134 μΙ_, 1.22 mol) and isobutyl chloroformate (74 μΙ_, 0.57 mmol). The solution was stirred 15 minutes at 0 °C and then 4-[(4-fluorophenoxy)methyl]piperidine hydrochloride (100 mg, 0.41 mmol) was added. The mixture was stirred at room temperature overnight, diluted with water (7 ml_) and extracted twice with DCM (2 x 5 ml_). The combined organic phases were washed with water, dried over sodium sulphate and concentrated in vacuo. The residue obtained was purified by preparative TLC (eluent: dichloromethane/MeOH 95/5) to give the title compound (30 mg, 28%) as a yellow oil.
LCMS (ESI+) m/z 264 (M + H)+: 100%.
Step 2: 6-Bromo-3-(hydroxymethyl)-3 4-dihydro-l 8-naphthyridin-2(lH)- one
Figure imgf000085_0002
To a suspension of methyl 6-bromo-2-oxo-l,2,3,4-tetrahydro-l,8-naphthyridine-3- carboxylate (285 mg, 1 mmol) in THF (10 ml_) under Argon at room temperature was added sodium borohydride (151 mg, 4 mmol). The reaction mixture was stirred at 60°C for 4h, then diluted in EtOAc and washed four times with a NH4CI solution (pH = 6.5). The white organic phase was filtered to give the title compound contamined by impurities as a white solid (59 mg). The filtrate was dried over sodium sulphate, filtered and concentrated in vacuo to give a yellow solid (143 mg). The crude was purified by preparative TLC (eluent: dichloromethane/MeOH 93/7) to give the title compound (10 mg, 4%) as a white solid.
LCMS (ESI+) m/z 257/259 (M + H)+ : 100%.
Step 3: 3-(Hydroxymethyl)-6-[(lE)-3-{4-[(4- fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l-yl]-3 4-dihydro- l,8-naphthyridin-2(lH)-one
Figure imgf000086_0001
To a suspension of 6-bromo-3-(hydroxymethyl)-3,4-dihydro-l,8-naphthyridin- 2(lH)-one (10 mg, 0.039 mmol; which may be prepared as described in Step 2) in DMF (200 μΙ_) and proprionitrile (200 μΙ_) under Argon were added DIPEA (8 μΙ_, 0.047 mmol), l-acryloyl-4-[(4-fluorophenoxy)methyl]piperidine (14 mg, 0.053 mmol ; which may be prepared as described in Step 1), tri(o-tolyl)phosphine (2 mg, 0.008 mmol) and palladium acetate (1 mg, 0.004 mmol). The mixture was stirred at 100 °C for 2 days, then was allowed to come back to room temperature, filtered through Celite pad . The residue obtained after concentration of the filtrate was purified by preparative TLC (eluent: DCM/MeOH 9/1) to give the title compound as a white solid (1 mg, 6%).
LCMS (ESI+) m/z 440 (M + H)+: 100%.
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.31 (s, 1H), 8.20 (br s, 1H), 7.70-7.58 (m, 2H), 6.99-6.80 (m, 5H), 4.84-4.72 (m, 1 H), 4.22-4.10 (m, 1 H), 4.03-3.87 (m, 2H), 3.85-3.72 (m, 2H), 3.25-3.13 (m, 1H), 3.03-2.61 (m, 5H), 2.15-1.87 (m, 3H), 1.44-1.31 (m, 2H).
Example 29
(E)-6-(3-Oxo-3-(3-(2-(thiophen-2-yl)ethoxy)azetidin-l-yl)prop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2( lH)-one (E29)
Step 1: l-Benzhydrylazetidin-3-yl methanesulfonate
Figure imgf000086_0002
Triethylamine (870 ml, 62.67 mmol) and mesyl chloride (390 μΙ_, 50.13 mmol) were successively added to a solution of l-benzhydrylazetan-3-ol (1.0 g, 41.78 mmol) in dichloromethane (10 mL) at room temperature. The reaction mixture was stirred for 1 hour and then diluted by addition of water (20 mL). The aqueous phase was separated and extracted with dichloromethane (2 x 40 mL). The combined organic phases were washed with a saturated solution of sodium chloride (40 mL), dried over sodium sulfate, filtered and concentrated to dryness. The title compound was obtained as a yellow solid (1.5 g, 100%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 7.41-7.19 (m, 10H), 5.12 (q, J = 6 Hz, 1H), 4.41 (s, 1 H), 3.68-3.66 (m, 2H), 3.23-2.21 (m, 2H), 2.99 (s, 3H).
Step 2: l-Benzhydryl-3-(2-(thiophen-2-yl)ethoxy)azetidine
Figure imgf000087_0001
A solution of l-benzhydrylazetidin-3-yl methanesulfonate (324 mg, 1.0 mmol) in thiophene ethanol (2.3 mL, 20.4 mmol) was stirred under microwave irradiations (100 W) at 110°C for 30 minutes. The reaction mixture was then partitioned between dichloromethane (20 mL) and a solution of sodium hydroxyde (IN, 10 mL). The aqueous layer was separated and extracted with dichloromethane (2 x 10 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (85 : 15) as eluent. The title product was obtained as a yellow solid (210 mg, 59%).
LCMS (ESI-APCI) m/z 350.2 (M + H)+
Step 3: 3-(2-(Thiophen-2-yl)ethoxy)azetidine hydrochloride hydrochloride
Figure imgf000087_0002
1-Chloroethylchloroformate (361 pL, 3.33 mmol) was added to a solution of 1- benzhydryl-3-(2-(thiophen-2-yl)ethoxy)azetidine (1.11 g, 3.17 mmol) in dichloromethane (15 mL) at room temperature. The reaction mixture was stirred overnight at room temperature, then 1 hour at 70°C. After cooling down to room temperature, ethanol (15 mL) was added and the reaction mixture was stirred at 70 °C for 1 hour. After concentration to dryness, the crude mixture was triturated in pentane (2 x 15 mL) to give a yellow oil (698 mg, quantitative) which was used in the next step without further purification. LCMS (ESI-APCI) m/z 184.2 (M + H)+
Step 4: (E)-6-(3-Oxo-3-(3-(2-(thiophen-2-yl)ethoxy)azetidin-l-yl)prop-l- enyl)-3 -dihydro-l 8-naphthyridin-2(l )-one
Figure imgf000088_0001
3-(2-(Thiophen-2-yl)ethoxy)azetidine hydrochloride (128 mg, 0.6 mmol), EDCI (113 mg, 0.6 mmol), HOBt (80 mg, 0.6 mmol) and diisopropylethylamine (170 μΙ_, 1.0 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (100 mg, 0.4 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred overnight and then partitioned between ethyl acetate (40 mL) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (99 : 1 to 95 : 5) as eluent. The residue was triturated with acetone to give a white solid (40 mg, 27%).
LCMS (ESI-APCI) 384.1 m/z (M + H)+
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.68 (s, NH), 8.34 (s, 1H), 8.01 (s, 1H), 7.4 (d, J = 15.6 Hz, 1 H), 7.36-7.33 (m, 1H), 6.97-6.82 (m, 2H), 6.72 (d, J = 15.6 Hz, 1H), 4.50-4.38 (m, 2H), 4.14-4.03 (m, 2H), 3.77-3.70 (m, 1H), 3.63-3.59 (m, 2H), 3.07 (t, J = 6.2 Hz, 2H), 2.91 (t, J = 7.6 Hz, 2H), 2.5 (t, J = 7.6 Hz, 2H). The CH2 at 2.5 ppm is partially hidden by DMSO. Example 30
(E)-6-(3-Oxo-3-(3-(3-(thiophen-2-yl)propoxy)azetidin-l-yl)prop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2( lH)-one (E30)
Step 1: 3-(2-Thienyl)propanol
Figure imgf000088_0002
Borane methylsulfide complex (6.4 mL, 12.8 mmol) was added to a solution of 3- (2-thienyl)propanoic acid (1.0 g, 6.4 mmol) in THF (18 mL) at 0°C. The reaction mixture was stirred at 0°C for 2 hours and at room temperature for 3 additional hours. After cooling down to 0°C, the reaction was quenched by addition of a saturated solution of potassium carbonate (5 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 15 mL) and diethyl ether (2 x 15 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated to dryness. The title compound was obtained as a colorless oil ( 1.0 g, 100%).
*H NMR (CDC , 400 MHz) : δ (ppm) : 7.18-7.17 (m, 1H), 6.99-6.96 (m, 1H), 6.87- 6.86 (m, 1H), 3.79-3.74 (m, 2H), 3.0 (t, J = 7.6 Hz, 2H), 2.4-1.97 (m, 2H).
Step 2: 2-(3-Chloropropyl)thiophene
Figure imgf000089_0001
Thionyl chloride (420 pL, 5.7 mmol) was added to a solution of 3-(2- thienyl)propanol (682.0 mg, 4.8 mmol) in THF (3 mL) at room temperature. The reaction mixture was stirred at 50°C for 2 hours and then concentrated to dryness to afford the title compound as a brown oil. The product was used in the next step without further purification.
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 7.34-7.32 (m, 1H), 6.96-6.94 (m, 1H), 6.89-6.88 (m, 1H), 3.69-3.63 (m, 2H), 2.84 (t, J = 7.6 Hz, 2H), 2.08-2.01 (m, 2H).
Step 3: l-Benzhydryl-3-(3-(thiophen-2-yl)propoxy)azetidine
Figure imgf000089_0002
Sodium hydride (60% in oil, 200.0 mg, 5 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (500.0 mg, 2.1 mmol) in dimethylformamide (3 mL) at room temperature. The mixture was stirred for 30 minutes prior to the addition of 2-(3-chloropropyl)thiophene (772.0 mg, 4.8 mmol) in solution in dimethylformamide (2 mL). The reaction mixture was stirred at 80°C overnight then concentrated to dryness. The residue was partitioned between ethyl acetate (30 mL) and water (30 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 15 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (99 : 1 to 90 : 10) as eluent. The title product was obtained as a yellow oil (320 mg, 42%).
LCMS (ESI-APCI) m/z 364.2 (M + H)+ Step 4: 3-(4-Methyl-thiophen-2-ylmethoxy)-azetidine hydrochloride
Figure imgf000090_0001
1-Chloroethyl chloroformate (65.5 μΙ_, 21.5 mmol) was added to a solution of 1- benzhydryl-3-(3-(thiophen-2-yl)propoxy)azetidine (220 mg, 0.61 mmol) in dichloromethane (7 mL) at 0°C. The reaction mixture was stirred 2 hours at 0°C and then allowed to warm up to room temperature. Ethanol (9 mL) was added and the reaction mixture was stirred for 2 additional hours at room temperature. After concentration to dryness, the crude mixture was triturated in pentane (2 x 15 mL) to give a brown solid (140 mg, quantitative) which was used in the next step without further purification.
LCMS (ESI-APCI) m/z 198.2 (M + H)+
Step 5: (E)-6-(3-Oxo-3-(3-(3-(thiophen-2-yl)propoxy)azetidin-l-yl)prop- l-enyl)-3,4-dihydro-l,8-naphthyridin-2(l/ )-one
Figure imgf000090_0002
HCI
3-(4-Methyl-thiophen-2-ylmethoxy)-azetidine hydrochloride (128.0 mg, 0.6 mmol), EDCI (113. mg, 0.6 mmol), HOBt (80.0 mg, 0.6 mmol) and diisopropylethylamine (170 pL, 1.0 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (100.0 mg, 0.4 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred overnight and then partitioned between ethyl acetate (30 mL) and water (30 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (99 : 1 to 95 : 5) as eluent. The residue was triturated in acetone to give the title compound as a white solid (40.0 mg, 27%).
LCMS (ESI-APCI) 398.1 m/z (M + H) +
1 NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.69 (br s, NH), 8.34 (s, 1H), 8.02 (s, 1H), 7.40 (d, J = 15.6 Hz, 1H), 7.34-7.31 (m, 1H), 6.96-6.94 (m, 1H), 6.88-6.87 (m, 1H), 6.72 (d, J = 15.6 Hz, 1H), 4.49-4.47 (m, 1H), 4.45 (m, 1H), 4.34-4.06 (m, 2H), 3.76-3.72 (m, 1H), 3.42 (t, J = 7.6 Hz, 2H), 2.92-2.85 (m, 4H), 2.55 (t, J = 7.6 Hz, 2H), 1.9-1.83 (m, 2H). The CH2 at 2.5 ppm is partially hidden by DMSO. Example 31
(E)-6-(3-(3-((3-Methylthiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l- enyl)-3,4-dihydro-l,8-naphthyridin-2(ltt)-one (E31)
Step 1: (3-Methylthiophen-2-yl)methanol
Figure imgf000091_0001
Sodium borohydride (718 mg, 19.02 mmol) was added portionwise, at 0°C, to a solution of 3-methylthiophene-2-carbaldehyde (2.0 g, 15.85 mmol) in a mixture of ethanol and toluene (1 : 1, 12 mL). The reaction mixture was stirred 2 hours at room temperature and then partitioned between ethyl acetate (15 mL) and water (15 mL). The aqueous layer was separated and extracted with ethyl acetate (3 x 45 mL). The combined organic phases were washed with a saturated solution of sodium chloride (1 x 10 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give the title product as a pink oil (2.24 g, 99%).
1 NMR (CDCI3, 400 MHz) : δ (ppm) : 7.16 (d, J = 5.2 Hz, 1H), 6.84 (d, J = 5.2 Hz, 1H), 4.76 (S, 2H), 2.23 (S, 3H).
Step 2: 2-(Chloromethyl)-3-methylthiophene
Figure imgf000091_0002
Thionyl chloride (430 pL, 5.8 mmol) was added at 0°C to a solution of (3- methylthiophen-2-yl)methanol (624 mg, 4.8 mmol) in tetrahydrofuran (3 mL). The reacction mixture was stirred 2 hours at 50°C then concentrated to dryness. The title compound was used in the next step without further purification.
Step 3: l-Benzhydryl-3-((3-methylthiophen-2-yl)methoxy)azetidine H
Figure imgf000092_0001
Sodium hydride (60% in oil, 106 mg, 2.3 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (580 mg, 2.0 mmol) in dimethylformamide (3 mL) at room temperature. The reaction mixture was stirred at room temperature for 30 minutes prior to the addition of 2-(chloromethyl)-3-methylthiophene (714 mg, 4.8 mmol) in solution in dimethylformamide (2 mL). The reaction mixture was stirred at 80°C overnight and cooled to room temperature. The mixture was then partitioned between ethyl acetate (30 mL) and water (30 mL). The aqueous layer was separated and extracted with ethyl acetate (3 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (95 : 5 to 9 : 1) as eluent. The title product was obtained as a yellow oil (267 mg, 36%).
LCMS (ESI-APCI) m/z 350.2 (M + H)+
Step 4: 3-((3-Methylthiophen-2-yl)methoxy)azetidine hydrochloride
Figure imgf000092_0002
1-Chloroethyl chloroformate (90 pL, 0.84 mmol) was added to a solution of 1- benzhydryl-3-((3-methylthiophen-2-yl)methoxy)azetidine (290 mg, 0.83 mmol) in dichloromethane (9 mL) at 0°C. The reaction mixture was stirred 3 hours, then 30 minutes at room temperature. Ethanol (9 mL) was added and the reaction mixture was stirred at 35°C for an additional 3 hours. After concentration to dryness, the crude was triturated in pentane to give a yellow solid (200 mg, quantitative) which was used in the next step without further purification .
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 9.79 (s, 1H), 9.50 (s, 1H), 7.19 (d, J = 5.6 Hz, 1H), 6.82 (d, J = 5.6 Hz, 1H), 4.57 (s, 2H), 4.50-4.46 (m, 1H), 4.06-4.01 (m, 2H), 3.94-3.89 (m, 2H), 2.23 (s, 3H). Step 5: (E)-6-(3-(3-((3-Methylthiophen-2-yl)methoxy)azetidin-l-yl)-3- oxoprop- -enyl)-3,4-dihydro-l,8-naphthyridin-2(lW)-one
Figure imgf000093_0001
3-((3-methylthiophen-2-yl)methoxy)azetidine hydrochloride (129.0 mg, 0.6 mmol), EDCI (112.0 mg, 0.6 mmol), HOBt (82.0 mg, 0.6 mmol) and diisopropylethylamine (170 μΙ_, 1.0 mmol) were successively added to a solution of (E)-3-(7-Oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (100.0 mg, 0.4 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred overnight and then partitioned between ethyl acetate (30 mL) and water (30 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (100 : 0 to 95 : 5) as eluent. The residue was triturated in acetone to give a white solid (66.0 mg, 44%).
LCMS (ESI-APCI) m/z 384.2 (M + H)+
*H NMR (CDCIs, 400 MHz) : δ (ppm) : 8.67 (br s, NH), 8.32 (s, 1H), 7.63 (s, 1H), 7.57 (d, J = 15.6 Hz, 1 H), 7.21 (d, J = 4.8 Hz, 1H), 6.85 (d, J = 4.8 Hz, 1H), 6.39 (d, J = 15.6 Hz, 1H), 4.62-4.61 (m, 2H), 4.46-4.40 (m, 2H), 4.28-4.23 (m, 1H), 4.16-4.14 (m, 1H), 4.01-3.98 (m, 1H), 2.99 (t, J = 8 Hz, 2H), 2.69 (t, J = 8 Hz, 2H), 2.25 (S, 3H).
Example 32
6-[3-(3-(4-Methyl-thiophen-2ylmethoxy)-azetidin-l-yl)-3-oxo-propenyl]- 3,4-dihydro-lH-[l,8]naphthyridin-2-one (E32)
Step 1: (4-Methyl-thiophen-2-yl)methanol
Figure imgf000093_0002
Sodium borohydride (719.0 mg, 19 mmol) was added to a solution of 4-methyl- thiophene-2-carbaldehyde (2.0 g, 15.8 mmol) in a mixture of ethanol and toluene (1 : 1, 12 mL) at 0°C. The reaction mixture was stirred for 2 hours at room temperature and then directly partitioned between water (10 mL) and ethyl acetate (15 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride, dried over sodium sulfate, filtered and concentrated to dryness. The title product was obtained as a yellow oil (2.1 g, 95%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 6.85 (s, 1 H), 6.83 (s, 1 H), 4.76 (d, J = 5.6 Hz, 2H), 2.34 (s, 3H), 1.81 (t, J = 6 Hz, OH).
Step 2: 2-Chloromethyl-4-meth -thiophene
Figure imgf000094_0001
Thionyl chloride (1.3 mL, 17.7 mmol) was added to a solution of (4-methyl- thiophen-2-yl)methanol (1.9 g, 14.8 mmol) in tetrahydrofuran (7 mL) at 0°C. The reaction mixture was stirred at 50°C for 2 hours then concentrated to dryness. The title product was obtained as a brown oil (2.17 g, quantitative) which was used in the next step without further purification .
Step 3: l-Benzhydryl-3-(4-methyl-thiophen-2-ylmethoxy)-azetidine
Figure imgf000094_0002
Sodium hydride (60% in oil, 88.0 mg, 2.3 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (500 mg, 2.0 mmol) in dimethylformamide (3 mL) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of 2-chloromethyl-4-methyl-thiophene (714 mg, 4.8 mmol) in solution in dimethylformamide (2 mL). The reaction mixture was stirred at 80°C overnight and cooled to room temperature. The mixture was then partitioned between ethyl acetate (30 ml) and water (30 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (95 : 5 to 90 : 10) as eluent. The title product was obtained as a yellow solid (400 mg, 55%).
LCMS (ESI-APCI) m/z 350.2 (M + H)+
Step 4: 3-(4-Methyl-thiophen-2-ylmethoxy)-azetidine hydrochloride
Figure imgf000095_0001
1-Chloroethyl chloroform ate (50.0 μΙ_, 0.4 mmol) was added to a solution of 1- benzhydryl-3-(4-methylthiophen-2-ylmethoxy)-azetidine (150.0 mg, 0.4 mmol) in dichloromethane (4.5 ml_) at 0°C. The reaction mixture was stirred 3 hours, then 30 minutes at room temperature. Ethanol (6 ml_) was added and the reaction mixture was stirred at 35°C for an additional 4 hours. After concentration to dryness, the crude was triturated in pentane (2 x 10 ml_) to give a yellow solid (94.0 mg, quantitative) which was used in the next step without further purification.
*H NMR (DMSO-c/e, 400 MHz) : δ (ppm) : 8.99 (br s, NH2), 7.12 (s, 1H), 6.92 (s, 1H), 4.61 (s, 2H), 4.45-4.42 (m, 1H), 4.11-4.05 (m, 2H), 3.78-3.75 (m, 2H), 2.19 (s, 3H).
Step 5: 6-[3-(3-(4-Methyl-thiophen-2ylmethoxy)-azetidin-l-yl)-3-oxo- propenyl]-3,4-dihydro-lW-[l,8]naphthyridin-2-one
Figure imgf000095_0002
HCI
3-(4-methyl-thiophen-2-ylmethoxy)-azetidine hydrochloride (128.0 mg, 0.6 mmol), EDCI (113.0 mg, 0.6 mmol), HOBt (80.0 mg, 0.6 mmol) and diisopropylethylamine (170 μΙ_, 1.0 mmol) were successively added to a solution of (E)-3-(7-Oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (100.0 mg, 0.4 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred at room temperature overnight and then partitioned between ethyl acetate (20 mL) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 ml). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 20 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (99 : 1 to 95 : 5) as eluent. The residue was triturated with acetone to give a white solid (40 mg, 27%).
LCMS (ESI-APCI) 384.2 m/z (M + H)+ *H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.39 (br s, NH), 8.30 (s, 1H), 7.64 (s, 1H), 7.57 (d, J = 15.6 Hz, 1H), 6.90 (s, 1H), 6.84 (s, 1H), 6.39 (d, J = 15.6 Hz, 1H), 4.62 (s, 2H), 4.47-4.39 (m, 2H), 4.28-4.24 (m, 1H), 4.18-4.15 (m, 1H), 4.02-3.99 (m, 1 H), 3.00 (t, J = 7.2 Hz, 2H), 2.70 (t, J = 7.6 Hz, 2H), 2.24 (s, 3H).
Example 33
(E)-6-(3-(3-((5-Methylthiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l- enyl)-3,4-dihydro-l,8-naphthyridin-2( ltt)-one (E33) Step 1 : (5-Methyl-thiophen-2-yl)-methanol
Figure imgf000096_0001
Sodium borohydride (720 mg, 19.02 mmol) was added to a solution of 5-methyl- thiophene-2-carbaldehyde (2.0 g, 15.85 mmol) in a mixture of ethanol and toluene (1 : 1, 12 mL) at 0°C. The reaction mixture was stirred 2 hours at room temperature and then partitioned between water (15 mL) and ethyl acetate (15 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with a saturated solution of sodium chloride (20 mL), dried over sodium sulfate, filtered and concentrated to dryness. The title product was obtained as a yellow oil (2.01 g, 99%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 6.79 (d, J = 2.8 Hz, 1H), 6.61 (d, J = 2.8 Hz, 1H), 4.73 (S, 2H), 2.47 (s, 3H).
Step 2: 2-(Chloromethyl)-5-methylthiophene
Figure imgf000096_0002
Triethylamine (2.2 mL, 16.0 mmol) and a solution of thionyl chloride (1.3 mL, 17.7 mmol) in dichloromethane (20 mL) were successively added to a solution of (5- methyl-thiophen-2-yl)-methanol (1.9 g, 14.6 mmol) in dichloromethane (20 mL) at 0°C. The reaction mixture was stirred 2 hours at reflux then cooled to room temperature. The mixture was then partitioned between water (15 mL) and ethyl acetate (20 mL). The organic phase was separated, dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (10 : 0 to 9 : 1) as eluent. The title product was obtained as a brown oil (1.5 g, 71%). *H NMR (CDCI3, 400 MHz) : δ (ppm) : 6.87 (d, J = 3.2 Hz, 1 H), 6.59 (d, J = 3.2 1H), 4.75 (S, 2H), 2.47 (s, 3H).
Step 3: l-Benzhydryl-((5-methylthiophen-2-yl)methoxy)-azetidine
Figure imgf000097_0001
Sodium hydride (60% in oil, 204.0 mg, 5.1 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (816.0 mg, 3.4 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of 2-(chloromethyl)-5-methylthiophene (1.5 g, 10.2 mmol) in solution in dimethylformamide (5 mL). The reaction mixture was stirred at 50°C for 60 hours and cooled to room temperature. The reaction mixture was then partionned between ethyl acetate (20 mL) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL). The organic phase was dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (90 : 10) as eluent. The title product was obtained as a yellow solid (580.0 mg, 49%).
LCMS (ESI-APCI) m/z 350.2 (M + H)+
Step 4: 3-((5-Methylthiophen-2-yl)methoxy)-azetidine hydrochloride
Figure imgf000097_0002
1-Chloroethyl chloroformate (198 pL, 1.8 mmol) was added to a solution of 1- benzhydryl-((5-methylthiophen-2-yl)methoxy)-azetidine (580.0 mg, 1.6 mmol) in dichloromethane (10 mL) at 0°C. The reaction mixture was stirred for lh30 at the same temperature and 30 minutes at room temperature. Methanol (10 mL) was then added and the reaction mixture was stirred for an additional 3 hours at 35 °C. After concentration to dryness, the crude was triturated in petroleum ether (10 mL) and diethyl ether (10 mL) to give a yellow oil (190 mg, 52%) which was used in the next step without further purification. *H NMR (DMSO-de, 400 MHz) : δ (ppm) : 8.87 (br s, NH2), 6.89 (d , J = 2.8 Hz, 1 H), 6.69 (d , J = 2.8 Hz, 1H), 4.57 (s, 2H), 4.44-4.40 (m, 1H), 4.07-4.04 (m, 2H), 3.78-3.75 (m, 2H), 2.43 (s, 3H). Step 5: (E)-6-(3-(3-((5-Methylthiophen-2-yl)methoxy)azetidin-l-yl)-3- oxoprop- -enyl)-3,4-dihydro-l,8-naphthyridin-2(lW)-one
Figure imgf000098_0001
3-((5-Methylthiophen-2-yl)methoxy)-azetidine hydrochloride (190.0 mg, 0.9 mmol), EDCI (190.0 mg, 1.0 mmol), HOBt (137 mg, 1.0 mmol) and diisopropylethylamine (287 μΙ_, 1.6 mmol) were successively added to a solution of (E)-3-(7-Oxo-5,6,7,8-tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (168.0 mg, 0.7 mmol) in dimethylformamide (15 ml_) at room temperature. The reaction mixture was stirred overnight and then partionned between ethyl acetate (30 ml_) and water (30 ml_). The aqueous layer was separated and extracted with ethyl acetate (2 x 30 ml). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 ml_), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (98: 2 to 95 : 5) as eluent. The residue was triturated in diethyl ether to give a yellow solid (74.0 mg, 30%).
LCMS (ESI-APCI) 384.1 m/z (M + H)+
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.68 (br s, NH), 8.33 (s, 1H), 8.01 (s, 1 H), 7.39 (d, J = 15.6 Hz, 1 H), 6.89 (d, J = 3.2 Hz, 1 H), 6.7 (d, J = 15.6 Hz, 1 H), 6.69 (d, J = 3.2 Hz, 1H), 4.57 (s, 2H), 4.46-4.41 (m, 2H), 4.12-4.06 (m, 2H), 3.73-3.69 (m, 1 H), 2.89 (t, J = 8 Hz, 2H), 2.50 (t, J = 8 Hz, 2H), 2.43 (s, 3H). The CH2 at 2.5 ppm is partially hidden by DMSO.
Example 34
fE^-6-[3-(2-Methoxyethoxy)azetidin-l-yl)-3-oxoprop-l-enyl]-3 4-dihydro- l,8-naphthyridin-2( lH)-one (E34)
Step 1: l-Benzhydryl-3-(2-methoxyethoxy)-azetidine
Figure imgf000099_0001
Sodium hydride (60% in oil, 55.0 mg, 1.4 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (300 mg, 1.2 mmol) in dimethylformamide (2.6 ml_) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of l-bromo-2-methoxyethane (1.5 ml_, 1.9 mmol). The reaction mixture was stirred overnight and then directly partitioned between dichloromethane (20 ml_) and water (20 ml_). The aqueous phase was separated and extracted with dichloromethane (2 x 30 ml_). The combined organic layer were washed with a saturated solution of sodium chloride (3 x 30 ml_), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using pentane/ethyl acetate (98: 2 to 80 : 20) as eluent. The title product was obtained as an orange oil (230 mg, 62%).
LCMS (ESI-APCI) m/z 298.0 (M + H)+. Step 2: 3-(2-Methoxyethoxy)-azetidine hydrochloride
Figure imgf000099_0002
1-Chloroethyl chloroformate (102 μΙ_, 0.9 mmol) was added to a solution of 1- benzhydryl-3-(2-methoxyethoxy)-azetidine (215 mg, 0.7 mmol) in 1,2- dichloroethane (3 ml_) at room temperature. The reaction mixture was then heated up to 70°C and stirred for 2.5 hours. After cooling down to room temperature, methanol (3 ml_) was added and the reaction mixture was stirred overnight at 70°C. The mixture was then concentrated to dryness and the residue was triturated in pentane (2 x 15 ml_) to give a yellow oil (109 mg, 90 %) which was used in the next step without further purification.
^ NMR (CDCI3, 400 MHz) : δ (ppm) : 9.69 and 9.45 (br s, NH2), 4.43-4.41 (m, 1H), 4.13-4.10 (m, 2H), 3.97-3.94 (m, 2H), 3.52-3.50 (m, 2H), 3.42-3.40 (m, 2H), 3.28 (s, 3H).
Step 3: (E 6-[3-(2-Methoxyethoxy)azetidin-l-yl)-3-oxoprop-l-enyl]-3,4- dihydro-l,8-naphthyridin-2( lH)-one
Figure imgf000100_0001
3-(2-Methoxyethoxy)-azetidine hydrochloride (98 mg, 0.6 mmol), EDCI (117 mg, 0.6 mmol), HOBt (82 mg, 0.6 mmol) and diisopropylethylamine (170 μΙ_, 1.0 mmol) were successively added to a solution of (E)-3-(7-Oxo-5,6,7,8-tetrahydro-l,8- naphthyridin-3-yl)-acrylic acid hydrochloride (100.0 mg, 0.4 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred overnight and then partitioned between ethyl acetate (30 mL) and water (30 mL). The aqueous layer was separated and successively extracted with ethyl acetate (2 x 30 mL) and dichloromethane (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 20 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (98: 2 to 95 : 5) as eluent. After precipitation in a mixture of dichloromethane and diethyl ether, the title product was obtained as a yellow solid (70 mg, 54%).
LCMS (ESI-APCI) m/z 332.0 (M + H)+
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.65 (br s, NH), 8.35 (s, 1H), 8.01 (s, 1H), 7.40 (d, J = 15.6 Hz, 1H), ), 6.72 (d, J = 15.6 Hz, 1H), 4.49-4.45 (m, 1H), 4.38-4.35 (m, 1 H), 4.15-4.06 (m, 2H), 3.75-3.72 (m, 1 H), 3.72-3.46 (m, 4H), 3.27 (s, 3H), 2.92 (t, J = 7.2 Hz, 2H), 2.54 (t, J = 7.2 Hz, 2H). The triplet CH2 at 2.54 ppm is partially hidden by DMSO.
Example 35
(E 6-[3-(3-Methoxypropoxy)azetidin-l-yl)-3-oxoprop-l-enyl]-3,4- dihydro-l,8-naphthyridin-2( lH)-one (E35)
Step 1: l-Benzh dryl-3-(3-methoxypropoxy -azetidine
Figure imgf000100_0002
Sodium hydride (60% in oil, 92 mg, 2.3 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (500 mg, 2.1 mmol) in dimethylformamide (2 mL) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of l-chloro-3-methoxypropane (520 pL, 4.8 mmol) in solution in dimethylformamide (3 mL). The mixture was then stirred at 80°C overnight. Since the conversion was still incomplete, sodium hydride (60% in oil, 42 mg, 1.1 mmol) and l-chloro-3-methoxypropane ( 111 μ Ι_, 1.1 mmol) were added a second time. The reaction mixture was then stirred at 80°C for one extra night. The mixture was then directly partitioned between ethyl acetate (30 mL) and water (30 mL) . The aqueous layer was separated and extracted with ethyl acetate (2 x 30 mL) . The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (8 : 2) as eluent. The title product was obtained as a white solid (460 mg, 71%) .
LCMS (ESI-APCI) m/z 312.0 (M + H)+
Step 2: 3-(3-Methoxypropoxy)-azetidine hydrochloride
Figure imgf000101_0001
1-Chloroethyl chloroformate (210 p L, 1.9 mmol) was added to a solution of 1- benzhydryl-3-(3-methoxypropoxy)-azetidine (460 mg, 1.5 mmol) in 1,2- dichloroethane (7 mL) at room temperature. The reaction mixture was then heated up to 70°C and stirred for 1.5 hours. After cooling down to room temperature, methanol (7 mL) was added and the mixture was again warmep up to 70°C and stirred for an additional 2 hours. After concentration to dryness, the crude was triturated in pentane (2 x 10 mL) to afford a yellow oil (247 mg, 92%) which was used in the next step without further purification .
N M R (DMSO-de, 400 M Hz) : δ (ppm) : 9.00 (br s, N H2), 4.33-4.30 (m, 1 H), 4.13- 4.10 (m, 2H), 3.79-3.75 (m, 2H), 3.42-3.35 (m, 4H), 3.22 (s, 3H), 1.74- 1.72 (m, 2H) .
Step 3: (E 6-[3-(3-methoxypropoxy)azetidin-l-yl)-3-oxoprop-l-enyl]- 3,4-dihydro-l,8-naphthyridin-2(l/ )-one
Figure imgf000102_0001
3-(3-Methoxypropoxy)-azetidine hydrochloride (107 mg, 0.6 mmol), EDCI (117 mg, 0.6 mmol), HOBt (82 mg, 0.6 mmol) and diisopropylethylamine (170 μΙ_, 1.0 mmol) were successively added to a solution of (E)-3-(7-Oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (100 mg, 0.4 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred over the week-end then partitioned between ethyl acetate (30 mL) and water (30 mL). The aqueous layer was separated and successively extracted with ethyl acetate (2 x 30 mL) and dichloromethane (2 x 30 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 20 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (98: 2 to 95 : 5) as eluent. The title product was obtained as a yellow solid (98 mg, 72%). LCMS (ESI-APCI) m/z 346.2 (M + H)+
*H NMR (DMSO-c/e, 400 MHz) : δ (ppm) : 10.64 (br s, NH), 8.34 (s, 1H), 8.00 (s, 1 H), 7.39 (d, J = 14.8 Hz, 1H), 6.71 (d, J = 16 Hz, 1H), 4.48-4.44 (m, 1 H), 4.35- 4.30 (m, 1H), 4.14-4.05 (m, 2H), 3.71 (d, J = 10.8 Hz, 1H), 3.43-3.39 (m, 4H), 3.22 (s, 3H), 2.90 (t, J = 7.6 Hz, 2H), 2.55-2.50 (t, J = 7.6 Hz, 2H), 1.77-1.74 (m, 2H). The multiplet CH2 at 2.5 ppm is partially hidden by DMSO.
Example 36
CE^-e-CS-iS-Butoxyazetidin-l-y -S-oxoprop-l-enyn-S^-dihydro-l^- naphthyridin-2( lH)-one (E36)
Step 1: l-Benzhydryl-3-butoxyazetidine
Figure imgf000102_0002
Sodium hydride (60% in oil, 92 mg, 2.3 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (500 mg, 2.1 mmol) in dimethylformamide (3 mL) at room temperature. The resulting mixture was stirred for 30 minutes prior to the addition of 1-chlorobutane (500 pL, 4.8 mmol) in solution in dimethylformamide (3 mL). The reaction mixture was then stirred at 80°C overnight and cooled to room temperature prior to the addition of ethyl acetate (20 mL) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed twice with a saturated solution of sodium chloride (2 x 100 mL). The organic phase was dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (95 : 5) as eluent. The title product was obtained as a white solid (370 mg, 60%).
LCMS (ESI-APCI) m/z 296.0 (M + H)+
Step 2: 3-Butoxyazetidine hydrochloride
Figure imgf000103_0001
1-Chloroethyl chloroformate (180 pL, 1.6 mmol) was added to a solution of 1- benzhydryl-3-butoxyazetidine (370 mg, 1.2 mmol) in 1,2-dichloroethane (6 mL) at room temperature. The reaction mixture was then heated up to 70°C and stirred for 1.5 hours. After cooling down to room temperature, methanol (7 mL) was added. The reaction mixture was again heated up to 70°C and stirred for an additional 1.5 hours. After concentration to dryness, the crude mixture was triturated in pentane (2 x 5 mL) to give a yellow oil (179 mg, 86%) which was used in the next step without further purification.
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 9.82 and 9.61 (br s, NH2), 4.43-4.41 (m, 1H), 4.19-4.15 (m, 2H), 4.01-3.98 (m, 2H), 3.37 (t, J = 6.8 Hz, 2H), 1.55-1.50 (m, 2H), 1.39-1.33 (m, 2H), 0.94-0.90 (m, 3H). Step 3: (E 6-[3-(3-Butoxyazetidin-l-yl)-3-oxoprop-l-enyl]-3,4-dihydro- l,8-naphthyridin-2( lH)-one
Figure imgf000103_0002
HCI
3-Butoxyazetidine hydrochloride (100 mg, 0.6 mmol), EDCI (113 mg, 0.6 mmol), HOBt (80 mg, 0.6 mmol) and diisopropylethylamine (170 pL, 1.0 mmol) were successively added to a solution of (E)-3-(7-oxo-5,6,7,8-tetrahydro-l,8- naphthyridin-3-yl)-acrylic acid hydrochloride (100 mg, 0.4 mmol) in dimethylformamide (10 ml_) at room temperature. The reaction mixture was stirred overnight and then partioned between ethyl acetate (30 ml_) and water (30 ml_). The aqueous layer was separated and extracted successively with ethyl acetate (2 x 20 ml_) and dichloromethane (2 x 20 ml_). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 20 ml_), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (99 : 1 to 97 : 3) as eluent. The title product was obtained as a grey solid (30 mg, 23%).
LCMS (ESI-APCI) m/z 330.2 (M + H)+
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.64 (br s, NH), 8.33 (s, 1H), 8.00 (s, 1 H), 7.38 (d, J = 16 Hz, 1 H), 6.70 (d, J = 15.6 Hz, 1H), 4.48-4.44 (m, 1H), 4.34- 4.30 (m, 1 H), 4.15-4.05 (m, 2H), 3.73-3.68 (m, 1 H), 3.38-3.35 (m, 2H), 2.91 (t, J = 8 Hz, 2H), 2.55-2.50 (t, J = 8 Hz, 2H), 1.52-1.47 (m, 2H), 1.37-1.31 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H). The CH2 at 2.5 ppm is partially hidden by DMSO.
Example 37
^E^-e-CS-iS-Isobutoxyazetidin-l-y -S-oxoprop-l-enyn-S^-dihydro-l^- naphthyridin-2( lH)-one (E37) Step 1: l-Benzhydryl-3-isobutoxyazetidine
Figure imgf000104_0001
Sodium hydride (60% in oil, 146 mg, 3.6 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (400 mg, 1.7 mmol) in dimethylformamide (2 ml_) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of l-chloro-2-methylpropane (820 μΙ_, 7.8 mmol). The reaction mixture was stirred at 80°C overnight and cooled to room temperature. The mixture was then immediately partitioned between ethyl acetate (30 ml_) and water (30 ml_). The aqueous phase was separated and extracted with ethyl acetate (2 x 20 ml_) . The combined organic phases were washed with a saturated solution of sodium chloride (3 x 20 ml_), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (99 : 1 to 9 : 1) as eluent. The title product was obtained as a white solid (200 mg, 40%). LCMS (ESI-APCI) m/z 296.0 (M + H)+
Step 2: 3-Isobutoxyazetidine h drochloride
Figure imgf000105_0001
1-Chloroethyl chloroform ate (83 μΙ_, 0.77 mmol) was added to a solution of 1- benzhydryl-3-isobutoxyazetidine (175 mg, 0.60 mmol) in 1,2-dichloroethane (3 mL) at room temperature. The reaction mixture was then heated up to 70°C and stirred for 1.5 hours. After cooling down to room temperature, methanol (3 mL) was added and the reaction mixture was heated again to 70°C and stirred for an additional 1.5 hours. After concentration to dryness, the crude mixture was triturated in pentane (2 x 5 mL) to give a yellow oil (98 mg, quantitative) which was used in the next step without further purification .
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 9.78 and 9.61 (br s, NH2), 4.42 (m, 1H), 4.19- 4.15 (m, 2H), 4.03-3.98 (m, 2H), 3.11 (d, J = 6.4 Hz, 2H), 1.83-1.79 (m, 1H), 0.88 (d, J = 2 Hz, 6H).
Step 3: (E 6-[3-(3-Isobutoxyazetidin-l-yl)-3-oxoprop-l-enyl]-3,4- dihydro- -naphthyridin-2( lH)-one
Figure imgf000105_0002
HCI
3-Isobutoxyazetidine hydrochloride (98 mg, 0.6 mmol), EDCI (113 mg, 0.6 mmol), HOBt (80 mg, 0.6 mmol) and diisopropylethylamine (170 pL, 1.0 mmol) were successively added to a solution of 3-(chloromethyl)-l-methyl-lH-pyrazole (100 mg, 0.4 mmol) in dimethylormamide (10 mL) at room temperature. The reaction mixture was stirred over a week-end and then diluted by addition ethyl acetate (20 mL) and water (2 x 20 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 20 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (98: 2 to 92 : 8) as eluent. The title product was obtained as a white solid (40 mg, 31%). LCMS (ESI-APCI) m/z 330.2 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.65 (br s, NH), 8.33 (s, 1H), 7.64 (s, 1H), 7.58 (d, J = 15.6 Hz, 1 H), 6.43 (d, J = 15.6 Hz, 1H), 4.46-4.43 (m, 1H), 4.34-4.26 (m, 2H), 4.17-4.15 (m, 1H), 4.01-3.98 (m, 1H), 3.16-3.15 (m, 2H), 3.00 (t, J = 7.2 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H), 1.89-1.83 (m, 1H), 0.93 (d, J = 6.8 Hz, 6H).
Example 38
(E)-6-(3-(3-((l-Methyl-lH-pyrazol-3-yl)methoxy)azetidin-l-yl)-3- oxoprop-l-enyl)-3 4-dihydro-l 8-naphthyridin-2(l )-one (E38)
Step 1: 3-(Chloromethy -l-methyl-lH-pyrazole
Figure imgf000106_0001
Thionyl chloride (274 μΙ_, 3.75 mmol) was added to a solution of (1-methyl-lH- pyrazol-3-yl)methanol (350 mg, 3.13 mmol) in THF (2 mL) at room temperature. The reaction mixture was then heated up to 50°C and stirred for 2 hours. After cooling down to room temperature, the mixture was concentrated to dryness. The title compound was used in the next step without further purification.
Step 2: 3-(( l-Benzhydrylazetidin-3-yloxy)methyl-lH-pyrazole
Figure imgf000106_0002
Sodium hydride (60% in oil, 200 mg, 2.30 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (500 mg, 2.09 mmol) in dimethylformamide (3 mL) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of 3-(chloromethyl)-l-methyl-lH-pyrazole (523 mg, 3.13 mmol). The reaction mixture was then heated up to 80°C and stirred overnight. Since the LCMS monitoring indicated the presence of remained starting material, a second portion of sodium hydride (60% in oil, 200 mg, 2.30 mmol) was added . After an additional 8 hours at 80°C, the reaction mixture was partioned between ethyl acetate (30 mL) and water (30 mL). The aqueous phase was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with brine (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroleum ether/dichloromethane/ethyl acetate (5 : 0 : 5 to 0 : 5 : 5) as eluent. The title product was obtained as a yellow oil (301 mg, 67%).
LCMS (ESI-APCI) m/z 334.2 (M + H)+ Step 3: 3-((Azetidin-3-yloxy)methyl)-l-methyl-lH-pyrazole hydrochloride
Figure imgf000107_0001
1-Chloroethyl chloroformate (70.8 μΙ_, 0.65 mmol) was added to a solution of 3-((l- benzhydrylazetidin-3-yloxy)-methyl-lH-pyrazole (218 mg, 0.65 mmol) in dichloromethane (7 mL) at 0°C. The reaction mixture was stirred for 2 hours. Ethanol (9 mL) was added and the reaction mixture was stirred for an additional 1 hour at room temperature. After concentration to dryness, the crude mixture was triturated in pentane (4 x 10 mL) to give a yellow oil (133 mg, quantitative) which was used in the next step without further purification .
*H NMR (CDCIs, 400 MHz) : δ (ppm) : 9.97 and 9.66 (s, NH2), 7.34 (s, 1 H), 6.27 (s, 1H), 4.52 (s, 2H), 4.14-4.10 (m, 2H), 3.97-3.91 (m, 5H), 3.78-1.76 (m, 1H).
Step 4: (E)-6-(3-(3-((l-Methyl-lH-pyrazol-3-yl)methoxy)azetidin-l-yl)-3- oxoprop- -enyl)-3,4-dihydro- -naphthyridin-2(l/ )-one
Figure imgf000107_0002
3-((Azetidin-3-yloxy)methyl)-l-methyl-lH-pyrazole hydrochloride (120 mg, 0.59 mmol), EDCI (113 mg, 0.59 mmol), HOBt (80.0 mg, 0.59 mmol) and diisopropylethylamine (3.0 mL, 2.01 mmol) were successively added to a solution of (E)-3-(7-oxo-5,6,7,8-tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (100 mg, 0.42 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred overnight and then diluted by addition of ethyl acetate (30 mL) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with a saturated solution of sodium chloride (4 x 100 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (98: 2 to 95 : 5) as eluent. The trituration of the residue in methanol allowed the isolation of the title product as a white solid (39 mg, 27%).
LCMS (ESI-APCI) m/z 368.2 (M + H)+
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.68 (s, NH), 8.33 (s, 1H), 8.01 (s, 1H), 7.64 (d, J = 2.2 Hz, 1H), 7.38 (d, J = 15.6 Hz, 1H), 6.70 (d, J = 15.6 Hz, 1H), 6.24 (d, J 2.2 Hz, 1H), 4.45-438 (m, 2H), 4.38 (s, 2H), 4.11-4.04 (m, 2H), 3.8 (s, 3H), 3.7-3.6 (m, 1H), 2.90 (t, J = 7.6 Hz, 2H), 2.51 (t, J = 7.6 Hz, 2H).The CH2 at 2.5 ppm is partially hidden by DMSO.
Example 39
(E)-6-(3-Oxo-3-(3-(thiazol-5-ylmethoxy)azetidin-l-yl)prop-l-enyl)-3 4- dihydro-l,8-naphthyridin-2( lH)-one (E39) Step 1: 5-(Chloromethyl)thiazole hydrochloride
rswOH J» rswcl
HCI
Thionyl chloride (608 ml_, 8.34 mmol) was added to a solution of thiazol-5- methanol (800 mg, 6.95 mmol) in THF (4.3 ml_) at 0°C. The reaction mixture was stirred at room temperature for 30 minutes and then at 50°C for 2 hours. After cooling down to room temperature, the mixture was concentrated to dryness. The title compound was used in the next step without further purification.
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 9.14 (s, 1H), 7.97 (s, 1H), 5.12 (s, 2H).
Step 2: tert- Buty - thiazol-5- lmethox -azetidine-l-carboxylate
Figure imgf000108_0001
DIEA, DMF, 80°C
Sodium hydride (60% in oil, 292 mg, 7.30 mmol) was added to a solution of tert- butyl 3-hydroxyazetidine-l-carboxylate (602 mg, 3.47 mmol) in
dimethylformamide (8 ml_) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of a solution of 5-(chloromethyl)thiazole hydrochloride (1.18 g, 6.85 mmol) and diisopropylethylamine (2.42 ml_, 13.89 mmol) in dimethylformamide (3 ml_) at 0°C. The reaction mixture was then heated up to 80°C and stirred overnight. Since the LCMS monitoring still indicated the presence of starting material, an additional portion of sodium hydride (60% in oil, 139 mg, 3.47 mmol) was added. The reaction mixture was then stirred again at 80°C. After 17 hours stirring at 80°C, the reaction mixture was partitioned between ethyl acetate (20 mL) and water (20 mL). The aqueous phase was separated and extracted with ethyl acetate (2 x 40 mL). The combined organic phases were washed with a solution of sodium hydroxide (5 x 50 mL) and with brine (3 x 100 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroelum
ether/dichloromethane/ethyl acetate (7/0/3 to 2/0/8, then 0 : 5 : 5 to 0/2/8) as eluent. A second purification was performed on silica gel, using petroelum
dichloromethane/acetone (9/1 to 8/2) as eluent. The title product was obtained as a yellow oil (150 mg, 16%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.74 (s, 1H), 7.72 (s, 1H), 4.62 (s, 2H), 4.26- 4.23 (m, 1H), 4.01-3.97 (m, 2H), 3.79-3.75 (m, 2H), 1.50 (s, 9H). Step 3: 5-((Azetidin-3-yloxy)methyl)thiazole hydrochloride
Figure imgf000109_0001
A solution of HCI in diethyiether (2N, 5.5 mL) was added to a solution of terf-butyl 3-(thiazol-5-ylmethoxy)-azetidine-l-carboxylate (150 mg, 0.55 mmol) in diethyiether (2 mL) at room temperature. The reaction mixture was stirred 30 minutes then concentrated to dryness. After trituration in diethyl ether (10 mL), the title compound was obtained as a yellow solid (113 mg, quantitative).
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 9.16 (s, 1H), 7.92 (s, 1H), 4.76 (s, 2H), 4.48-4.44 (m, 1H), 4.15-4.05 (m, 2H), 3.82-3.77 (m, 2H). Step 4: (E)-6-(3-Oxo-3-(3-(thiazol-5-ylmethoxy)azetidin-l-yl)prop-l- enyl)-3,4-dihydro-l,8-naphthyridin-2(l/ )-one
Figure imgf000109_0002
5-((Azetidin-3-yloxy)methyl)thiazole hydrochloride (113 mg, 0.54 mmol), EDCI (121 mg, 0.63 mmol), HOBt (87.7 mg, 0.63 mmol) and diisopropylethylamine (183 pL, 1.05 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (107 mg, 0.42 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred overnight then partitioned between ethyl acetate (30 mL) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (10 : 0 to 98: 2) as eluent then on Ci8 using dichloromethane/methanol (98: 2) as eluent. In order to reach the required purity, the residue was finally recristallized in methanol to afford the title product as a white solid (2.8 mg, 2%).
LCMS (ESI-APCI) m/z 371.1 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.89 (br s, NH), 8.84 (s, 1H), 8.33 (s, 1H), 7.82 (s, 1H), 7.63 (s, 1H), 7.58 (d, J = 15.6 Hz, 1H), 6.39 (d, J = 15.6 Hz, 1H), 4.77-4.74 (m, 2H), 4.75-4.41 (m, 2H), 4.31-4.27 (m, 1H), 4.17-4.15 (m, 1H), 4.05-4.01 (m, 1 H), 2.99 (t, J = 7.6 Hz, 2H), 2.7 (t, J = 7.6 Hz, 2H).
Example 40
(E)-6-(3-(3-(Furan-2-ylmethoxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2( lH)-one (E40) Step 1: 2-(Chloromethyl)furan
Figure imgf000110_0001
Triethylamine (10.3 mL, 74 mmol) and a solution of thionyl chloride (2.9 mL, 40.7 mmol) in chloroforme (19 mL) were successively added to a solution of furfuryl alcohol (3.7 g, 37 mmol) in chloroforme (38 mL) at 0°C. The reaction mixture was then allowed to reach room temperature and stirred for 2 hours. Water (50 mL) was then added and the organic phase was separated and washed with water (2 x 50 mL), dried over sodium sulphate, filtered and concentrated to dryness. The resulting residue was distilled under reduced pressure (T = 50°C, P = 10 mbars) to give a colorless oil (2.0 g, 45%) which was directly used in the next step.
*H NMR (CDCI3, 400 MHz) : 7.43 (s, 1H), 6.39-6.35 (m, 2H), 4.60 (s, 2H).
Step 2: l-Benzhydryl-3-(furan-2-ylmethoxy)-azetidine
Figure imgf000111_0001
Sodium hydride (60% in oil, 877 mg, 22mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (2.62 g, 11 mmol) in dimethylformamide (15 mL) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of 2-(chloromethyl)furan (2.94 g, 25.2 mmol) in solution in dimethylformamide (10 mL). The reaction mixture was then stirred at room temperature overnight. The reaction mixture was diluted by addition of ethyl acetate (50 mL) and water (50 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulphate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using petroleum ether/ethyl acetate (9 : 1) as eluent. The title product was obtained as a yellow oil (3.2 g, 91%).
LCMS (ESI-APCI) m/z 320.2 (M + H)+
Step 3: 3-(Furan- -ylmethoxy)-azetidine hydrochlo
Figure imgf000111_0002
1-Chloroethyl chloroformate (534 pL, 4.93 mmol) was added to a solution of 1- benzhydryl-3-(furan-2-ylmethoxy)-azetidine (1.5 g, 4.7 mmol) in dichloromethane (36 mL) at 0°C. The reaction mixture was then heated up to 40°C and stirred for 2 hours. Ethanol (50 mL) was added and the reaction mixture was stirred for an additional lh30 at 40°C. After concentration to dryness, the crude mixture was triturated in petroleum ehter (2 x 20 mL) to give a yellow oil (558 mg, 74%) which was used in the next step without further purification .
^ NMR (DMSO-de, 400 MHz) : δ (ppm) : 9.22 (br s, NH2), 7.68 (m, 1H), 6.5-6.45 (m, 2H), 4.47 (s, 2H), 4.39-4.45 (m, 1H), 4.06-4.01 (m, 2H), 3.48-3.42 (m, 2H).
Step 4: (E)-6-(3-(3-(Furan-2-ylmethoxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3 4-dihydro-l 8-naphthyridin-2(l )-one
Figure imgf000112_0001
3-(Furan-2-ylmethoxy)-azetidine hydrochloride (558 mg, 2.94 mmol), EDCI (563 mg, 2.94 mmol), HOBt (410 mg, 2.94 mmol) and diisopropylethylamine (853 μΙ_, 4.9 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (500 mg, 1.96 mmol) in dimethylformamide (50 mL) at room temperature. The reaction mixture was stirred for 2 days and then diluted by addition of ethyl acetate (50 mL) and water (50 mL). The aqueous layer was separated and successively extracted with ethyl acetate (2 x 50 mL) and dichloromethane (2 x 50 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 60 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (10 :0 to 95 : 5) as eluent. After trituration of the isolated solid in diethylether, the title product was obtained as a white solid (236 mg, 34%).
LCMS (ESI-APCI) m/z 354.2 (M + H)+
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.69 (s, NH), 8.34 (s, 1H), 8.01 (s, 1H), 7.68 (s, 1H), 7.39 (d, J = 15.6 Hz, 1H), 6.69 (d, J = 15.6 Hz, 1H), 6.49-6.45 (m, 2H), 4.45 (s, 2H), 4.44-4.39 (m, 2H), 4.1-4.02 (m, 2H), 3.66-3.63 (m, 1H), 2.91 (t, J = 7.6 Hz, 2H), 2.51 (t, J = 7.6 Hz, 2H). The CH2 at 2.5 ppm is partially hidden by DMSO.
Example 41
(E)-l'-Methyl-6-(3-oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l- enyl)-lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E41)
Step 1: JV-Boc ethylisopinecotate
Figure imgf000112_0002
Boc20 (15.8 g, 71.4 mmol) and triethylamine (10 mL, 77.8 mmol) were successively added to a solution of ethylisopinecotate (10.2 g, 64.9 mmol) in dichloromethane (50 mL) at room temperature. The reaction mixture was stirred overnight. The reaction mixture was diluted by addition of a saturated solution of ammonium chloride (50 ml_). The aqueous layer was separated and extracted with dichloromethane (2 x 50 ml_). The combined organic phases were dried over sodium sulphate, filtered and concentrated to dryness. The title product was obtained as a yellow oil (16.7 g, 100%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 4.18 (q, J = 6.8 Hz, 2H), 4.08-4.04 (m, 2H), 2.88 (m, 2H), 2.49-2.45 (m, 1H), 1.93-1.88 (m, 2H), 1.71-1.63 (m, 2H), 1.50 (s, 9H), 1.30 (t, J = 6.8 Hz, 3H).
Step 2: 1-tert-Butyl 4-ethyl 4-((2-amino-5-bromopyridin-3- yl)methyl)piperidi -l,4-dicarboxylate
Figure imgf000113_0001
Freshly prepared LDA (14 ml_, 1M in THF, 14 mmol) was added dropwise over 15 minutes to a cold (-78°C) solution of 5-bromo-3-(bromomethyl)pyridine-2-amine hydrobromide (4.8 g, 14 mmol) in THF (56 ml_) under argon. The reaction mixture was stirred for an additional 15 minutes. In a separate flask, freshly prepared LDA (42 mL, 1M in THF, 42 mmol) was added dropwise over 30 minutes to a cold solution of /V-Boc ethylisopinecotate (10.9 g, 42 mmol) was in THF (100 ml). The reaction mixture was stirred for an additional 30 minutes. The lithium salt of /V-Boc ethylisopinecotate was then canulated dropwise over 30 minutes to the lithium salt of 5-bromo-3-(bromomethyl)pyridine-2-amine. The mixture was stirred at -78°C for 2 hours and allowed to warm to room temperature. The reaction mixture was quenched with a saturated solution of ammonium chloride (150 mL) and ethyl acetate (150 mL) was added. The organic phase was washed with water (2 x 50 mL) and brine (100 mL), dried over sodium sulphate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/AcOEt (95 : 5 to 9 : 1) as eluent. The title product was obtained as a yellow oil (1.25 g, 20%).
LCMS (ESI-APCI) m/z 442.1-444.1 (M + H)+ Step 3: tert-Butyl 6-bromo-2-oxo-2,4-dihydro-lH- spiro[[l,8]naphthyridine-3,4'-piperidine]-l'-carboxylate
Figure imgf000114_0001
Sodium hydride (201 mg, 5.3 mmol) was added to a solution of 1-tert-butyl 4-ethyl 4-((2-amino-5-bromopyridin-3-yl)methyl)piperidine-l,4-dicarboxylate (1.71 g, 3.87 mmol) suspended in THF (17 ml_) at room temperature. The reaction mixture was stirred for 1 hour and then diluted by addition of water (50 ml_). The resulting precipitate was filtered and washed with pentane. The title compound was obtained as a beige solid (1.2 g, 78%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.23 (s, 1H), 8.03 (br s, 1H), 7.61 (s, 1H), 3.7-3.45 (m, 4H), 2.84 (s, 2H), 2.00-1.88 (m, 2H), 1.45 (s, 9H), 1.45-1.40 (m, 2H).
Step 4: (E)-tert-Butyl 6-(3-ethoxy-3-oxoprop-l-enyl)-2-oxo-2 4-dihydro- lH-spiro[[l,8]naphthyridine-3,4'-piperidine]-l'-carboxylate
Figure imgf000114_0002
Ethyl acrylate (2.3 ml_, 21.2 mmol), diisopropylethylamine (3.7 ml_, 21.2 mmol) and P(o-tolyl)3 (323 mg, 1.06 mmol) were successively added to a suspension of tert-butyl 6-bromo-2-oxo-2,4-dihydro-lH-spiro[[l,8]naphthyridine-3,4'-piperidine]- l'-carboxylate (2.10 g, 5.3 mmol) in propionitrile (20 ml_) and dimethylformamide (5 ml_) in a sealed tube. The resulting mixture was then purged with argon prior to the addition of palladium acetate (120 mg, 0.53 mmol). The mixture was purged with argon again and refluxed overnight. The reaction mixture was then filtered on Celite®. The filtrate was concentrated to dryness and the residue was solubilized in dichloromethane (100 ml_). The resulting solution was washed with a saturated solution of ammonium chloride (100 ml_), dried over sodium sulfate, filtered and concentrated to dryness. The residue was precipitated in dichloromethane/diethylether/pentane, the title product was obtained as an off- white solid (1.52 g, 70%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.39 (br s, 1H), 8.31 (s, 1H), 7.66 (s, 1H), 7.61 (d, J = 16 Hz, 1H), 6.40 (d, J = 16 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 3.65- 3.40 (m, 4H), 2.89 (s, 2H), 2.05-1.95 (m, 2H), 1.46 (s, 9H), 1.46-1.43 (m, 2H), 1.34 (t, J = 7.2 Hz, 3H). Step 5: (E)-Ethyl 3-(2-oxo-2,4-dihydro-lH-spiro[[l,8]naphthyridine-3,4'- piperidine]-6-yl)acrylate
Figure imgf000115_0001
Trifluoroacetic acid (5 mL) was added to a suspension of (E)-tert- butyl 6-(3-ethoxy- 3-oxoprop-l-enyl)-2-oxo-2,4-dihydro-lH-spiro[[l,8]naphthyridine-3,4'-piperidine]- l'-carboxylate (1.52 g, 3.66 mmol) in dichloromethane (20 mL). The reaction mixture was stirred at room temperature for 1 hour and concentrated to dryness. The resulting residue was partitioned between an aqueous solution of sodium hydroxide (IN, 60 mL) and dichloromethane (40 mL). The aqueous layer was separated and extracted with dichloromethane (2 x 70 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated to dryness. The title product was obtained as a pale yellow solid (904 mg, 79%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.29 (s, 1H), 8.27 (br s, 1H), 7.68 (s, 1H), 7.61 (d, J = 16 Hz, 1H), 6.40 (d, J = 16 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 3.06- 3.04 (m, 2H), 2.94 (s, 2H), 2.90-2.87 (m, 2H), 1.99-1.96 (m, 2H), 1.44-1.40 (m, 2H), 1.34 (t, J = 7.6 Hz, 3H).
Step 6: (E)-Ethyl 3-(l'-methyl-2-oxo-2,4-dihydro-lH- spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylate
Figure imgf000115_0002
Sodium triacetoxyborohydride (1.2 g, 5.73 mmol) and paraformaldehyde (172 mg, 5.73 mmol) were successively added to a suspension of (E)-ethyl 3-(2-oxo-2,4- dihydro-lH-spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylate (904 mg, 2.87 mmol) in 1,2-dichloroethane (40 mL) at room temperature. The reaction mixture was then heated up to 70°C and stirred for 2 hours. After cooling down to room temperature, the reaction mixture was diluted by addition of ethyl acetate (50 mL) and water (50 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with a saturated solution of sodium hydrogenocarbonate (3 x 60 mL), dried over sodium sulfate, filtered and concentrated to dryness. The title product was obtained as a white solid (862 mg, 91%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.29 (s, 1H), 8.24 (br s, 1H), 7.67 (s, 1H), 7.61 (d, J = 16 Hz, 1 H), 6.40 (d, J = 16 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 2.88 (s, 2H), 2.64-2.60 (m, 2H), 2.42-2.40 (m, 2H), 2.32 (s, 2H), 2.08-2.04 (m, 2H), 1.54- 1.51 (m, 2H), 1.34 (t, J = 7.2 Hz, 3H).
Step 7: (E)-3-(7-Oxo-5,6,7,8-tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride
Figure imgf000116_0001
An aqueous solution of sodium hydroxide (IN, 7.83 mL) was added to a solution of (E)-ethyl 3-(l'-methyl-2-oxo-2,4-dihydro-lH-spiro[[l,8]naphthyridine-3,4'- piperidine]-6-yl)acrylate (860 mg, 2.61 mmol) in a mixture of dichloromethane (10 mL) and ethanol (10 mL) at room temperature. The reaction mixture was stirred at 45°C overnight then concentrated to dryness. The residue was acidified by addition of an aqueous solution of hydrochloric acid (IN, 30 mL) until pH 1. The resulting solid was filtered and washed with water and diethyl ether. The title product was obtained as a white solid (586 mg, 66%).
LCMS (ESI-APCI) m/z 302.2 (M + H)+
Step 8: (E)-l'-Methyl-6-(3-oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l- yl)prop-l-enyl)-l -spiro[[l 8]naphthyridine-3 4'-piperidin]-2(4H)-one
Figure imgf000116_0002
HCI
3-(Thiophen-2-ylmethoxy)-azetidine hydrochloride (45.8 mg, 0.22 mmol), EDCI (40.26 mg, 0.21 mmol), HOBt (28.5 mg, 0.21 mmol) and diisopropylethylamine (62 pL, 0.35 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (47.0 mg, 0.14 mmol) in dimethylformamide (5 mL) at room temperature. The reaction mixture was stirred overnight and then diluted by addition of ethyl acetate (20 ml) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 20 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (95 : 5 to 0 : 1) as eluent. After precipitation in a mixture dichloromethane/diethylether/pentane, the title product was obtained as a white solid (12 mg, 24%).
LCMS (ESI-APCI) m/z 453.1 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.33 (s, 1H), 8.22 (s, 1H), 7.68 (s, 1H), 7.62 (d, J = 15.6 Hz, 1 H), 7.41-7.38 (m, 1H), 7.10-7.04 (m, 2H), 6.44 (d, J = 15.6 Hz, 1H), 4.76-4.74 (m, 2H), 4.53-4.45 (m, 2H), 4.32-4.20 (m, 2H), 4.09-4.04 (m, 1H), 2.93 (s, 2H), 2.72-2.67 (m, 2H), 4.50-2.38 (m, 2H), 2.38 (s, 3H), 2.16-2.09 (m, 2H), 1.68-1.65 (m, 2H).
Example 42
(E)-7-(3-Oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l-enyl)-4 5- dihydro-lH-pyrido[2,3-e] [l,4]diazepin-2(3tf)-one (E42)
Step 1: (E)-Methyl 2-(4-methoxybenzylideneamino)acetate
Figure imgf000117_0001
Triethylamine (4.6 mL, 33 mmol) and glycine methyl ester hydrochloride (3.8 g, 30.26 mmol) were successively added to a solution of p-anisaldehyde (2.0 g, 14.7 mmol) in dichloromethane (150 mL) at 0°C. Sodium sulfate (10 g) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was then filtered and concentrated to dryness. The resulting residue was portioned in ethyl acetate and filtered in order to remove the triethylamine salts. The title compound was obtained as a pale yellow solid (4.43 g, 100%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.22 (s, 1H), 7.23 (d, J =8.4 Hz, 2H), 6.93 (d, J = 8.4 Hz, 2H), 4.39 (s, 2H), 3.85 (s, 3H), 3.78 (s, 3H).
Step 2: Methyl 2-( -methoxybenzylamino)acetate
Figure imgf000117_0002
Sodium borohydride (438 mg, 1.2 mmol) was added to a solution of (E)-methyl 2- (4-methoxybenzylideneamino)acetate (2.0 g, 9.6 mmol) in a mixture of methanol (22 mL) and THF (11 mL) at 0°C. The reaction mixture was stirred 1 hour at room temperature then partionned between a solution of saturated ammonium chloride (20 mL) and ethyl acetate (30 mL). The aqueous phase was separated and extracted with ethyl acetate (3 x 50 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated to dryness. The title compound was obtained as a white oil (1.7 g, 85%).
^ NMR (CDCI3, 400 MHz) : δ (ppm) : 7.31 (m, 2H), 6.92 (m, 2H), 3.85 (s, 2H), 3.83 (s, 3H), 3.78 (s, 3H), 3.48 (s, 2H), 2.49 (br s, 1H).
Step 3: Methyl 2-(((2-amino-5-bromopyridin-3-yl)methyl)(4- methoxybenzyl)amino)acetate
Figure imgf000118_0001
Methyl 2-(4-methoxybenzylamino)acetate (760 mg, 3.63 mmol) and triethylamine (840 pL, 6.60 mmol) were successively added to a solution of 5-bromo-3- (bromomethyl)pyridine-2-amine hydrobromide (1.0 g, 3.30 mmol) in DMF (17 mL) at room temperature. The reaction mixture was stirred for 8 hours then diluted by addition of water (50 mL) and ethyl acetate (50 mL). The aqueous phase was separated and extracted with ethyl actetate (3 x 50 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 50 mL), dried over sodium sulphate, filtered and concentrated to dryness. The title compound was obtained as an orange oil (1.05 g, 93%) which was used in the next step without further purification.
LCMS (ESI-APCI) m/z 394.1 (M + H)+
Step 4: 7-Bromo-4-(4-methoxybenzyl)-4,5-dihydro-lH-pyrido[2,3- e] [l,4]diazepin-2(3tt)-one
Figure imgf000118_0002
Sodium hydride (60% in oil, 140 mg, 3.40 mmol) was added to a solution of methyl 2-(((2-amino-5-bromopyridin-3-yl)methyl)(4-methoxybenzyl)amino)acetate (1.05 g, 2.66 mmol) in DMSO (17 mL) at room temperature. The reaction mixture was stirred overnight then diluted by addition of water (45 mL). After 2 hours stirring at room temperature, the reaction mixture was filtered. The resulting solid was dried under high vacuum to give the title compound as a yellow solid (600 mg, 63%) *H NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.37 (s, 1H), 8.37 (s, 1H), 7.88 (s, 1H), 7.19 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 8.4 Hz, 2H), 3.81 (s, 2H), 3.75 (s, 3H), 3.62 (s, 2H), 3.39 (s, 2H).
Step 5: (E)-tert-Butyl 3-(4(4-methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro- lH-pyrido[2,3-e] [l,4]diazepin-7-yl)acrylate
Figure imgf000119_0001
terf-Butyl acrylate (972 μΙ_, 6.64 mmol), diisopropylethylamine (612 μΙ_, 3.47 mmol) and P(o-tolyl)3 (100 mg, 0.33 mmol) were successively added to a suspension of 7-bromo-4-(4-methoxybenzyl)-4,5-dihydro-lH-pyrido[2,3- e][l,4]diazepin-2(3H)-one (600 mg, 1.66 mmol) in propionitrile (10 mL) and dimethylformamide (2 mL). The resulting mixture was then purged with argon prior to the addition of palladium acetate (40 mg, 0.16 mmol). The mixture was purged with argon a second time and refluxed overnight. The reaction mixture was then filtered on Celite®. The filtrate was concentrated to dryness and the residue was solubilized in ethyl acetate (30 mL). The aqueous phase was separated and extracted with ethyl acetate (2 x40 mL). The combined organic phases were washed with a saturated solution of sodium chloride (2x 20 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/ethyl actetate (7 : 3) as eluent. The title product was obtained as a yellow solid (112 mg, 16%).
LCMS (ESI-APCI) m/z 410.2 (M + H)+
Step 6: (E)-3-(4-(4-Methoxybenzyl)-2-oxo-2,3,4,5-tetrahyd pyrido[2,3-e] [l,4]diazepin-7-yl)acrylic acid hydrochloride
Figure imgf000119_0002
Trifluoroacetic acid (1 mL) was added to a suspension of (E)-tert- butyl 3-(4(4- methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-lH-pyrido[2,3-e][l,4]diazepin-7- yl)acrylate (112 mg, 0.27 mmol) in dichloromethane (1 mL) at room temperature. The reaction mixture was then stirred for 1 hour and concentrated to dryness. The resulting residue was suspended in a solution of hydrochloric acid in dioxane 4N (2 mL). After 10 minutes stirring at room temperature, the precipitate was filtered and washed with diethyl ether to afford the title product as a pale yellow solid (110 mg, quantitative).
LCMS (ESI-APCI) m/z 354.2 (M + H)+
Step 7: (E)-4-(4-Methoxybenzyl)-7-(3-oxo-3-(3-(thiophen-2- ylmethoxy)azetidin-l-yl)prop-l-enyl)-4,5-dihydro-lH-pyrido[2,3- e] [l,4]diazepin-2(3H)-one
Figure imgf000120_0001
3-(Thiophen-2-ylmethoxy)-azetidine hydrochloride (231 mg, 1.12 mmol), EDCI (215 mg, 1.12 mmol), HOBt (152 mg, 1.12 mmol) and diisopropylethylamine (321 pL, 1.87 mmol) were successively added to a solution of (E)-3-(4-(4- methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-lH-pyrido[2,3-e][l,4]diazepin-7- yl)acrylic acid hydrochloride (292 mg, 0.75 mmol) in dimethylformamide (20 mL) at room temperature. The reaction mixture was stirred overnight and then diluted by addition of ethyl acetate (30 ml) and water (30 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 30 mL) and dichloromethane (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 20 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was precipitated from a mixture ethyl acetate/diethyl ether to afford the title product as an off-white solid (151 mg, 40%).
LCMS (ESI-APCI) m/z 505.2 (M + H)+
Step 8: (E)-2-Chloropropyl 2-oxo-7-(3-oxo-3-(3-(thiophen-2- ylmethoxy)azetidin-l-yl)prop-l-enyl)-2,3-dihydro-lW-pyrido[2,3- e] [l,4]diazepine-4(5/ )-carboxylate
Figure imgf000120_0002
1-Chloroethyl chloroform ate (49 μ Ι_, 0.45 mmol) was added to a solution of (E)-4- (4-methoxybenzyl)-7-(3-oxo-3-(3-(thiophen-2-ylmethoxy)azetidin- l-yl)prop- l- enyl)-4,5-dihydro- lH-pyrido[2,3-e] [ l,4]diazepin-2(3H)-one ( 151 mg, 0.3 mmol) in dichloroethane (4.5 mL) at 0°C. The reaction mixture was stirred for 1 hour at room temperature and for 2 hours at reflux. After concentration to dryness, the residue was purified by chromatography on silica gel, using dichloromethane/methanol (98 : 2) as eluent. A final trituration in diethyl ether afforded the title product as a white solid (75 mg, 51%) .
LCMS (ESI-APCI) m/z 491.1 (M + H)+
Step 9: (E)-7-(3-Oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l- enyl)- -dihydro-lH-pyrido[2,3-e] [ l,4]diazepin-2(3«)-one
Figure imgf000121_0001
A solution of (E)-2-chloropropyl 2-oxo-7-(3-oxo-3-(3-(thiophen-2- ylmethoxy)azetidin- l-yl)prop- l-enyl)-2,3-dihydro- lH-pyrido[2,3-e] [ l,4]diazepine-
4(5H)-carboxylate (75 mg, 0.15 mmol) in methanol (3 mL) was refluxed for 2 hours. After concentration to dryness, the residue was triturated in methanol . The title product was obtained as a white solid (75 mg, 19%).
LCMS (ESI-APCI) m/z 385.1 (M + H)+
*H NM R (DMSO-de, 400 M Hz) : δ (ppm) : 11.10 (s, 1 H), 9.77 (s, 1 H), 8.72 (s, 1 H),
8.23 (s, 1 H), 7.57-7.55 (m, 1 H), 7.48 (d, J = 15.6 Hz, 1 H), 7.12 (s, 1 H), 7.05-7.02
(m, 1 H), 6.80 (d , J = 15.6 Hz, 1 H), 4.68 (s, 2H), 4.49-4.46 (m, 2H), 4.26 (s, 2H),
4.15-4.09 (m, 2H), 3.84 (s, 2H), 3.77-3.74 (m, 1 H) . Example 43
(E)-Ethyl 2-(2-oxo-6-(3-oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l- yl)prop-l-enyl)-l,2-dihydropyrido[2,3-d] pyrimidin-3(4H)-yl)acetate (E43)
Step 1 : Ethyl 2-((2-amino-5-bromopyridin-3-yl)methylamino)acetate
Figure imgf000121_0002
Glycine ethyl ester hydrochloride (805 mg, 5.7 mmol) and triethylamine (2.6 mL, 18.46 mmol) were successively added to a solution of 5-bromo-3- (bromomethyl)pyridin-2-amine hydrobromide (2, 5.7 mmol) in dimethylformamide (65 mL) at room temperature. The reaction mixture was stirred overnight then partitioned between ethyl acetate (70 ml) and water (100 mL). The aqueous phase was separated and extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 40 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel, using dichloromethane/methanol (10 :0 to 95 : 5) as eluent. The title product was obtained as a yellow solid (1.1 g, 68%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 7.96 (s, 1H), 7.29 (s, 1H), 5.66 (br s, NH2), 4.15 (q, J = 7.6 Hz, 2H), 3.64 (s, 2H), 3.31 (s, 2H), 1.21 (t, J = 7.6 Hz, 3H).
Step 2: Ethyl 2-(6-bromo-2-oxo-l,2-dihydropyrido[2,3-d]pyrimidin-3(4H)- yl)acetate
Figure imgf000122_0001
CDI (1.8 g, 114 mmol) was added to a solution of ethyl 2-((2-amino-5- bromopyridin-3-yl)methylamino)acetate (1.1 g, 38.17 mmol) in dioxane (36 mL). The reaction mixture was stirred at reflux for 5 hours and then concentrated to dryness. The residue was partitioned between dichloromethane (40 mL) and water (30 mL). The aqueous phase was separated and extracted with dichloromethane (2 x 30 mL). The combined organic phases were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The isolated compound was finally precipitated from a mixture dichloromethane/pentane to give the title product as a yellow solid (670 mg, 56%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.16 (s, 1H), 7.87 (s, 1H), 7.41 (s, 1H), 4.48 (s, 2H), 4.14 (q, J = 7.6 Hz, 2H), 4.11 (s, 2H), 1.23 (t, J = 7.6 Hz, 3H).
Step 3: (E)-tert-Butyl 3-(3-(2-ethoxy-2-oxoethyl)-2-oxo-l, 2,3,4- tetrahydropyri -tf] pyrimidin-6-yl)acrylate
Figure imgf000122_0002
terf-Butyl acrylate (1.25 mL, 8.53 mmol), diisopropylethylamine (730 pL, 4.26 mmol) and P(o-tolyl)3 (130 mg, 0.43 mmol) were successively added to a suspension of ethyl 2-(6-bromo-2-oxo-l,2-dihydropyrido[2,3-c/]pyrimidin-3(4H)- yl)acetate (670 mg, 2.13 mmol) in propionitrile (11 mL) and dimethylformamide (2.5 mL). The resulting mixture was purged with argon prior to the addition of palladium acetate (48 mg, 0.213 mmol). The mixture was purged with argon a second time and refluxed overnight. The reaction mixture was then filtered on Celite® and washed with ethyl acetate (75 mL) and dichloromethane (75 mL). The filtrate was concentrated to dryness and the residue was partitioned between dichloromethane (50 mL) and water (50 mL). The aqueous phase was separated and extracted with dichloromethane (2 x 100 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 100 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was precipitated from a mixture dichloromethane/diethylether to afford the title product as a white solid (460 mg, 60%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.27 (s, 1H), 7.58 (s, 1H), 7.52 (s, 1H), 7.48 (d, J = 16 Hz, 1 H), 6.28 (d, J = 16 Hz, 1 H), 4.58 (s, 2H), 4.25 (q, J = 6.8 Hz, 2H), 4.19 (s, 2H), 1.52 (s, 9H), 1.30 (t, J = 6.8 Hz, 3H).
Step 4: (E)-3-(3-(2-Ethoxy-2-oxoethyl)-2-oxo-l,2,3,4- tetrahydropy -tf]pyrimidin-6-yl)acryli acid hydrochloride
Figure imgf000123_0001
Trifluoroacetic acid (5 mL) was added to a solution of (E)-tert- butyl 3-(3-(2-ethoxy- 2-oxoethyl)-2-oxo-l,2,3,4-tetrahydropyrido[2,3-c/]pyrimidin-6-yl)acrylate (460 mg, 1.27 mmol) in dichloromethane (5 mL) at room tempearture. The reaction mixture was stirred at room temperature for 30 minutes. After concentration to dryness, the residue was suspended in a solution of hydrochloric acid in dioxane 4N (10 mL). The resulting white precipitate was filtered and washed with diethyl ether to give the title compound (470 mg; quantitative).
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 8.37 (s, 1H), 7.95 (s, 1H), 7.54 (d, J = 15.6 Hz, 1H), 6.48 (d, J = 15.6 Hz, 1H), 4.52 (s , 2H), 4.14 (m, 4H), 1.22 (t, J = 6.8 Hz, 3H)
Step 5: (E)-Ethyl 2-(2-oxo-6-(3-oxo-3-(3-(thiophen-2-ylmethoxy)azetidin- l-yl)prop-l-enyl)-l,2-dihydropyrido[2,3-d] pyrimidin-3(4/ )-yl)acetate
Figure imgf000124_0001
3-(Thiophen-2-ylmethoxy)-azetidine hydrochloride (243 mg, 1.18 mmol), EDCI (227 mg, 1.18 mmol), HOBt (160 mg, 0.6 mmol) and diisopropylethylamine (340 μΙ_, 1.97 mmol) were successively added to a solution of (E)-3-(3-(2-ethoxy-2- oxoethyl)-2-oxo-l,2,3,4-tetrahydropyrido[2,3-c/]pyrimidin-6-yl)acrylic acid hydrochloride (270 mg, 0. 79 mmol) in dimethylformamide (15 ml_) at room temperature. The reaction mixture was stirred for 2 days then partitioned between ethyl acetate (30 ml_) and water (40 ml_). The aqueous layer was separated and successively extracted with ethyl acetate (2 x 30 ml_) and dichloromethane (2 x 30 ml_). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 40 ml_), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (10 : 0 to 98 : 2) as eluent. The title product was obtained as an off-white solid (215 mg, 60%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.36 (s, 1H), 7.76 (s, 1H), 7.59 (d, J = 15.6 Hz, 1H), 7.54 (s, 1H), 7.39 (m, 1H), 7.09-7.04 (m, 2H), 6.69 (d, J = 15.6 Hz, 1H), 4.77-4.72 (m, 2H), 4.64 (s, 2H), 4.53-4.43 (m, 2H), 4.31-4.17 (m, 6H), 4.08-4.03 (m, 1H), 1.35 (t, J = 6.8 Hz, 3H).
Step 6: Sodium (E)-2-(2-oxo-6-(3-oxo-3-(3-(thiophen-2- ylmethoxy)azetidin-l-yl)prop-l-enyl)-l,2-dihydropyrido[2,3-tf] pyrimid 3(4H)-yl)acetate
Figure imgf000124_0002
A solution of sodium hydroxyde (IN, 438 μΙ_, 0.44 mmol) was added to a suspension of (E)-ethyl 2-(2-oxo-6-(3-oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l- yl)prop-l-enyl)-l,2-dihydropyrido[2,3-c/]pyrimidin-3(4H)-yl)acetate (100 mg, 0.22 mmol) in methanol (5 ml_) at room temperature. The reaction mixture was refluxed for 15 minutes then poured into cold water. The resulting precipitate was filtered and washed with diethyl ether. The title product was obtained as a white solid (53.5 mg, 54%).
LCMS (ESI-APCI) m/z 429.1 (M + H)+ (acid form) *H NMR (DMSO-de, 400 MHz) : δ (ppm) : 9.66 (br s, NH), 8.27 (s, 1H), 7.89 (s, 1 H), 7.57-7.54 (m, 1H), 7.36 (d, J = 15.6 Hz, 1H), 7.13-7.11 (m, 1H), 7.05-7.02 (m, 1H), 6.63 (d, J = 15.6 Hz, 1H), 4.67 (s, 2H), 4.48 (s, 2H), 4.48-4.43 (m, 2H), 4.18-4.05 (m, 2H), 3.74-3.70 (m, 1H), 3.53 (s, 2H).
Example 44
(E)-3-(2-(4-Methylpiperazin-l-yl)ethyl)-6-(3-oxo-3-(3-(thiophen-2- ylmethoxy)azetidin-l-yl)prop-l-enyl)-3,4-dihydropyrido[2,3-d] pyrimidin- 2(l«)-one (E44)
Step 1: 2-Amino-5-bromonicotinaldehyde hydrobromide
Figure imgf000125_0001
A solution of bromine (1.05 mL, 20.0 mmol) in acetic acid (20 mL) was added to a solution of 2-amino-3-pyridinecarboxaldehyde (2.5 g, 20 mmol) in acetic acid (50 mL) at room temperature. The reaction mixture was then stirred overnight. The resulting precipitate was filtered and washed with diethyl ether to give the title compound as a white solid (4.66 g, 80%).
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 9.82 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 7.74 (br s, NH2).
Step 2: 5-Bromo-3-((2-(4-methylpiperazin-l- yl)ethylamino) methyl) pyridin-2-amine
Figure imgf000125_0002
Triethylamine (1.0 mL, 7.09 mmol) was added to a solution of 2-amino-5- bromonicotinaidehyde hydrobromide (1.0 g, 3.54 mmol) in methanol (24 mL) at room temperature. The reaction mixture was stirred for 10 minutes prior to the addition of 2-(4-methylpiperazin-l-yl)ethanamine (558 mg, 3.90 mmol). The reaction mixture was then stirred overnight and cooled to 0°C. Sodium borohydride (201 mg, 5.32 mmol) was added portionwise at 0°C and the reaction mixture was allowed to reach room temperature and stirred for 4 hours. After concentration to dryness, the residue was purified by chromatography on silica gel using dichloromethane/methanol/ammoniac (10 : 0 : 0.1 to 9 : 1 : 0.1) as eluent. The title product was obtained as a yellow solid (560 mg, 48%).
LCMS (ESI-APCI) m/z 328.1-330.1 (M + H)+ Step 3: 6-Bromo-3-(2-(4-methylpiperazin-l-yl)ethyl)-3,4- dihydropyrido[2,3- pyrimidin-2(lH)-one
Figure imgf000126_0001
CDI (815 mg, 5.0 mmol) was added to a solution of 5-bromo-3-((2-(4- methylpiperazin-l-yl)ethylamino)methyl)pyridin-2-amine (550 mg, 1.67 mmol) in dioxane (13 mL). The reaction mixture was stirred overnight at reflux. After concentration to dryness, the residue was purified by chromatography on silica gel using dichloromethane/methanol/ammoniac (10 : 0 : 0.1 to 9 : 1 : 0.1) as eluent. The title product was obtained as a yellow solid (430 mg, 72%).
LCMS (ESI-APCI) m/z 354.1-356.1 (M + H)+
Step 4: (E)-tert- Butyl 3-(3-(2-(4-methylpiperazin-l-yl)ethyl)-2- l,2,3,4-tetrahydropyrido[2,3-d] pyrimidin-6-yl)acrylate
Figure imgf000126_0002
terf-Butyl acrylate (830 pL, 5.64 mmol), diisopropylethylamine (500 D L, 2.82 mmol) and P(o-tolyl)3 (86 mg, 0.28 mmol) were successively added to a suspension of 6-bromo-3-(2-(4-methylpiperazin-l-yl)ethyl)-3,4-dihydropyrido[2,3-d]pyrimidin- 2(lH)-one (500 mg, 1.41 mmol) in propionitrile (6 mL) and dimethylformamide (2 mL). The resulting mixture was purged with argon prior to the addition of palladium acetate (32 mg, 0.14 mmol). The mixture was then purged a second time with argon and refluxed overnight. The reaction mixture was filtered on Celite® and washed with ethyl acetate (100 mL) and dichloromethane (100 mL). The filtrate was concentrated to dryness and the residue was solubilized in dichloromethane (100 mL). The resulting solution was washed with a saturated solution of sodium chloride (3 x 100 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol/ammoniac (1 : 0 : 0.1 to 98: 2 : 0.1) as eluent. The title product was obtained as a brown solid (83 mg, 15%).
LCMS (ESI-APCI) m/z 402.3 (M + H)+
Step 5: (E)-3-(3-(2-(4-Methylpiperazin-l-yl)ethyl)-2-oxo-l,2,3,4- tetrahydropyrido[2,3-tf]pyrimidin-6-yl)acryl acid hydrochloride
Figure imgf000127_0001
Trifluoroacetic acid (2 mL) was added to a suspension (E)-tert- butyl 3-(3-(2-(4- methylpiperazin-l-yl)ethyl)-2-oxo- 1,2,3, 4-tetrahydropyrido[2,3-c/]pyrimidin-6- yl)acrylate (1.1 g, 3.76 mmol) in dichloromethane (2 mL). The reaction mixture was stirred at room temperature for 1 hour and concentrated to dryness. The resulting residue was solubilized in a solution of hydrochloric acid in dioxane (4N, 10 mL). After 10 minutes stirring at room temperature, the precipitate was filtered and washed with diethyl ether to afford the title product as a pale yellow solid (90 mg, quantitative).
LCMS (ESI-APCI) m/z 346.2 (M + H)+
Step 6: (E)-3-(2-(4-Methylpiperazin-l-yl)ethyl)-6-(3-oxo-3-(3-(th
2-ylmethoxy)azetidin-l-yl)prop-l-enyl)-3,4-dihydropyrido[2,3- d] pyrimidin-2( lH)-one
Figure imgf000127_0002
3-(Thiophen-2-ylmethoxy)-azetidine hydrochloride (38 mg, 0.18 mmol), EDCI (35 mg, 0.18 mmol), HOBt (26 mg, 0.18 mmol) and diisopropylethylamine (54 pL, 0.31 mmol) were successively added to a solution of (E)-3-(3-(2-(4-methylpiperazin-l- yl)ethyl)-2-oxo-l,2,3,4-tetrahydropyrido[2,3-c/]pyrimidin-6-yl)acrylic acid hydrochloride (54 mg, 0.12 mmol) in dimethylformamide (6 mL) at room temperature. The reaction mixture was stirred for 2 days and then diluted by addition of ethyl acetate (50 mL) and water (50 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methano/ammoniac (1 : 0 : 0.1 to 9 : 1 : 0.1) as eluent. After several triturations of the compound in diethylether and pentane and a recristallisation from acetone, the title product was obtained as an off-white solid (2 mg, 3%).
LCMS (ESI-APCI) m/z 497.3 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.28 (s, 1 H), 7.54 (d, J = 15.6 Hz, 1H), 7.49- 4.47 (m, 2H), 7.35-7.33 (m, 1H), 7.04-6.98 (m, 2H), 6.34 (d, J = 15.6 Hz, 1H), 4.69 (d, J = 6 Hz, 2H), 4.56 (s, 2H), 4.48-4.38 (m, 2H), 4.28-4.23 (m, 1H), 4.16- 4.13 (m, 1 H), 4.03-3.99 (m, 1H), 3.58 (t, J = 7.6 Hz, 2H), 2.63 (t, J = 7.6 Hz, 2H), 2.68-2.46 (m, 8H), 1.65 (s, 3H).
Example 45
(E)-3-(3-((Dimethylamino)methyl)-lH-pyrrolo[2 3-ft]pyridin-5-yl)-l-(3- (thiophen-2-ylmethoxy)azetidin-l-yl)prop-2-en-l-one (E45)
Step 1: (E)-tert-Buty\ 3-(lH-pyrrolo[2,3-6]pyridin-5-yl)acrylate
Figure imgf000128_0001
terf-Butyl acrylate (5.9 mL, 40.6 mmol), diisopropylethylamine (3.5 mL, 20.3 mmol) and P(o-tolyl)3 (618 mg, 2.0 mmol) were successively added to a suspension of 5-bromo-lH-pyrrolo[2,3-£>]pyridine (2.0 g, 10.15 mmol) in propionitrile (40 mL) and dimethylformamide (10 mL). The resulting mixture was purged with argon prior to the addition of palladium acetate (227 mg, 1.0 mmol). The mixture was then purged with argon a second time and refluxed overnight. The reaction mixture was filtered on Celite®. The filtrate was concentrated to dryness and the residue was solubilized in ethyl acetate (3 x 100 mL). The organic layers were washed with a saturated solution of sodium chloride (3 x 50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The crude was purified by flash chromatography on silica gel using dichloromethane/ethyl acetate (1 : 0 to 7 : 3) as eluent. The title compound was obtained as a yellow solid (465 mg, 28%)
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 10,39 (s, 1H, NH), 8.49 (s, 1H), 8,12 (s, 1 H), 7,75 (d, J = 16 Hz, 1H), 7,38 (d, J = 1.6 Ηζ,ΙΗ), 6.54 (d , J = 2.8 Hz, 1H) , 6,45 (d, J = 16 Hz, 1H), 1.55 (s, 9H). Step 2: (E)-tert-Butyl 3-(3-((dimethylamino)methyl)-lH-pyrrolo[2,3- fr]pyridin-5-yl)acrylate
Formaldehyde
Figure imgf000129_0001
Formaldehyde (37% in water, 219 μΙ_, 2.92 mmol) and dimethylamine hydrochloride (237 mg, 2.92 mmol) were added to a solution of (E -terf-butyl 3- (lH-pyrrolo[2,3-£>]pyridin-5-yl)acrylate (420 mg, 1.72 mmol) in isopropanol (42 mL) at room temperature. The reaction mixture was stirred at reflux overnight. Since the LCMS monitoring still indicated the presence of remaining starting materal, formaldehyde (25 μΙ_) and dimethyl amine hydrochloride (28 mg) were added. The reaction mixture was stirred at reflux for an additional 4 hours and concentrated to dryness. The residue was solubilized in an aqueous solution of potassium carbonate (3N, 100 mL) and the solution was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with a saturated solution of sodium chloride (50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The crude was tritured in pentane to give the title compound as a white solid (242 mg, 46%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.75 (s, 1 H), 8.38 (s, 1H), 8.14 (s, 1H), 7.65 (d, J = 16 Hz, 1H), 6.37 (d, J = 16 Hz, 1H), 3.54 (s, 2H), 2.21 (s, 6H), 1.06 (s, 9H).
Step 3: (E)-3-(3-((Dimethylamino)methyl)-lH-pyrrolo[2,3-6]pyridin-5- yl)acrylic acid hydrochloride
Figure imgf000129_0002
Trifluoroacetic acid (2 mL) was added to a suspension of (E)-tert- butyl 3-(3- ((dimethylamino)methyl)-lH-pyrrolo[2,3-/3]pyridin-5-yl)acrylate (120 mg, 0.39 mmol) in dichloromethane (2 mL). The reaction mixture was stirred at room temperature for 30 minutes and concentrated to dryness. The resulting residue was solubilized in a solution of hydrochloric acid in dioxane (4N, 2 mL). After 10 minutes stirring at room temperature, the precipitate was filtered and washed with diethyl ether to afford the title product as a pale yellow solid (112 mg, quantitative). Step 4: (E)-3-(3-((Dimethylamino)methyl)-lH-pyrrolo[2 3-ft]pyridin-5-yl)- l-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-2-en-l-one
Figure imgf000130_0001
3-(Thiophen-2-ylmethoxy)-azetidine hydrochloride (61 mg, 0.30 mmol), EDCI (71.5 mg, 0.37 mmol), HOBt (52 mg, 0.37 mmol) and diisopropylethylamine (110 μΙ_, 0.62 mmol) were successively added to a solution of (E)-3-(3- ((dimethylamino)methyl)-lH-pyrrolo[2,3-/3]pyridin-5-yl)acrylic acid hydrochloride (70 mg, 0.25 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred overnight then partitioned between ethyl acetate (30 mL) and water (30 mL). The aqueous layer was separated, basified with an aqueous solution of sodium hydroxyde (2N) until pH 12 and finally extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 50 mL), dried over sodium sulfate and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol/ammoniac (1 : 0 : 0.1 to 9 : 1 : 0.1) as eluent. The title product was obtained as a yellow solid (10 mg, 10%).
LCMS (ESI-APCI) m/z 397.2 (M + H)+
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 11.69 (s, NH), 8.51 (s, 1H), 8.29 (s, 1H), 7.56 (d , J = 15.6 Hz, 1H), 7.54 (s, 1H), 7.39 (s, 1H), 7.13-7.11 (m, 1H), 7.03- 7.01 (m, 1H), 6.74 (d, J = 15.6 Hz, 1H), 4.67 (s, 2H), 4.53-4.43 (m, 2H), 4.17- 4.10 (m, 2H), 3.75-3.56 (m, 1H), 3.56 (s, 2H), 2.16 (s, 6H).
Example 46
(E)-6-(3-Oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l-enyl)-l - imidazo[4,5-b]pyridin-2(3H)-one (E46)
Step 1: 6-Bromo-l -imidazo[4,5-Z>]pyridin-2(3H)-one
Figure imgf000130_0002
DSC (4.4 g, 17.54 mmol) was added to a suspension of 5-bromopyridine-2,3- diamine (3.0 g, 15.95 mmol) in chloroform (150 mL) at room temperature. The reaction mixture was then heated up to 70°C and stirred overnight. After concentration to dryness, the resulting brown solid was triturated in a mixture petroleum ether/ethyl acetate (6:4, 300 mL) and washed successively with water (100 mL) and diethyl ether (100 mL). The title product was isolated as a brown solid (2.7 g, 81%).
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 11.53 (s, 1 H, NH), 11.04 (s, 1H, NH), 7.95 (d, J = 2 Hz, 1 H), 7.41 (d, J = 2 Hz, 1H).
Step 2: (E)-tert-Butyl 3-(3-(2-(4-methylpiperazin-l-yl)ethyl)-2-oxo- l,2,3,4-tetrahydropyrido[2,3-d] pyrimidin-6-yl)acrylate
Figure imgf000131_0001
terf-Butyl acrylate (2.74 mL, 18.6 mmol), diisopropylethylamine (1.6 mL, 9.8 mmol) and P(o-tolyl)3 (272 mg, 0.89 mmol) were successively added to a suspension of 6-bromo-lH-imidazo[4,5-£>]pyridin-2(3H)-one (1.0 g, 4.67 mmol) in propionitrile (27 mL) and dimethylformamide (7 mL) at room temperature. The resulting mixture was purged with argon prior to the addition of palladium acetate (100 mg, 0.44 mmol). The mixture was then purged with argon a second time and refluxed overnight. The reaction mixture was filtered on Celite® and the filtrate was concentrated to dryness. The residue was partitioned between ethyl acetate (20 mL) and water (30 mL). The organic phase was washed with a saturated solution of sodium chloride (2 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was triturated in diethyl ether to give the title product as a brown solid (667 mg, 56%).
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 11.55 (s, 1 H, NH), 11.05 (s, 1H, NH), 8.14 (s, 1 H), 7.59 (s, 1H), 7.56 (d, J= 16 Hz, 1 H), 6.51 (d, J= 14 Hz, 1H), 1.49 (s, 9H). Step 3: (E)-3-(2-Oxo-2 3-dihydro-lH-imidazo[4 5-ft]pyridin-6-yl)acrylic acid hydrochloride
Figure imgf000131_0002
Trifluoroacetic acid (2 mL) was added to a suspension of (E)-tert- butyl 3-(2-oxo- 2,3-dihydro-lH-imidazo[4,5-£>]pyridin-6-yl)acrylate (400 mg, 1.54 mmol) in dichloromethane (2 mL) at room temperature. The reaction mixture was stirred for 1 hour then concentrated to dryness. The resulting residue was suspended in a solution of hydrochloric acid in dioxane 4N (2 mL). After 10 minutes stirring at room temperature, the precipitate was filtered and washed with diethyl ether to afford the title product as a pale yellow solid (381 mg, quantitative).
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 11.58 (br s, NH), 11.06 (s, NH), 8.14 (s, 1H), 7.60 (d, J = 16 Hz, 1H), 7.58 (s, 1H), 6.51 (d, J = 16 Hz, 1 H).
Step 4: (E)-6-(3-Oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l- enyl)-l -imidazo[4 5-b]pyridin-2(3 )-one
Figure imgf000132_0001
HCI
3-(Thiophen-2-ylmethoxy)-azetidine hydrochloride (127 mg, 0.62 mmol), EDCI (120 mg, 0.62 mmol), HOBt (86 mg, 0.62 mmol) and diisopropylethylamine (180 μΙ_, 1.03 mmol) were successively added to a solution of (E)-3-(2-oxo-2,3-dihydro- lH-imidazo[4,5-£>]pyridin-6-yl)acrylic acid hydrochloride (100 mg, 0.41 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred overnight then partitioned between ethyl acetate (20 mL) and water (30 mL). The aqueous layer was separated and successively extracted with ethyl acetate (2 x 20 mL) and dichloromethane (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (98: 2 to 93 : 7) as eluent. The residue was triturated in pentane to afford the title product as a pale orange solid (21 mg, 14%).
LCMS (ESI-APCI) m/z 357.1 (M + H)+
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 11.54 (s, NH), 11.06 (s, NH), 8.13 (s, 1 H), 7.6 (s, 1 H), 7.57-7.54 (m, 1H), 7.44 (d, J= 15.6 Hz, 1 H), 7.13-7.10 (m, 1H), 7.05- 7.02 (m, 1H), 6.69 (d, J = 15.6 Hz, 1H), 4.67 (s, 2H), 4.48-4.45 (m, 2H), 4.13- 4.08 (m, 2H), 3.75-3.70 (m, 1H).
Example 47
(E)-6-(3-Oxo-3-(3-(3 3 3-trifluoropropoxy)azetidin-l-yl)prop-l-enyl)-3 4- dihydro-l,8-naphthyridin-2( lH)-one (E47)
Step 1: l-Benzhydryl-3-(3,3,3-trifluoropropoxy)azetidine
Figure imgf000133_0001
A solution of l-benzhydrylazetidin-3-yl methanesulfonate (500 mg, 1.57 mmol) in trifluoroethanol (3.5 mL, 30.7 mmol) was stirred under microwaves at 110°C for 30 minutes. The reaction mixture was diluted by addition of dichloromethane ( 100 mL) and a saturated solution of sodium hydrogencarbonate (25 mL). The aqueous layer was separated and extracted with dichloromethane (2 x 10 mL). The combined organic phase was dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/ethyl acetate (90 : 10) as eluent. The title product was obtained as a light yellow gum (170 mg, 32%).
LCMS (ESI-APCI) m/z 336.1 (M + H)+
Step 2: 3-(3,3,3-Trifluoropropoxy)azetidine hydrochlo
Figure imgf000133_0002
1-Chloroethyl chloroformate (136 pL, 1.25 mmol) was added to a solution of 1- benzhydryl-3-(3,3,3-trifluoropropoxy)-azetidine (400 mg, 1.19 mmol) in dichloromethane (10 mL) at 0°C. The reaction mixture was stirred for 1 hour. Ethanol (10 mL) was added and the reaction mixture was stirred for 1 hour at room temperature and for 2 hours at 45°C. After concentration to dryness, the crude mixture was triturated in petroleum ether (2 x 20 mL) to give a yellow oil (245 mg, quantitative) which was used in the next step without further purification.
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 9.25 (s, NH2), 4.43-4.40 (m, 1H), 4.13- 4.09 (m, 2H), 3.80-3.77 (m, 2H), 3.61 (t, J = 6.4 Hz, 2H), 2.65-2.55 (m, 2H). Step 3: (E)-6-(3-Oxo-3-(3-(3,3,3-trifluoropropoxy)azetidin-l-yl)prop-l- enyl)-3,4-dihydro-l,8-naphthyridin-2(l/ )-one
Figure imgf000133_0003
3-(3,3,3-Trifluoropropoxy)azetidine hydrochloride (194 mg, 0.94 mmol), EDCI (181 mg, 0.94 mmol), HOBt (128 mg, 0.94 mmol) and diisopropylethylamine (274 μΙ_, 1.57 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (160 mg, 0.63 mmol) in dimethylformamide (15 mL) at room temperature. The reaction mixture was stirred overnight then diluted by addition of ethyl acetate (30 mL) and water (40 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (98: 2) as eluent. The residue was finally precipitated from methanol to afford the title product as a white solid (90 mg, 39%).
LCMS (ESI-APCI) m/z 370.1 (M + H)+
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.68 (s, NH), 8.34 (s, 1H), 8.02 (s, 1H), 7.40 (d, J = 15.6 Hz, 1 H), 6.72 (d, J = 15.6 Hz, 1H), 4.50-4.38 (m, 2H), 4.18-4.07 (m, 2H), 3.76-3.72 (m, 1H), 3.63-3.59 (m, 2H), 2.91 (t, J = 7.6 Hz, 2H), 2.5 (t, J = 7.6 Hz, 2H), 2.63-2.51 (m, 2H). The CH2 at 2.5 ppm is partially hidden by DMSO.
Example 48
(E)-6-(3-Oxo-3-(3-(4 4 4-trifluorobutoxy)azetidin-l-yl)prop-l-enyl)-3 4- dihydro-l,8-naphthyridin-2( lH)-one (E48)
Step 1: l-Benzhydryl-3-(4,4,4-trifluorobutoxy)-azetidine
Figure imgf000134_0001
A suspension of l-benzhydrylazetidin-3-yl methanesulfonate (247 mg, 0.78 mmol) in trifluoropropanol (1 g, 7.8 mmol) was placed under micro-wave irradiations (100 W) and heated at 100°C during 30 minutes. The reaction mixture was diluted by addition of dichloromethane (50 mL) and water (30 mL). The two phases were separated and the aqueous phase was extracted with dichloromethane (2 x 20 mL). The combined organic phases were dried over sodium sulphate and concentrated to dryness. The residue was purified by chromatography on silica gel using petroleun ether/ethyl acetate (8: 2) as eluent. The title product was isolated as a yellow oil (191 mg, 33%).
LCMS (ESI-APCI) m/z 350.2 (M + H)+ Step 2: 3-(4,4,4-Trifluorobutoxy)-azetidine hydrochloride
Figure imgf000135_0001
1-Chloroethyl chloroform ate (65 μΙ_, 0.60 mmol) was added to a solution of 1- benzhydryl-3-(4,4,4-trifluorobutoxy)-azetidine (200 mg, 0.57 mmol) in dichloromethane (5 mL) at 0°C. The reaction mixture was stirred for 3 hours and 30 minutes at room temperature. Ethanol (5 mL) was then added and the mixture was stirred for an additional 2 hours at 0°C and 2 hours at 70°C. The reaction mixture was concentrated under vacuum and the residue was triturated in petroleum ether (2 x 20 mL) to give a colorless oil (130 mg, quantitative) which was used without further purification.
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 9.14 (br s, NH2), 4.36-4.32 (m, 1H), 4.15-4.05 (m, 2H), 3.82-3.75 (m, 2H), 3.45-3.40 (m, 2H), 2.34-2.31 (m, 2H), 1.74-1.70 (m, 2H). Step 3: (E)-6-(3-Oxo-3-(3-(4,4,4-trifluorobutoxy)azetidin-l-yl)prop-l- enyl)-3,4-dihydro-l,8-naphthyridin-2(l/ )-one
Figure imgf000135_0002
3-(4,4,4-Trifluorobutoxy)-azetidine (129 mg, 0.59 mmol), EDCI (113 mg, 0.59 mmol), HOBt (80 mg, 0.59 mmol) and diisopropylethylamine (170 pL, 0.97 mmol) were successively added to a solution of (E)-3-(7-oxo-5,6,7,8-tetrahydro-l,8- naphthyridin-3-yl)-acrylic acid hydrochloride (100 mg, 0. 039 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred overnight then diluted with ethyl acetate (50 mL) and water (50 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 100 mL), dried over sodium sulfate and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (95 : 5 to 9 : 1) as eluent. The residue was finally triturated in diethylether to give the title product as a pale yellow solid (52.5 mg, 35%).
LCMS (ESI-APCI) m/z 384.2 (M + H)+ *H NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.68 (s, NH), 8.34 (s, 1H), 8.01 (s, 1H), 7.4 (d, J = 15.6 Hz, 1H), 6.72 (d, J = 15.6 Hz, 1H), 4.51-4.33 (m, 2H), 4.17-4.07 (m, 2H), 3.77-3.73 (m, 1H), 3.46-3.42 (m, 2H), 2.92 (t, J = 7.6 Hz, 2H), 2.5 (t, J = 7.6 Hz, 2H), 2.36-2.29 (m, 2H), 1.79-1.24 (m, 2H). The CH2 at 2.5 ppm is partially hidden by DMSO.
Examples 49 and 50
6-((E)-3-(3-((E)-But-2-enyloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3 4- dihydro-l,8-naphthyridin-2( lH)-one (E49) & 6-((E)-3-(3-((Z)-But-2- enyloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3 4-dihydro-l 8-naphthyridin- 2(l«)-one (E50)
Step 1: l-Benzhydryl-3-(but-2-enyloxy)-azetidine
Figure imgf000136_0001
Sodium hydride (60% in oil, 160 mg, 4.17 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (500 mg, 2.09 mmol) in dimethylformamide (2 mL) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of crotyl bromide (430 pL, 4.17 mmol) in solution in dimethylformamide (3 mL). The reaction mixture was stirred at 80°C overnight and cooled to room temperature. The mixture was then partitioned between ethyl acetate (30 mL) and water (50 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 100 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 100 mL), dried over sodium sulfate and concentrated to dyness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (1 :0 to 98: 2) as eluent. The title product was obtained as a yellow oil (292 mg, 74%, mixture of the 2 isomers).
LCMS (ESI-APCI) m/z 294.2 (M + H)+
Step 2: 3-(But-2-enyloxy)-azetidine hydrochloride
Figure imgf000136_0002
1-Chloroethylchloroformate (140 μΙ_, 1.28 mmol) was added to a solution of 1- benzhydryl-3-(but-2-enyloxy)-azetidine (290 mg, 0.98 mmol) in dichloroethane (5 mL) at room temperature. The reaction mixture was then heated up to 70°C and stirred for 1 hour. After cooling down to room temperature, methanol (5 mL) was added and the reaction mixture was stirred for an additional 1 hour at 70 °C. After concentration to dryness, the crude mixture was triturated in pentane (2 x 15 mL) to give a yellow solid (161 mg, quantitative) which was used in the next step without further purification.
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 9.77 and 9.57 (br s, NH2), 5.77-5.69 (m, 1H), 5.51-5.46 (m, 1 H), 4.46-4.42 (m, 1H), 4.17-4.12 (m, 2H), 4.04-3.97 (m, 2H), 3.98 (d, J = 6.2 Hz, 2H), 1.66 (d, J = 6.2 Hz, 3H).
Step 3: 6-((E)-3-(3-((E)-But-2-enyloxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2( lH)-one & 6-((E)-3-(3-((Z)-But-2- enyloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3 4-dihydro-l 8-naphthyridin- 2(l«)-one
Figure imgf000137_0001
3-(But-2-enyloxy)-azetidine hydrochloride (129 mg, 0.79 mmol), EDCI (151 mg, 0.79 mmol), HOBt (106 mg, 0.79 mmol) and diisopropylethylamine (230 pL, 1.31 mmol) were successively added to a solution of (E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (134 mg, 0.52 mmol) in dimethylformamide (13 mL) at room temperature. The reaction mixture was stirred overnight then diluted by addition of ethyl acetate (50 mL) and a saturated solution of water (50 mL). The aqueous layer was successively extracted with ethyl acetate (3 x 50 mL) and dichloromethane (3 x 50 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 50 mL), dried over sodium sulfate and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (1 : 0 to 95 : 5) as eluent. The 2 isomers were finally separated by preparative HPLC to afford the trans- isomer (45 mg, 26%) and the c/s-isomer (14 mg, 8%).
Trans-isomer: LCMS (ESI-APCI) m/z 328.2 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.35 (s, IH), 8.30 (s, IH), 7.63 (s, IH), 7.58 (d, J = 15.6 Hz, I H), 6.41 (d, J = 15.6 Hz, I H), 5.81-5.72 (m, I H), 5.62-5.56 (m, IH), 4.46-4.36 (m, 2H), 4.30-4.25 (m, I H), 4.18-4.15 (m, I H), 4.03-3.99 (m, IH), 3.91 (d, J = 6.2 Hz, 2H), 3.02 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.6 Hz, 2H), 1.74 (d, J = 6.2 Hz, 3H).
C/s-isomer:
LCMS (ESI-APCI) m/z 328.2 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.33 (s, 2H), 7.63 (s, IH), 7.58 (d, J = 15.6 Hz, IH), 6.42 (d, J = 15.6 Hz, IH), 5.76-5.71 (m, IH), 5.58-5.54 (m, IH), 4.45- 4.38 (m, 2H), 4.32-4.27 (m, IH), 4.21-4.17 (m, I H), 4.06-4.03 (m, 3H), 3.00 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.6 Hz, 2H), 1.69 (d, J = 6.8 Hz, 3H).
Example 51
6-((E)-3-(3-((E)-2-methylbut-2-enyloxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2( lH)-one (E51)
Step 1: (£)-2-Methylbut-2-en-l-ol
Figure imgf000138_0001
Sodium borohydride (1.08 g, 28.5 mmol) was added to a solution of trans-2- methyl-2-butenal (2.0 g, 23.8 mmol) in methanol (10 mL) at 0°C. The reaction mixture was stirred for 1 hour then diluted by addition of water (10 mL) and ethyl acetate (15 mL). The aqueous layer was separated and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with a saturated solution of sodium chloride (2 x 25 mL), dried over sodium sulfate, filtered and concentrated carefully to dryness (volatile compound). The title product was obtained as a colorless oil (1.2 g, 60%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 5.46-5.42 (m, IH), 3.42 (s, 2H), 1.87 (s, OH), 1.62 (s, 3H), 1.57 (d, J = 2 Hz, 3H).
Step 2: (£)-l-Benzhydryl-3-(2-methylbut-2-enyloxy)azetidine
Figure imgf000138_0002
A solution of l-benzhydrylazetidin-3-yl methanesulfonate (447 mg, 1.41 mmol) in (E)-2-methylbut-2-en- l-ol ( 1.2 g, 14.1 mmol) was stirred under microwaves at 110°C for 30 minutes. After concentration to dryness, the residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate (9 : 1) as eluent. The title product was obtained as a colorless oil (290 mg, 67%) .
LCMS (ESI-APCI) m/z 308.2 (M + H)+
Step 3: (£)-3-(2-Methylbut-2-enyloxy)azetidine hydrochloride
Figure imgf000139_0001
1-Chloroethyl chloroformate ( 107 μ Ι_, 1.0 mmol) was added to a solution of (E)- l- benzhydryl-3-(2-methylbut-2-enyloxy)azetidine (290 mg, 0.941 mmol) in dichloromethane ( 10 mL) at 0°C. The reaction mixture was stirred for 2 hours. Ethanol ( 10 mL) was then added and the reaction mixture was stirred for an additional 2 hours at 0°C and 16 hours at room temperature. After concentration to dryness, the crude mixture was triturated in pentane (5 mL) and petroleum ether (5 mL) to afford a colorless oil (211 mg, quantitative) .
*H NM R (CDCI3, 400 M Hz) : δ (ppm) : 9.87 (br s, NH2), 9.55 (br s, NH2), 5.52-5.45 (m, 1 H), 4.43-4.37 (m, 1 H), 4.16-4.12 (m, 2 H), 4.02-4.0 (m, 2H), 3.8 (s, 2H), 1.63- 1.60 (m, 6H) .
Step 4: 6-((E)-3-(3-((E)-2-Methylbut-2-enyloxy)azetidin-l-yl)-3-oxoprop- l-enyl)-3,4-dihydro-l,8-naphthyr l/ )-one
Figure imgf000139_0002
(E)-3-(2-Methylbut-2-enyloxy)azetidine hydrochloride ( 168 mg, 0.94 mmol), EDCI ( 182 mg, 0.94 mmol), HOBt ( 132 mg, 0.94 mmol) and diisopropylethylamine (276 p L, 1.58 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro- l,8-naphthyridin-3-yl)-acrylic acid hydrochloride ( 161 mg, 0.63 mmol) in dimethylformamide ( 12 mL) at room temperature. The reaction mixture was stirred overnight then diluted by addition of ethyl acetate (40 mL) and water (40 mL) . The aqueous layer was separated and extracted with ethyl acetate (2 x 40 mL) . The combined organic phases were washed with a saturated solution of sodium chloride (3 x 50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (98: 2) as eluent. After trituration in diethyl ether, petroleum ether and methanol, the title product was obtained as a white solid (46 mg, 21%).
LCMS (ESI-APCI) 342.2 m/z (M + H) +
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 10.68 (s, 1H), 8.37 (s, 1H), 8.04 (s, 1H), 7.43 (d, J = 16 Hz, 1 H), 6.74 (d, J = 16 Hz, 1H), 5.56-5.50 (m, 1 H), 4.51-4.46 (m, 1H), 4.36-4.33 (m, 1H), 4.17-4.08 (m, 2H), 3.84 (s, 2H), 3.78-3.74 (m, 1H), 2.94 (t, J = 7.6 Hz, 2H), 2.5 (t, J = 7.6 Hz, 2H), 1.64 (s, 3H), 1.63 (d, J = 8 Hz, 3H). The CH2 at 2.5 ppm is partially hidden by DMSO.
Example 52
(E)-6-(3-(3-(Benzo[fc]thiophen-2-ylmethoxy)azetidin-l-yl)-3-oxoprop-l- enyl)-3,4-dihydro-l,8-naphthyridin-2(ltt)-one (E52)
Step 1: 2-(Bromomethyl)benzo[b]thiophene
Figure imgf000140_0001
HBr in acetic acid (6 mL) was added to a suspension of benzo[b]thiophen-2- ylmethanol (1 g, 6.1 mmol) in dichloromethane (6 mL) at room temperature. The reaction mixture was stirred for 3 hours then diluted by addition of chloroform (20 mL). The organic phase was washed with a saturated solution of hydrogenocarbonate (20 mL), dried over sodium sulfate and concentrated to dryness. The title product was obtained as a yellow oil (1.3 g, quantitative).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 7.91 (m, 1H), 7.83 (m, 1H), 7.53-7.45 (m, 2H), 7.33 (s, 1 H), 4.86 (s, 2H). Step 2: l-Benzhydryl-3-(benzo[b]thiophen-2-ylmethoxy)-azetidine
Figure imgf000140_0002
Sodium hydride (60% in oil, 243 mg, 6.0 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (727 mg, 3.0 mmol) in dimethylformamide (5 mL) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of a solution of 2-(bromomethyl)benzo[b]thiophene ( 1.38 g, 6 mmol) in dimethylformamide (5 mL). The reaction mixture was stirred for 3 hours at room temperature. The reaction mixture was then diluted by addition of ethyl acetate (30 mL) and water (30 mL) . The aqueous layer was separated and extracted with ethyl acetate (2 x 30 mL) . The combined organic phases were washed with a saturated solution of sodium chloride (3 x 50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate (9 : 1 to 8 : 2) as eluent. The title product was obtained as a white solid ( 1.04 g, 85%) .
LCMS (ESI-APCI) m/z 386.2 (M + H)+ Step 3: 3-(Benzo[/>]thiophen-2-ylmethoxy)-azetidine hydrochloride
Figure imgf000141_0001
1-Chloroethyl chloroformate (322 p L, 1.1 mmol) was added to a solution of 1- benzhydryl-3-(benzo[b]thiophen-2-ylmethoxy)-azetidine ( 1.04 g, 2.7 mmol) in dichloromethane ( 17 mL) at room temperature. The reaction mixture was stirred for 2 hours. Methanol ( 17 mL) was added and the reaction mixture was stirred for an additional 16 hours at room temperature. The reaction mixture was then concentrated to dryness and the residue was triturated in petroleum ether (20 mL) to afford the title compound as a yellow solid (600 mg, 90%).
NM R (DMSO-de, 400 M Hz) : δ (ppm) : 8.92 (br s, NH), 8.77 (br s, NH), 7.97-7.95 (m, 1 H), 7.85-7.83 (m, 1 H), 7.39-7.35 (m, 3H), 4.81 (s, 2H), 4.53-4.56 (m, 1 H), 4.14-4.09 (m, 2H), 3.88-8.84 (m, 2H) .
Step 4: (E)-6-(3-(3-(Benzo[6]thiophen-2-ylmethoxy)azetidin-l-yl)-3- oxoprop-l-enyl)-3,4-dihydro-l,8-naphthyridin-2( lW)-one
Figure imgf000141_0002
3-(Benzo[b]thiophen-2-ylmethoxy)-azetidine hydrochloride (136 mg, 0.76 mmol), EDCI (146 mg, 0.76 mmol), HOBt (103 mg, 0.76 mmol) and diisopropylethylamine (222 μΙ_, 1.27 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (130 mg, 0.51 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred for 3 days. The reaction mixture was then diluted by addition of ethyl acetate (50 mL) and water (50 mL). The aqueous phase was extracted with ethyl acetate (3 x 100 mL) and dichloromethane (3 x 100 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 50 mL), dried over sodium sulfate and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (1 : 0 to 95 : 5) as eluent. After trituration in acetone and methanol, the title product was obtained as a white solid (112 mg, 45%).
LCMS (ESI-APCI) m/z 420.2 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.33 (s, 1 H), 8.29 (s, 1H), 7.96-7.94 (m, 1 H), 7.84-7.81 (m, 1H), 7.43-7.34 (m, 4H), 7.71 (d, J = 15.6 Hz, 1H), 4.8 (s, 2H), 4.52-4.48 (m, 2H), 4.17-4.11 (m, 2H), 3.79-3.76 (m, 1H), 2.99 (t, J = 7.6 Hz, 2H), 2.69 (t, J = 7.6 Hz, 2H). Example 53
(E)-6-(3-(3-((4-Bromothiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l- enyl)-3,4-dihydro-l,8-naphthyridin-2(ltt)-one (E53)
Step 1: 4-Bromothiophen-2-yl)methanol
Figure imgf000142_0001
Sodium borohydride (594 mg, 15.7 mmol) was added to a solution of 2- bromothiophene carboxaldehyde (2.5 g, 13 mmol) in a mixture toluene/ethanol (16 mL, 1 : 1) at 0°C. The reaction mixture was stirred for 2 hours at room temperature then partitioned between water (20 mL) and ethyl acetate (20 mL). The aqueous phase was separated and extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with a saturated solution of sodium chloride (2 x 20 mL), dried over sodium sulphate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate (7 : 3) as eluent. The title product was obtained as a white solid (2.47 g, 98%). *H NMR (CDCI3, 400 MHz) : δ (ppm) : 7.21 (d, J = 1.2 Hz, 1 H), 6.88 (d, J = 1.2 Hz, 1H), 4.75 (d, J = 6 Hz, 2H).
Step 2: 4-Bromo-2-(chloromethyl)thiophene
Figure imgf000143_0001
Thionyl chloride (1.12 mL, 15.3 mmol) was added to a solution of 4- bromothiophen-2-yl)methanol (2.47 g, 12.8 mmol) in dichloromethane (25 mL) at 0°C. The reaction mixture was stirred for 2h30 at room temperature. The reaction mixture was then diluted by addition of water (20 mL) and dichloromethane (20 mL). The aqueous phase was separated and the organic phase was washed with a saturated solution of sodium chloride (20 mL), dried over sodium sulphate, filtered and concentrated to dryness. The title product was obtained as a yellow oil (2.57 g, 95%) and used without further purification.
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 7.20 (s, 1H), 7.00 (s, 1H), 4.72 (s, 2H).
Step 3: l-Benzhydryl-3-((4-bromothiophen-2-yl)methoxy)-azetidine
Figure imgf000143_0002
Sodium hydride (60% in oil, 167 mg, 4.18 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (500 mg, 2.09 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of a solution of 4-bromo-2-(chloromethyl)thiophene (884 mg, 4.18 mmol) in dimethylformamide (3 mL). The reaction mixture was stirred overnight and then diluted by addition of ethyl acetate (30 mL) and water (30 mL). The aqueous layer was separated and extracted with ethyl acetate (3 x 30 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate (95 : 5) as eluent. The title product was obtained as a yellow solid (793 mg, 92%).
LCMS (ESI-APCI) m/z 414.1; 416.1 (M + H)+
Step 4: 3-((4-Bromothiophen-2-yl)methoxy)-azetidine hydrochloride
Figure imgf000144_0001
1-Chloroethyl chloroform ate (218 μΙ_, 2.0 mmol) was added to a solution of 1- benzhydryl-3-((4-bromothiophen-2-yl)methoxy)-azetidine (793 mg, 1.91 mmol) in dichloromethane (10 mL). The reaction mixture was stirred for 1 hour at 0°C and for an additional 1 hour at room temperature. Ethanol (10 mL) was then added and the reaction mixture was stirred overnight. After concentration to dryness, the crude mixture was precipitated from a mixture dichloromethane/diethyl ether to afford a white solid (417 mg, 77%) which was used in the next step whitout further purification.
*H NMR (DMSO-de, 400 MHz) : δ (ppm) : 8.81 (br s, NH2), 7.72 (s, 1H), 7.18 (s, 1H), 4.68 (s, 2H), 4.49-4.44 (m, 1H), 4.14-4.10 (m, 2H), 3.87-3.82 (m, 2H)
Step 5: (E)-6-(3-(3-((4-Bromothiophen-2-yl)methoxy)azetidin-l-yl)-3- oxoprop- -enyl)-3,4-dihydro-l,8-naphthyridin-2(lW)-one
Figure imgf000144_0002
3-((4-Bromothiophen-2-yl)methoxy)-azetidine hydrochloride (168 mg, 0.59 mmol), EDCI (113 mg, 0.59 mmol), HOBt (82 mg, 0. 59 mmol) and diisopropylethylamine (171 pL, 1.00 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (100 mg, 0.39 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred overnight then diluted by addition of ethyl acetate (40 mL) and water (40 mL). The aqueous phase was separated and extracted with ethyl acetate (2 x 40 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 40 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was triturated in diethyl ether to afford a pale yellow solid (109 mg, 62%).
LCMS (ESI-APCI) m/z 448.1; 450.0 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.39 (s, 1 H), 8.30 (s, 1H), 7.64 (s, 1 H), 7.58 (d, J = 15.6 Hz, 1 H), 7.23 (d, J = 1.2 Hz, 1 H), 6.95 (d, J = 1.2 Hz, 1H), 6.39 (d, J = 15.6 Hz, 1H), 4.63 (m, 2H), 4.47-4.43 (m, 2H), 4.29-4.26 (m, 1H), 4.19-4.16 (m, 1 H), 4.04-4.00 (m, 1 H), 3.00 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.6 Hz, 2H).
Example 54
(E)-6-(3-(3-((4-Chlorothiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l- enyl)-3,4-dihydro-l,8-naphthyridin-2(lf )-one (E54)
Step 1: (4-Chlorothiophen-2-yl)methanol
Figure imgf000145_0001
Lithium aluminium hydride (117 mg, 3.08 mmol) was added to a solution of 2- chlorothiophene carboxylique acid (500 mg, 3.08 mmol) in tetrahydrofuran (5 mL) at 0°C. The reaction mixture was stirred for 1 hour at room temperature and then diluted by addition of water (10 mL) and an aqueous solution of sodium hydroxide (IN, 10 mL). The aqueous solution was extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over sodium sulphate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate (9 : 1) as eluent. The title product was obtained as a white solid (330 mg, 72%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 7.05 (d, J = 1.6 Hz, 1 H), 6.88 (d, J = 1.6 Hz, 1H), 4.78 (S, 2H).
Step 2: 4-Chloro-2-(chloromethyl)thiophene
Figure imgf000145_0002
Thionyl chloride (117 D L, 1.60 mmol) in solution in dichloromethane (1 mL) was added to a solution of (4-chlorothiophen-2-yl)methanol (140 mg, 0.94 mmol) in dichloromethane (3 mL) at 0°C. The reaction mixture was stirred for 2h30 at room temperature then 30 minutes at 40°C. The reaction mixture was diluted by addition of water (20 mL) and dichloromethane (20 mL). The organic phase was washed with a saturated solution of sodium chloride (20 mL), dried over sodium sulphate, filtered and concentrated to dryness. The title product was obtained as an orange oil (165 mg, 77%) and used in the next step without further purification.
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 7.08 (d, J = 1.6 Hz, 1 H), 6.96 (d, J = 1.6 Hz, 1H), 4.69 (s, 2H). Step 3: l-Benzhydryl-3-((4-chlorothiophen-2-yl)methoxy)-azetidine
Figure imgf000146_0001
Sodium hydride (60% in oil, 167 mg, 4.18 mmol) was added to a solution of 1- benzhydryl-3-azetidin-3-ol (500 mg, 2.09 mmol) in dimethylformamide ( 10 mL) at room temperature. The reaction mixture was stirred for 30 minutes prior to the addition of a solution of 4-chloro-2-(chloromethyl)thiophene (884 mg, 4.18 mmol) in dimethylformamide (3 mL). The reaction mixture was then stirred overnight. The reaction mixture was diluted by addition of ethyl acetate (30 mL) and water (30 mL) . The aqueous layer was separated and extracted with ethyl acetate (3 x 30 mL) . The combined organic phases were washed with a saturated solution of sodium chloride (3 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate (95 : 5) as eluent. The title product was obtained as a yellow solid (793 mg, 92%).
LCMS (ESI-APCI) m/z 414.1 ; 416.1 (M + H)+
Step 4: 3-((4-Chlorothiophen-2-yl)methoxy)-azetidine hydrochloride
Figure imgf000146_0002
1-Chloroethyl chloroformate (218 p L, 2.0 mmol) was added to a solution of 1- benzhydryl-3-((4-chlorothiophen-2-yl)methoxy)-azetidine (793 mg, 1.91 mmol) in dichloromethane ( 10 mL) at 0°C. The reaction mixture was stirred for 1 hour at 0°C and for an additional 1 hour at room temperature. Ethanol ( 10 mL) was added and the reaction mixture was stirred overnight. After concentration to dryness, the crude mixture was precipitated from a mixture dichloromethane/diethyl ether to afford the title compound as a white solid (417 mg, 77%) which was used whitout further purification .
W NM R (DMSO-de, 400 M Hz) : δ (ppm) : 8.81 (br s, NH2), 7.72 (s, 1 H), 7.18 (s, 1 H), 4.68 (s, 2H), 4.49-4.44 (m, 1 H), 4.14-4.10 (m, 2H), 3.87-3.82 (m, 2H) . Step 5: (E)-6-(3-(3-((4-Chlorothiophen-2-yl)methoxy)azetidin-l-yl)-3- oxoprop-l-enyl)-3,4-dihydro-l,8-naphthyridin-2(lW)-one
Figure imgf000147_0001
3-((4-Chlorothiophen-2-yl)methoxy)-azetidine hydrochloride (141 mg, 0.59 mmol), EDCI (113 mg, 0.59 mmol), HOBt (82 mg, 0. 59 mmol) and diisopropylethylamine (171 μΙ_, 1.00 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (100 mg, 0.39 mmol) in dimethylformamide (6 mL) at room temperature. The reaction mixture was stirred overnight and then diluted by addition of ethyl acetate (40 mL) and water (40 mL). The aqueous phase was extracted with ethyl acetate (2 x 40 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 40 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was triturated in diethyl ether to afford the title compound as a pale yellow solid (37 mg, 23%).
LCMS (ESI-APCI) m/z 404.1 (M + H)+
*H NMR (CDCIs, 400 MHz) : δ (ppm) : 8.30 (s, 1H), 8.19 (s, 1H), 7.62 (s, 1H), 7.58 (d, J = 15.6 Hz, 1 H), 7.11 (d, J = 1.4 Hz, 1 H), 6.90 (d, J = 1.4 Hz, 1H), 6.39 (d, J = 15.6 Hz, 1H), 4.64-4.60 (m, 2H), 4.46-4.42 (m, 2H), 4.29-4.26 (m, 1H), 4.19- 4.15 (m, 1H), 4.06-4.02 (m, 1H), 2.99 (t, J = 7.2 Hz, 2H), 2.7 (m, J =7.2 Hz, 2H).
Example 55
6-((^)-3-Oxo-3-(3-((Z)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2( lH)-one (E55)
Step 1: Azetidine-l,3-dicarboxylic acid mono-tert-butyl ester
Figure imgf000147_0002
Di-tert-buyldicarbonate (2.5 g, 11.88 mmol) was added to a stirred solution of 3- azetidinecarboxylic acid (1.0 g, 9.9 mmol) in a mixture of THF / water (12 mL : 2 mL) and 1 M KOH (1 mL) at room temperature. The reaction mixture was stirred for 16 hours and then concentrated to dryness. The crude was partitioned between an aqueous solution of IN NaOH (10 mL) and diethyl ether (50 mL). The ether layer was discarded and the aqueous layer was acidified with a 3M aqueous solution of KHS04 untill pH = 2 and extracted with diethyl ether (3 x 100 ml). The combined organic phases were washed with brine, dried over magnesium sulfate and concentrated in vacuo to give the title compound as a white solid (1.4 g, 70%).
*H NMR (400 MHz, DMSO-d6) δ (ppm) : 12.64 (s, 1 H), 4.02-3.93 (m, 2H), 3.87-3.80 (m, 2H), 3.36-3.27 (m, 1 H), 1.36 (s, 9H).
Step 2: 3-(2,2-Dimethyl-4,6-dioxo-[l,3]dioxane-5-carbonyl)-azetidine-l- carboxylic acid te - butyl ester
Figure imgf000148_0001
Meldrum's acid (0.85 g, 5.97 mmol), DCC (1.22 g, 5.97 mmol), and DMAP (1.45 g, 11.94 mmol) were successively added to a solution of azetidine-l,3-dicarboxylic acid mono-teri"- butyl ester (1.2 g, 5.97 mmol) in dichloromethane (25 mL) at room temperature. The reaction mixture was stirred overnight and then diluted by addition of cyclohexane (25 mL). The precipitate of dicyclohexyl urea was then filtered and rinsed with diethyl ether (100 mL). The mother liquors were diluted with DCM (100 mL) and washed with a 1M solution of aqueous HCI (2 x 30 mL), dried over sodium sulfate, filtered and concentrated to dryness. After trituration in diethyl ether the title compound was obtained as a white solid (1.9 g, 100%).
*H NMR (400 MHz, CDCI3) δ (ppm) : 4.52-4.48 (m, 1H), 4.25-4.20 (t, 2H), 4.12- 4.07 (m, 2H), 3.36-3.27 (m, 1H), 1.71 (s, 6H), 1.41 (s, 9H).
Step 3: 3-Acetyl-azetidine-l-carboxylic acid tert- butyl ester
Figure imgf000148_0002
A solution of 3-(2,2-dimethyl-4,6-dioxo-[l,3]dioxane-5-carbonyl)-azetidine-l- carboxylic acid terf-butyl ester (1.0 g, 3.05 mmol) in a mixture of actic acid (0.5 mL), water 0.25 mL and dioxane (3 mL) was stirred under microwaves at 100°C for 30 minutes. After concentration to dryness, the residue was coeveoparted with dichloromethane (2 x 100 mL). The title product was obtained as a colorless gum (600 mg, 100%).
LCMS (ESI-APCI) m/z 308.2 (M + H)+
Step 4: l-Azetidin-3- -ethanone
Figure imgf000149_0001
Trifluoroacetic acid (8 mL) was added to a suspension of 3-acetyl-azetidine-l- carboxylic acid terf-butyl ester (800 mg, 4.0 mmol) in dichloromethane (20 mL). The reaction mixture was stirred at room temperature for 4 hours and concentrated to dryness to afford the title product as a colorless gum (800 mg, 100%).
*H NMR (400 MHz, DMSO-c/6) δ (ppm) : 4.02-4.06 (m, 4H), 3.75-3.80 (m, 1H), 2.13 (s, 3H).
Step 5: 6-[3-(3-Acetyl-azetidin-l-yl)-3-oxo-propenyl]-3,4-dihydro-lH- [l,8]naphthyridin-2-one
Figure imgf000149_0002
EDCI, HOBt, DIEA, DMF, r.t.
l-Azetidin-3-yl-ethanone TFA (700 mg, 3.54 mmol), EDCI (676 mg, 3.54 mmol), HOBt (477 mg, 3.54 mmol) and diisopropylethylamine (2.1 mL, 11.8 mmol) were successively added to a solution of (E)-3-(7-oxo-5,6,7,8-tetrahydro-l,8- naphthyridin-3-yl)-acrylic acid hydrochloride (600 mg, 2.36 mmol) in dimethylformamide (15 mL) at room temperature. The reaction mixture was stirred overnight. The reaction mixture was then diluted by addition of ethyl acetate (40 mL) and water (40 mL). The organic layer was discarded and the aqueous layer was basified with an aqueous solution of saturated sodium carbonate until pH = 12 and finally extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 50 mL), dried over sodium sulfate and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (1 : 0 to 95 : 5) as eluent to obtain the title compound as a white solid (354 mg, 50%).
LCMS (ESI-APCI) m/z 390.1 (M + H)+ *H NMR (DMSO-c/e, 400 MHz) : δ (ppm) : 10.64 (s, IH), 8.34 (d, IH), 8.01 (s, IH), 7.41- 7.37(d, IH), 6.72-6.68 (d, 2H), 4.33-4.44 (m, 2H), 4.05-4.09 (m, I H), 3.96- 3.99 (m, IH), 3.62-3.66 (m, IH), 3.31-3.51 (m, IH), 2.89-2.92 (t, 3H), 2.50 (t, 2H), 2.16 (s, 3H)
Step 6: 6-((E)-3-Oxo-3-(3-((Z)-l-(propoxyimino)ethyl)azetidin-l-yl)prop- l-enyl)-3, -dihydro-l,8-naphthyridin-2(l/ )-one
Figure imgf000150_0001
l-(Amino-oxy)-propane hydrochloride (32 mg, 0.29 mmol) was added to a solution of (E)-6-(3-(3-acetylazetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (61.3 mg, 0.20 mmol) in a mixture methanol/dichloromethane (8: 2, 3.5 ml_) at room temperature. The reaction mixture was stirred overnight. After concentration to dryness, the residue was purified by chromatography on silica gel using dichloromethane/methanol (95 : 5) as eluent. The title product was obtained as a white solid (56.0 mg, 76%).
HPLC isomer ratio 86: 14, geometry not assigned (the minor isomer has the shortest retention time).
LCMS (ESI-APCI) m/z 357.2 (M + H)+
*H NMR (DMSO-c/e, 400 MHz) (mixture of 2 isomers) : δ (ppm) : 10.64 (s, IH), 8.35 (s, IH), 8.03 (s, IH), 7.40 (d, J = 15.6 Hz, IH), 6.72 (d, J = 15.6 Hz, IH), 4.45- 4.33 (m, 2H), 4.13-4.10 (m, IH), 3.99-3.94 (m, 3H), 3.48-3.44 (m, I H), 2.92 (t, J = 7.2 Hz, 2H), 2.54 (t, J = 7.2 Hz, 2H), 1.96-1.84 (s, 3H), 1.65-1.57 (m, 2H), 0.92-0.86 (m, 3H). The CH2 at 2.5 ppm is partially hidden by DMSO. Example 56
6-((E)-3-Oxo-3-(3-((Z)-l-(2 2 2-trifluoroethoxyimino)
ethyl)azetidin-l-yl)prop-l-enyl)-3 4-dihydro-l 8-naphthyridin-2(l )-one
(E56)
Figure imgf000150_0002
2,2,2-Trifluoroethoxyamine hydrochloride (37 mg, 0.24 mmol) was added to a solution of (E)-6-(3-(3-acetylazetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (50 mg, 0.16 mmol) in methanol (4 mL). The reaction mixture was stirred at room temperature for 3 hours. After concentration to dryness the residue was diluted by addition of dichloromethane (50 ml_) and saturated sodium bicarbonate solution (10 ml_). The aqueous phase was extracted with dichloromethane (2 x 40 ml_). The combined organic phases were washed with a saturated solution of sodium chloride (1 x 20 ml_), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using ethyl acetate/methanol (95 : 5) as eluent to obtain the title product as a white solid (47 mg, 50 %).
HPLC isomer ratio 90 : 10, geometry not assigned (the minor isomer has the shortest retention time).
LCMS (ESI-APCI) m/z 397.1 (M + H)+
*H NMR (CDCI3, 400 MHz) (mixture of 2 isomers) : δ (ppm) : 8.31 (s, 1H), 8.26 (s, 1H), 7.63 (s, 1H), 7.59 (d, J = 15.6 Hz, 1H), 6.42 (d, J = 15.6 Hz, 1H), 4.46-4.39 (m, 2H), 4.33-4.28 (m, 2H), 4.16-4.11 (m, 2H), 3.50-3.41 (m, 1H), 2.99 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.6 Hz, 2H), 2.04-1.95 (s, 3H).
Example 57
6-((^)-3-(3-((Z)-l-(Ethoxyimino)ethyl)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydr -l,8-naphthyridin-2( lH)-one (E57)
Figure imgf000151_0001
l-(Aminooxy)ethane hydrochloride (23 mg, 0.23 mmol) was added to a solution of (E)-6-(3-(3-acetylazetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8-naphthyridin- 2(lH)-one (50.0 mg, 0.16 mmol) in a mixture methanol/dichloromethane (8: 2, 3.5 ml_) at room temeprature. The reaction mixture was stirred overnight. After concentration to dryness, the residue was purified by chromatography on silica gel using ethyl acetate/methanol (95 : 5) as eluent. The title product was obtained as a white solid (20 mg, 35%).
HPLC isomer ratio 87 : 13, geometry not assigned (the minor isomer has the shortest retention time).
LCMS (ESI-APCI) m/z 343.1 (M + H)+
*H NMR (CDCI3, 400 MHz) (mixture of 2 isomers) : δ (ppm) : 8.45 (s, 1H), 8.26 (s, 1H), 7.57 (s, 1H), 7.52 (d, J = 15.6 Hz, 1H), 6.37 (d, J = 15.6 Hz, 1H), 4.39-3.99 (m, 6H), 3.39-3.37 (m, 1H), 2.93 (t, J = 7.2 Hz, 2H), 2.63 (t, J = 7.2 Hz, 2H), 1.94-1.83 (s, 3H), 1.22-1.15 (m, 3H). Example 58
(E)-6-(3-(3-(Benzofuran-3-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2( lH)-one (E58)
Step 1: l-Benzhydrylazetidin-3-one
Figure imgf000152_0001
Triethylamine (29.1 mL, 209 mmol) and a solution of sulphur trioxide pyridine complex (21.3 g, 134 mmol) in DMSO ( 100 mL) were added at 10°C to a solution of l-benzhydrylazetidin-3-ol (5.0 g, 20.9 mmol) in DMSO (60 mL) . The resulting mixture was stirred at 10°C for 45 minutes, then at room temperature for 4 hours, subsequently quenched by pouring onto crushed ice (~200 g) and extracted with ethyl acetate (3 x 200 mL) . The combined organic layers were washed with water (400 mL) and brine (400 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using petroleum ether/ethyl acetate (80 : 20 to 70 : 30) as eluent. The title product was obtained as a yellowish solid (4.35 g, 88%) .
NM R (CDCI3, 400 M Hz) : δ (ppm) : 7.50-7.20 (m, 10H), 4.60 (s, 1 H), 4.01 (s,
4H) .
Step 2: l-Benzhydryl-3-(benzofuran-3-yl)azetidin-3-ol
Figure imgf000152_0002
A 2.5 M solution of n-butyllithium in hexanes (3.25 mL, 8.13 mmol) was added dropwise to a solution of 3-bromobenzofuran ( 1.0 g, 5.08 mmol) in diethyl ether (22 mL) at -78°C. The reaction mixture was stirred for 20 minutes at -78°C and then a solution of l-benzhydrylazetidin-3-one ( 1.2 g, 5.08 mmol) in diethyl ether ( 10 mL) was added dropwise at the same temperature. The mixture was stirred for 15 minutes at -78°C, then allowed to warm back to room temperature and stirred for 2 hours. Water (30 mL) was added and the mixture was extracted with ethyl acetate (3 x 30 mL) . The combined organic layers were dried over sodium sulfate, filtered and concentrated . The crude residue was combined with another crude mixture which was obtained in the same manner from 3-bromobenzofuran (500 mg, 0.25 mmol) . The combined crude materials were purified by chromatography on silica gel using petroleum ether/dichloromethane (50 : 50 to 0 : 100) as eluent. The title compound was obtained as a yellow sticky solid (761 mg, 40%) .
LCMS (ESI-APCI) m/z 356.2 (M + H)+.
*H NM R (CDCI3, 400 M Hz) : δ (ppm) : 7.91 (d, J = 7.2 Hz, 1 H), 7.66 (s, 1 H), 7.52- 7.13 (m, 13H), 4.53 (s, 1 H), 3.73 (d, J = 8.8 Hz, 2H), 3.43 (d, J = 8.8 Hz, 2H), 2.42 (br s, 1 H) . Step 3: l-Benzhydryl-3-(benzofuran-3-yl)-3-chloroazetidine
Figure imgf000153_0001
To a solution of l-benzhydryl-3-(benzofuran-3-yl)azetidin-3-ol (760 mg, 2.14 mmol) in dichloromethane ( 10 mL) was added at 0°C triethylamine (387 μ Ι_, 2.78 mmol) and then dropwise a solution of methanesulfonyl chloride (216 μ Ι_, 2.78 mmol) in dichloromethane (3 mL) . The reaction mixture was stirred for 1 hour at room temperature, then diluted with water (50 mL) and extracted with dichloromethane (3 x 50 mL) . The combined organic layers were dried over sodium sulfate, filtered and concentrated to dryness. The crude title compound was obtained as a yellow gum (873 mg, 109%) and used for the next step without further purification .
LCMS (ESI-APCI) m/z 374.1 (M + H)+.
*H NM R (CDCI3, 400 M Hz) : δ (ppm) : 7.77 (d, J = 8.0 Hz, 1 H), 7.65 (s, 1 H), 7.57- 7.17 (m, 13H), 4.58 (s, 1 H), 3.92-3.86 (m, 4H) . Step 4: l-Benzhydryl-3-(benzofuran-3-yl)azetidine
Figure imgf000153_0002
A mixture of l-benzhydryl-3-(benzofuran-3-yl)-3-chloroazetidine as obtained in the previous step (873 mg, < 2.14 mmol), triethylamine (299 p L, 2.14 mmol) and 10% palladium on carbon (227 mg) in ethyl acetate ( 15 mL) and ethanol ( 15 mL) was stirred at room temperature under hydrogen atmosphere (~1 atm) for 3 days. After removal of hydrogen, the mixture was diluted with dichloromethane ( 100 mL), filtered through Clarcel® and concentrated . The residue was taken up in dichloromethane (50 mL) and washed with aqueous saturated sodium hydrogencarbonate (50 mL). The aqueous layer was back-washed with dichloromethane (2 x 50 mL) and all the combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate (100 : 0 to 95 : 5) as eluent followed by preparative TLC on reversed phase C18 using acetonitrile/water (90 : 10) as eluent. The title compound was obtained as a yellow gum (52 mg, 7%).
LCMS (ESI-APCI) m/z 340.2 (M + H)+.
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 7.68 (d, J = 7.6 Hz, 1H), 7.47-7.17 (m, 14H), 4.45 (s, 1 H), 3.84-3.76 (m, 1H), 3.72-3.68 (m, 2H) , 3.27-3.23 (m, 2H).
Step 5: 3-(Benzofuran-3-yl)azetidine hydrochloride
Figure imgf000154_0001
1-Chloroethyl chloroformate (18 pL, 0.16 mmol) was added to a solution of 1- benzhydryl-3-(benzofuran-3-yl)azetidine (52 mg, 0.15 mmol) in dichloromethane (1.5 mL) at 0°C. The reaction mixture was stirred for 15 minutes at 0°C and for 4 hours at room temperature. An additional amount of 1-chloroethyl chloroformate (8 pL, 0.07 mmol) was added and stirring continued for 1 hour at room temperature. Ethanol (1.5 mL) was added and the reaction mixture was stirred for 3 days at room temperature. After concentration to dryness, the crude mixture was triturated in /7-pentane (2 x 2 mL) to afford the title compound as a pink solid (42 mg, 130%) which was used without further purification.
LCMS (ESI-APCI) m/z 174.1 (M + H)+.
Step 6: (E)-6-(3-(3-(Benzofuran-3-yl)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2(l/ )-one
Figure imgf000154_0002
A mixture of (E)-3-(7-oxo-5,6,7,8-tetrahydro-l,8-naphthyridin-3-yl)acrylic acid hydrochloride (26 mg, 0.10 mmol), 3-(benzofuran-3-yl)azetidine hydrochloride as obtained in the previous step (42 mg, < 0.15 mmol), EDCI (29.3 mg, 0.15 mmol), HOBt (20.7 mg, 0.15 mmol) and diisopropylethylamine (105 μΙ_, 0.61 mmol) in DMF (3 mL) was stirred at room temperature for 19 hours, then diluted with water (15 mL) and extracted with ethyl acetate (3 x 15 mL). The combined organic phases were washed with brine (3 x 50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (100 : 0 to 97 : 3) as eluent. After trituration in acetone (3 x 2 mL), co-evaporation with dichloromethane (3 x 2 mL) and vacuum- drying, the title compound was obtained as an off-white solid (8 mg, 21%).
MS (ESI-APCI) m/z 374.1 (M + H)+.
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.32-8.31 (m, 1H), 8.05 (s, 1H), 7.68-7.51 (m, 5H), 7.37-7.26 (m, 2H, overlapping with CDCI3), 6.49 (d, J = 15.6 Hz, 1H), 4.78-4.74 (m, 1 H), 4.62-4.57 (m, 1H), 4.49-4.46 (s, 1 H), 4.40-4.36 (m, 1 H), 4.10- 4.02 (m, 1H), 3.00 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.6 Hz, 2H). Example 59
(E)-6-(3-(3-(Benzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2( lH)-one (E59)
Step 1: l-Benzhydryl-3-(benzofuran-2-yl)azetidin-3-ol
Figure imgf000155_0001
A 2.5 M solution of n-butyllithium in hexanes (2.23 mL, 5.58 mmol) was added dropwise to a solution of 3-bromobenzofuran (1.0 g, 5.08 mmol) in THF (35 mL) at -78°C. The reaction mixture was stirred for 30 minutes at -78°C and then a solution of l-benzhydrylazetidin-3-one (1.2 g, 5.08 mmol, as prepared in step 1 of example FAB270) in THF (10 mL) was added dropwise at the same temperature. The mixture was allowed to warm back to room temperature overnight. Water (50 mL) was added and the mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel using petroleum ether/dichloromethane (50 : 50 to 0 : 100) as eluent. The title compound was obtained as a yellow solid (230 mg, 13%).
LCMS (ESI-APCI) m/z 356.2 (M + H)+. *H NM R (CDCI3, 400 M Hz) : δ (ppm) : 7.60-7.17 (m, 14H), 6.79 (s, 1 H), 4.58 (s, 1 H), 3.82-3.72 (m, 2H), 3.55-3.45 (m, 2H), 2.95 (br s, 1 H) .
Step 2: l-Benzhydryl-3-(benzofuran-2-yl)-3-chloroazetidine
Figure imgf000156_0001
To a solution of l-benzhydryl-3-(benzofuran-2-yl)-3-chloroazetidine (400 mg, 1.13 mmol) and triethylamine (204 μ Ι_, 1.46 mmol) in dichloromethane (5 mL) was added at 0°C dropwise a solution of methanesulfonyl chloride ( 114 μ Ι_, 1.46 mmol) in dichloromethane ( 1.6 mL) . The reaction mixture was stirred for 1 hour at room temperature, then diluted with water (30 mL) and extracted with dichloromethane (3 x 30 mL) . The combined organic layers were dried over sodium sulfate, filtered and concentrated to dryness. The crude title compound was obtained as a yellow solid (430 mg, 102%) and used without further purification .
LCMS (ESI-APCI) m/z 374.1 (M + H)+.
*H NM R (CDCI3, 400 M Hz) : δ (ppm) : 7.58-7.10 (m, 14H), 6.77 (s, 1 H), 4.57 (s, 1 H), 3.98-3.92 (m, 2H), 3.79-3.73 (m, 2H) .
Step 3: l-Benzhydryl-3-(benzofuran-2-yl)azetidine
Figure imgf000156_0002
A mixture of l-benzhydryl-3-(benzofuran-2-yl)-3-chloroazetidine (458 mg, 1.23 mmol) and 10% palladium on carbon ( 130 mg) in ethyl acetate (6 mL) and ethanol (6 mL) was stirred at room temperature under hydrogen atmosphere (~ 1 atm) for 1 day. An additional amount of 10% palladium on carbon ( 130 mg) was added as well as triethylamine ( 171 p L, 1.23 mmol) and hydrogenation was continued under same conditions for 3 days. After removal of hydrogen, the mixture was diluted with dichloromethane (50 mL), filtered through Clarcel® and concentrated . The residue was taken up in dichloromethane (30 mL) and washed with aqueous saturated sodium hydrogencarbonate (30 mL) . The aqueous layer was back-washed with dichloromethane (2 x 30 mL) and all the combined organic layers were dried over sodium sulfate, filtered and concentrated . The residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate ( 100 : 0 to 95 : 5) as eluent. The title compound was obtained as a yellow gum ( 111 mg, 27%) . LCMS (ESI-APCI) m/z 340.2 (M + H)+.
NM R (CDCI3, 400 M Hz) : δ (ppm) : 7.52-7.17 (m, 14H), 6.50 (s, 1 H), 4.48 (s, 1 H), 3.91-3.59 (m, 3H), 3.40-3.28 (m, 2H) . Step 4: 3-(Benzofuran-2-yl)azetidine hydrochloride
Figure imgf000157_0001
1-Chloroethyl chloroform ate (36 pL, 0.33 mmol) was added to a solution of 1- benzhydryl-3-(benzofuran-2-yl)azetidine ( 108 mg, 0.32 mmol) in dichloromethane (3 mL) at 0°C. The reaction mixture was stirred for 2 hours at 0°C and for 1 hour at room temperature. Ethanol (3 mL) was added at 0°C and the reaction mixture was stirred for 2 hours at 0°C, for 19 hours at room temperature and for 4 hours at 40°C. After concentration to dryness, the crude mixture was triturated in n-pentane (2 x 4 mL) to afford the title compound as a pink solid (82 mg, 123%) which was used without further purification .
LCMS (ESI-APCI) m/z 174.2 (M + H)+.
Step 5: (E)-6-(3-(3-(Benzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro- -naphthyridin-2( l/ )-one
Figure imgf000157_0002
A mixture of (E)-3-(7-oxo-5,6,7,8-tetrahydro- l,8-naphthyridin-3-yl)acrylic acid hydrochloride (54 mg, 0.21 mmol), 3-(benzofuran-2-yl)azetidine hydrochloride as obtained in the previous step (82 mg, < 0.32 mmol), EDCI (61 mg, 0.32 mmol), HOBt (43 mg, 0.32 mmol) and diisopropylethylamine ( 181 p L, 1.06 mmol) in DMF (6 mL) was stirred at room temperature for 19 hours, then diluted with water ( 15 mL) and extracted with ethyl acetate (3 x 15 mL) . The combined organic phases were washed with brine (45 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol ( 100 : 0 to 97 : 3) as eluent, preparative TLC on silica gel using ethyl acetate/methanol (90 : 10) as eluent and finally preparative TLC on reversed phase C18 using acetonitrile/water (70 : 30) as eluent. After trituration in acetone (3 x 3 mL) and co-evaporation with dichloromethane (4 x 3 mL), the title compound was obtained as a beige solid (15 mg, 19%).
MS (ESI-APCI) m/z 374.1 (M + H)+.
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.36-8.33 (m, 2H), 7.66-7.62 (m, 2H), 7.54- 7.45 (m, 2H), 7.30-7.20 (m, 2H, overlapping with CDCI3), 6.60 (s, 1H), 6.48 (d, J = 15.6 Hz, 1H), 4.69-4.65 (m, 1H), 4.55-4.49 (m, 2H), 4.41-4.37 (s, 1H), 4.11- 4.03 (m, 1H), 3.00 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.6 Hz, 2H).
Example 60
(E)-6-(3-(3-(Benzofuran-7-yloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2( lH)-one (E60)
Step 1: l-Benzhydryl-3-(benzofuran-7-yloxy)-azetidine
Figure imgf000158_0001
Potassium carbonate (348 mg, 2.52 mmol) and benzofuran-7-ol (169 mg, 1.26 mmol) were successively added to a solution of l-benzhydrylazetidin-3-yl methanesulfonate (400 mg, 1.26 mmol) in DMF (8 mL). The reaction mixture was stirred overnight at 90°C and then diluted by addition of ethyl acetate (20 mL) and water (20 mL). The aqueous phase was separated and extracted with ethyl acetate (4 x 50 mL). The combined organic phases were washed with a saturated solution of sodium chloride (5 x 50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using petroleum ether/dichloromethane (1 : 0 to 2 : 8 to 0 : 1) as eluent. The title product was obtained as a yellow oil (350 mg, 69%).
LCMS (ESI-APCI) m/z 356.2 (M + H)+
Step 2: 3-(Benzofuran-7-yloxy)-azetidine hydrochloride
Figure imgf000158_0002
1-Chloroethyl chloroformate (107 pL, 0.99 mmol) was added to a solution of 1- benzhydryl-3-(benzofuran-7-yloxy)-azetidine (349 mg, 0.98 mmol) in dichloromethane (10 mL) at 0°C. The reaction mixture was stirred for 4 hours at room temperature. Ethanol (10 ml_) was added and the reaction mixture was stirred for an additional 2 hours at room temperature and 3 hours at 40°C. After concentration to dryness, the residue was taken in a mixture dichloromethane/diethyl ether to afford the title compound as a white solid (193 mg, 87%).
*H NMR (CDCI3, 400 MHz) : 10.11 (s, NH2), 9.98 (s, 1H), 7.60 (d, J = 2 Hz, 1H), 7.11 (t, J = 2 Hz, 1H), 6.77 (d, J = 2 Hz, 1 H), 6.65 (d, J = 7.6 Hz, 1 H), 5.41-5.34 (m, 1 H), 4.55-4.49 (m, 2H), 4.42-4.35 (m, 2H). Step 3: (E)-6-(3-(3-(Benzofuran-7-yloxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3 4-dihydro-l 8-naphthyridin-2( l )-one
Figure imgf000159_0001
3-(Benzofuran-7-yloxy)-azetidine hydrochloride (190 mg, 0.84 mmol), EDCI (161 mg, 0.84 mmol), HOBt (113 mg, 0. 84 mmol) and diisopropylethylamine (240 μΙ_, 1.40 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (143 mg, 0.56 mmol) in dimethylformamide (14 ml_) at room temperature. The reaction mixture was stirred overnight. The reaction mixture was then diluted by addition of ethyl acetate (40 ml_) and water (40 ml_). The aqueous phase was separated and extracted with ethyl acetate (2 x 40 ml_). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 40 ml_), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (1 : 0 to 95 : 5) as eluent. After trituration in diethyl ether and acetone, the title compound was obtained as a white solid (80 mg, 37%).
LCMS (ESI-APCI) m/z 390.1 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.31 (s, 1H), 8.22 (s, 1H), 7.64 (s, 1H), 7.63 (s, 1 H), 7.62 (d, J = 15.6 Hz, 1H), 7.28 (d, J = 8 Hz, 1 H), 7.15 (t, J = 7.6 Hz, 1H), 6.79 (s, 1H), 6.61 (d, 8 Hz, 1H), 6.45 (d, J = 15.6 Hz, 1H), 5.31-5.26 (m, 1H), 4.75-4.70 (m, 1 H), 4.60-4.55 (m, 1H), 4.51-4.48 (m, 1 H), 4.35-4.31 (m, 1H), 3.00 (t, J = 8 Hz, 2H), 2.70 (t, J = 8 Hz, 2H).
Example 61 (E)-6-(3-(3-(Benzo[ft]thiophen-3-yloxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E61)
Step 1': Benzo[/>]thiophen-3-ol
Figure imgf000160_0001
A solution of methyl 2-(methylthio)benzoate (4.0 g, 22.00 mmol) in THF (60 mL) was added to a solution of freshly prepared LDA (2M in THF, 17.5 mL, 35 mmol) placed at -78°C. The reaction mixture was stirred for 1 hour at -78°C, then overnight at room temperature. The reaction mixture was diluted by addition of a saturated solution of ammonium chloride (50 mL). The aqueous phase was separated and extracted with ethyl acetate (3 x 70 mL). The combined organic phases were washed with a saturated solution of sodium chloride (40 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate (95 : 5 to 9 : 1) as eluent. The title product was obtained as a pink solid (1.74 g, 53%).
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 7.71 (d, J = 8 Hz, 1H), 7.49 (t, J = 8 Hz, 1H), 7.38 (d, J = 8 Hz, 1H), 7.17 (t, J = 8 Hz, 1H), 3.73 (s, 2H).
Step 1: l-Benzhydryl-3-iodoazetidine
Figure imgf000160_0002
Potassium iodide (530 mg, 3.14 mmol) was added to a solution of 1- benzhydrylazetidin-3-yl methanesulfonate (500 mg, 1.57 mmol) in a mixture of water (2.5 mL) and 1,2-dimethoxyethane (2.5 mL) at room temperature. The reaction mixture was then heated up to reflux and stirred for 3 hours. After cooling down to room temperature, the reaction mixture was diluted by addition of water (50 mL) and ethyl acetate (50 mL). The aqueous phase was separated and extracted with ethyl acetate (2 x 70 mL). The combined organic phases were washed with a saturated solution of sodium chloride (40 mL), dried over sodium sulfate, filtered and concentrated to dryness. The title compound was obtained as a yellow solid (550 mg, 100%). LCMS (ESI-APCI) m/z 350.0 (M + H)+
Step 2: l-Benzhydryl- -(benzo[/>]thiophe -3-yloxy)azetidine
Figure imgf000161_0001
Benzo[£>]thiophen-3-ol (215 mg, 1.43 mmol) and potassium carbonate (237 mg, 1.72 mmol) were successively added to a solution of l-benzhydryl-3-iodoazetidine (500 mg, 1.43 mmol) in a mixture of 1,2-dimethoxyethane (12 mL) and water (6 mL) at room temperature. The reaction mixture was then heated up to 95°C and stirred for 3 hours. After cooling down to room temperature, the reaction mixture was diluted by addition of water (50 mL) and ethyl acetate (50 mL). The aqueous phase was separated and extracted with ethyl acetate (5 x 50 mL). The combined organic phases were washed with a saturated solution of sodium chloride (2 x 50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate (1 : 0 to 9 : 1) as eluent. The title compound was obtained as a yellow oil (220 mg, 21%).
LCMS (ESI-APCI) m/z 372.1 (M + H)+
Step 3: 3-(Benzo[/>]thiophen-3-yloxy)azetidine hydrochloride
Figure imgf000161_0002
1-Chloroethyl chloroformate (67.3 pL, 0.621 mmol) was added to a solution of 1- benzhydryl-3-(benzo[£>]thiophen-3-yloxy)azetidine (220 mg, 0.592 mmol) in dichloromethane (5 mL) at 0°C. The reaction mixture was stirred for 2 hours at 0°C and for 5 hours at room temperature. Ethanol (5 mL) was added and the reaction mixture was stirred for 1 hour at 40°C. After concentration to dryness, the crude mixture was precipitated from a mixture dichloromethane/pentane to afford a pale orange solid (140 mg, quantitative) which was used without further purification. ^ NMR (DMSO-d6, 400 MHz) : δ (ppm) : 9.23 (s, 1H), 9.08 (s, 1H), 7.96-7.63 (m, 1H), 7.79-7.77 (m, 1H), 7.47-7.42 (m, 2H), 6.80 (s, 1H), 5.15-5.18 (m, 1H), 4.45- 4.52 (m, 2H), 4.09-4.02 (m, 2H). Step 4: (E)-6-(3-(3-(Benzo[6]thiophen-3-yloxy)azetidin-l-yl)-3-oxoprop- l-enyl)- -dihydro-l,8-naphthyridin-2(l/ )-one
Figure imgf000162_0001
3-(benzo[£>]thiophen-3-yloxy)azetidine hydrochloride (140 mg, 0.58 mmol), EDCI (111 mg, 0.48 mmol), HOBt (78 mg, 0.58 mmol) and diisopropylethylamine (420 μΙ_, 2.41 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (123 mg, 0.48 mmol) in dimethylformamide (10 mL) at room temperature. The reaction mixture was stirred overnight and then diluted by addition of ethyl acetate (40 mL) and water (40 mL). The aqueous phase was extracted with ethyl acetate (2 x 40 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 40 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (98: 2 to 95 : 5) as eluent. The title product was obtained as a white solid (52 mg, 26%).
LCMS (ESI-APCI) m/z 406.1 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.32 (s, 1 H), 8.23 (s, 1H), 7.83-7.76 (m, 2H), 7.65-7.61 (m, 2H), 7.41-7.38 (m, 2H), 6.46 (d, J = 15.6 Hz, 1H), 6.13 (s, 1H), 5.17-5.13 (m, 1H), 4.75-4.71 (m, 1H), 4.61-4.56 (m, 1H), 4.46-4.43 (m, 1H), 4.34-4.30 (m, 1 H), 2.99 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.6 Hz, 2H).
Example 62
(E)-6-(3-Oxo-3-(3-(thiophen-2-ylthio)azetidin-l-yl)prop-l-enyl)-3 4- dihydro-l,8-naphthyridin-2( lH)-one (E62)
Step 1: l-Benzhydryl- -(thiophen-2-ylthio)-azetidine
Figure imgf000162_0002
Potassium hydroxide (141 mg, 2.52 mmol) and thiophene-2-thiol (292 mg, 238 pL) were added to a solution of l-benzhydrylazetidin-3-yl methanesulfonate (400 mg, 1.26 mmol) solubilized in THF (7 mL). The reaction mixture was stirred a first time under microwave irradiations (100 W) at 80°C for 30 minutes. Potassium hydroxide (141 mg, 2.52 mmol) and thiophene-2-thiol (292 mg, 238 μΙ_) were added and the reaction mixture was stirred for a second time under microwave irradiations (100 W) at 80°C for 30 minutes. After concentration to dryness, the residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate (1 :0 to 9 : 1) as eluent. The title product was obtained as a yellow solid (160 mg, 37%).
LCMS (ESI-APCI) m/z 338.1 (M + H)+
Step 2: 3-(Thioph -2-ylthio)-azetidine hydrochlo
Figure imgf000163_0001
1-Chloroethyl chloroformate (140 μΙ_, 1.3 mmol) was added to a solution of 1- benzhydryl-3-(thiophen-2-ylthio)-azetidine (340 mg, 1.00 mmol) in dichloroethane (11 mL) at 0°C. The reaction mixture was stirred for 3 hours at room temperature and for 2 hours at 70°C. Ethanol (11 mL) was added and the reaction mixture was stirred for an additional 2 days at room temperature. After concentration to dryness, the residue was triturated in pentane (2 x 20 mL) to afford a brown oil (171 mg, 81%) which was used in the next step without further purification.
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 9.87 and 8.44 (s, NH2), 7.43-7.41 (m, 2H), 7.02-7.00 (m, 1H), 4.16-4.13 (m, 2H), 4.04-4.02 (m, 1H), 3.94-3.90 (m, 2H). Step 3: (E)-6-(3-Oxo-3-(3-(thiophen-2-ylthio)azetidin-l-yl)prop-l-enyl)- 3 4-dihydro-l 8-naphthyridin-2(l )-one
Figure imgf000163_0002
3-(Thiophen-2-ylthio)-azetidine hydrochloride (170 mg, 0.82 mmol), EDCI (157 mg, 0.82 mmol), HOBt (110 mg, 0.82 mmol) and diisopropylethylamine (240 pL, 1.36 mmol) were successively added to a solution of (E)-3-(7-oxo-5, 6,7,8- tetrahydro-l,8-naphthyridin-3-yl)-acrylic acid hydrochloride (139 mg, 0.55 mmol) in dimethylformamide (14 mL) at room temperature. The reaction mixture was stirred overnight and then diluted by addition of ethyl acetate (40 mL) and water (40 mL). The aqueous phase was extracted with ethyl acetate (2 x 40 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 40 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using petroleum ether/ethyl acetate (1 : 0 to 95 : 5) as eluent. After trituration in acetone, the title product was obtained as a white solid (114 mg, 37%).
LCMS (ESI-APCI) m/z 372.1 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.29 (s, 1H), 8.27 (s, 1H), 7.61 (s, 1H), 7.55 (d, J = 15.6 Hz, 1H), 7.44-4.72 (m, 1H), 7.23-7.21 (m, 1H), 7.06-7.03 (m, 1H), 6.34 (d, J = 15.6 Hz, 1H), 4.60-4.55 (m, 1H), 4.43-4.38 (m, 1H), 4.27-4.22 (m, 1H), 4.12-4.06 (m, 1H), 3.96-3.87 (m, 1H), 2.99 (t, J = 7.2 Hz, 2H), 2.69 (t, J = 7.2 Hz, 2H). Example 63
(E)-6-(3-(3-Butoxyazetidin-l-yl)-3-oxoprop-l-enyl)-l'-methyl-l - spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E63)
Figure imgf000164_0001
3-Butoxyazetidine hydrochloride (33 mg, 0.20 mmol), EDCI (72 mg, 0.4 mmol), HOBt (54 mg, 0.4 mmol) and diisopropylethylamine (116 μΙ_, 0.66 mmol) were successively added to a solution of (E)-3-(7-oxo-5,6,7,8-tetrahydro-l,8- naphthyridin-3-yl)-acrylic acid hydrochloride (45 mg, 0.13 mmol) in dimethylformamide (5 mL) at room temperature. The reaction mixture was stirred overnight and then diluted by addition of ethyl acetate (40 mL) and water (40 mL). The aqueous phase was extracted with ethyl acetate (2 x 40 mL). The combined organic phases were washed with a saturated solution of sodium chloride (3 x 40 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel using dichloromethane/methanol (7 : 3 to 5 : 5) as eluent. After precipitation in DCM/Et20 and triturations in acetone, the title product was obtained as a white solid (10 mg, 17%).
LCMS (ESI-APCI) m/z 413.3 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.55 (s, 1H), 8.31 (s, 1H), 7.66 (s, 1H), 7.58 (d, J = 15.6 Hz, 1 H), 6.43 (d, J = 15.6 Hz, 1 H), 4.46-3.98 (m, 5H), 3.42-3.40 (m, 2H), 2.89 (s, 2H), 2.88-2.81 (m, 2H), 2.46-2.42 (m, 2H), 2.44 (s, 3H), 2.06-2.02 (m, 2H), 1.78-1.74 (m, 2H), 1.61-1.56 (m, 2H), 1.42-1.37 (m, 2H), 0.93 (t, J = 5.2 Hz, 3H).
Example 64 l'-Methyl-6-((E)-3-oxo-3-(3-((E)-l-(benzyloxyimino)ethyl)azetidin-l- yl)prop-l-enyl)-lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one
(E64)
Figure imgf000165_0001
O-benzylhydroxylamine hydrochloride (13.5 mg, 0.08 mmol) was added to a solution of (E)-6-(3-(3-acetylazetidin-l-yl)-3-oxoprop-l-enyl)-l '-methyl- 1H- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (23.0 mg, 0.06 mmol) in methanol (1.5 ml_) at room temperature. The reaction mixture was stirred overnight. After concentration to dryness, the residue was purified by chromatography on silica gel using dichloromethane/methanol (9 : 1) as eluent. The title product was obtained as a pink solid (9 mg, 31%).
HPLC isomer ratio 88: 12, the major isomer adopts an (E) configuration (determined by ^MR and selective NOE experiments).
LCMS (ESI-APCI) m/z 488.3 (M + H)+
*H NMR (CDCI3, 400 MHz) : δ (ppm) : 8.34 (s, 1H), 8.30 (s, 1H), 7.67 (s, 1H), 7.59 (d, J = 15.6 Hz, 1H), 7.36-7.37 (m, 5H), 6.43 (d, J = 15.6 Hz, 1H), 5.10 (s, 2H), 4.44-4.12 (m, 4H), 3.47-3.43 (m, 1 H), 2.89 (s, 2H), 2.90-2.83 (m, 2H), 2.73-2.68 (m, 2H), 2.46 (s, 3H), 2.02-1.98 (m, 2H), 1.93 (s, 3H), 1.76-1.72 (m, 2H). Example 65
l'-Methyl-6-((E)-3-oxo-3-(3-((E)-l-(propoxyimino)ethyl)azetidin-l- yl)prop-l-enyl)-l -spiro[[l 8]naphthyridine-3 4'-piperidin]-2(4 )-one
(E65) Step 1: (E)-6-(3-(3-Acetylazetidin-l-yl)-3-oxoprop-l-enyl)-l'-methyl-l«- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one
Figure imgf000165_0002
HCI
l-(Azetidin-3-yl)ethanone hydrochloride (110 mg, 0.8 mmol), EDCI (153 mg, 0.8 mmol), HOBt (108 mg, 0.8 mmol) and diisopropylethylamine (700 μΙ_, 4.0 mmol) were successively added to a solution of (E)-3-(l'-methyl-2-oxo-2,4-dihydro-lH- spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylic acid hydrochloride (136 mg, 0.4 mmol) in dimethylformamide (15 ml_) at room temperature. The reaction mixture was stirred overnight. After concentration to dryness, the residue was purified by chromatography on silica gel using dichloromethane/methanol/ammoniac (9 : 1 :0.1) as eluent. Precipitation in a mixture DCM/pentane allowed isolation of the title product as a yellow solid (44.6 mg, 29%).
LCMS (ESI-APCI) m/z 383.3 (M + H)+
Step 2: l'-Methyl-6-((E)-3-oxo-3-(3-((E)-l- (propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)-lH- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one
Figure imgf000166_0001
l-(Aminooxy)propane hydrochloride (10.5 mg, 0.093 mmol) was added to a solution of (E)-6-(3-(3-acetylazetidin-l-yl)-3-oxoprop-l-enyl)-l '-methyl- 1H- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (20.0 mg, 0.052 mmol) in methanol/dichloromethane (1.5 ml_, 9 : 1) at room temperature. The reaction mixture was stirred overnight. After concentration to dryness, the residue was purified by chromatography on silica gel using chloroforme/methanol (9 : 1) as eluent. Triturations in acetone allowed isolation of the title product as a white solid (9 mg, 39%).
HPLC isomer ratio 89 : 11, geometry not assigned (the minor isomer has the shortest retention time).
LCMS (ESI-APCI) m/z 440.3 (M + H)+
*H NMR (CDCIs, 400 MHz) (mixture of 2 isomers) : δ (ppm) : 8.20 (s, 1H), 7.95 (s, 1H), 7.65 (s, 1H), 7.52 (d, J = 15.6 Hz, 1H), 6.39 (d, J = 15.6 Hz, 1H), 4.39-4.36 (m, 2H), 4.24-4.19 (m, 1H), 4.11-4.07 (m, 1H), 3.96-3.93 (m, 2H), 3.41-3.28 (m, 5H), 2.88 (s, 2H), 2.72 (s, 3H), 2.44-2.40 (m, 2H), 1.96-1.92 (m, 2H), 1.84 (s, 3H), 1.62-1.58 (m, 2H), 0.87 (t, J = 7.2 Hz, 3H).
Example 66
(E)-l'-Methyl-6-(3-oxo-3-(3-(2-(thiophen-2-yl)ethoxy)azetidin-l-yl)prop- l-en-l-yl)-lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E66)
HCI
Figure imgf000166_0002
3-(2-(Thiophen-2-yl)ethoxy)azetidine hydrochloride (0.377 g, 1.718 mmol), EDCI. HCI (0.658 g, 3.44 mmol), l-hydroxy-7-azabenzotriazole (0.468 g, 3.44 mmol) and N,N-diisopropylethylamine (0.980 mL, 5.73 mmol) were successively added to a solution of (E)-3-(l'-methyl-2-oxo-2,4-dihydro-lH- spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylic acid hydrochloride (0.387 g, 1.145 mmol) in dry DMF (25 mL) at room temperature. The reaction mixture was stirred during for 4 days and then diluted by addition of EtOAc (40 mL) and water (40 mL). The aqueous phase was separated and extracted with EtOAc (2x 40 mL). The combined organic phases were washed with brine (60 mL), dried over Na2S04, filtered and concentrated to dryness to yield a dark orange oil from which some solids precipitated (0.7g). The crude product was purified using preparative LCMS (Waters X-Bridge 50x19 mm 5pm ODB in combination with Waters X-Bridge guard 10x19mm 5pm, at 25 ml/min flow rate; detection of product by mass and UV signal; eluent 10 mM ammonia in milliQ water to 10 mM ammonia in MeCN 5% to 95% gradient). After lyophilization, FAB306 was obtained as a tan powder (53 mg, 10%) which was still contaminated by a minor impurity. This material was stirred in 10 ml Et20 for 2h, then filtered off and dried in an air stream to yield target FAB306 (22 mg, 4%), which was pure according to LCMS and NMR analysis.
LCMS (ESI+) : 467.2 (M + H)+;
^-NMR (CDCIs, 400 MHz) : δ (ppm) : 8.29 (d, J = 2Hz, 1 H), 8.15 (br s, 1H), 7.65 (d, J = 2Hz, 1H), 7.59 (d, J = 15Hz, 1H), 7.17 (dd, J = l Hz, 5Hz, 1H), 6.95 (m, 1H), 6.87 (m, 1H), 6.42 (d, J = 15Hz), 4.45 (m, 1H), 4.38 (m, 1H), 4.29 (m, 1H), 4.17 (m, 1H, 4.03 (m, 1H), 6.67 (m, 2H), 3.13 (t, J=4Hz, 2H), 2.88 (s, 1H), 2.62 (m, 2H), 2.42 (m, 2H), 2.32 (s, 3H), 2.08 (m, 2H), 1.5-1.7 (m, 2H + H20)
Example 67
(E)-6-(3-(3-(3-Methylbenzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E67) -Benzhydrylazetidin-3-one
Figure imgf000167_0001
To a stirring solution of DMSO (12.45 ml, 176 mmol) in DCM (150 mL) at -78 °C under an argon atmosphere was added dorpwise oxalyl chloride (8.61 mL, 100 mmol). After stirring for 30 minutes at -78 °C, a solution of l-benzhydrylazetidin-3- ol (20 g, 84 mmol) in DCM (75 mL) was added dropwise. The reaction mixture was stirred for 1 h at -78 °C before triethylamine (58.2 ml, 418 mmol) was added . The reaction mixture was allowed to reach 0 °C and was quenched with saturated NH4CI (150 mL), and then extracted with DCM (3x). The combined organic layers were washed with water, brine, dried on Na2S04 and concentrated to give crude 1- benzhydrylazetidin-3-one (20.8 g, 105%) as a yellow solid.
LCMS (ESI+) : m/z 238.2 (M + H)+ -Benzhydryl-3-(3-methylbenzofuran-2-yl)azetidin-3-ol
Figure imgf000168_0001
A solution of 3-methylbenzofuran (550 mg, 4.16 mmol) in dry THF (17 mL) was cooled to -78 °C and LDA (1.8 M in THF/heptane/ethylbenzene) (2.8 mL, 5.04 mmol) was added dropwise under N2 over 5 min. After stirring for 30 min, 1- benzhydrylazetidin-3-one (1.61 g, 6.78 mmol) was added portionwise over 10 min. The reaction was stirred under N2 at -78 °C for 15 min, and was then allowed to warm to rt and stirred for 1.5 h. The reaction was quenched with 0.5N HCI and extracted with EtOAc. The organic layer was washed with water and brine, dried on Na2S04 and concentrated. The residue was purified by flash chromatography (heptane/EtOAc, 5% -> 35%), yielding the product (472 mg, 31%) as a yellow oil . LCMS (ESI+) : m/z 370.2 (M + H)+ -Benzhydryl-3-(3-methylbenzofuran-2-yl)azetidine
Figure imgf000168_0002
To a cooled (0 °C) solution of l-benzhydryl-3-(3-methylbenzofuran-2-yl)azetidin-3- ol (406 mg, 1.099 mmol) in dichloromethane (50 mL) were added triethylsilane (1.775 mL, 10.99 mmol) and trifluoroacetic acid (1.630 mL, 22.01 mmol). The reaction mixture was warmed to rt and stirred for 23 h. After 18h, boron trifluoride etherate (0.6 mL, 4.73 mmol) was added and the reaction was allowed to stir for an additional 5 h. The reaction mixture was partitioned between sat. NaHC03 and DCM. The layers were separated, the organic layer was washed with sat. NaHC03 and brine, dried on Na2S04 and concentrated . The residue was purified by flash chromatography (heptane/EtOAc, 0% -> 30%), yielding the title product (244 mg, 63%) as an off-white solid.
LCMS (ESI+) : m/z 354.2 (M + H)+ -(3-Methylbenzofuran-2-yl)azetidine hydrochloride
Figure imgf000169_0001
To a cooled (0 °C) solution of l-benzhydryl-3-(3-methylbenzofuran-2-yl)azetidine (52.0 mg, 0.147 mmol) in DCM (4 ml_) under N2 was added 1-chloroethyl chloroformate (18.0 μΙ_, 0.167 mmol) and the reaction was stirred at rt under N2 for 4 h. Next, EtOH was added and the mixture was stirred under nitrogen at 50 °C for 21 h. The mixture was concentrated in vacuo and the residue triturated with Et20 (3 x 5 ml_), yielding the title product (20.4 mg, 62%) as an off-white solid.
LCMS (ESI+) : m/z 188.2 (M + H)+
Step 5: (E)-6-(3-(3-(3-Methylbenzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l- enyl)-3 4-dihydro-l 8-naphthyridin-2(lH)-one
Figure imgf000169_0002
To a solution of 3-(3-methylbenzofuran-2-yl)azetidine hydrochloride (19.9 mg, 0.089 mmol) in DMF (2 ml_) were added (E)-3-(7-oxo-5,6,7,8-tetrahydro-l,8- naphthyridin-3-yl)acrylic acid hydrochloride (15.8 mg, 0.062 mmol), EDCI. HCI (19.9 mg, 0.104 mmol), HOAt (14.0 mg, 0.103 mmol) and N,N- diisopropylethylamine (58 μΙ_, 0.339 mmol). The reaction was stirred at rt for 21 h, after which the mixture was partitioned between EtOAc and H20. The layers were separated and the aqueous layer extracted with EtOAc. The combined organic layers were washed with brine (3 x), dried with Na2S04 and concentrated . The residue was triturated twice with Et20 and the dried to yield (the title compound (14.0 mg, 58%) as a pale orange solid.
LCMS (APCI+) : m/z 388 (M + H)+
^-NMR (CDCIs, 400 MHz) : δ (ppm) : 8.82 (br s, 1H), 8.38 (s, 1H), 7.66 (m, 2H), 7.45 (m, 2H), 7.26 (m, 2H, partially overlapping with solvent signal), 6.51 (d, J = 15.6 Hz, 1H), 4.62 (m, 2H), 4.45 (m, 2H), 4.12 (m, 1H), 3.01 (t, J = 7.6 Hz, 2H), 2.71 (t, J = 7.6 Hz, 2H), 2.21 (s, 3H).
Example 68
(E)-l'-Methyl-6-(3-(3-(3-methylbenzofuran-2-yl)azetidin-l-yl)-3-oxoprop- l-enyl)-lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E68)
Step 1: (E)-Ethyl 3-(l'-methyl-2-oxo-2,4-dihydro-lH- spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylate
Figure imgf000170_0001
To a suspension of (E)-ethyl 3-(2-oxo-2,4-dihydro-lH-spiro[[l,8]naphthyridine- 3,4'-piperidine]-6-yl)acrylate (99.8 mg, 0.316 mmol) in 1,2-dichloroethane (5 mL) were added sodium triacetoxyborohydride (139 mg, 0.656 mmol) and paraformaldehyde (21 mg, 0.699 mmol). The reaction mixture was heated to 70 °C for 5 h. After cooling to room temperature, the reaction mixture was partitioned between DCM (25 mL) and water (25 mL). The aqueous layer was separated and extracted with DCM (2 x 20 mL). The combined organic phases were washed with saturated NaHC03 (3 x 25 mL) and brine (25 mL), dried over sodium sulfate and concentrated . The crude product was used directly in the next step.
LCMS (ESI+) : 330.2 (M + H)+
Step 2: (E)-3-(l'-Methyl-2-oxo-2,4-dihydro-lH- spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylic acid hydrochloride
Figure imgf000170_0002
To a solution of (E)-ethyl 3-(l'-methyl-2-oxo-2,4-dihydro-lH- spiro[[l,8]naphthyridine-3,4'-piperidine]-6-yl)acrylate (95 mg, 0.288 mmol) in DCM (2 mL) and EtOH (2 mL) was added IN aqueous sodium hydroxide (1 mL, 1.000 mmol) and the reaction was stirred at rt overnight, after which TLC (DCM/MeOH, 9 : 1) showed full conversion. Next, the mixture was concentrated and the residue acidified with IN HCI (5 mL) and stirred for 1 h. The resulting white solids were isolated by filtration, washed with H20 and Et20 and dried on the filter. The product (47 mg, 48%) was obtained as an off-white solid.
LCMS (ESI+) : m/z 302.2 (M + H)+ Step 3: (E)-l'-Methyl-6-(3-(3-(3-methylbenzofuran-2-yl)azetidin-l-yl)-3- oxoprop-l-enyl)-lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one
Figure imgf000171_0001
To a solution of 3-(3-methylbenzofuran-2-yl)azetidine hydrochloride (21.7 mg, 0.097 mmol) and (E)-3-(l'-methyl-2-oxo-2,4-dihydro-lH-spiro[[l,8]naphthyridine- 3,4'-piperidine]-6-yl)acrylic acid hydrochloride (22.0 mg, 0.065 mmol) in DMF (3 ml_) were added EDCI.HCI (18.9 mg, 0.099 mmol), HOAt (13.9 mg, 0.102 mmol) and N,N-diisopropylethylamine (57 μΙ_, 0.333 mmol). The reaction was stirred at rt for 20h., after which the mixture was partitioned between DCM and H20. The layers were separated and the aqueous layer extracted with DCM (3 x). The combined organic layers were washed with brine (3 x), dried over Na2S04 and concentrated and the redisue was purified by flash chromatography (DCM/MeOH, 5% -> 20%). The product (10.6 mg, 35%) was obtained as a white powder.
LCMS (ESI+) : m/z 471.3 (M + H)+
^-NMR (CDCI3/CD3OD, 400 MHz) : δ (ppm) : 8.79 (br s, 1H), 8.30 (s, 1H), 7.80 (s, 1H), 7.64 (d, 15.6 Hz, 1H), 7.45 (dd, J = 7.7, 12.4 Hz, 2H), 7.24 (m, 2H, overlapping with solvent signal), 6.54 (d, J = 15.4 Hz, 1 H), 4.67 (m, 2H), 4.47 (m, 2H), 4.12 (m, 1H), 2.97 (s, 2H), 2.80 (s, 3H), 2.31 (m, 2H), 2.21 (s, 3H), 2.05 (m, 2H), 1.95-1.50 (m, 4H, overlapping with H20-signal). Example 69
(E)-6-(3-(3-(Benzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-en-l-yl)-l'- methyl-lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E69)
Figure imgf000171_0002
To a solution of 3-(benzofuran-2-yl)azetidine hydrochloride (30 mg, 0.086 mmol) and (E)-3-(l'-methyl-2-oxo-2,4-dihydro-lH-spiro[[l,8]naphthyridine-3,4'- piperidine]-6-yl)acrylic acid hydrochloride (20 mg, 0.059 mmol) in dry DMF (4 ml_) were added EDCI. HCI (17.02 mg, 0.089 mmol), HOAt (12.09 mg, 0.089 mmol) and DIPEA (51 μΙ_, 0.296 mmol). The reaction was stirred at room temperature overnight. The mixture was partitioned between dichloromethane and H20, the layers were separated and the aqueous layer was extracted with dichloromethane (2 x 5 ml_). The combined organic layers were washed with brine (3 x 3 ml_), dried over Na2S04 and concentrated. The residue was chromatographic purified (silica gel, eluent dichloromethane/7M NH3 in MeOH 98: 2 to 95 : 5). The residue was further purified by preparative LCMS (Waters X-Bridge 50x19 mm 5pm ODB in combination with Waters X-Bridge guard 10x19mm 5pm, at 25 ml/min flow rate; detection of product by mass and UV signal; eluent 10 mM ammonia in milliQ water to 10 mM ammonia in MeCN 5% to 95% gradient), to yield the title compound (2.6 mg, 9.6%).
LCMS (ESI+) : no target mass observed.
*H NMR (CDCIs, 400 MHz) : δ (ppm) : 8.30 (d, J = 2.0 Hz, 1H), 7.83 (s, 1H), 7.67- 7.62 (m, 2H), 7.53 (d, J = 7.6 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.31-7.21 (m, 2H, overlapping with CDCI3), 6.60 (s, 1H), 6.48 (d, J = 15.4 Hz, 1H), 4.68 (t, J = 8.3 Hz, 1H), 4.53 (q, J=8.6 Hz, 2H), 4.40 (dd, J = 6.0 Hz and 10.3 Hz, 1H), 4.08 (m, 1H), 2.88 (s, 2H), 2.65-2.61 (m, 2H), 2.43-2.39 (m, 2H), 2.32 (s, 3H), 2.07-2.01 (m, 2H), 1.55-1.48 (m, 2H, overlapping with H20).
Example 70 and 71
6-((E)-3-Oxo-3-(3-((E)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2( lH)-one (E70) and 6-((E)-3-Oxo-3-(3- ((Z)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)-3 4-dihydro-l 8- naphthyridin-2(lH)-one (E71)
Figure imgf000172_0001
An isomeric mixture (ratio 87 : 13) of 6-((lE)-3-oxo-3-(3-(l- (propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)-3,4-dihydro-l,8-naphthyridin- 2(lH)-one (162 mg, 0.455 mmol) was separated by preparative LCMS (Waters X- Bridge 50x19 mm 5pm ODB in combination with Waters Xbridge guard 10x19mm 5μ ΓΠ , at 25 ml/min flow rate; detection of product by mass and UV signal; eluent 10 mM ammonia in milliQ water to 10 mM ammonia in MeCN 5% to 95% gradient). The first eluting isomer (6.4 mg, 0.018 mmol) was identified as the Z-isomer (FAB311) and the second eluting isomer (89.0 mg, 0.25 mmol) was identified as the E-isomer (FAB310). This identification was based on a weak NOE-interaction which was observed between the methyl-group (1.91 ppm) and the propyl-tail (4.01 ppm) for the E-isomer, which was absent in the NOESY-spectrum of the Z- isomer.
E-isomer (FAB310) : LCMS (ESI+) : 357.2 (M + H)+;
^-NMR (CDCI3, 400 MHz) : δ (ppm) : 10.38 (s, 1H), 8.42 (s, 1H), 7.62 (m, 2H),
6.45 (d, J = 15.7 Hz, 1H), 4.44 (m, 2H), 4.30 (m, 1H), 4.15 (m, 1H), 4.01 (t, J =
6.7 Hz, 2H), 3.45 (m, 1 H), 3.01 (t, J = 7.6 Hz, 2H), 2.71 (t, J = 7.6 Hz, 2H), 1.91
(s, 3H), 1.67 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H).
Z-isomer (FAB311) : LCMS (ESI+) : 357.2 (M + H)+;
^-NMR (CDCI3, 400 MHz) : δ (ppm) : 9.53 (s, 1H), 8.39 (s, 1 H), 7.63 (m, 2H), 6.43
(d, J = 15.6 Hz, 1H), 4.54 (m, 1H), 4.36-4.23 (m, 2H), 4.14 (m, 1H), 3.98 (m,
3H), 3.01 (t, J = 7.6 Hz, 2H), 2.71 (t, J = 7.6 Hz, 2H), 2.02 (s, 3H), 1.64 (m, 2H),
0.93 (t, J = 7.5 Hz, 3H). Assay Data
1. FabI inhibition
The compounds of the invention are useful inhibitors of bacterial FabI enzyme. Compound inhibitory activity of FabI enzyme is measured in vitro by the IC50 determination using a fluorescence based assay.
The protein FabI from S. aureus is prepared and purified using standard methods for recombinant protein expression after cloning of the gene in a prokaryotic expression vector.
The biochemical activity of the FabI enzyme is assessed using the following method . The assay buffer "AB" contained 50mM ADA (N-(2-acetamido)iminodiacetic acid monosodium salt) pH 6.5, ImM dithiothreitol, 0.006% Triton-X100 and 50mM NaCI. The following components are added in a white polystyrene Costar plate (Ref 3912) up to a final volume of 55.5μΙ_: 1.5μΙ_ DMSO or inhibitor dissolved in DMSO and 54μΙ_ of a FabI/NADPH/NADP+ mixture in AB. After 60min of pre-incubation at room temperature, the reaction is started by addition of 5μΙ_ of trans-2-octenoyl N- acetylcysteamine thioester (t-o-NAC) to a final volume of 60.5μΙ_. This reaction mixture is then composed of 2nM Fabl, 40μΜ NADPH (Sigma, N7505), ΙΟμΜ NADP+ (Sigma, N5755), ΙΟΟμΜ t-O-NAC and compound at defined concentration. Fluorescence intensity of NADPH (Aex=360 nm, Aem = 520 nm) is measured immediately after t-O-NAC addition (TO), and approximately 50min later (T50) by a Fluostar Optima (BMG) so as to achieve ±30% of NADPH conversion. Enzyme activity is calculated by first subtracting TO signal to T50 and then subtracting background signal (Fabl=0). Percentages of inhibition are calculated against untreated samples (Inhibitor =0) and IC50 are fitted to a classical Langmuir equilibrium model using XLFIT (IDBS).
Table 1: In vitro inhibition of recombinant S. aureus Fabl enzyme by selected compounds of formula (I)
Example Fabl Inhibition
ICso (MM)
1 11
2 5.5
3 9.9
4 5.3
5 0.25
6 1.0
7 7.1
8 0.041
9 1.3
10 0.12
11 0.15
12 0.013
13 4.1
14 0.34
15 0.025 16 0.93
17 0.05
18 1.8
19 0.17
20 0.057
21 0.87
22 8.6
23 1.8
24 0.26
25 0.060
26 0.078
27 0.55
28 0.081
2. Antibacterial activity
The compounds of the invention are useful antibacterial agents having a selective spectrum of activity in vitro against bacterial strains relying on Fabl and related targets. Notably the compounds of the invention show activity against Staphylococcus aureus including multiresistant strains. The activity is presented as Minimum Inhibitory Concentration (MIC) expressed in pg/rnl and was determined using broth microdilution or Agar dilution methods.
Strains
Antibacterial activity was determined on strains from Mutabilis internal collection. A description of the strains used in this study is provided in Table 2 :
Table 2: Description of Strains Used in Antibacterial Study
Genus Species Strain ID Phenotype Genotype Provider
Staphylococcus aureus CIP 54.146 MSSA CRBIP
Staphylococcus aureus NRS22 MRSA GISA, EryR, ClinR, SxtR, GmR, LevR mecA+, USA600 NARSA
Staphylococcus aureus NRS100 MRSA TetR mecA+ NARSA
Staphylococcus aureus NRS1 19 MRSA LinR, GmR, SxtR, CipR mecA+, G2576T NARSA
Staphylococcus aureus NRS120 MRSA LinR, GmR, SxtR, CipR mecA+, G2576T NARSA
Staphylococcus aureus NRS121 MRSA LinR, CipR mecA+, G2576T NARSA
Staphylococcus aureus NRS123 MRSA TetR mecA+, USA400 NARSA
Staphylococcus aureus NRS127 MRSA LinR, CipR, EryR mecA+ NARSA
Staphylococcus aureus NRS128 MSSA PenR, EryR, ClinR mecA- NARSA
Staphylococcus aureus NRS130 MSSA EryR mecA- NARSA
Staphylococcus aureus NRS192 MRSA mecA+ NARSA
Staphylococcus aureus NRS262 MSSA PenR mecA- NARSA
Staphylococcus aureus NRS269 MRSA TiqR, EryR, ClinR, CipR, GenR mecA+ NARSA
Staphylococcus aureus NRS382 MRSA EryR, ClinR, CipR mecA+, USA100 NARSA
Staphylococcus aureus NRS383 MRSA EryR, ClinR, TetR, SxtR, LevR, GmR mecA+, USA200 NARSA
Staphylococcus aureus NRS384 MRSA EryR, TetR mecA+, USA300 NARSA
Staphylococcus aureus NRS385 MRSA EryR, ClinR, TetR, SxtR, LevR, GmR mecA+, USA500 NARSA
Staphylococcus aureus NRS386 MRSA EryR mecA+, USA700 NARSA
Staphylococcus aureus NRS482 MRSA CipR, EryR, OxaR USA300 NARSA
Staphylococcus aureus NRS483 MRSA mecA+, USA1000 NARSA
Sta h lococcus aureus NRS484 MRSA mecA+ USA1100 NARSA (NARSA= Network on Antimicrobial Resistance in Staphylococcus aureus, CRBIP= Centre de Ressources Biologiques de I'Institut Pasteur)
MIC determination using broth microdilution method
This protocol is compliant with Clinical Laboratory Standards Institute (CLSI) methodology as described in M7-A7 document of the CLSI. The compound to be tested is diluted according to a geometric series of reason 2 in pure DMSO. Dilutions are transferred in sterile polystyrene microplates, followed by mid-log phase bacteria in cation-adjusted Muller-Hinton broth (ca-MHB, Fluka, Reference 90922) with a final inoculum of 5xl05 cfu/ml . Microplates are incubated overnight at 35°C. MIC is defined as the lowest concentration of antimicrobial agent that completely prevents visible bacterial growth. All manipulations, but compound handling (in pure DMSO), are performed under sterile conditions. The final concentration of DMSO in the plates is 2%.
Table 3: Representative Examples of MIC (pg/ml) (Broth microdilution) by selected compounds of formula (I):
Figure imgf000176_0001
MIC determination using Agar dilution method
This protocol is compliant with Clinical Laboratory Standards Institute (CLSI) methodology as described in M7-A7 document of the CLSI. The compound to be tested is incorporated into Mueller-Hinton Agar medium (Fluka, Reference 70191) at one concentration per plate according to a geometric series of reason 2. Plates are inoculated with mid-log phase bacteria (inoculum = lxlO4 cfu/spot) and incubated overnight at 35°C. MIC is defined as the lowest concentration of antimicrobial agent that completely inhibits bacterial growth. All manipulations, but compound handling (in pure DMSO), are performed under sterile conditions. The final DMSO concentration of DMSO in the plates is 2%. Vancomycin is used as reference. Table 4: Representative examples of MIC (pg/ml) (Agar dilution) by selected compounds (Examples 12 and 15) of formula (I):
Figure imgf000177_0001
MIC determination using susceptibility method
Minimum inhibitory concentrations (MICs) were determined by broth microdilution according to CLSI guidelines (CLSI, M 100-201, M7-A82, M27-A33). The compounds were tested in the range from 012-128 pg/ml. Colonies were taken directly from a second-pass culture plate and prepared to a suspension equivalent to the 0.5 McFarland standard using normal saline. Inoculation of the MIC plates took place within 15 minutes after adjustment of the inoculum suspension turbidity. The panels were incubated at 35 °C for 16 to 20 hours before reading the MIC endpoints. The compounds of Examples 12, 29, 59, 63 and 66-71 were dissolved in DMSO to make the initial solutions of 5120 pg/ml . These solutions were diluted 1 : 10 in sterile water to a stock solution of 512 pg/ml . The stock solutions were further diluted into the appropriate broth medium for the sequential dilutions used in the broth microdilution panels. S. pneumoniae was tested in Mueller Hinton (MH) broth with 3% lysed horse blood and C. albicans was tested in RPMI- 1640 medium . All other organisms were tested in M H broth. Table 5: Representative Examples of MIC (pg/ml) (Broth microdilution) of compounds of Examples 12, 29, 59, 63 and 66-71;
Figure imgf000178_0001
The most active compounds were found to be Examples 59 and 67 which exhibited MICs of 0.06 pg/ml against both M RSA and MSSA strains.
3. In vivo Antibacterial Activity of Examples 12 and 15
An experimental model of infection by S. aureus was used to assess the antibacterial activity of Fabl inhibitors.
Briefly in vivo studies were performed using groups of 5 week-old neutropenic female Swiss mice (five mice per group for each condition). The virulent methicillin susceptible Staphylococcus aureus strain ATCC 29213 was grown to exponential phase in Tryptic soy (TS) broth culture. The bacterial culture is diluted to obtain a bacterial suspension of 1-3 105 cfu/ml, washed in physiological serum and then inoculated to mice (ΙΟΟμΙ per mouse) by intra-muscle injection. The inoculums count was verified by plating 10-fold dilutions of the suspension on TS agar plates immediately after inoculation.
The compound of Example 12 was dissolved and diluted in a formulation containing 80% Poly-Ethylen Glycol (PEG) 400 and an appropriate volume of the solution (corresponding to a dose level of 100 mg/kg of body weight) was administered orally to each mouse, 1.5h after the bacterial infection. The negative control group received the 80% PEG400 solution alone and Linezolid at lOOmg/kg was used as the positive control. The compound of Example 15 was dissolved and diluted in a formulation containing 10% dimethyl sulfoxide (DMSO) and 20% hydroxy-propyl beta cyclodextrine (HPCD) and an appropriate volume of the solution (corresponding to a dose level of 50 mg/kg of body weight) was administered subcutaneously to each mouse, 1.5h after the bacterial infection. The negative control group received the 10% DMSO and 20% HPCD solution alone and Linezolid at 50mg/kg was used as the positive control .
Mice health and clinical signs were recorded during 20h. At the end of this period mice were euthanized, thigh muscle recovered and homogenized and bacterial count was determined by 10 fold dilution and plating method on TS agar plates.
All animal experiments were carried out in accordance with institutional guidelines. Compound activity is measure by its effect at a given dose to reduce the bacterial burden in the thigh of infected mice.
As shown in Figure 1 with the compound of Example 12 at 100 mg/kg and Figure 2 with the compound of Example 15 at 50 mg/kg, the compounds of the invention, are able to protect mice against thigh dissemination.
4. HSA binding analysis of Examples 12, 29, 59, 63 and 67-71 using chiral HSA column Test system
The test system used in this analysis was an HSA chiral column. Reagents and Chemicals
Potassium phosphate monobasic KH2P04 and potassium phosphate dibasic trihydrate K2HP04, 3H20 were obtained from Sigma-Aldrich. DMSO, 2-propanol and sodium azide were purchased from Sigma-Aldrich. Water was MilliQ grade obtained from Millipore system Milli-Q Plus (Waters).
Preparation of Reagents
20 mM K2HP04: 3.484 g in 1L of water
20 mM KH2P04: 2.722 g in 1L of water
20 mM Phosphate buffer pH 7.0 : 58.7% of 20 mM K2HP04 + 41.3% of 20 mM KH2P04 (the pH is adjusted if necessary).
Preparation of Stock Solutions, Calibration and Quality Control Samples
Solutions of Examples 12, 29, 59, 63 and 67-71 were prepared in potassium phosphate buffer, pH 7.0 to concentrations of 1 mM.
Equipment
HPLC system Alliance 2695 (Waters)
PDA UV detector 996 (Waters)
Column Chiral HSA 50 x 3.0 mm, 5 prn (Chromtec)
AT261 scale (Mettler-Toledo)
pH-meter easy seven (Mettler-Toledo)
Pipetman (Eppendorf)
Vortex (Fisher-Bioblock)
Ultrasound bath
4 ml_ glass vials (Dutscher)
2 ml_ glass vials for chromatography (Waters)
Liquid Chromatography Parameters
Liquid Chromatography was used in accordance with the parameters shown in Table 6: Table 6: Chromatographic parameters
Figure imgf000181_0001
Percentage Binding Calculation
The relationship between the retention time (Tr) and percentage of albumin binding (AB%) depended on the dead time (TO) and the capacity factor (k') :
AB% = [k'/(k'+ l)]* 100 where k' = (Tr-T0)/T0
HSA binding was classified as follows:
AB < 75% : Low binding
75% < AB < 90% : Moderate binding
AB > 90% : High binding
Results
The results of the HSA binding analysis are shown in Table 7 wherein it can be seen that five compounds had a low affinity (E12, E29, E63, E70 and E71), three compounds had a moderate affinity (E59, E67 and E69) and one compound (E68) had a high affinity in vitro to human albumin.
Table 7: HSA binding data for Examples 12, 29, 59, 63 and 67-71
Figure imgf000182_0001
CLSI Guideline References
1. M 100-S20
Clinical and Laboratory Standards Institute, 2010. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI document M 100-S20. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA 19087-1898 USA.
2. M7-A8
Clinical and Laboratory Standards Institute (CLSI), 2009. Methods for Dilution
Antimicrobial Test for Bacteria That Grow Aerobically; Approved Standard— Eighth Edition. CLSI document M07-A8 [ISBN 1-56238-689-1] . CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA. 3. M27-A3 Clinical and Laboratory Standards Institute, 2009. Reference method for broth dilution antifungal broth susceptibility testing of yeasts-Approved Standard Third Edition. CLSI document M27-A3. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA 19087-1898 USA.
The invention embraces all combinations of preferred and more preferred groups and suitable and more suitable groups and embodiments of groups recited above.
Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps. All patents and patent applications referred to herein are incorporated by reference in their entirety.
The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the claims.

Claims

WE CLAIM :
1. A compound of formula (I) :
Figure imgf000184_0001
R1
(I)
wherein :
- W and X independently represent a bond or a -(CH2)i-4 group, such that W and X together contain 1-5 carbon atoms;
- Rl represents an H, F, CN, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, C02Rd, CORd, CONRaRb, OCORd, ORd, NRaRb, ON = CRdRe, NRcCORd, NRcCOORd,
OCONRaRb, NRcCONRaRb, NRcS02Ra, S(0)nRa, S02NRaRb, -C(Ra) = N-0-Rf, Y-Ar or a Z- Het group, wherein Ar represents phenyl or naphthyl, Het represents a 4-10 membered monocyclic or bicyclic saturated or unsaturated heterocycie containing 1-5 heteroatoms selected from N, O and S and Y and Z independently represent a bond or a linker selected from O, S, CO, (Ci-C6) alkylene, -0-(d-C6) alkylene, -CO- (Ci-C6) alkylene or -ON=CRd-(Ci-C6) alkylene, wherein said Rl group may be optionally substituted by one or more R4 groups;
- R2 represents an H, F, CN, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, C02Rd, CORd, CONRaR , OCORd, ORd, NRaRb, ON = CRdRe, NRcCORd, NRcCOORd, OCONRaRb, NRcCONRaRb, NRcS02Ra, S(0)nRa or S02NRaRb group;
- Ra, Rb and Rc independently represent H, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2- C6) alkynyl, or an NRaRb group may optionally form a 3- to 7-membered nitrogen containing saturated heterocycie optionally containing 1 to 3 additional heteroatoms selected from N, O or S wherein said heterocycie may be optionally substituted by one or more (Ci-C6) alkyl groups;
- Rd and Re independently represent H, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, halo(d-C6) alkyl, halo(d-C6) alkyl-0-(d-C6) alkyl- or (Ci-C6) alkyl-0-(Ci- C6) alkyl-;
- Rf represents (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, halo(d-C6) alkyl or -(Ci-Ce) alkyl-Ar, wherein Ar represents phenyl or naphthyl;- R4 represents halogen, CN, (Ci-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, C02Rd, CORd, CONRaRb, OCORd, ORd, NRaRb, ON = CRdRe, NRcCORd, NRcCOORd, OCONRaRb, NRcCONRaRb, NRcS02Ra, S(0)nRa, or S02NRaRb;
- n represents an integer selected from 0 to 2;
- R3 is a pyridyl ring optionally fused to a 5, 6 or 7 membered aromatic, partially aromatic or saturated heterocycle containing 1-3 heteroatoms selected from N, O and S, wherein said R3 group may be optionally substituted by one or more R5 groups;
- R5 is selected from the group consisting of F, C02Rd, CORd, CONRaRb, ORd, =0, NRaR , NRcCORd or (Ci-C6) alkyl optionally substituted by F, C02Rd,CONRaR , ORd, NRaR , NRaCORd or Het optionally substituted by one or more (Ci-Ce) alkyl groups, or two R5 groups together with the atom to which they are attached may together form a Het group optionally substituted by one or more (Ci-C6) alkyl groups;
or a pharmaceutically acceptable salt or solvate thereof.
2. A compound as defined in claim 1, wherein W and X both represent CH2, one of W and X represents CH2 and the other represents CH2CH2,
one of W and X represents a bond and the other represents CH2CH2CH2,
W and X both represent CH2CH2, one of W and X represents CH2 and the other represents CH2CH2, or one of W and X represents a bond and the other represents CH2CH2CH2CH2.
3. A compound as defined in claim 2, wherein W and X both represent CH2.
4. A compound as defined in any preceding claims, wherein Rl represents an H, F, (Ci-C6) alkyl, (C2-C6) alkenyl, ORd, S(0)nRa, -C(Ra) = N-0-Rf, Y-Ar or Z-Het group each of which may be optionally substituted by one or more R4 groups.
5. A compound as defined in claim 4, wherein Rl represents ORd, Z-Het or - C(Ra) = N-0-Rf, such as a Z-Het group, in particular benzofuranyl optionally substituted by a methyl group.
6. A compound as defined in any preceding claims, wherein R2 represents an H or ORd group, such as an H or OH group, in particular, H .
7. A compound as defined in any preceding claims, wherein R4 represents halogen, such as bromine, chlorine or fluorine, (Ci-C6) alkyl, such as methyl, (C2- C6) alkenyl or (C2-C6) alkynyl, in particular fluorine or methyl.
8. A compound as defined in any preceding claims, wherein R3 represents a heterocycle of formula (a), (b), (c), (d), (f), (i), (j) or (k) :
Figure imgf000186_0001
(j) (k) each of which may be optionally substitutedby one or more R5 groups, such as C02Rd (e.g . C02Me), NRaRb (e.g . NH2), CONRaRb (e.g . CONH2), NRcCORd (e.g . NHCOMe) or (Ci-Ce) alkyl optionally substituted by F, C02Rd (e.g . -CH2-C02H), CONRaRb, ORd (e.g . CH2OH), NRaRb (e.g . -CH2-N(Me)2), NRaCORd or Het optionally substituted by one or more (Ci-C6) alkyl groups (e.g . -(CH2)2-piperazinyl-Me).
9. A compound as defined in claim 8, wherein R3 represents a heterocycle of formula (a) or (j) :
Figure imgf000187_0001
(a) (j)
each of which may be optionally substituted, or further substituted as appropriate, by one or more R5 groups, such as C02Rd (e.g. C02Me), NRaRb (e.g . NH2), CONRaRb (e.g . CONH2), NRcCORd (e.g . NHCOMe) or (Ci-C6) alkyl optionally substituted by F, C02Rd (e.g . -CH2-C02H), CONRaRb, ORd (e.g . CH2OH), NRaRb (e.g . -CH2-N(Me)2), NRaCORd or Het optionally substituted by one or more (Ci-C6) alkyl groups (e.g . - (CH2)2-piperazinyl-Me).
10. A compound as defined in claim 8 or claim 9, wherein R3 represents heterocycle of formula (a) :
Figure imgf000187_0002
(a)
optionally substituted by one or more R5 groups, such as C02Rd (e.g . 3-C02Me), CONRaR (e.g . 3-CONH2) or (Ci-C6) alkyl optionally substituted by ORd (e.g . 3- CH2OH), in particular a heterocycle of formula (a) which has no further R5
substituents.
11. A compound of formula (I) as defined in claim 1 which is:
6-[(lE)-3-Azetidin-l-yl-3-oxoprop-l-en-l-yl]-3,4-dihydro-l,8-naphthyridin-2(lH)- one (El);
6-[(lE)-3-Oxo-3-pyrrolidin-l-ylprop-l-en-l-yl]-3,4-dihydro-l,8-naphthyridin- 2(lH)-one (E2);
6-[(lE)-3-Oxo-3-piperidin-l-ylprop-l-en-l-yl]-3,4-dihydro-l,8-naphthyridin-2(lH)- one (E3);
6-{(lE)-3-[4-(2-Hydroxyethyl)piperidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E4); 6-[(lE)-3-{[4-(4-Fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l-yl]-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E5);
6-[(lE)-3-Oxo-3-(3-phenoxyazetidin-l-yl)prop-l-en-l-yl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E6);
6-[(lE)-3-Oxo-3-(2-phenylpyrrolidin-l-yl)prop-l-en-l-yl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E7);
6-[(lE)-3-Oxo-3-(4-propylpiperidin-l-yl)prop-l-en-l-yl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E8);
6-[(lE)-3-{[3-(4-Fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l-yl]-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E9);
6-[(lE)-3-Oxo-3-(3-phenoxypyrrolidin-l-yl)prop-l-en-l-yl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E10);
6-{(lE)-3-[3-(5-Methyl-l,2,4-oxadiazol-3-yl)azetidin-l-yl]-3-oxoprop-l-en-l-yl}- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (El l);
6-{(lE)-3-Oxo-3-[3-(2-thienylmethoxy)azetidin-l-yl]prop-l-en-l-yl}-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E12);
6-{(lE)-3-[2-(5- Methyl- 1,2, 4-oxadiazol-3-yl)piperid in- l-yl]-3-oxoprop- 1-en-l-yl}- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E13);
6-{(lE)-3-[4-Hydroxy-4-phenylpiperidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E14);
6-{(lE)-3-Oxo-3-[3-(pentyloxy)azetidin-l-yl]prop-l-en-l-yl}-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E15);
6-{(lE)-3-Oxo-3-[3-(pyridin-3-yloxy)pyrrolidin-l-yl]prop-l-en-l-yl}-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E16);
6-{(lE)-3-[3-(Benzyloxy)azetidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E17);
6-{(lE)-3-[2-(l,3-Benzoxazol-2-yl)piperidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E18);
6-[(lE)-3-{3-[(2-Methylprop-2-en-l-yl)oxy]azetidin-l-yl}-3-oxoprop-l-en-l-yl]- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E19);
6-{(lE)-3-Oxo-3-[3-(l,3-thiazol-2-ylmethoxy)azetidin-l-yl]prop-l-en-l-yl}-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E20);
6-{(lE)-3-[3-({[(lE)-l-Methyl-2-pyrimidin-2-ylethylidene]amino}oxy)azetidin-l- yl]-3-oxoprop-l-en-l-yl}-3,4-dihydro-l,8-naphthyridin-2(lH)-one (E21);
6-{(lE)-3-[3-(Pentylsulfonyl)azetidin-l-yl]-3-oxoprop-l-en-l-yl}-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E22); 5- {(lE)-3-Oxo-3-[3-(pyridin-4-ylmethoxy)azetidin-l-yl]prop-l-en-l-yl}pyridin-2- amine (E23);
N-(5-{(lE)-3-Oxo-3-[3-(pyridin-4-ylmethoxy)azetidin-l-yl]prop-l-en-l-yl}pyridin-
2- yl)acetamide (E24);
Methyl 6-[(lE)-3-{4-[(4-fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l- yl]-2-oxo-l,2,3,4-tetrahydro-l,8-naphthyridine-3-carboxylate (E25);
6- [(lE)-3-{4-[(4-Fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l-yl]-2- oxo-l,2,3,4-tetrahydro-l,8-naphthyridine-3-carboxamide (E26);
6-[(lE)-3-{4-[(4-Fluorophenoxy)methyl]piperidin-l-yl}-3-oxoprop-l-en-l-yl]-2- oxo-1, 2-dihydro-l,8-naphthyridine-3-carboxamide (E27);
3- (Hydroxymethyl)-6-[(lE)-3-{4-[(4-fluorophenoxy)methyl]piperidin-l-yl}-3- oxoprop-l-en-l-yl]-3,4-dihydro-l,8-naphthyridin-2(lH)-one (E28);
(E)-6-(3-Oxo-3-(3-(2-(thiophen-2-yl)ethoxy)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E29);
(E)-6-(3-Oxo-3-(3-(3-(thiophen-2-yl)propoxy)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E30);
(E)-6-(3-(3-((3-Methylthiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E31);
6-[3-(3-(4-Methyl-thiophen-2ylmethoxy)-azetidin-l-yl)-3-oxo-propenyl]-3,4- dihydro-lH-[l,8]naphthyridin-2-one (E32);
(E)-6-(3-(3-((5-Methylthiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E33);
E 6-[3-(2-Methoxyethoxy)azetidin-l-yl)-3-oxoprop-l-enyl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E34);
E 6-[3-(3-Methoxypropoxy)azetidin-l-yl)-3-oxoprop-l-enyl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E35);
E 6-[3-(3-Butoxyazetidin-l-yl)-3-oxoprop-l-enyl]-3,4-dihydro-l,8-naphthyridin- 2(lH)-one (E36);
E 6-[3-(3-Isobutoxyazetidin-l-yl)-3-oxoprop-l-enyl]-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E37);
(E)-6-(3-(3-((l- Methyl- lH-pyrazol-3-yl)methoxy)azetid in- l-yl)-3-oxoprop- 1-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E38);
(E)-6-(3-Oxo-3-(3-(thiazol-5-ylmethoxy)azetidin-l-yl)prop-l-enyl)-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E39);
(E)-6-(3-(3-(Furan-2-ylmethoxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E40); (E)-l'-Methyl-6-(3-oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l-enyl)-lH- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E41);
(E)-7-(3-Oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l-enyl)-4,5-dihydro- lH-pyrido[2,3-e][l,4]diazepin-2(3H)-one (E42);
(E)- Ethyl 2-(2-oxo-6-(3-oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l- enyl)-l,2-dihydropyrido[2,3-c/]pyrimidin-3(4H)-yl)acetate (E43);
(E)-3-(2-(4-Methylpiperazin-l-yl)ethyl)-6-(3-oxo-3-(3-(thiophen-2- ylmethoxy)azetidin-l-yl)prop-l-enyl)-3,4-dihydropyrido[2,3-c/]pyrirnidin-2(lH)-one (E44);
(E)-3-(3-((Dimethylamino)methyl)-lH-pyrrolo[2,3-/3]pyridin-5-yl)-l-(3-(thiophen- 2-ylmethoxy)azetidin-l-yl)prop-2-en-l-one (E45);
(E)-6-(3-Oxo-3-(3-(thiophen-2-ylmethoxy)azetidin-l-yl)prop-l-enyl)-lH- imidazo[4,5-b]pyridin-2(3H)-one (E46);
(E)-6-(3-Oxo-3-(3-(3,3,3-trifluoropropoxy)azetidin-l-yl)prop-l-enyl)-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E47);
(E)-6-(3-Oxo-3-(3-(4,4,4-trifluorobutoxy)azetidin-l-yl)prop-l-enyl)-3,4-dihydro- l,8-naphthyridin-2(lH)-one (E48);
6-((E)-3-(3-((E)-But-2-enyloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E49);
6-((E)-3-(3-((Z)-But-2-enyloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E50);
6-((E)-3-(3-((E)-2-Methylbut-2-enyloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E51);
(E)-6-(3-(3-(Benzo[/3]thiophen-2-ylmethoxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E52);
(E)-6-(3-(3-((4-Bromothiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E53);
(E)-6-(3-(3-((4-Chlorothiophen-2-yl)methoxy)azetidin-l-yl)-3-oxoprop-l-enyl)- 3,4-dihydro-l,8-naphthyridin-2(lH)-one (E54);
6-((E)-3-Oxo-3-(3-((Z)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E55);
6-((E)-3-Oxo-3-(3-((Z)-l-(2,2,2-trifluoroethoxyimino)
ethyl )azetid in- l-yl)prop-l-enyl)-3,4-dihydro-l,8-naphthyridin-2(lH)-one (E56); 6-((E)-3-(3-((Z)-l-(Ethoxyimino)ethyl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E57); (E)-6-(3-(3-(Benzofuran-3-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E58);
(E)-6-(3-(3-(Benzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E59);
(E)-6-(3-(3-(Benzofuran-7-yloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E60);
(E)-6-(3-(3-(Benzo[/3]thiophen-3-yloxy)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E61);
(E)-6-(3-Oxo-3-(3-(thiophen-2-ylthio)azetidin-l-yl)prop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E62);
(E)-6-(3-(3-Butoxyazetid in- l-yl)-3-oxoprop-l-enyl)-l '-methyl- 1H- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E63);
l'-Methyl-6-((E)-3-oxo-3-(3-((E)-l-(benzyloxyimino)ethyl)azetidin-l-yl)prop-l- enyl)-lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E64);
l'-Methyl-6-((E)-3-oxo-3-(3-((E)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)- lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E65);
(E)-l'-Methyl-6-(3-oxo-3-(3-(2-(thiophen-2-yl)ethoxy)azetidin-l-yl)prop-l-en-l- yl)-lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E66);
(E)-6-(3-(3-(3-Methylbenzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E67);
(E)-l'-Methyl-6-(3-(3-(3-methylbenzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)- lH-spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E68);
(E)-6-(3-(3-(Benzofuran-2-yl)azetid in- l-yl)-3-oxoprop-l-en-l-yl)-l '-methyl- 1 H- spiro[[l,8]naphthyridine-3,4'-piperidin]-2(4H)-one (E69);
6-((E)-3-Oxo-3-(3-((E)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E70); or
6-((E)-3-Oxo-3-(3-((Z)-l-(propoxyimino)ethyl)azetidin-l-yl)prop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E71);
or a pharmaceutically acceptable salt or solvate thereof.
12. A compound of formula (I) as defined in claim 11 which is :
(E)-6-(3-(3-(Benzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4-dihydro-l,8- naphthyridin-2(lH)-one (E59); or
(E)-6-(3-(3-(3-Methylbenzofuran-2-yl)azetidin-l-yl)-3-oxoprop-l-enyl)-3,4- dihydro-l,8-naphthyridin-2(lH)-one (E67);
or a pharmaceutically acceptable salt or solvate thereof.
13. A pharmaceutical composition comprising a compound of formula (I) as defined in any of claims 1 to 12, in association with a pharmaceutically acceptable excipient or carrier.
14. A compound of formula (I) as defined in any of claims 1 to 12 for use in therapy.
15. A method of treatment of microbial infections which comprises administering to a patient in need thereof an efficient amount of a compound of formula (I) as defined in any of claims 1 to 12.
16. A compound of formula (I) as defined in any of claims 1 to 12 for use in the treatment of microbial infections.
17. Use of a compound of formula (I) as defined in any of claims 1 to 12 in the manufacture of a medicament for the treatment of microbial infections.
18. A pharmaceutical composition comprising a compound of formula (I) as defined in any of claims 1 to 12 for use in the treatment of microbial infections.
19. A method, compound, composition or use as defined in any of claims 15 to 18 wherein said microbial infection is a human or animal infection by microbial pathogens such as Staphylococcus aureus including multiresistant strains such as methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) strains, Acinetobacter baumannii, Bacillus anthracis, Chlamydophila pneumoniae, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Neisseria meningitidis, S. intermedius, P. multocida, B. bronchiseptica, M. haemolytica and A. pleuropneumoniae. and also bacteria such as Mycobacterium tuberculosis or other organisms such as Plasmodium falciparum.
20. A method, compound, composition or use as defined in claim 19 wherein said microbial infection is a human or animal infection by Staphylococcus aureus including multiresistant strains such as methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin- intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) strains.
21. A process for preparing the compound of formula (I) as defined in any of claims 1 to 12, which comprises:
(a) reacting a compound of formula (II) :
Figure imgf000193_0001
(Π)
wherein R3 is as defined above for compounds of formula (I), with a compound of formula (III) :
Figure imgf000193_0002
wherein W, X, Rl and R2 are as defined above for compounds of formula (I); or
(b) reacting a compound of formula (IV) :
Figure imgf000193_0003
(IV)
wherein R3 is as defined above for compounds of formula (I) and L1 represents a suitable leaving group, such as a halogen atom, e.g . fluorine, chlorine, bromine or an alkoxy group, with a compound of formula (III) :
H
Figure imgf000193_0004
R1
(HI) wherein W, X, Rl and R2 are as defined above for compounds of formula (I); or
(c) reacting a compound of formula (V) :
Figure imgf000194_0001
R1
(V)
wherein W, X, Rl and R2 are as defined above for compounds of formula (I), with a compound of formula L2-R3, wherein L2 represents a suitable leaving group, such as a halogen atom, e.g. fluorine, chlorine, bromine or an alkoxy group; optionally thereafter followed by:
(d) deprotecting a protected derivative of compound (I); and optionally thereafter followed by:
(e) interconversion of a compound of formula (I) to a further compound of formula (I).
PCT/EP2010/067647 2009-11-18 2010-11-17 Novel heterocyclic acrylamides and their use as pharmaceuticals WO2011061214A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
BR112012011793A BR112012011793A2 (en) 2009-11-18 2010-11-17 "heterocyclic acrylamides and their use as pharmaceuticals"
AU2010320963A AU2010320963B2 (en) 2009-11-18 2010-11-17 Novel heterocyclic acrylamides and their use as pharmaceuticals
PL10776385T PL2501693T3 (en) 2009-11-18 2010-11-17 Aza heterocyclic acrylamides and their use as bactericides
CA2776849A CA2776849A1 (en) 2009-11-18 2010-11-17 Novel heterocyclic acrylamides and their use as pharmaceuticals
US13/510,564 US8846711B2 (en) 2009-11-18 2010-11-17 Heterocyclic acrylamides and their use as pharmaceuticals
KR1020127011047A KR20130010456A (en) 2009-11-18 2010-11-17 Novel heterocyclic acrylamides and their use as pharmaceuticals
MX2012005759A MX2012005759A (en) 2009-11-18 2010-11-17 Novel heterocyclic acrylamides and their use as pharmaceuticals.
ES10776385.6T ES2526567T3 (en) 2009-11-18 2010-11-17 Azaheterocyclic acrylamides and their use as bactericides
CN201080051981.2A CN102656158B (en) 2009-11-18 2010-11-17 Novel heterocyclic acrylamides and their use as pharmaceuticals
JP2012539312A JP5816629B2 (en) 2009-11-18 2010-11-17 Novel heterocyclic acrylamide and its use as a medicament
NZ599444A NZ599444A (en) 2009-11-18 2010-11-17 Novel heterocyclic acrylamides and their use as pharmaceuticals
EP10776385.6A EP2501693B1 (en) 2009-11-18 2010-11-17 Aza heterocyclic acrylamides and their use as bactericides
DK10776385.6T DK2501693T3 (en) 2009-11-18 2010-11-17 Aza-heterocyclic acrylamides and their use as bactericides
IL218934A IL218934A0 (en) 2009-11-18 2012-03-29 Novel heterocyclic acrylamides and their use as phermaceuticals
ZA2012/02489A ZA201202489B (en) 2009-11-18 2012-04-04 Novel heterocyclic acrylamides and their use as pharmaceuticals
HK13103790.1A HK1176358A1 (en) 2009-11-18 2013-03-26 Aza heterocyclic acrylamides and their use as bactericides
US14/463,994 US9051321B2 (en) 2009-11-18 2014-08-20 Heterocyclic acrylamides and their use as pharmaceuticals
US14/703,004 US9321769B2 (en) 2009-11-18 2015-05-04 Heterocyclic acrylamides and their use as pharmaceuticals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26230909P 2009-11-18 2009-11-18
US61/262,309 2009-11-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/510,564 A-371-Of-International US8846711B2 (en) 2009-11-18 2010-11-17 Heterocyclic acrylamides and their use as pharmaceuticals
US14/463,994 Division US9051321B2 (en) 2009-11-18 2014-08-20 Heterocyclic acrylamides and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
WO2011061214A1 true WO2011061214A1 (en) 2011-05-26

Family

ID=44059228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/067647 WO2011061214A1 (en) 2009-11-18 2010-11-17 Novel heterocyclic acrylamides and their use as pharmaceuticals

Country Status (17)

Country Link
US (3) US8846711B2 (en)
EP (1) EP2501693B1 (en)
JP (1) JP5816629B2 (en)
KR (1) KR20130010456A (en)
CN (1) CN102656158B (en)
AU (1) AU2010320963B2 (en)
BR (1) BR112012011793A2 (en)
CA (1) CA2776849A1 (en)
DK (1) DK2501693T3 (en)
ES (1) ES2526567T3 (en)
HK (1) HK1176358A1 (en)
IL (1) IL218934A0 (en)
MX (1) MX2012005759A (en)
NZ (1) NZ599444A (en)
PL (1) PL2501693T3 (en)
WO (1) WO2011061214A1 (en)
ZA (1) ZA201202489B (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013021051A1 (en) 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial homopiperidinyl substituted 3,4 dihydro 1h [1,8]naphthyridinones
WO2013021052A1 (en) 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
WO2013021054A1 (en) 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones
WO2013080222A1 (en) * 2011-12-02 2013-06-06 Aurigene Discovery Technologies Limited Substituted pyridine derivatives as fabi inhibitors
WO2013164337A1 (en) * 2012-04-30 2013-11-07 Janssen R&D Ireland New compounds and new use
WO2014023815A1 (en) 2012-08-10 2014-02-13 Janssen R&D Ireland New antibacterial compounds
WO2014023814A1 (en) * 2012-08-10 2014-02-13 Janssen R&D Ireland New antibacterial compounds
WO2014072930A2 (en) * 2012-11-09 2014-05-15 Aurigene Discovery Technologies Limited Fused pyridine derivatives as antibacterial agents
US8895545B2 (en) 2006-07-20 2014-11-25 Debiopharm International Sa Acrylamide derivatives as Fab I inhibitors
US8901105B2 (en) 2012-06-19 2014-12-02 Debiopharm International Sa Prodrug derivatives of (E)-N-methyl-N-((3-M ethylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
WO2014195844A1 (en) * 2013-06-04 2014-12-11 Aurigene Discovery Technologies Limited TETRAHYDROPYRIDINE DERIVATIVES AS FabI INHIBITORS
WO2015071780A1 (en) * 2013-11-12 2015-05-21 Aurigene Discovery Technologies Limited Alkylidine substituted heterocyclyl derivatives as anti-bacterial agents
US9062075B2 (en) 2011-12-02 2015-06-23 Aurigene Discovery Technologies Limited Tetrahydropyridine derivatives as FabI inhibitors
US9115149B2 (en) 2011-09-19 2015-08-25 Vitas Pharma Research Private Limited Heterocyclic compounds as inhibitors of fatty acid biosysnthesis for bacterial infections
US10751351B2 (en) 2016-02-26 2020-08-25 Debiopharm International S.A. Medicament for treatment of diabetic foot infections

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010320963B2 (en) 2009-11-18 2015-07-09 Fab Pharma Sas Novel heterocyclic acrylamides and their use as pharmaceuticals
CN104292142B (en) * 2013-07-17 2019-05-14 天津大地康和医药技术有限公司 A kind of de- aryl method of N- aryl-heterocyclic butane
CN104529854B (en) * 2015-01-14 2016-10-05 武汉金联药业有限公司 A kind of synthetic method of substituted azetidine class pharmaceutical intermediate compound
ES2770113T3 (en) 2015-07-02 2020-06-30 Horizon Orphan Llc ADO-resistant cysteamine analogues and their uses
CN108440523A (en) * 2018-04-23 2018-08-24 爱斯特（成都）生物制药股份有限公司 A kind of new method of synthesis bromo- 3,4- dihydros -1H- [1,8] naphthyridines -2- ketone of 6-
CN114351128B (en) * 2021-12-10 2022-12-13 江阴纳力新材料科技有限公司 Copper plating solution additive, copper plating solution, copper plated film and preparation method thereof, negative current collector and lithium battery

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027103A1 (en) 1999-10-08 2001-04-19 Smithkline Beecham Corporation Fab i inhibitors
WO2003088897A2 (en) 2001-04-06 2003-10-30 Affinium Pharmaceuticals, Inc. Fab i inhibitors
WO2004052890A1 (en) 2002-12-06 2004-06-24 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2007053131A2 (en) 2004-06-04 2007-05-10 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as antibiotic agents
WO2007067416A2 (en) 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
WO2007135562A2 (en) 2006-04-14 2007-11-29 Mutabilis S.A. Hydroxyphenyl derivatives and biological applications thereof
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
WO2008074413A2 (en) 2006-12-20 2008-06-26 Sanofi-Aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial no synthase
WO2008080511A1 (en) 2006-12-20 2008-07-10 Sanofi-Aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020864C (en) * 1988-09-14 1993-05-26 中国科学院上海有机化学研究所 Catalysts for olefination of aldehyde and their application
TW224042B (en) * 1992-04-04 1994-05-21 Basf Ag
US6046218A (en) 1996-03-15 2000-04-04 Ss Pharmaceutical Co., Ltd. Pyridine derivative and medicament containing the same as an effective ingredient
PT923555E (en) 1996-05-01 2005-09-30 Ortho Mcneil Pharm Inc DERIVATIVES CARBOXAMIDE OF PYRROLIDINE, PIPERIDINE AND HEXA-HYDROAZEPINE FOR THE TREATMENT OF TROMBOTIC DISTURBLES
JP2004099499A (en) * 2002-09-09 2004-04-02 Sanei Gen Ffi Inc Antimicrobial agent
JP5042040B2 (en) * 2005-01-26 2012-10-03 アラーガン、インコーポレイテッド 1-Aryl-1-hydroxy-2,3-diamino-propylamine, 1-heteroaryl-1-hydroxy-2,3-diamino-propylamine and related compounds having analgesic and / or immunostimulatory activity
WO2007086584A1 (en) * 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. NOVEL INHIBITOR OF FabK AND FabI/K
WO2009110002A1 (en) * 2008-03-05 2009-09-11 Council Of Scientific & Industrial Research Novel efflux pump inhibitors
JP2012102018A (en) * 2009-03-03 2012-05-31 Astellas Pharma Inc Amide compound
AU2010320963B2 (en) 2009-11-18 2015-07-09 Fab Pharma Sas Novel heterocyclic acrylamides and their use as pharmaceuticals

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027103A1 (en) 1999-10-08 2001-04-19 Smithkline Beecham Corporation Fab i inhibitors
WO2003088897A2 (en) 2001-04-06 2003-10-30 Affinium Pharmaceuticals, Inc. Fab i inhibitors
WO2004052890A1 (en) 2002-12-06 2004-06-24 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2007053131A2 (en) 2004-06-04 2007-05-10 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as antibiotic agents
WO2007067416A2 (en) 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
WO2007135562A2 (en) 2006-04-14 2007-11-29 Mutabilis S.A. Hydroxyphenyl derivatives and biological applications thereof
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
WO2008074413A2 (en) 2006-12-20 2008-06-26 Sanofi-Aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial no synthase
WO2008080511A1 (en) 2006-12-20 2008-07-10 Sanofi-Aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"Reference method for broth dilution antifungal broth susceptibility testing of yeasts-Approved Standard", 2009, CLINICAL AND LABORATORY STANDARDS INSTITUTE
ANTIMICROB. AGENTS CHEMOTHER., vol. 46, 2002, pages 3118
BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 4982
BIOORG. MED. CHEM., vol. 15, 2007, pages 1106
J. PHARM. SCI., vol. 66, 1977, pages 2
KITAGAWA ET AL., J. MED. CHEM., vol. 50, 2007, pages 4710
KOZIKOWSKI ET AL., BIOORG. MED. CHEM. LETT., vol. 18, 2008, pages 3565
KWAK ET AL., INT. J. ANTIMICRO. AG., vol. 30, 2007, pages 446
LEE ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 51, 2007, pages 2591
MOIR ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 48, 2004, pages 1541
MONTELLANO ET AL., J. MED. CHEM., vol. 49, 2006, pages 6308
PAYNE ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 46, 2002, pages 3118
SACCHETTINI ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 20851
SEEFELD ET AL., J. MED. CHEM., vol. 46, 2003, pages 1627
TAKAHATA ET AL., J. ANTIBIOT., vol. 60, 2007, pages 123
TONGE ET AL., ACC. CHEM. RES., vol. 41, 2008, pages 11

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895545B2 (en) 2006-07-20 2014-11-25 Debiopharm International Sa Acrylamide derivatives as Fab I inhibitors
US9290493B2 (en) 2011-08-10 2016-03-22 Janssen Sciences Ireland Uc Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
KR101967174B1 (en) * 2011-08-10 2019-04-09 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
AU2012293619B2 (en) * 2011-08-10 2017-05-04 Janssen Sciences Ireland Uc Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
AU2012293618B2 (en) * 2011-08-10 2017-04-20 Janssen Sciences Ireland Uc Antibacterial homopiperidinyl substituted 3,4 dihydro 1H (1,8)naphthyridinones
EA038317B1 (en) * 2011-08-10 2021-08-09 Янссен Сайенсиз Айрлэнд Юси Antibacterial homopiperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
CN103874698B (en) * 2011-08-10 2016-03-23 爱尔兰詹森科学公司 3,4-dihydro-1H-[1, the 8] naphthyridones that antibacterial cyclopenta [C] pyrroles replaces
US10526331B2 (en) 2011-08-10 2020-01-07 Janssen Sciences Ireland Unlimited Company Antibacterial cyclopenta[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
KR20140072025A (en) * 2011-08-10 2014-06-12 얀센 알 앤드 디 아일랜드 Antibacterial homopiperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
KR20140072034A (en) * 2011-08-10 2014-06-12 얀센 알 앤드 디 아일랜드 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
CN105461684A (en) * 2011-08-10 2016-04-06 爱尔兰詹森科学公司 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
KR20140079759A (en) * 2011-08-10 2014-06-27 얀센 알 앤드 디 아일랜드 Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
CN103917540A (en) * 2011-08-10 2014-07-09 爱尔兰詹森研发公司 Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
US10501463B2 (en) 2011-08-10 2019-12-10 Janssen Sciences Ireland Unlimited Company Antibacterial cyclopenta[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
JP2014521715A (en) * 2011-08-10 2014-08-28 ヤンセン・アールアンドデイ・アイルランド Antibacterial piperidinyl-substituted 3,4-dihydro-1H- [1,8] -naphthyridinones
CN104039782A (en) * 2011-08-10 2014-09-10 爱尔兰詹森研发公司 Antibacterial Homopiperidinyl Substituted 3,4 Dihydro 1h [1,8]naphthyridinones
WO2013021052A1 (en) 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
JP2014531403A (en) * 2011-08-10 2014-11-27 ヤンセン・アールアンドデイ・アイルランド Antibacterial homopiperidinyl substituted 3,4-dihydro-1H- [1,8] -naphthyridinones
WO2013021054A1 (en) 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones
US8906923B2 (en) 2011-08-10 2014-12-09 Janssen R&D Ireland Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
KR101996866B1 (en) 2011-08-10 2019-07-05 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Antibacterial homopiperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
US9617262B2 (en) 2011-08-10 2017-04-11 Janssen Sciences Ireland Uc Antibacterial cyclopental[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
US9012634B2 (en) 2011-08-10 2015-04-21 Janssen R&D Ireland Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
KR101996862B1 (en) 2011-08-10 2019-07-05 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
US9598407B2 (en) 2011-08-10 2017-03-21 Janssen Sciences Ireland Uc Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
TWI568731B (en) * 2011-08-10 2017-02-01 健生科學愛爾蘭無限公司 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones
JP2016190843A (en) * 2011-08-10 2016-11-10 ヤンセン・サイエンシズ・アイルランド・ユーシー Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]-naphthyridinones
AU2012293621B2 (en) * 2011-08-10 2016-07-21 Janssen Sciences Ireland Uc Antibacterial cyclopenta[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
US10155759B2 (en) 2011-08-10 2018-12-18 Janssen Sciences Ireland Uc Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
US9394295B2 (en) 2011-08-10 2016-07-19 Janssen Sciences Ireland Uc Antibacterial homopiperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
CN105503869A (en) * 2011-08-10 2016-04-20 爱尔兰詹森科学公司 Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
JP2017222646A (en) * 2011-08-10 2017-12-21 ヤンセン・サイエンシズ・アイルランド・ユーシー Antibacterial homopiperidinyl substituted 3,4 dihydro 1h[1,8]naphthyridinones
CN108003155A (en) * 2011-08-10 2018-05-08 爱尔兰詹森科学公司 3,4 dihydro -1H [1,8] naphthyridones of the homopiperidinyl substitution of antibacterial
CN103917540B (en) * 2011-08-10 2016-03-16 爱尔兰詹森科学公司 3,4-dihydro-1H-[1, the 8] naphthyridones that antibacterial piperidyl replaces
WO2013021051A1 (en) 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial homopiperidinyl substituted 3,4 dihydro 1h [1,8]naphthyridinones
US9884864B2 (en) 2011-08-10 2018-02-06 Janssen Sciences Ireland Uc Antibacterial cyclopenta[C]pyrrole substituted 3,4-Dihydro-1H-[1,8]naphthyridinones
JP2017222647A (en) * 2011-08-10 2017-12-21 ヤンセン・サイエンシズ・アイルランド・ユーシー Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]-naphthyridinones
CN103874698A (en) * 2011-08-10 2014-06-18 爱尔兰詹森研发公司 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones
EP3330269A1 (en) 2011-09-19 2018-06-06 Vitas Pharma Research Private Limited Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
US9115149B2 (en) 2011-09-19 2015-08-25 Vitas Pharma Research Private Limited Heterocyclic compounds as inhibitors of fatty acid biosysnthesis for bacterial infections
US9062002B2 (en) 2011-12-02 2015-06-23 Aurigene Discovery Technologies Limited Substituted pyridine derivatives as FabI inhibitors
US9062075B2 (en) 2011-12-02 2015-06-23 Aurigene Discovery Technologies Limited Tetrahydropyridine derivatives as FabI inhibitors
WO2013080222A1 (en) * 2011-12-02 2013-06-06 Aurigene Discovery Technologies Limited Substituted pyridine derivatives as fabi inhibitors
EA030899B1 (en) * 2012-04-30 2018-10-31 Янссен Сайенсиз Айрлэнд Юси 5-phenyl-pyrimidine derivatives with antibacterial properties
CN104487425B (en) * 2012-04-30 2016-09-14 爱尔兰詹森科学公司 The pyrimidine derivatives for the treatment of bacterial disease
US10221157B2 (en) 2012-04-30 2019-03-05 Janssen Pharmaceutica Nv Pyrimidine derivatives for the treatment of bacterial diseases
US9725432B2 (en) 2012-04-30 2017-08-08 Janssen Sciences Ireland Us Pyrimidine derivatives for the treatment of bacterial diseases
CN104487425A (en) * 2012-04-30 2015-04-01 爱尔兰詹森研发公司 New compounds and new use
WO2013164337A1 (en) * 2012-04-30 2013-11-07 Janssen R&D Ireland New compounds and new use
US8901105B2 (en) 2012-06-19 2014-12-02 Debiopharm International Sa Prodrug derivatives of (E)-N-methyl-N-((3-M ethylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
US10035813B2 (en) 2012-06-19 2018-07-31 Debiopharm International Sa Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
KR20150043347A (en) * 2012-08-10 2015-04-22 얀센 사이언시즈 아일랜드 유씨 NEW Antibacterial COMPOUNDS
KR102323873B1 (en) 2012-08-10 2021-11-09 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 NEW Antibacterial COMPOUNDS
AU2013301451B2 (en) * 2012-08-10 2017-09-14 Janssen Sciences Ireland Uc New antibacterial compounds
CN104981466A (en) * 2012-08-10 2015-10-14 爱尔兰詹森科学公司 New antibacterial compounds
JP2015528438A (en) * 2012-08-10 2015-09-28 ヤンセン・サイエンシズ・アイルランド・ユーシー New antibacterial compounds
US9315522B2 (en) 2012-08-10 2016-04-19 Janssen Sciences Ireland Uc Antibacterial compounds
JP2015524463A (en) * 2012-08-10 2015-08-24 ヤンセン・サイエンシズ・アイルランド・ユーシー New antibacterial compounds
CN104781250A (en) * 2012-08-10 2015-07-15 爱尔兰詹森科学公司 New antibacterial compounds
KR102323876B1 (en) 2012-08-10 2021-11-09 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 NEW Antibacterial COMPOUNDS
WO2014023814A1 (en) * 2012-08-10 2014-02-13 Janssen R&D Ireland New antibacterial compounds
KR20150042801A (en) * 2012-08-10 2015-04-21 얀센 사이언시즈 아일랜드 유씨 NEW Antibacterial COMPOUNDS
CN104981466B (en) * 2012-08-10 2019-06-14 爱尔兰詹森科学公司 Antibacterium compound
WO2014023815A1 (en) 2012-08-10 2014-02-13 Janssen R&D Ireland New antibacterial compounds
US9296760B2 (en) 2012-08-10 2016-03-29 Janssen Sciences Ireland Uc Antibacterial compounds
WO2014072930A2 (en) * 2012-11-09 2014-05-15 Aurigene Discovery Technologies Limited Fused pyridine derivatives as antibacterial agents
WO2014072930A3 (en) * 2012-11-09 2014-07-31 Aurigene Discovery Technologies Limited Fused pyridine derivatives as antibacterial agents
WO2014195844A1 (en) * 2013-06-04 2014-12-11 Aurigene Discovery Technologies Limited TETRAHYDROPYRIDINE DERIVATIVES AS FabI INHIBITORS
WO2015071780A1 (en) * 2013-11-12 2015-05-21 Aurigene Discovery Technologies Limited Alkylidine substituted heterocyclyl derivatives as anti-bacterial agents
US10751351B2 (en) 2016-02-26 2020-08-25 Debiopharm International S.A. Medicament for treatment of diabetic foot infections

Also Published As

Publication number Publication date
JP2013511486A (en) 2013-04-04
AU2010320963B2 (en) 2015-07-09
DK2501693T3 (en) 2014-12-08
PL2501693T3 (en) 2015-03-31
ES2526567T3 (en) 2015-01-13
US20120277207A1 (en) 2012-11-01
JP5816629B2 (en) 2015-11-18
AU2010320963A1 (en) 2012-05-03
US20140357617A1 (en) 2014-12-04
US9051321B2 (en) 2015-06-09
NZ599444A (en) 2014-02-28
US8846711B2 (en) 2014-09-30
HK1176358A1 (en) 2013-07-26
BR112012011793A2 (en) 2019-09-24
CN102656158B (en) 2015-02-11
IL218934A0 (en) 2012-07-31
US20150232466A1 (en) 2015-08-20
EP2501693B1 (en) 2014-09-17
US9321769B2 (en) 2016-04-26
MX2012005759A (en) 2012-10-03
CA2776849A1 (en) 2011-05-26
KR20130010456A (en) 2013-01-28
EP2501693A1 (en) 2012-09-26
CN102656158A (en) 2012-09-05
ZA201202489B (en) 2013-02-27

Similar Documents

Publication Publication Date Title
EP2501693B1 (en) Aza heterocyclic acrylamides and their use as bactericides
US10301305B2 (en) Heteroaromatic derivatives and their use as pharmaceuticals
AU2008254270B2 (en) Spiroindalones
US20240217962A1 (en) Tau-protein targeting compounds and associated methods of use
US10000501B2 (en) Inhibitors of HIF prolyl hydroxylase
US9062002B2 (en) Substituted pyridine derivatives as FabI inhibitors
AU2006287976A1 (en) Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases
KR20110083746A (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
MX2010007430A (en) (1-azinone) -substituted pyridoindoles as mch antagonists.
CA3140257C (en) Next-generation modulators of stimulator of interferon genes (sting)
AU2010333024B2 (en) MK2 inhibitors
CN115594666B (en) Synthesis and application of phosphatase degradation agent
KR20190091339A (en) Imidazo [1,5-A] pyrazine derivatives as PI3K delta inhibitors
WO2023186069A1 (en) Bifunctional chimeric heterocyclic compound of interleukin-1 receptor-associated kinase 4, preparation method therefor, pharmaceutical composition thereof and use thereof
WO2014072930A2 (en) Fused pyridine derivatives as antibacterial agents
CA2719234A1 (en) Spiroazaindoles
CN114341125A (en) TREX1 modulators
CN117126231A (en) Peptoid STAT protein degradation agent, composition and application thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080051981.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10776385

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 218934

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2776849

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010320963

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20127011047

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2010320963

Country of ref document: AU

Date of ref document: 20101117

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 4179/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2012539312

Country of ref document: JP

Ref document number: MX/A/2012/005759

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010776385

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13510564

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012011793

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012011793

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120517